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Hyperlipidemia plays a central role in the development of atherosclerotic plaque 
that impairs arterial blood flow leading to arterial obstruction and myocardial infarction 
in coronary vessels.  The management of hyperlipidemia is crucial in the prevention of 
coronary heart disease (CHD).  Primary, secondary, and angiographic trials have 
demonstrated the beneficial effects of lipid-lowering drugs, especially statins, in the 
reduction of CHD associated mortality and morbidity.   
The purpose of the study was to evaluate statin utilization patterns, medication 
compliance, and lipid and safety monitoring of patients on statin drug therapy in the 
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Texas Medicaid system.  The study was a retrospective cohort analysis using the Texas 
Medicaid database. The study population included patients who were new statin users 
between the ages of 21 and 64 years and were eligible for Texas Medicaid benefits 
between September 1, 1998 to August 31, 2003.   
Of the total (N = 7,440) patients, 65.2% were females and the mean age of all 
patients was 49.7 years (S.D. = 9.4 years).  Non-Hispanic whites (42.7%), Hispanics 
(32.7%), and non-Hispanic blacks (22.5%) formed the majority of the ethnic categories.  
The most commonly prescribed statins, based on the total number of prescription claims 
for the two-year follow-up period, were Lipitor® (57.1%), Zocor® (23.2%) and 
Pravachol® (14.2%).  Compliance was measured using the medication possession ratio 
(MPR) and persistence.  The mean MPR was 0.7 and at the end of 310 days, only 50 
percent of the patients were still persistent with their therapy.  The cumulative probability 
of being persistent with therapy at the end of the two-year period was 0.41.  Within three 
months prior to the start of therapy, less than half (42.5%) of the patients had their LDL 
levels monitored.  Only 15.6 percent and 9.7 percent of the patients had LDL tests and 
liver function tests (LFTs) within three months since the start of therapy.   
The study showed the lack of adherence to statin drugs and lack of monitoring of 
the response to the drugs, as well as associated adverse events, both of which could cost 
the Medicaid system valuable dollars in the long run. Steps need to be taken to promote 
adherence and monitoring in order to reduce the risk and the long-term costs associated 
with CHD.  
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INTRODUCTION AND LITERATURE REVIEW 
 
 
Cardiovascular diseases (CVD) are the leading causes of mortality and morbidity 
among men and women from developed countries.1  According to the American Heart 
Association, in the year 2001, CVDs were associated with 38.5 percent of all deaths (1 in 
every 2.6 deaths) in the United States (U.S.), claiming 1,408,000 lives.2  Coronary heart 
disease (CHD), also referred to as coronary artery disease, accounts for about half of all 
cardiovascular-related deaths in the U.S.3  A total of 13 million people suffer from CHD, 
of which, 7.1 million suffer from myocardial infarction (MI) and 6.4 million suffer from 
angina pectoris.  CHD was responsible for one in every five deaths in the U.S in the year 
2002.  The estimated U.S. annual cost of CHD in 2005, including both direct and indirect 
costs was $142.1 billion.   
                                                 
1 McKenney JM. Pharmacotherapy of dyslipidemia. Cardiovascular Drugs & Therapy. 
2001;15(5):413-422. 
2 American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 
American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed January 15, 
2005. 
3 American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 
American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed January 15, 
2005. 
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Moreover, CHD is the leading cause of “premature, permanent disability in the U.S. labor 
force, accounting for 19 percent of disability allowances by the Social Security 
Administration.” 4 
The epidemiological literature has documented the association between elevated 
cholesterol level (hyperlipidemia) and the increased risk for CHD.5,6  A substantial 
number of U.S. adults are hyperlipidemic.  Based on the data from NHANES III, overall 
50.7 million (28.2 percent) of U.S. adults > 20 years are eligible for treatment based on 
the Adult Treatment Panel (ATP) II guidelines.7  The management of hyperlipidemia is 
crucial in preventing the occurrence of CHD.  However, under-diagnosis and under-
treatment of this disorder prevails in clinical practice.8   
The National Cholesterol Education Program (NCEP) of the National Institute of 
Health provides updates and recommendations for cholesterol testing and management.   
                                                 
4 American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 
American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed January 15, 
2005. 
5 Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk 
of coronary heart disease. The Framingham study. Annals of Internal Medicine. 
1971;74(1):1-12. 
6 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk 
of premature death from coronary heart disease continuous and graded? Findings in 
356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). 
Journal of the American Medical Association. 1986;256(20):2823-2828. 
7 Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-
density lipoprotein cholesterol levels in treatment-eligible United States adults. American 
Journal of Cardiology. 1998;82(1):61-65. 
8 Lai L, Poblet M, Bello C. Are patients with hyperlipidemia being treated? Investigation 
of cholesterol treatment practices in an HMO primary care setting. Southern Medical 
Journal. 2000;93(3):283-286. 
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The lipid-lowering agents, statins, are recommended as the first line of drug therapy in 
the treatment of hyperlipidemia.9  Clinical trials have demonstrated the beneficial effects 
of statins in reducing cholesterol levels as well as CHD mortality and morbidity.10,11,12  
Despite, these beneficial effects, the use of statins for lipid management remains sub-
optimal.  Moreover, the compliance to statin therapy is low.13   
Given the expense and the life-long treatment of the condition, it is important to 
understand the treatment and monitoring of hyperlipidemia.  There has been no published 
study on the management of hyperlipidemia and adherence to lipid and safety monitoring 
guidelines in the Texas Medicaid program.  Moreover, limited data exists on the 
management of hyperlipidemia among women and minority populations such as 
Hispanics and African-Americans.  This study aims to understand treatment patterns, 
adherence to lipid and safety monitoring guidelines and compliance to statin drug  
                                                 
9 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in 
Adults. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical 
Association. 2001;285(19):2486-2497. 
10 Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with 
pravastatin in men with hypercholesterolemia. New England Journal of Medicine. 
1995;333(20):1301-1307. 
11 Kjekshus J, Pedersen TR. Reducing the Risk of Coronary Events: Evidence from the 
Scandinavian Simvastatin Survival Study (4S). American Journal of Cardiology. 
1995;76(1):64C-68C. 
12 Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL 
concentrations during treatment with pravastatin and recurrent coronary events in the 
Cholesterol and Recurrent Events Trial. Circulation. 1998;97(15):1446-1452. 
13 Andrade SE, Walker AM, Gottolieb LK, et al. Discontinuation of antihyperlipidemic 
drugs-do rates reported in clinical trials reflect rates in primary care settings? New 
England Journal of Medicine. 1995;332(17):1125-1131. 
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regimen among hyperlipidemic patients enrolled in the Texas Medicaid program.   
 
This chapter is divided into the following nine sections: 
 
1. Background on hyperlipidemia; 
2. Clinical evidence of lipid-lowering with anti-hyperlipidemic drugs and its effect 
on CHD; 
3. Compliance with lipid-lowering therapy; 
4. Lipid management in primary care settings and in special populations; 
5. Impact of physician specialty on management of hyperlipidemia and CHD; 
6. Pharmacoeconomic evaluations of lipid-lowering therapy; 
7. Use of claims databases in health outcomes research; 
8. Texas Medicaid database and cardiovascular disease in Texas; and 






BACKGROUND ON HYPERLIPIDEMIA 
 
This section presents information on: the epidemiology of hyperlipidemia in the 
U.S. population; the process of atherosclerosis including the role of lipids and 
lipoproteins in the development of CHD; the risk factors associated with hyperlipidemia; 
the guidelines for its treatment; and finally, the dietary and pharmacological management 
of the disease. 
 
Definition of Hyperlipidemia and Its Association with CHD 
Hyperlipidemia (also referred to as dyslipidemia or hypercholesterolemia), is 
defined as elevated plasma cholesterol levels.  Grundy et al. defined hyperlipidemia as 
“cholesterol concentration associated with significantly increased risk for coronary heart 
disease.”14  There are five major types of lipids in the blood plasma: cholesterol, 
cholesteryl esters, phospholipids, triglycerides and unesterified fatty acids.  Lipoproteins 
are responsible for the transport of lipids, mainly triglycerides and cholesterol, through 
the plasma.  The four main classes of lipoproteins include high-density lipoprotein 
(HDL), low-density lipoprotein (LDL), very low-density lipoprotein (VLDL) and  
                                                 
14 Grundy SM. Cholesterol and coronary heart disease:  A new era. Journal of the 
American Medical Association. 1986;256(20):2849-2858. 
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chylomicrons.15 LDL makes up about 60-70 percent of the total serum cholesterol and is 
the primary target of cholesterol lowering therapy as recognized by the National 
Cholesterol Education Panel (NCEP).16  LDL cholesterol plays an important role in the 
occurrence of CHD.   
The epidemiological literature has documented the association between elevated 
cholesterol level (hyperlipidemia) and the increased risk for CHD.  Studies such as the 
Framingham Heart Study,17 the Multiple Risk Factor Intervention Trial (MRFIT),18 and 
the Lipid Research Clinics Primary Prevention Trial (LRCPPT)19,20 show a direct 
association between the prevalence of high cholesterol and the occurrence of CHD in 
subjects initially free of CHD.  
                                                 
15 Patsch JR. An introduction to the biochemistry and biology of blood lipids and 
lipoproteins. Berlin Heidelberg: Springer-Verlag; 1994. 
16 Grundy SM, Becker DM, Clark L, et al. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal 
of the American Medical Association. 2001;285(19):2486-2497. 
17 Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk 
of coronary heart disease. The Framingham study. Annals of Internal Medicine. 
1971;74(1):1-12. 
18 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk 
of premature death from coronary heart disease continuous and graded? Findings in 
356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). 
Journal of the American Medical Association. 1986;256(20):2823-2828. 
19 Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary 
Prevention results. I: Reduction in the incidence of coronary heart disease. Journal of the 
American Medical Association. 1984;251(3):351-364. 
20 Lipid Research Clinics Program Group. The Lipid Research Clinics Coronary Primary 
Prevention Trial results. II. The relationship of reduction in incidence of coronary heart 
disease to cholesterol lowering. Journal of the American Medical Association. 
1984;251(3):365-374. 
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  In the Framingham Heart Study, over 5,000 men and women who were followed 
for a period of 14 years showed a direct association between elevated cholesterol levels 
and the occurrence of ischemic heart disease.21  A 12 year follow up of 350,977 men in 
the MRFIT showed a significant and graded association between cholesterol levels and 
death from CVD.22,23  The LRCPPT followed 3,806 middle aged men for a period of 7.4 
years and established a strong relationship of the causal role of elevated cholesterol on 
the incidence of CHD.24,25  In summary, hyperlipidemia is an important risk factor in the 
development of CHD.  
 
                                                 
21 Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk 
of coronary heart disease. The Framingham study. Annals of Internal Medicine. 
1971;74(1):1-12. 
22 Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality 
findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk 
Factor Intervention Trial Research Group. Archives of Internal Medicine. 
1992;152(7):1490-1500. 
23 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk 
of premature death from coronary heart disease continuous and graded? Findings in 
356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). 
Journal of the American Medical Association. 1986;256(20):2823-2828. 
24 Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary 
Prevention results. I: Reduction in the incidence of coronary heart disease. Journal of the 
American Medical Association. 1984;251(3):351-364. 
25 Lipid Research Clinics Program Group. The Lipid Research Clinics Coronary Primary 
Prevention Trial results. II. The relationship of reduction in incidence of coronary heart 
disease to cholesterol lowering. Journal of the American Medical Association. 
1984;251(3):365-374. 
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Prevalence of High Blood Cholesterol among U.S. Adults 
According to the most recent cholesterol management guidelines published in 
May 2001, cholesterol levels of 200-239 mg/dl are considered borderline-high whereas 
levels ≥ 240 mg/dl are considered high.  An estimated 102.3 million U.S. adults have 
cholesterol values of 200 mg/dl or higher and approximately 37.7 million adults have 
levels ≥ 240 mg/dl.26  Since 1976, blood cholesterol levels among the U.S. adults have 
decreased substantially.  Based on two National Health and Nutrition Examination 
Surveys (NHANES II and NHANES III), between 1976 and 1991, the percentage of U.S. 
adults with blood cholesterol levels greater than 240 mg/dl dropped from 26 percent to 20 
percent.  During the same time period, adults with desirable blood cholesterol levels rose 
from 44 percent to 49 percent.27  However, based on the results of the latest NHANES IV 
conducted between 1999 and 2000, the trend in decreases in total cholesterol 
concentration appears to have slowed down.28  A substantial number of U.S. adults are 
hyperlipidemic.  Based on the data from NHANES III, overall 50.7 million (28.2 percent)  
                                                 
26Cholesterol statistics. American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=4506. Accessed February 1, 
2005. 
27 Sempos C, Cleeman JI, Carroll M, et al. Prevalence of high blood cholesterol among 
US adults: an update based on guidelines from the second report of the National 
Cholesterol Education Program Adult Treatment Panel. Journal of the American Medical 
Association. 1993;269(23):3009-3014. 
28 Ford E, Mokdad A, Giles W, et al. Serum total cholesterol concentrations and 
awareness, treatment, and control of hypercholesterolemia among US adults: Findings 
from the National Health and Nutrition Examination Survey 1999 to 2000. Circulation. 
2003;107(17):2185-2189. 
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of U.S. adults > 20 years are eligible for treatment based on the Adult Treatment Panel 
(ATP) II guidelines.  As per the ATP II guidelines, 29.5 million (16.4 percent) qualify for 
dietary therapy alone and 21.2 million (11.8 percent) qualify for drug therapy.29  Under 
the new ATP III guidelines, an estimated 36 million Americans will be eligible for drug 
therapy of which 55 percent are males and 45 percent females.  Thirty-two percent of 
Americans under the age of 45 years, and 28 percent >65 years will be eligible for drug 
therapy for hyperlipidemia.30   
 
Primary Causes of Hyperlipidemia 
Hyperlipidemia is a lipid abnormality with genetic or familial origins (primary 
hyperlipidemia).  Hyperlipidemia could also be caused by endocrine, hepatic or renal 
diseases (secondary hyperlipidemia).  Primary hyperlipidemia includes familial or 
polygenic hypercholesterolemia, familial combined hyperlipidemia, familial 
hypertriglyceridemia, and dysbetalipoproteinemia.31,32  Different forms of hyperlipidemia  
                                                 
29 Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-
density lipoprotein cholesterol levels in treatment-eligible United States adults. American 
Journal of Cardiology. 1998;82(1):61-65. 
30 Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III 
guidelines for primary prevention lipid-lowering drug therapy: projected impact on the 
size, sex, and age distribution of the treatment-eligible population. Circulation. 
2002;105(2):152-156. 
31 Grundy SM, Vega GL, Garg A. Use of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors in various forms of dyslipidemia. American Journal of Cardiology. 
1990;66(8):31B-38B. 
32 Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of 
statins. American Journal of Cardiology. 1998;82(4B):3J-10J. 
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can be classified based on the Fredrickson classification of lipoprotein phenotype.33 
Primary hyperlipidemia occurs due to abnormalities in gene encoding of LDL receptors 
which causes a decrease in the functioning of LDL receptors.  This leads to an increase in 
the LDL concentration since the major pathway of the removal of LDL is via LDL 
receptors in the liver cells.  Increased production of very low-density lipoprotein 
(VLDL), which is the precursor to LDL, could also result in elevated LDL concentration.  
In addition to genetic factors, diet can be a significant factor contributing to 
hyperlipidemia.34   
 
Secondary Causes of Hyperlipidemia 
Secondary hyperlipidemia occurs as a complication of conditions such as diabetes 
where poor control of glucose levels could lead to elevated triglyceride levels.  Other 
medical conditions associated with hyperlipidemia include hypothyroidism, liver disease, 
and Cushing’s syndrome.35  In addition, use of alcohol and drugs such as corticosteroids, 
thiazide diuretics, estrogen and beta-blockers have also been associated with 
hyperlipidemia.   
 
                                                 
33 Grundy SM, Vega GL, Garg A. Use of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors in various forms of dyslipidemia. American Journal of Cardiology. 
1990;66(8):31B-38B. 
34 Grundy SM. Cholesterol and coronary heart disease:  A new era. Journal of the 
American Medical Association. 1986;256(20):2849-2858. 
35 Chin-Dusting JP, Shaw JA. Lipids and atherosclerosis: clinical management of 
hypercholesterolaemia. Expert Opinion on Pharmacotherapy. 2001;2(3):419-430. 
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Formation of Atherosclerosis 
Hyperlipidemia plays a central role in the development of atherosclerotic plaque 
that impairs arterial blood flow and could lead to arterial obstruction and myocardial 
infarction in coronary vessels.36  The initial development of atherosclerosis occurs due to 
the deposition of cholesterol in the arteries forming “fatty streaks” on the endothelial 
surface of the aorta and coronary arteries.  The advancement of atherosclerosis is 
depicted by development of fibrous plaque.37  Several other processes involved in the 
development and growth of atherosclerosis including oxidation of LDL, enzyme activity, 
inflammation, intimal thickening and plaque formation, vascular dysfunction and plaque 
instability and eventually plaque rupture may result in thrombosis or infarction.38  Plaque 
rupture or erosion is responsible for most acute coronary syndromes including 
myocardial infarction, unstable angina and coronary death.39  
Oxidized LDL is capable of initiating abnormal arterial wall activation processes 
that lead to vascular dysfunction.40  LDL consists of various subspecies that differ in their 
association with cardiovascular risk.  LDL particles that are small and dense have greater 
                                                 
36 Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of 
statins. American Journal of Cardiology. 1998;82(4B):3J-10J. 
37 Chin-Dusting JP, Shaw JA. Lipids and atherosclerosis: clinical management of 
hypercholesterolaemia. Expert Opinion on Pharmacotherapy. 2001;2(3):419-430. 
38 Selwyn AP, Kinlay S, Ganz P. Atherogenesis and ischemic heart disease. American 
Journal of Cardiology. 1997;80(2):3H-7H. 
39 Libby P, Schoenbeck U, Mach F, et al. Current concepts in cardiovascular pathology: 
The role of LDL cholesterol in plague rupture and stabilization. American Journal of 
Medicine. 1998;104(2A):14S-18S. 
40 Selwyn AP, Kinlay S, Ganz P. Atherogenesis and ischemic heart disease. American 
Journal of Cardiology. 1997;80(2):3H-7H. 
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oxidative susceptibility than the larger and buoyant particles.41  Smaller and denser LDL 
particles are associated with up to a threefold increase in the risk of myocardial infarction 
than larger, buoyant LDL particles.42  The management of hyperlipidemia is crucial in 
order to prevent CHD, and to do so, it is important to understand the risk factors 
associated with hyperlipidemia.  
 
Risk Factors for Hyperlipidemia 
A number of risk factors have been associated with the occurrence of CHD.  
Important risk factors include high levels of LDL and triglycerides, low levels of HDL, 
increasing age, male gender, presence of conditions such as diabetes and hypertension, 
obesity, smoking status, and family history of CHD.  A brief explanation of each of the 
risk factors is as follows. 
 
LDL, HDL and Triglycerides  
High levels of LDL and triglycerides and low levels of HDL are important risk 
factors for the development of CHD.  LDL accounts for most of the association between 
plasma cholesterol levels and risk of CHD since most of the plasma cholesterol is  
                                                 
41 Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced 
antioxidant content of metabolic precursors of small, dense low-density lipoproteins. 
American Journal of Medicine. 2001;110(2):103-110. 
42 Austin M, Breslow J, Hennekens CH, et al. Low-density lipoprotein subclass patterns 
and risk of myocardial infarction. Journal of the American Medical Association. 
1988;260(13):1917-1921. 
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transported in the LDL.  Studies such as the Framingham Heart Study, 43,44 the MRFIT,45 
and the LRCPPT46,47 have shown a positive association between LDL cholesterol levels 
and  the risk of CHD among men and women initially free of CHD. 
Epidemiologic studies such as the Framingham Heart Study have established a 
negative association between HDL cholesterol levels and the occurrence of CHD.48,49 
Results from the Framingham study showed that HDL cholesterol had an inverse 
association with the incidence of CHD in both men and women (p<0.001). A one percent 
rise in HDL was associated with a two percent fall in CHD risk.50  The incidence of CHD 
was eight times more in individuals with HDL cholesterol below 35 mg/dl than in those 
                                                 
43 Castelli WP. Cholesterol and lipids in the risk of coronary heart disease: the 
Framingham Heart Study. Canadian Journal of Cardiology. 1988;4(suppl 1):5A-10A. 
44 Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. 
The Framingham Study. Annals of Epidemiology. 1992;2(1-2):23-28. 
45 Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk 
of premature death from coronary heart disease continuous and graded? Findings in 
356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). 
Journal of the American Medical Association. 1986;256(20):2823-2828. 
46 Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary 
Prevention results. I: Reduction in the incidence of coronary heart disease. Journal of the 
American Medical Association. 1984;251(3):351-364. 
47 Lipid Research Clinics Program Group. The Lipid Research Clinics Coronary Primary 
Prevention Trial results. II. The relationship of reduction in incidence of coronary heart 
disease to cholesterol lowering. Journal of the American Medical Association. 
1984;251(3):365-374. 
48 Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective 
factor against coronary heart disease: the Framingham Study. American Journal of 
Medicine. 1977;62(5):707-714. 
49 Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and 
lipoprotein cholesterol levels. The Framingham Study. Journal of the American Medical 
Association. 1986;256(20):2835-2838. 
50 Castelli WP. Cholesterol and lipids in the risk of coronary heart disease: the 
Framingham Heart Study. Canadian Journal of Cardiology. 1988;4(suppl 1):5A-10A. 
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with HDL levels 65 mg/dl or above.51  A review of trials by Boden, showed that a 
number of studies such as the CPPT, MRFIT, the Lipid Research Clinics Follow-up 
Study (LRCF), the Helsinki Heart Study and Air Force/Texas Coronary Atherosclerosis 
Prevention Study (AFCAPS/TexCAPS) have also shown a similar inverse relationship 
between HDL cholesterol and the risk of CHD.52  
In addition to LDL and HDL, triglycerides also contribute as a risk factor for 
CHD.  In the Framingham Heart Study, triglyceride was an independent risk factor for 
CHD.53  Based on a meta-analysis of 17 population-based prospective studies by 
Hokanson and Austin, elevated triglyceride was associated with a 30 percent and 75 
percent increase in cardiovascular risk in men and women, respectively.54  Triglycerides 
in conjunction with other risk factors such as high LDL levels and low HDL levels 
contribute as strong predictors for the development of CHD.55  
 
                                                 
51 Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective 
factor against coronary heart disease: the Framingham Study. American Journal of 
Medicine. 1977;62(5):707-714. 
52 Boden WE. High-density lipoprotein cholesterol as an independent risk factor in 
cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs 
High-Density Lipoprotein Intervention Trials. American Journal of Cardiology. 
2000;86(suppl 12A):19L-22L. 
53 Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. 
The Framingham Study. Annals of Epidemiology. 1992;2(1-2):23-28. 
54 Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular 
disease independent of high-density lipoprotein cholesterol level: a meta-analysis of 
population-based prospective studies. Journal of Cardiovascular Research. 
1996;3(2):213-219. 
55 Sprecher DL. Triglyceride as a risk factor for coronary artery disease. American 
Journal of Cardiology. 1998;82(2):49U-56U. 
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Diabetes 
Epidemiologic studies have shown an increased risk of CHD for diabetic patients 
as compared to non-diabetics.  The mortality rates for CHD in diabetic subjects are 
higher than in non-diabetic subjects.  The average annual age-adjusted incidence of CHD 
per 1000 is 24.8 among diabetic men compared to 14.9 among non-diabetic men. 
Similarly, the incidence of CHD is 17.8 among diabetic women compared to 6.9 among 
non-diabetic women.56  The effect of diabetes on cardiovascular mortality and morbidity 
is higher for women as compared to men.  Low HDL levels in women in the presence of 
diabetes put women at a higher risk for CHD compared to men.57 
 
Hypertension 
Hypertension is a major independent risk factor for CHD.  Observational studies 
have demonstrated a strong association between high blood pressure and CHD.  This 
association holds true for both genders and younger as well as older persons.58,59   
 
                                                 
56 Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for 
cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120-126. 
57 Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for 
cardiovascular disease: the Framingham study. Diabetes Care. 1979;2(2):120-126. 
58 Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and 
cardiovascular risk.  US population data. Archives of Internal Medicine. 
1993;153(5):598-615. 
59 Franklin S, Khan S, Wong ND, et al. Is pulse pressure useful in predicting risk for 




Obesity is an important risk factor for CHD in both men and women.60,61  Effects 
of obesity on lipid metabolism are mediated by insulin resistance.62  Obesity and insulin 
resistance are both strong predictors of CHD risk.63  A high prevalence of cardiovascular 
risk factors such as hypertension, glucose intolerance, hypertriglyceridemia, high total 
cholesterol and LDL cholesterol and low serum HDL cholesterol among obese patients 
increases the risk for CHD.64,65  
 
Age and Gender 
Advancing age and male sex are risk factors for CHD.  The risk for older people 
is higher than in younger people at any given level of LDL cholesterol.  Men in their  
mid-forties (> 45 years) and women around the time of menopause (> 55 years) are at a 
                                                 
60 Denke MA, Sempos CT, Grundy S. Excess body weight: an underrecognized 
contributor to high blood cholesterol levels in white American men. Archives of Internal 
Medicine. 1993;153(9):1093-1103. 
61 Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of 
coronary heart disease in women. New England Journal of Medicine. 1990;322(13):882-
889. 
62 Carmena R, Ascaso JF, Real JT. Impact of obesity in primary hyperlipidemias. 
Nutrition Metabolism & Cardiovascular Diseases. 2001;11(5):354-359. 
63 Abbasi F, Brown B, Lamendola C, et al. Relationship between obesity, insulin 
resistance, and coronary heart disease risk. Journal of the American College of 
Cardiology. 2002;40(5):937-943. 
64 Abbasi F, Brown B, Lamendola C, et al. Relationship between obesity, insulin 
resistance, and coronary heart disease risk. Journal of the American College of 
Cardiology. 2002;40(5):937-943. 
65 Berchtold P, Berger M, Jorgens V, et al. Cardiovascular risk factors and HDL-
cholesterol levels in obesity. International Journal of Obesity. 1981;5(1):1-10. 
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Cigarette smoking is an important risk factor for CHD and other forms of 
cardiovascular diseases.  In the MRFIT, the numbers of cigarettes smoked per day were 
significant predictors of death due to CHD in all age groups in combination with risk 
factors such as high blood pressure and cholesterol.67  Studies have shown that smoking 
cessation was related to a reduction in the risk for cardiovascular events.68,69 
                                                 
66 Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using 
risk factor categories. Circulation. 1998;97(18):1837-1847. 
67 Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and 
death from coronary heart disease. Archives of Internal Medicine. 1992;152(1):56-64. 
68 Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of 
coronary heart disease among women who smoke cigarettes. New England Journal of 
Medicine. 1987;317(21):1303-1309. 
69 Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for 
stroke: the Framingham Study. Journal of the American Medical Association. 
1988;259(7):1025-1029. 
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Family History of Premature CHD 
Several studies have shown that family history of CHD is an independent risk 
factor for CHD.70,71,72,73,74  The risk of CHD increases with an increase in the number of 
first-degree relatives with CHD75 and the onset of the disease at an early age in the 
relative.76  The risk of CHD due to family history is caused by the interaction of genetic 
and environmental factors.77,78 
 
                                                 
70 Shea S, Ottman R, Gabrieli C, et al. Family history as an independent risk factor for 
coronary artery disease. Journal of the American College of Cardiology. 1984;4(4):793-
801. 
71 Hopkins PN, Williams RR, Kuida H, et al. Family history as an independent risk factor 
for incident coronary artery disease in a high-risk cohort in Utah. American Journal of 
Cardiology. 1988;62(10 pt 1):703-707. 
72 Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of 
myocardial infarction and coronary artery disease in men. American Journal of 
Cardiology. 1991;67(11):933-938. 
73 Li R, Bensen JT, Hutchinson RG, et al. Family risk score of coronary heart disease 
(CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) Study 
and the NHLBI Family Heart Study. Genetic Epidemiology. 2000;18(3):236-250. 
74 Yarnell J, Yu S, Patterson C, et al. Family history, longevity, and risk of coronary heart 
disease: the PRIME Study. International Journal of Epidemiology. 2003;32(1):71-77. 
75 Hopkins PN, Williams RR, Kuida H, et al. Family history as an independent risk factor 
for incident coronary artery disease in a high-risk cohort in Utah. American Journal of 
Cardiology. 1988;62(10 pt 1):703-707. 
76 Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of 
myocardial infarction and coronary artery disease in men. American Journal of 
Cardiology. 1991;67(11):933-938. 
77 Li R, Bensen JT, Hutchinson RG, et al. Family risk score of coronary heart disease 
(CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) Study 
and the NHLBI Family Heart Study. Genetic Epidemiology. 2000;18(3):236-250. 
78 Shea S, Ottman R, Gabrieli C, et al. Family history as an independent risk factor for 
coronary artery disease. Journal of the American College of Cardiology. 1984;4(4):793-
801. 
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National Cholesterol Education Program   
The National Cholesterol Education Program (NCEP) of the National Institute of 
Health provides updates and recommendations for cholesterol testing and management.  
In May 2001, the Third Report on the Detection, Evaluation and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel III or ATP III) was released by the 
NCEP.  The ATP III guidelines were preceded by ATP I guidelines released in 1988 and 
ATP II guidelines released in 1993.  The core of ATP III guidelines is based on ATP I 
and II.  The ATP I guidelines outlined a strategy for primary prevention of CHD in 
individuals with high or borderline high LDL cholesterol and multiple risk factors.  ATP 
II guidelines focused both on the primary and secondary prevention of CHD.  Based on 
the results from recent clinical trials, ATP III calls for a more intensive LDL lowering 
and focuses on primary prevention in persons with multiple risk factors.79  Both ATP II 
and ATP III guidelines will be discussed because patients in this study overlapped the 






                                                 
79 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in 
Adults. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical 
Association. 2001;285(19):2486-2497. 
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Adult Treatment Panel II 
As per ATP II guidelines, dietary therapy is recommended as the first line of 
treatment for hyperlipidemia.  Drug therapy is reserved for patients at a high risk for 
CHD.  Patients are classified into three risk factor categories ranging from very high to 
low based on the presence of risk factors and prior CHD event.  ATP II continues to 
identify elevated LDL as the primary target of cholesterol-lowering therapy.  ATP II 
classifies blood cholesterol into three categories which are desirable, borderline and high 
blood cholesterol.80 
 
Table 1.1: Initial Classification of Blood Cholesterol Based on Total Cholesterol Based 
on ATP II Guidelines 
Cholesterol Level Initial Classification 
<200 mg/dl Desirable blood cholesterol 
200-239 mg/dl Borderline-high blood cholesterol 
>240 mg/dl High blood cholesterol 
Adapted from: JAMA 1993;269(23):3015-3023 
 
                                                 
80 Expert Panel on Detection Evaluation and  Treatment of High Blood Cholesterol in 
Adults. Summary of the Second Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel II). Journal of the American Medical 
Association. 1993;269(23):3015-3023. 
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Factors (other than elevated LDL) that increase the risk of CHD as per ATP II include:81  
• Age (men > 45 years; women > 55 years) 
• Family history of premature CHD (definite myocardial infarction or sudden death 
before 55 years of age in father or other male first-degree relative, or before 65 
years of age in mother or other female first-degree relative) 
• Current cigarette smoking 
• Hypertension (> 140/90 mmHg, or on antihypertensive medication) 
• Low HDL cholesterol (< 35 mg/dl) 
 
 
Table 1.2: LDL Cholesterol Goals and Cutpoints for Treatment Decisions Based on 
ATP II Guidelines 
 
Risk Category LDL Goal 
(mg/dl) 
LDL Level at 
Which to Initiate 
Dietary Therapy 
(mg/dl) 
LDL Level at 
Which to Consider 
Drug Therapy 
(mg/dl) 
Without CHD and  
< 2 risk factors 
< 160 > 160 > 190 
Without CHD and ≥ 
2 risk factors 
< 130 > 130 > 160 
With CHD < 100 >100 > 130 
Adapted from: JAMA. 1993;269(23):3015-3023. 
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Adults. Summary of the Second Report of the National Cholesterol Education Program 
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Cholesterol in Adults (Adult Treatment Panel II). Journal of the American Medical 
Association. 1993;269(23):3015-3023. 
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ATP II guidelines recommend dietary therapy in patients with LDL levels of 160 
mg/dl or greater and fewer than two other CHD risk factors or in patients with LDL 
levels above 130 mg/dl and presence of two or more other CHD risk factors.  In patients 
with CHD, dietary therapy should be initiated if LDL levels are greater than 100 mg/dl.  
If the LDL levels do not reach the desired levels with dietary therapy, drug therapy may 
be considered.   
For patients with low HDL levels, the panel recommends physical activity, 
smoking cessation and, in the case of obese patients, weight loss as first line of treatment.  
Drug therapy should be reserved for individuals with high LDL levels in addition to low 
HDL levels.  For younger men and premenopausal women, drug therapy should only be 
considered at very high LDL levels (220 mg/dl) or in the presence of multiple other risk 
factors such as diabetes or family history of premature CHD.  In postmenopausal women 
with high LDL cholesterol levels, the panel recommends considering the use of estrogen 
replacement therapy.  However, the ATP III guidelines are against this recommendation. 
Drug therapy should be considered in patients with LDL levels of 190 mg/dl or 
greater and fewer than two other CHD risk factors or 160 mg/dl or greater in patients 
with two or more CHD risk factors.  In secondary prevention patients, (i.e. patients with 
prior CHD and/or atherosclerotic disease), drug therapy should be started when LDL 




 After initiating lipid-lowering drug therapy, LDL levels should be measured at 
four to six weeks and then at three months.  If patients achieve the LDL goals then they 
should be seen every four months to monitor their response to the drug as well as 
potential side effects.  If the initial drug therapy is inadequate, the patient should be 
switched to another drug or combination therapy should be used.  The guidelines 
emphasize the “vigorous efforts at dietary therapy” prior to initiation of drug therapy.  In 
May 2001, the NCEP introduced a new set of guidelines (ATP III) for the management of 
high cholesterol.  The important features of the new guidelines are discussed below.  
 
New Features of ATP III 
The new features of ATP III are summarized as follows.  The following section 
has been adapted from the executive summary of the guidelines in the Journal of the 
American Medical Association.82 
Focus on Multiple Risk Factors 
• Raises persons with diabetes without CHD, most of whom have multiple risk 
factors, to the risk level of CHD risk equivalent  
                                                 
82 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in 
Adults. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical 
Association. 2001;285(19):2486-2497. 
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• Uses Framingham projections of 10-year absolute CHD risk (i.e. the  percent 
probability of having a CHD event in 10 years) to identify certain patients 
with multiple (2+) risk factors for more intensive treatment 
• Identifies persons with multiple metabolic risk factors (metabolic syndrome) 
as candidates for intensified therapeutic lifestyle changes 
Modifications of Lipid and Lipoproteins Classification 
• Identifies LDL cholesterol < 100 mg/dl as optimal. 
• Raises categorical low HDL cholesterol from < 35 mg/dl to < 40 mg/dl 
because the latter is a better measure of a depressed HDL. 
• Lowers the triglyceride classification cutpoints to give more attention to 
moderate elevations. 
Support for implementation 
• Recommends a complete lipoprotein profile (total, LDL and HDL cholesterol 
and triglycerides) as the preferred initial test, rather than screening for total 
cholesterol and HDL alone. 
• Encourages use of plant stanols/sterols and viscous (soluble) fiber as 
therapeutic dietary options to enhance lowering of LDL cholesterol. 
• Presents strategies for promoting adherence to therapeutic lifestyle changes 
and drug therapies. 
• Recommends treatment beyond LDL lowering for persons with triglycerides  
> 200 mg/dl. 
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The following features are shared by ATP II and ATP III guidelines: 
• Continued identification of LDL cholesterol lowering as the primary goal of 
therapy. 
• Consideration of high LDL cholesterol (>160 mg/dl) as a potential target for 
LDL-lowering drug therapy. 
• Emphasis on intensive LDL-lowering therapy in persons with established 
CHD.   
• Identification of three categories of risk for different LDL goals and different 
intensities of LDL-lowering therapy. 
• Identification of three subpopulations, besides middle-aged men, for detection 
of high LDL cholesterol and other lipid risk factors for intervention. 
• Emphasis on weight loss and physical activity to enhance risk reduction in 
persons with elevated LDL cholesterol. 
Based on the above risk factors, ATP III identifies three categories of risk that modify the 
goals of LDL-lowering therapy.  
1. The category with the highest risk consists of CHD and CHD risk equivalent.  
Individuals with risk level of CHD risk equivalent and without established CHD 
will have an absolute, 10-year risk for developing major coronary events equal to 
that of a person with CHD, i.e. > 20 percent per 10 years (i.e., more than 20 in 
100 such individuals will develop CHD or have CHD events within 10 years).  
CHD risk equivalent consists of : 
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• Other clinical forms of atherosclerotic disease (including peripheral 
arterial disease, abdominal aortic aneurysm, and symptomatic carotid 
artery disease). 
• Diabetes (diabetes counts as a CHD risk factor as it confers a high risk of 
new CHD within 10 years, partly due to its association with other multiple 
risk factors). 
• Multiple risk factors that confer a 10-year risk for CHD > 20 percent. 
The LDL cholesterol goal for individuals with CHD or CHD risk equivalents is 
the lowest (< 100 mg/dl). 
2. The second category consists of individuals with multiple (two or more) risk 
factors, in whom 10-year risk for CHD is < 20 percent.  The LDL goal for 
individuals in this category is < 130 mg/dl.  
3. The third category consists of individuals with 0-1 risk factor.  Most persons in 
this category have a 10-year risk for CHD of less than 10 percent.  The LDL 
cholesterol goal is < 160 mg/dl. 












Table 1.3: LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes 
and Drug therapy in Different Risk Categories Based on ATP III 
 
Risk Category LDL Goal 
(mg/dl) 
LDL Level at 




LDL Level at 
Which to Consider 
Drug Therapy 
(mg/dl) 
CHD or CHD 
equivalents (10-year 
risk > 20%) 
< 100 > 100 > 130 
(100-129: drug 
optional) 
2 + Risk Factors 
(10-year risk            
< 20%) 
< 130 > 130 10-year risk 10-
20%: > 130 
10-year risk < 10%: 
> 160 




Adapted from: JAMA 2001; 285(19):2486-97 
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The ATP III guidelines present the following algorithm for the use of drug therapy for  
primary prevention of CHD.   
 























higher dose of 
statin or  
Add bile acid 
sequestrant or 
nicotinic acid 
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Management of Hyperlipidemia 
The two main approaches to the management of hyperlipidemia are lifestyle 
modification such as dietary intervention and/or lipid-lowering drugs. 
 
Dietary Management of Hyperlipidemia 
Dietary management is the initial step of therapeutic lifestyle changes for the 
management of hyperlipidemia.  In most cases, diet management should be initiated prior 
to drug therapy.  ATP III recommends the reduced intake of saturated fats and cholesterol 
and increased intake of agents such as plant stanols/sterols and increased soluble fiber for 
the lowering of LDL levels.83  Diet can also help control CHD risk factors such as 
obesity, hypertension and diabetes.  In addition to diet therapy, weight reduction and 
increased physical activity are also recommended as a part of therapeutic lifestyle 
changes for the management of hyperlipidemia.84 
 
                                                 
83 Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in 
Adults. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical 
Association. 2001;285(19):2486-2497. 
84 Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. 
Journal of Clinical Endocrinology & Metabolism. 2003;88(6):2445-2461. 
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Pharmacological Management of Hyperlipidemia 
A portion of patients with a high-risk for CHD will require lipid-lowering drugs 
in addition to dietary therapy.  The major drugs used in the treatment of hyperlipidemia 
include fibrates, bile acid sequestrants, nicotinic acid derivatives, estrogen replacement 
therapy and statins.  The following section provides an overview of each of drugs used in 
the treatment of hyperlipidemia.   
 
Fibrates 
Fibric acid derivatives (fibrates) are used in adjunct with dietary modification in 
adults with primary hyperlipidemia or mixed dyslipidemias. Currently, in the U.S. there 
are two fibrates available: gemfibrozil and fenofibrate.  The main indication for fibrates is 
reduction of triglycerides.  The LDL lowering effects of fenofibrates range between 15 to 
20 percent when triglycerides are not elevated.  However, in persons with 
hypertriglyceridemia, fibrates are known to increase LDL-cholesterol levels.85  Fibrates 
decrease triglyceride levels by 25-50 percent and increase the HDL cholesterol levels by 
10-35 percent.86  Fenofibrates decreased the triglycerides and VLDL-cholesterol levels 
by 38 percent, total cholesterol by 17 percent and LDL by 20 percent, and increased HDL 
                                                 
85 Knopp RH, Brown WV, Dujovne CA, et al. Effects of finofibrate on plasma 
lipoproteins in hypercholesterolemia and combined hyperlipidemia. American Journal of 
Medicine. 1987;83(5):50-59. 
86 Leaf DA, Connor WE, Illingworth DR, et al. The hypolipidemic effects of gemfibrozil 
in type V hyperlipidemia: a doube-blind, crossover study. Journal of the American 
Medical Association. 1989;262(22):3154-3160. 
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by 11 percent.87  Fibrates mainly act by increasing the lipoprotein lipase activity which 
increases fatty acid oxidation thereby reducing the formation of triglycerides.88  Fibrates 
also cause reduction in the size of the LDL particles which result in an increased 
resistance of LDL to oxidation.89  
Gemfibrozil therapy reduces in the risk of cardiovascular events mainly due to an 
increase in HDL levels and a decrease in triglycerides among secondary prevention 
patients.  In a double-blind trial of 2531 men with CHD, a 24 percent reduction in death 
due to CHD, non-fatal myocardial infarction and stroke was observed in the gemfibrozil 
group compared to the placebo group.90  In the Helsinki Heart Study, gemfibrozil 
treatment was associated with a 37 percent reduction in fatal and non-fatal myocardial 
infarctions.91 Fibrates are generally well-tolerated; however, gastrointestinal 
complications are common side effects of this drug class.  They appear to increase the 
                                                 
87 Knopp RH, Brown WV, Dujovne CA, et al. Effects of finofibrate on plasma 
lipoproteins in hypercholesterolemia and combined hyperlipidemia. American Journal of 
Medicine. 1987;83(5):50-59. 
88 Schwandt P. Fibrates and triglyceride metabolism. European Journal of Clinical 
Pharmacology. 1991;40 (suppl 1):S41-S43. 
89 Staels B, Dallongeville J, Auwerz J, et al. Mechanism of action of fibrates on lipid and 
lipoprotein metabolism. Circulation. 1998;98(19):2088-2093. 
90 Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of 
coronary heart disease in men with low levels of high-density lipoprotein cholesterol. 
New England Journal of Medicine. 1999;341(6):410-418. 
91 Frick M, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with 
Gemfibrozil in middle-aged men with dyslipidemia. Journal of the American Medical 
Association. 1987;317(20):1237-1245. 
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lithogenecity of bile acids and thus, increase the likelihood of the formation of cholesterol 
gallstones.92 
 
Bile acid resins  
Bile acid resins include cholestyramine, colestipol, and colesevelam.  The main 
action of bile acids resins is to lower LDL cholesterol.  They act by binding bile acids in 
the intestine thereby promoting excretion of bile acids in the feces.  Bile acids are formed 
in the liver from the degradation of cholesterol.  Due to the depletion of bile acids, their 
hepatic synthesis is increased.  An increased amount of cholesterol is transported to the 
liver for the production of bile acids which results in a decrease in intrahepatic 
cholesterol.93  Bile acid sequestrants reduce LDL cholesterol by 20 percent and 
triglycerides levels by 5-20 percent.  In the Lipid Research Clinics Coronary Primary 
Prevention Trial, treatment with cholestyramine reduced the risk of CHD.94,95    
                                                 
92 Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. American 
Journal of Medicine. 1987;83(suppl 5B):37-43. 
93 Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering 
drugs. Cardiology. 1989;76(suppl 1):65-74. 
94 Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary 
Prevention results. I: Reduction in the incidence of coronary heart disease. Journal of the 
American Medical Association. 1984;251(3):351-364. 
95 Lipid Research Clinics Program Group. The Lipid Research Clinics Coronary Primary 
Prevention Trial results. II. The relationship of reduction in incidence of coronary heart 
disease to cholesterol lowering. Journal of the American Medical Association. 
1984;251(3):365-374. 
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Bile acids are often poorly tolerated due to side effects such as bloating, 
abdominal discomfort, nausea and constipation.96 Moreover, when taken concurrently, 
they inhibit the absorption of drugs such as digitalis glycosides, thiazides diuretics, beta-
blockers, warfarin, and exogenous thyroid hormones.97  Another disadvantage of bile acid 
sequestrants includes an increase in triglyceride concentrations in some patients.  
Addition of statins to the bile acid therapy can inhibit this activity.98  Colesevelam is a 
newer bile acid sequestrant currently launched in the U.S. which has fewer side effects 
than the other bile acids.99 
 
Nicotinic Acid 
Nicotinic acid or niacin inhibits the transport of free fatty acids from peripheral 
tissues to the liver.  This leads to the reduction in the hepatic synthesis of triglycerides 
and the hepatic secretion of very low density lipoprotein.  It may also limit the conversion 
of VLDL to LDL.  Nicotinic acid can increase the HDL levels by up to 30 percent.100  
                                                 
96 Chin-Dusting JP, Shaw JA. Lipids and atherosclerosis: clinical management of 
hypercholesterolaemia. Expert Opinion on Pharmacotherapy. 2001;2(3):419-430. 
97 Cziraky M. Clinical positioning of HMG-CoA reductase inhibitors in lipid 
management protocols. Pharmacoeconomics. 1998;14(suppl 3):29-38. 
98 Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering 
drugs. Cardiology. 1989;76(suppl 1):65-74. 
99 Steinmetz K. Colesevelam hydrochloride. American Journal of Health System 
Pharmacy. 2002;59(10):932-939. 
100 Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine. 
1999;341(7):498-411. 
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Studies have shown decreased risk in total mortality101 and morbidity from CHD102 in 
patients treated with niacin.    
The use of niacin in combination with statin therapy has been cautioned due to 
case reports of the occurrence of myopathy.103  The major side-effect of nicotinic acid is 
flushing of the skin.  Other side-effects are conjunctivitis, nasal stuffiness, diarrhea and 
itching.104  A new extended-release preparation of niacin (Niaspan®) has shown to have 
fewer side effects of vasodilatory skin reaction than the usual preparations.105 
 
Estrogen Replacement Therapy 
The use of estrogen replacement therapy (ERT) to reduce the risk of CHD in 
postmenopausal women have been subject to mixed results.106  Some observational and 
randomized trials have shown beneficial effects of ERT on CHD.  O’Keefe et al., showed 
that ERT improved the overall survival of postmenopausal women following the first 
episode of percutaneous transluminal coronary angioplasty (PTCA) compared with 
                                                 
101 Canner P, Berge K, Wenger N, et al. Fifteen year mortality in Coronary Drug Project 
patients: long-term benefit with niacin. Journal of the American College of Cardiology. 
1986;8(6):1245-1255. 
102 Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart 
disease. Journal of the American Medical Association. 1975;231(4):360-381. 
103 Reaven P, Witztum J. Lovastatin, nicotinic acid and rhabdomylosis. Annals of Internal 
Medicine. 1988;109(7):597-598. 
104 Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine. 
1999;341(7):498-411. 
105 Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing 
of extended-release niacin alone and in combination for hypercholesterolemia. American 
Journal of Cardiology. 1998;82(6):737-743. 
106 Khan S, Malhotra S. Effect of hormone replacement therapy on cardiovascular 
disease: current opinion. Expert Opinion on Pharmacotherapy. 2003;4(5):667-674. 
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placebo (93 percent vs. 73 percent).107  In the Nurses’ Health Study, 2489 women with a 
history of CHD showed an increase in relative risk for major CHD to 1.25 (95% 
Confidence Interval (CI): 0.78 - 2.00) with use of ERT.  However, after long-term 
hormone use, the rate of CHD events was lower in patients on hormone therapy 
compared with those who had never used hormone therapy (RR=0.38, 95% CI: 0.22-
0.66).108  Based on two meta-analyses conducted by Barrett-Connor and Grady et al. 
hormone therapy lowered the incidence of cardiovascular diseases  among  users by 35 
percent.109,110   
Some studies such as the Women’s Health Initiative Trial showed an increased 
risk of stroke by 37 percent in women who were part of the estrogen plus progestin group 
compared to those who had never been on hormone therapy.  The study concluded that 
estrogen plus progestin increased the risk of stroke in postmenopausal women who were 
in general in good health.111  Recently published results recommend against the 
                                                 
107 O'Keefe J, Kim SC, Hall R, et al. Estrogen replacement therapy after coronary 
angioplasty in women. Journal of the American College of Cardiology. 1997;29(1):1-5. 
108 Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin 
use and the risk of cardiovascular disease. New England Journal of Medicine. 
1996;335(7):453-461. 
109 Barrett-Connor E. Postmenopausal estrogen and heart disease. Atherosclerosis. 
1995;118(suppl):S7-10. 
110 Grady D, Rubin S, Petitti D, et al. Hormone therapy to prevent disease and prolong 
life in post-menopausal women. Annals of Internal Medicine. 1992;117(12):1016-1037. 
111 Smoller-Wassertheil S, Hendrix S, Limacher M, et al. Effect of estrogen plus 
progestin on stroke in postmenopausal women: The Women's Health Initiative: A 
randomized trial. Journal of the American Medical Association. 2003;289(20):2673-
2684. 
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prescribing of hormone replacement therapy for protection against cardiovascular 
disease.112 
Similarly, the Heart and Estrogen/Progesterone Replacement Study (HERS) 
concluded that ERT did not lower the risk of CHD among postmenopausal women.113 
Furthermore, an additional follow up of the women in the HERS study for 6.8 years 
showed no reduction in the risk of cardiovascular disease and advised against the use of 
hormone therapy to reduce the risk of CHD events.114  Hormone therapy also failed to 
show a significant effect on the progression of atherosclerosis.115,116   The ATP III does 
not favor the use of HRT in the prevention of CHD in postmenopausal women.117    
 
                                                 
112 Manson J, Hsia J, Johnson K, et al. Estrogen plus progestin and the risk of coronary 
heart disease. New England Journal of Medicine. 2003;349(6):523-534. 
113 Hulley S. Randomized trial of estrogen plus progestin for secondary prevention of 
coronary heart disease in postmenopausal women. Journal of the American Medical 
Association. 1998;280(7):605-613. 
114 Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 
years of hormone therapy: Heart and estrogen/progestin replacement study follow-up 
(HERS-II). Journal of the American Medical Association. 2002;288(1):49-57. 
115 Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of 
coronary-artery atherosclerosis in postmenopausal women. New England Journal of 
Medicine. 2003;349(6):535-545. 
116 Herrington D, Reboussin D, Brosnihan K, et al. Effects of estrogen replacement on the 
progression of coronary-artery atherosclerosis. New England Journal of Medicine. 
2000;343(8):522-529. 
117 Grundy SM, Becker DM, Clark L, et al. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal 
of the American Medical Association. 2001;285(19):2486-2497. 
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Statins 
Statins, also known as 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) 
reductase inhibitors, are the most commonly prescribed medications for hyperlipidemia 
and are recommended as first line therapy under ATP III guidelines.  Currently there are 
six statins available in the U.S. market.  The earlier statins, lovastatin (Mevacor® by 
Merck marketed in 1987) and pravastatin (Pravachol® by Bristol-Myers Squibb, 
marketed in 1991), were isolated from fungal cultures.  Simvastatin (Zocor® by Merck 
marketed in 1992) is a semi-synthetic derivative whereas fluvastatin (Lescol® by 
Novartis, marketed in 1992) was the first entirely synthetic compound.  A new generation 
of synthetic statins include atorvastatin (Lipitor® by Parke-Davis, marketed in 1996) and 
the most recent rosuvastatin (Crestor® by AstraZeneca, marketed in 2003).  Cerivastatin 
(Baycol® by Bayer, marketed in 1998), a synthetic statin, was withdrawn from the market 
in 2001 due to the occurrence of fatal rhabdomylosis.   
According to data compiled by IMS Health, in 2003, cholesterol and triglyceride 
reducers, of which statins make up a vast majority, comprised the world’s second largest 
therapy class with sales of $16 billion.118  The two top selling statins, Lipitor® and 
Zocor®, were the top selling drugs in 2003, accounting for $12.5 billion in sales.119      
                                                 
118 Are statins wonder drugs. IMS Health. URL: http://www.ims-
global.com/insight/news_story/0104/news_story_010404.htm Accessed on 10/1/2003. 
119 Barrett A. A bare-knuckle battle over cholesterol drugs. Business Week Online; 2003. 
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Statins have proven to be effective in the treatment of various forms of 
hyperlipidemia.120  Statins act by inhibiting the synthesis of cholesterol.  They do so by 
inhibiting the HMG-CoA reductase enzyme that acts as a catalyst in the synthesis of 
cholesterol.121  The reduction in the hepatocyte cholesterol concentration leads to an 
increased number of LDL receptors which increases the clearance of LDL from the 
circulation.122  In addition to this, statins reduce the production and secretion of 
lipoproteins.123  Depending upon the statin and the dose administered, LDL reduction 
ranges from 18-55 percent.  The increase in HDL levels range from 5-10 percent, 
whereas the decrease in triglycerides ranges from 7-30 percent.124  
 
                                                 
120 Grundy SM, Vega GL, Garg A. Use of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors in various forms of dyslipidemia. American Journal of Cardiology. 
1990;66(8):31B-38B. 
121 Shepherd J. The statin era: in search of the ideal lipid regulating agent. Heart. 
2001;85(3):259-264. 
122 Grundy S. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New 
England Journal of Medicine. 1988;319(1):24-33. 
123 Slater E, MacDonald J. Mechanism of action and biological profile of HMG-CoA 
reductase inhibitors: a new therapeutic alternative. Drugs. 1988;36(suppl 3):72-82. 
124 Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin 
versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with 
hypercholesterolemia (the CURVES study). American Journal of Cardiology. 
1998;81(5):582-587. 
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Comparison of statins 
Statins differ in their ability to lower the LDL levels.  Knopp et al. compared the 
properties of six statins available in 1999 in the U.S. (Table 1.4).125  In addition, 
information on rosuvastatin obtained from the package insert has been inserted in Table 
1.4.  For all six statins, the dose-response relationship was curvilinear. Doubling the dose 
above the minimal effective dose decreased the LDL levels by an additional six percent.  
The maximum reduction in LDL concentration ranged from 24 to 60 percent.126  The 
comparison of the effect of different statins on the lipid and lipoprotein levels is shown in 
Table 1.5.127  
Rosuvastatin is the newest statin launched in the later half of 2003.  Rosuvastatin 
has been shown to reduce the LDL cholesterol levels by up to 63 percent.  Data from five 
randomized, double-blind, parallel-group, comparator-controlled trials were pooled to 
compare the efficacy of rosuvastatin 5 mg and 10 mg with atorvastatin 10 mg, 
simvastatin 20 mg and pravastatin 20 mg.  Both doses of rosuvastatin were significantly 
associated with greater reduction in LDL levels than atorvastatin (p<0.001), simvastatin 
(p<0.001) and pravastatin (p<0.001).  Rosuvastatin showed consistent efficacy across all 
                                                 
125 Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine. 
1999;341(7):498-411. 
126 Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine. 
1999;341(7):498-411. 
127 Maron DJ, Fazio S, Linton MF. Current Perspectives on Statins. Circulation. 
2000;101(2):207-213. 
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patient subgroups.128,129  Rosuvastatin was more effective than atorvastatin, pravastatin 
and simvastatin in meeting the NCEP ATP III goals.130 
 
 
                                                 
128 Blasetto J, Stein EA, Brown WV, et al. Efficacy of Rosuvastatin compared with other 
statins at selected starting doses in hypercholesterolemic patients and in special 
population groups. American Journal of Cardiology. 2003;91(suppl):3C-10C. 
129 Jones P, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of 
rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR 
Trial). American Journal of Cardiology. 2003;92(2):152-160. 
130 Shepherd J, Hunninghake D, Barter P, et al. Guidelines for lowering lipids to reduce 
coronary artery disease risk: A comparison of Rosuvastatin with Atorvastatin, 
Pravastatin, and Simvastatin for achieving lipid-lowering goals. American Journal of 
Cardiology. 2003;91(suppl):11C-19C. 
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8.6% 12% 12% 6% 8% 10% 10% 
Plasma half-life 
(hr) 
8.6 12 12 6 8 10 19 
Effect of food on 
absorption of drug 




With meals Bedtime Evening Evening Bedtime Evening Anytime 
Penetration of 
CNS 
Yes  No Yes No No Yes No 
Renal excretion of 
absorbed dose (%) 




C-P450 3A4 Sulfation C-P4503A4 C-P4503A4 C-P4502C9 CYP-4503A4 
CYP-450 2C8 
CYP-450 2C9 
a The effect was elicited by a daily dose of 40 mg of lovastatin, pravastatin, simvastatin, atorvastatin, fluvastatin and rosuvastatin in patients with 
hypercholesterolemia 
bIn October 2000, fluvastatin 80 mg/day was approved and the serum LDL cholesterol reduction associated with it is 34-36% 
cInformation obtained from Rosuvastatin package insert, AstraZeneca Pharmaceuticals LP, Wilmington, DE. 2003 
Adapted from: Knopp RH: NEJM 1999;341(7):498-511
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Table 1.5: Comparative Efficacy of The Six  Statins on Lipids and Lipoprotein in Patients Without Hypertriglyceridemia 
 
Statin Drug and Dose (mg) Change in Lipid and Lipoprotein Levels 
Atorvastatin Simvastatin Lovastatin Pravastatin Fluvastatin Cerivastatin Total LDL HDL Triglycerides
--- 10 mg 20 mg 20 mg 40 mg 0.2 mg -22% -27% +4-8% -10-15% 
10 mg 20 mg 40 mg 40 mg 80 mg 0.4 mg -27% -34% +4-8% -10-20% 
20 mg 40 mg 80 mg --- --- --- -32% -41% +4-8% -15-25% 
40 mg 80 mg --- --- --- --- -37% -48% +4-8% -20-30% 
80 mg --- --- --- --- --- -42% -55% +4-8% -25-35% 




Combination therapy  
Combination therapy of statins with other lipid-lowering drugs may be necessary 
in lowering LDL levels in order to attain the NCEP goals.  Bile acids, niacin or fibrates 
are used in combination with statins to achieve the NCEP goals.  However, combination 
therapy needs to be closely monitored due to increased risk of rhabdomylosis.131   
Taher et al. conducted a retrospective chart review of 136 patients on combination 
therapy and found that eight percent of the patients had to discontinue the treatment due 
to the occurrence of muscle pain. However, overall the statin-fibrate and statin-niacin 
combination was safe and well tolerated by most patients.132  The decision to combine 
statin therapy with a fibrate or niacin is often influenced by baseline levels of 
triglycerides and HDL cholesterol. In patients with low-HDL, niacin might be a good 
choice as an add-on therapy whereas when triglycerides are elevated, fibrates are 
effective.133  Newer agents such as ezetimibe (Zetia®, by Schering-Plough Corporation, 
marketed in 2002) can be used in combination with statins.  Ezetimibe is a part of a new 
class of lipid-lowering drugs that are called cholesterol absorption inhibitors.  When 
added to statin therapy, ezetimibe reduced LDL cholesterol by an additional 14 percent 
                                                 
131 Brown AS. Use of combination therapy for dyslipidemia: a lipid clinic approach. 
American Journal of Cardiology. 2002;90(2):44-49. 
132 Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin 
combination therapy in dyslipidemic patients at high risk for cardiovascular events. 
American Journal of Cardiology. 2002;89(4):390-394. 





when used with simvastatin and an additional 12 percent with atorvastatin.  Ezetimibe 
appears to be well tolerated with few side effects.134    
 
Safety of Statins 
Statins are generally well tolerated by most patients, however, the use of statins 
has been associated with myopathy, which is defined as “muscle pain or weakness 
associated with creatine kinase levels higher than 10 times the upper normal limit.”135  
Myopathy occurs more frequently in statins in conjunction with drugs that inhibit the 
cytochrome P450 pathway and in patients with impaired drug metabolism.136  The 
American College of Cardiology/American Heart Association clinical advisory on the use 
and safety of statins put forth four syndromes associated with statin use including statin 
myopathy, myalgia, myositis and rhabdomylosis.137  Statin-associated myopathy is dose 
related. For example, the incidence rate of myopathy increases four to five-fold by 
increasing the dose of simvastatin or atorvastatin from 40 mg to 80 mg.138  Statin  
                                                 
134 Mckenney J. Combination therapy for elevated low-density lipoprotein cholesterol: 
the key to coronary artery disease risk reduction. American Journal of Cardiology. 
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associated rhabdomylosis is rare with an incidence of 0.15 deaths per one million 
prescriptions (of cerivastatin).139  Based on an update of the FDA reports on statin-
associated rhabdomylosis, between the periods of January 1, 1990 through March 31, 
2002, a total of 3339 cases were identified.  Cerivastatin was most often linked with the 
occurrence of rhabdomylosis (57%) followed by simvastatin (18%) and atorvastatin 
(12%).140  Due to increased report of deaths related to rhabdomylosis, cerivastatin was 
eventually withdrawn from the market in 2001.141   
The combination of statins with fibrates appears to be an attractive option due to 
increased LDL lowering compared with monotherapy; however, several case reports have 
been published regarding the occurrence of rhabdomylosis with statin-fibrates 
combination.  As per the reports, the risk levels for statin-gemfibrozil combination 
therapy are much higher than those of a statin and fenofibrate.142  The incidence rates for 
myopathy are lower with the statin-niacin combination than with statin-gemfibrozil 
combination.143  However, the incidence of rhabdomylosis appears to be relatively low in 
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patients who are monitored and when the statin doses are low.144  The risk of 
rhabdomylosis increases with the concomitant use of statins and cyclosporine in heart 
transplant patients.145  Other adverse effects of statins include dyspepsia, gastrointestinal 
disturbances, central nervous system disturbances and sleep disorders and 
headaches.146,147  In summary, patients on high doses of statins and those on combination 
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 CLINICAL EVIDENCE OF CHOLESTEROL LOWERING WITH ANTI-
HYPERLIPIDEMIC DRUGS AND ITS EFFECT ON CHD 
 
Clinical trials of lipid-lowering therapy have demonstrated the relationship 
between serum cholesterol concentrations and CHD risk over a wide range of cholesterol 
values.  These trials have also shown that decreasing cholesterol levels, decreases CHD 
mortality and morbidity, slows the progression of CHD and can lead to the regression of 
atherosclerotic lesions.  The trials are categorized as primary prevention trials, secondary 
prevention trials and angiographic trials.  A description of trials under each category 
follows. 
 
Primary Prevention Trials 
Primary prevention includes treating the risk factors (hyperlipidemia) before they 
cause CHD. Primary prevention trials include patients who are hyperlipidemic but 
without established CHD.  Most of the primary prevention trials (except for 
AFCAPS/TexCAPS) of lipid-lowering agents included middle-aged men with high 
cholesterol levels and no CHD.  The lipid-lowering agents evaluated in the trials included 
bile acid resins, fibrates and statins.  A total of 21,087 were followed for a period ranging 




in LDL levels and triglycerides and an increase in HDL cholesterol levels.  These 
changes in lipid profiles resulted in decreased incidence of CHD.  However, cholesterol 
lowering did not decrease total mortality in most trials and in some trials, this was 
attributed to lack of statistical power to address the mortality issue.  The findings of some 
of the trials are summarized below.  
 
Primary Prevention Trials of Statin Drugs 
 Two primary prevention statin trials have shown beneficial effects of the use of 
these drugs in the primary prevention of CHD.  Below is a brief discussion of the trials. 
  
The West of Scotland Coronary Prevention Study (WOSCOPS) 
 The study was a double-blinded trial in which 6595 men between the ages of 45-
64 years with mean plasma cholesterol levels of 272+23 mg/dl were randomly assigned 
to receive either pravastatin 40mg per day or placebo and were followed for an average 
of five years.  The date of completion of the trial was May 1995.  The average age of the 
patients was 55 years.  The objective of the study was to assess the effect of pravastatin 
on the reduction of combined incidence of non-fatal MI and death from CHD in men with 
hypercholesterolemia and no history of MI.148  Pravastatin lowered the plasma levels of 
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cholesterol by 20 percent, LDL cholesterol by 26 percent, and triglycerides by 12 percent 
whereas HDL cholesterol increased by 5 percent.149 
 A 31 percent reduction in non-fatal MI and death from CHD was observed in the 
pravastatin group as compared with the placebo (95% CI: 17-43%, p<0.001).  Treatment 
with pravastatin was associated with reduced frequency of coronary angiography by 31 
percent (95% CI: 10-47%, p=0.007) and revascularization procedures by 37 percent (95% 
CI: 11-56%, p=0.009).  The authors concluded that treatment with pravastatin reduced 
the incidence of MI and death from CVD in men with hypercholesterolemia.150   
 
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) 
This study was a randomized, double-blinded, placebo-controlled trial of men 
(N=5608) between the ages of 45 to 73 years and postmenopausal women (N=997) 
between the ages of 55 to 73 years with mildly elevated cholesterol levels.151  This trial 
was the first of its kind to assess primary prevention in women and was completed in 
1997.  The objective of the study was to evaluate the efficacy of 20-40 mg of lovastatin 
daily, in decreasing the incidence of first major coronary events.  Treatment with  
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lovastatin reduced the LDL cholesterol by 25 percent and increased HDL cholesterol by 6 
percent.  The risk for first major coronary event was reduced by 37 percent among 
subjects treated with lovastatin.  The benefits of treatment with lovastatin were observed 
across all subgroups including women, subjects above the average age of 58 years, 
diabetics, hypertensives, and those with a family history of CHD.  No statistically 
significant differences were found in the occurrence of CVD and total mortality due to 
low occurrence of these events in the study population.152 
 
Primary Prevention Trials of Other Lipid-Lowering Agents 
 Two trials have evaluated the effect of cholestyramine and gemfibrozil in the 
treatment of primary prevention patients.  Both trials showed a reduction in major 
coronary events associated with the use of the lipid-lowering drugs.  The results of the 
trials have been summarized below. 
 
The Lipid Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) 
In this study, 3,806 middle aged men aged 35 to 59 years with LDL-C level of 
190mg/dl or greater were randomized to receive the lipid-lowering agent cholestyramine 
24mg/day or placebo.  The main aim of the study was to test the efficacy of lowering 
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cholesterol levels for the primary prevention of CHD.153  The trial concluded in 1983 and 
the average period of follow up for the study was 7.4 years.  The cholestyramine group 
showed a decrease in the average plasma total cholesterol and LDL-C reductions of 13.4 
percent  and 20.3 percent respectively, which was 8.5 percent and 12.6 percent greater 
compared to the placebo group (p<0.001).  The combined primary endpoint of definite 
CHD death and/or definite non-fatal myocardial infarction was 19 percent lower in the 
treatment group vs. the placebo.  This study demonstrated that decrease in the incidence 
of CHD was primarily due to the reduction of total cholesterol and LDL cholesterol.154,155 
 
The Helsinki Heart Study  
 The study was conducted in the early 1980s and was a five-year randomized, 
double-blinded, placebo-controlled trial to test the efficacy of the lipid-lowering drug 
gemfibrozil in reducing the risk of CHD.  The mean follow-up period was five years.  A 
total of 4081 middle-aged men with dyslipidemia but initially free of CHD were 
randomized to receive gemfibrozil 600 mg twice daily or placebo along with 
recommendations to follow a cholesterol-lowering diet.  The mean plasma cholesterol 
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level was 244.7 mg/dl and mean age of the subjects was 47.3 years.  LDL cholesterol in 
the treatment group decreased by 10 percent, total cholesterol decreased by 11 percent 
and triglycerides decreased by 43 percent.  There was an increase in HDL cholesterol by 
10 percent.  Cardiac end-points in the gemfibrozil group were reduced overall by 34 
percent (95% CI: 8.2-52.6).  During the study period, the rate of occurrence of cardiac 
endpoints was lower in the gemfibrozil group (27.3 per 1000) compared to the placebo 
(41.4 per 1000) (p<0.02).  No difference in the mortality rates between the two groups 
was observed.  The study showed that treatment with gemfibrozil reduced the incidence 
of CHD in men with dyslipidemia.156 
 
Secondary Prevention Trials 
Secondary prevention includes the modification of risk factors to prevent 
subsequent coronary events in patients with established CHD.  Secondary prevention 
trials include patients who are hyperlipidemic and have established CHD including 
indications for acute myocardial infarction, angina, chronic ischemic heart disease, 
history of percutaneous coronary intervention and coronary artery bypass graft.  The 
trials evaluated lipid-lowering agents such as bile acid resins, fibrates, niacin and statins.  
However, a majority of the trials included statin drugs.  A total of 101,036 patients  
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(62,314 men and 38,722 women) were followed for three to six years except for the 
Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study 
in which the follow-up period was 16 weeks.  Most of the subjects were in their mid-
fifties to mid-sixties however, some trials such as the Long-term Intervention with 
Pravastatin in Ischemic Disease Study (LIPID), Prospective Study of Pravastatin in the 
Elderly at Risk (PROSPER), Heart Protection Study (HPS) and Women’s Health 
Initiative Trial (WHI) included elderly over 70 years of age.  The trials showed that lipid-
lowering drugs (mainly statins) can reduce the occurrence of major coronary events such 
as non-fatal MI and reduce the need for coronary revascularization.  In addition, the trials 
show that lipid-lowering therapy can reduce CHD-related deaths.  Some trials such as the 
HPS, LIPID and the Cholesterol and Recurrent Events (CARE) Study have also shown a 
reduction in the incidence of stroke in patients treated with statins.  Some of the 
secondary prevention trials including statins and non-statin drugs are summarized below. 
 
Secondary Prevention Trials of Statins 
 Eight statin trials have been summarized below.  The statins evaluated in the trials 
include simvastatin, pravastatin, and atorvastatin.  The results provide evidence of the 





The Scandinavian Simvastatin Survival Study (4S) 
 This study was a randomized, double-blinded, placebo-controlled multicenter 
clinical trial of 4,444 subjects (men=3,600; women=844) aged 37-70 years with a history 
of angina pectoris or MI and serum cholesterol of 212-309 mg/dl.  Patients were 
randomly assigned to receive simvastatin or placebo.  The mean age of the patients was 
58.7 years.  The date of completion of the trial was August 1994.  After an average 
follow-up period of 4.7 years, treatment with simvastatin reduced the mean total 
cholesterol by 25 percent, LDL cholesterol by 35 percent, serum triglycerides by 10 
percent and increased HDL cholesterol by 8 percent.  The six-year probability of survival 
in the simvastatin group was higher than in the placebo group (91.3% vs. 87.7%).  The 
relative risk of coronary death and major coronary events was 0.58 (95% CI: 0.46-0.73) 
and 0.66 (95% CI: 0.59-0.75, p<0.00001), respectively.157  In addition, simvastatin 
treatment reduced the risk of major coronary events by 34 percent and revascularization 
procedures by 37 percent.  
The authors estimated that with every one percent reduction in LDL cholesterol, 
level the risk of major coronary events were reduced by 1.7 percent (95% CI: 1.0%-2.4%, 
p<0.00001).  There were no major occurrences of side effects in the simvastatin group.  
The benefits of simvastatin were observed across various subgroups including women, 
subjects 60 year of age or higher, smokers, diabetics and hypertensives.  The authors 
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concluded that long-term treatment with simvastatin was safe and improved survival in 
patients with CHD.158 
 
The Cholesterol and Recurrent Events Study (CARE) 
This study was a double-blinded, placebo-controlled trial of 4,159 subjects 
(men=3,583; women=576) to evaluate the effect of pravastatin on cholesterol reduction 
in patients with acute MI and average cholesterol levels of 209 mg/dl.  The median 
follow-up period for the study was five years and the study was completed in February 
1996. The mean age of the subjects was 59 + 9 years.  Treatment with pravastatin 
reduced the occurrence of CHD related death or non-fatal MI by 24 percent compared to 
the placebo group.   
The incidence of fatal MI reduced by 37 percent whereas the incidence of stroke 
decreased by 31 percent.159  The pravastatin group demonstrated a reduction in total 
serum cholesterol by 20 percent, LDL cholesterol by 32 percent and triglycerides by 14 
percent. The HDL levels increased by five percent.  The relative risk reduction for the 
incidence of all types of stroke in the pravastatin group was 32 percent.160  The authors 
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concluded that treatment with pravastatin led to reduction in coronary events in subjects 
with average cholesterol levels. 
 
Long-term Intervention with Pravastatin in Ischemic Disease Study (LIPID) 
 The LIPID study was a multi-center, randomized, placebo-controlled trial of 
9,014 patients (men=7,498; women=1,516) aged 31 to 75 years (mean age=61 years) 
with a history of acute MI or a diagnosis of unstable angina.  The subjects were 
randomized to receive treatment with pravastatin 40mg/day or placebo and were followed 
for a mean duration of five years.  The date of completion of the trial was September 
1997.  The mean total cholesterol concentration was 220 mg/dl.  Pravastatin reduced the 
risk of occurrence of CHD by 24 percent, risk of total mortality by 23 percent, risk of 
stroke by 20 percent, risk of occurrence of fatal and non-fatal MI by 29 percent and the 
need for coronary artery bypass grafting (CABG) by 24 percent.91  These results were 
independent of baseline lipid levels.  Treatment with pravastatin was associated with a 42 
mg/dl fall in LDL cholesterol and a 2.32 mg/dl rise in HDL cholesterol compared with 
placebo.  The authors concluded that treatment with pravastatin therapy was associated 
with reduced occurrence of coronary events.161  
 Hunt et al. used data from the LIPID trial to further evaluate the effect of 
pravastatin in older patients between ages 65 to 75 years.  Similar effects were observed 
                                                 
161 Simes RJ, Marschner IC, Hunt D, et al. Relationship Between Lipid Levels and 
Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease 
(LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin 




in older patients as those observed among younger patients (31 to 64 years).162  
Pravastatin reduced mortality by 21 percent, CHD death or non-fatal MI by 22 percent, 
stroke by 12 percent, and MI by 26 percent.  The authors concluded that pravastatin 
treatment in older patients reduced the risk for cardiovascular events and mortality.163 
Tonkin et al.164 conducted a substudy of the LIPID trial to study the effect of 
pravastatin on subsequent cardiovascular risks in patients with angina or MI.  Among 
patients treated with placebo, survival for both groups was similar.  Among patients 
treated with pravastatin, the relative risk reduction for mortality was 20.6 percent in the 
MI group and 26.3 percent in the angina group; however, this difference was not 
statistically significant.  Pravastatin reduced all pre-specified coronary endpoints in the 
MI group.  A number of endpoints in the angina group including CHD mortality, total 
mortality, MI, coronary revascularization, number as well as length of hospital 
admissions were significantly lower in the patients treated with pravastatin.  The authors 
concluded that pravastatin provided beneficial effects for patients who have survived 
acute MI or angina. 
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The Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) 
Study 
The study was a multi-center, randomized, double-blinded trial of 3,086 patients 
with unstable angina or non-Q-wave acute MI.  Patients were followed for an average of 
16 weeks to determine if atorvastatin 80 mg/day initiated 24 to 96 hours after an acute 
coronary syndrome reduced ischemic events.  The date of completion of the trial was 
September 1999.  The mean age of the patients was 65 years.  The primary end-point in 
the study was defined as death, non-fatal acute MI, cardiac arrest that needed 
resuscitation, or symptomatic MI that was recurrent in nature and required urgent 
rehospitalization.  Fewer patients in the atorvastatin group experienced a primary event 
compared with placebo (14.8% vs. 17.4 %, p=0.048).  Recurrent symptomatic MI was 
significantly reduced in the atorvastatin group compared with placebo (RR=0.74; 95% 
CI: 0.57-0.95).  However, no significant differences were observed between the placebo 
and the atorvastatin group with respect to death, non-fatal acute MI and cardiac arrest.165   
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The Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT) 
  The study was a multi-center, randomized, non-blinded trial of 10,355 
(men=5,304; women=5,051) hypertensive subjects with moderate hypercholesterolemia 
with at least one other CHD risk factor.  The study concluded in 2002.  Mean age of the 
participants was 66 years and mean cholesterol level was 224 mg/dl.  The subjects were 
randomized to receive either pravastatin 40 mg/day or usual care.  All participants were 
advised to follow a cholesterol lowering diet.  Usual care included regular treatment by 
primary care physicians to lower LDL cholesterol.  At the end of four years of follow up, 
pravastatin treatment lowered the total cholesterol by 17.2 percent and LDL cholesterol 
by 27.7 percent.  No significant differences were found between all cause mortality, 
stroke and the risk for CHD events between the pravastatin and placebo group.  However, 
pravastatin lowered the relative risk of occurrence of CHD events to a greater extent in 
blacks compared with non blacks (RR=0.73 vs. 1.02, p=0.03). 
The authors attributed the lack of difference in outcomes to the similar cholesterol 
levels between the two groups and the non-blinded study design.166  Lack of adherence to 
pravastatin as evidenced by only 70.3 percent of patients still on therapy at the end of six 
years as well as increased crossover to lipid-lowering therapies in the usual care group 
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further explained the reason for insignificant findings.167  The participants in this study 
represented a unique population as almost half of the participants were females, over one 
third were black and over half were at least 65 years of age.  Moreover, this was the first 
trial of its kind conducted exclusively among patients treated for hypertension.168 
 
Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-lowering Arm (ASCOT-LLA) 
 This study was a part of the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) which was a multi-center, randomized, placebo-controlled trial.  In the 
ASCOT-LLA, 10,305 subjects (men=8,363; women=1,942) with treated hypertension 
and with at least three cardiovascular risk factors were randomly assigned to receive 
atorvastatin 10 mg or placebo.  The average follow up period was 3.3 years and the study 
concluded in 2002.  The mean age of the participants was 63 years and mean total 
cholesterol was 213 mg/dl.  At the end of a year of treatment, there was a reduction in 
total cholesterol by 24 percent, LDL cholesterol by 35 percent and triglycerides by 17 
percent  The atorvastatin group showed a reduction in the occurrence of non-fatal MI and 
fatal CHD by 36 percent (95% CI: 0.50-0.83, p=0.0005).  Revascularization procedures 
as well as total coronary events were reduced by 21 percent and 29 percent respectively  
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in the atorvastatin group compared to placebo.  All-cause mortality did not differ 
significantly between the two groups.  The authors concluded that treatment with 
atorvastatin led to a reduction in cardiovascular events in hypertensive subjects with 
average or lower than average cholesterol levels.169 
 
Prospective Study of Pravastatin in the Elderly at Risk (PROSPER)  
 This study was a double-blinded, randomized, placebo-controlled trial to 
determine the efficacy of pravastatin 40 mg/day in the reduction of cardiovascular and 
cerebrovascular events in 2,804 elderly men and 3,000 women between 70 to 82 years of 
age (mean age=75 years) and with vascular disease or at a high risk of developing it.170  
The study concluded in 2002.  Pravastatin reduced LDL cholesterol by 34 percent, 
triglycerides by 12 percent and increased the HDL cholesterol by 5 percent.  Coronary 
events were reduced by 19 percent whereas risk of death due to CHD was reduced by 24 
percent in the pravastatin group.  The risk of CHD death and non-fatal MI was reduced 
(Hazard Ratio=0.81; 95% CI: 0.69-0.94, p=0.006).  Treatment with pravastatin did not 
have any effect on the risk reduction for stroke. The authors concluded that pravastatin 
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reduced the risk of coronary risk in elderly and its use must be promoted to this age group 
of people.171   
 
Heart Protection Study (HPS) 
HPS was a secondary prevention randomized placebo-controlled trial of 20,536 
(men=15,454; women=5,082) adults aged 40-80 years which concluded in 2001.  The 
mean cholesterol level was 228 mg/dl.  Patients were randomized to receive simvastatin 
40 mg or placebo as well as vitamin therapy or placebo in a 2 X 2 factorial design for a 
five-year follow up period.172 The statin group had a significant reduction in vascular 
mortality compared with the placebo group (7.6% vs. 9.1%, death rate ratio: 0.83, CI: 
0.75-0.91, p<0.001).  There was a significant reduction of major coronary events 
including non-fatal MI and coronary death in the simvastatin group vs. the placebo (8.7% 
vs. 11.8%, P<0.001). Similarly, there were significant reduction in the occurrence of non-
fatal stroke or fatal stroke (4.3% vs. 5.7%, p<0.001) and coronary or non-coronary 
revascularization (9.1% vs. 11.7%, p<0.001) among the simvastatin group vs. the placebo 
group.173  The proportional reduction in event rate was observed across all patient 
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subgroups including the elderly, women and those with non-coronary vascular disease.174  
In this study, there was no difference in the reports of myopathy between the two groups.  
The findings of the study suggest that more intensive statin treatment is not associated 
with a marked increase in risk for liver and muscle toxicities.175     
 
Secondary Prevention Trials of Other Lipid-lowering drugs 
 Five trials have been summarized below which include lipid-lowering drugs other 
than statins such as bezafibrate, gemfibrozil, niacin, clofibrate and estrogen plus 
progestin therapy.  Gemfibrozil reduced the occurrence of major coronary events in the 
patients.  A long-term benefit of niacin was observed in reducing mortality of study 
subjects.  However, bezafibrate, clofibrate and hormone replacement therapy failed to 
show a significant effect on coronary outcomes in the patients treated with these drugs.   
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The Bezafibrate Infarction Prevention (BIP) Study 
 This study was a randomized, double-blinded, placebo-controlled trial conducted 
in Israel.  The main aim of the study was to evaluate the efficacy of bezafibrate treatment 
in the reduction of CHD mortality and non-fatal MI in 3,090 patients (men=2,825; 
women=265) with a mean age of 60 years and low HDL cholesterol and moderately 
elevated total cholesterol levels.  The subjects were followed for a mean period of 6.2 
years and the study concluded in 1999.  The mean total cholesterol level was 212 mg/dl.  
Patients were randomized to receive either 400 mg of bezafibrate or placebo once a day.   
The bezafibrate group showed an increase of HDL cholesterol by 18 percent and a 
decrease in triglycerides by 21 percent.  The rate of occurrence of primary endpoint (non-
fatal and fatal MI and sudden death) was 13.6 percent and 15.0 percent in the treatment 
and the placebo group, respectively (p=0.26).  At the end of 6.2 years, the cumulative 
probability of primary endpoint was reduced by 7.3 percent.  Rates for non-cardiac and 
cardiac mortality did not differ between the groups.  A post-hoc subgroup analysis of 
patients with hypertriglyceridemia revealed a significant reduction in coronary events by 
39.5 percent.  The authors concluded that bezafibrate treatment was effective in elevating 
HDL cholesterol and decreasing triglyceride levels and there was an overall reduction of 
clinical endpoints, though it was not statistically significant.176 
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Veterans Affairs HDL Cholesterol Intervention Trial (VA-HIT) 
 This study was a randomized, placebo-controlled trial conducted at 20 Veterans 
Affairs Medical Centers in the mid-1990s.  The main aim of the study was to determine 
the effect of lipid-lowering therapy in the reduction of the incidence of CHD and non-
fatal MI in men with low levels of HDL cholesterol and with “desirable” levels of LDL 
cholesterol.177  A total of 2,531 men aged less than 73 years and with a mean HDL 
cholesterol of 32mg/dl and total cholesterol of 175mg/dl were randomized to receive 
1200 mg of gemfibrozil or placebo daily.  The subjects were followed for a period of 
approximately six years.  The mean age of the patients was 64 years.  In patients treated 
with gemfibrozil, there was an increase in HDL levels by 6 percent, a decrease in 
triglycerides by 31 percent and no change in LDL levels.  A 22 percent reduction in the 
relative risk in the time to first non- fatal MI or CHD death was observed in the 
gemfibrozil group (95% CI: 7-35, p=0.006).  This study was the first of its kind to show 
that raising HDL levels and lowering triglyceride levels without changing LDL levels 
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The Coronary Drug Project (CDP) 
 The study was a multicenter, randomized, placebo-controlled trial of lipid 
lowering drugs (clofibrate and niacin) conducted in the 1980s.  A total of 8,341 men 
between the ages of 30-64 years were randomly assigned to the drugs or the placebo and 
were followed for an average of 6.2 years.  The clofibrate group did not show any effect 
on mortality or non-fatal cardiovascular events.  The niacin group experienced a 
significantly lower incidence of non-fatal MI than the placebo.  However, niacin did not 
have a significant effect on total mortality.179  Fifteen years of follow up after niacin was 
discontinued in the study subjects revealed 11 percent lower mortality in this group than 
the in the placebo group.  The authors stated that this delayed benefit of niacin could be 
attributed to its favorable effect of decreasing non-fatal MI or its lipid-lowering effect or 
both, early on in the treatment.180    
 
Heart and Estrogen/Progestin Replacement Study (HERS) 
 This study was a randomized, blinded, placebo-controlled trial of 2763 
postmenopausal women with CHD and younger than 80 years.  The main objective of the 
study was to determine if estrogen plus progestin therapy reduced the risk of CHD in  
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postmenopausal women.  The subjects were randomized to receive estrogens (0.625 mg) 
plus progestin (2.5 mg) or placebo.  The study concluded in 1998 and at the end of 4.1 
years of follow up, there was no difference in primary or secondary cardiovascular 
outcomes between the two groups.181  At the end of the first year of the study, LDL 
cholesterol decreased by 14 percent in the hormone group and three percent in the 
placebo group (p<0.001).  There was an increase in the HDL cholesterol by eight percent 
compared with two percent in the placebo group.  Women in the hormone group 
experienced greater venous thromboembolic events than the placebo group (34 vs. 12, 
RH=2.89, 95% CI: 1.50-5.58).  The rates of occurrence of breast cancer, endometrial 
cancer and other cancers or fractures did not differ between the two groups.  Similarly, 
the two groups did not differ in total mortality.182 
The authors concluded that estrogen replacement therapy did not lower the risk of 
coronary disease among postmenopausal women.  Furthermore, an additional follow up 
of the HERS study women for 6.8 years showed no reduction in risk of cardiovascular 
disease in women and advised against the use of hormone therapy to reduce risk for CHD 
events in women.   
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Women’s Health Initiative Trial 
This trial was conducted to gain an understanding of the various risks and benefits 
of strategies to reduce the incidence of heart disease, breast and colorectal cancer, and 
fractures in postmenopausal women.183  One arm of this study evaluated the effect of 
estrogen plus progestin on CHD.  The main aim of the study was to assess the effect of 
estrogen plus progestin on ischemic and hemorrhagic stroke.  It was a multi-center, 
double-blind, placebo-controlled, randomized, clinical trial that concluded in 2002.  A 
total of 16,608 postmenopausal women aged between 50 and 79 years were followed for 
an average of 5.6 years.  Participants were randomized to receive one tablet daily of 
0.625 mg of conjugated equine estrogen and 2.5 mg of medroxyprogesterone acetate or 
placebo.   
The occurrence of stroke was 1.8 percent (151 subjects) and 1.3 percent (107 
subjects) in the estrogen plus progestin group and placebo group, respectively.  The 
overall hazard ratio for all types of stroke was 1.31 (95% CI: 1.02-1.68).  The hazard 
ratio for all types of strokes was similar across all age groups.  There was an increased 
risk of stroke by 37 percent in women who were part of the estrogen plus progestin group 
and who had never used hormones prior to participating in the study (Hazard ratio: 1.37; 
95% CI: 1.03-1.82).  Other risk factors for stroke included ethnicity, current smoking 
status, hypertension, diabetes, increased white blood cell count, higher hematocrit levels 
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and blood markers for inflammation.  The study concluded that estrogen plus progestin 
increased the risk of stroke in postmenopausal women who were, in general, in good 
health.184  Recently published final results of the trial concluded that estrogen plus 
progestin did not provide protection against cardiac diseases and might increase the risk 
of coronary heart disease among normally healthy postmenopausal women and 
recommended against the use of HRT for the prevention of cardiovascular disease.185 
 
Angiographic Trials 
The use of angiographic techniques to measure the lumen of the coronary arteries 
and detect small changes in atherosclerotic lesion size led to the evaluation of the effect 
of cholesterol-lowering therapy in the progression of atherosclerosis.  Angiographic trials 
examined the disease changes based on the progression, regression or no change in 
angiographic measurements of the coronary arteries.186  Ten angiographic trials of statin 
drugs have been discussed below.  The statins evaluated in the trials include simvastatin, 
lovastatin, fluvastatin and pravastatin.  A total of 5,440 subjects were followed for a 
period ranging from two to four years.  The mean age of the subjects ranged from 47 to 
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62 years.  The trials have consistently shown that patients have benefited 
angiographically from long-term statin treatment.      
 
The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) 
 This study was a multi-center, randomized, double-blind, placebo-controlled, 
angiographic trial of cholesterol lowering drug simvastatin and ACE inhibitor enalapril.  
The purpose of the study was to evaluate the effects of simvastatin and enalapril on 
coronary atherosclerosis in 460 patients with average cholesterol 201 mg/dl on a total of 
460 subjects with a mean age of 61 years.  The average follow up period was 
approximately four years and the study concluded in 1998.  All cause mortality and 
occurrence of cardiovascular events did not differ between the treatment and placebo 
group.  The changes in the coronary angiographic measures included a decrease in mean 
diameter by 0.07 + 0.20 in the simvastatin group and 0.14 + 0.25 mm in the placebo 
group (p=0.004).  These differences were not observed in the enalapril group as 
compared to placebo.  Simvastatin patients as compared to placebo required fewer 
revascularization procedures (6% vs. 12%, p=0.021) and angioplasties (3% vs. 9%, 
p=0.020).  The occurrence of combined end-points of death, MI and stroke was lower in 
the enalapril group versus the placebo (7% vs. 13%, p=0.043).  All cause mortality and 




concluded that lipid-lowering therapy resulted in slowing CHD progression in patients 
with normal cholesterol levels.187 
 
The Monitored Atherosclerosis Regression Study (MARS) 
 The study was a multi-center, randomized, double-blind, placebo-controlled trial 
conducted in late 1980s to determine the effect of lovastatin on coronary angiography in 
270 patients (male=247; women=63) with CHD and cholesterol levels ranging from 190 
mg/dl to 295 mg/dl.  The subjects were also recommended a cholesterol lowering diet.  
Lovastatin treatment reduced the total cholesterol by 32 percent, LDL cholesterol by 38 
percent, and apoplipoprotein B by 26 percent, whereas HDL levels were raised by 8.5 
percent.  For lesions with stenosis of 50 percent or greater at baseline, there was a greater 
decrease in the diameter of stenosis in the lovastatin group compared with placebo (4.1% 
vs. 0.9%, p=0.005).  Regression of lesions was greater in patients on lovastatin as 
indicated by a lower global change score as compared with the placebo (0.41 + 1.14 vs. 
0.88 + 1.12, p=0.02).  No differences were observed for coronary events between the two 
groups.  The authors concluded that treatment with lovastatin could slow the rate of 
progression of coronary artery lesions.188 
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The Familial Atherosclerosis Treatment Study (FATS) 
This study assessed the effects of cholesterol lowering therapy in the regression of 
CHD in 120 men with a mean age of 47 years and with a high risk of cardiovascular 
diseases.  The study was conducted in the late 1980s.  Patients received advice on their 
diet and were randomly assigned to three treatment groups: lovastatin 20 mg twice a day 
and colestipol 10 g three times a day; or niacin 1 g four times a day and colestipol or 
conventional therapy with a placebo.  The reduction in LDL cholesterol level was 46 
percent in the lovastatin-colestipol group and 32 percent in the niacin-colestipol group.  
At the end of 2.5 years, the stenosis percent decreased by 0.7 points with the lovastatin-
colestipol group and 0.9 points with the niacin-colestipol group (p<0.003)  whereas it 
increased by 2.1 points in conventional therapy group.  Regression of coronary lesions 
was three times more common in the treatment group than in the conventional therapy 
group (p-0.005).  Reduction in LDL cholesterol, blood pressure as well as increase in 
HDL cholesterol correlated individually with the reduction in coronary lesions.  The 
authors concluded that lipid-lowering therapy reduced the progression of coronary lesions 
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The Post Coronary Artery Bypass Graft Trial (Post-CABG trial) 
The purpose of this trial was to study the effect of lipid-lowering and low-dose 
anticoagulation therapy on the progression of atherosclerosis in coronary bypass grafts.  
A total of 1,351 patients with a mean age of 61.5 years with cholesterol levels between 
130 to 175 mg/dl and those who had undergone bypass surgery during a period of one to 
eleven years prior to the start of the study were included.  The study was conducted in the 
early 1990s.  Patients were assigned to aggressive treatment with lovastatin 40 mg/day or 
moderate treatment with lovastatin 2.5 mg/day and warfarin 1 mg/day or placebo.  Based 
on the cholesterol levels, cholestyramine was added to the lovastatin therapy.  The mean 
duration of follow-up was 4.3 years.  Patients who were on aggressive therapy had 
cholesterol levels ranging from 93 to 97 mg/dl whereas those on moderate treatment, the 
levels ranged from 132 to 136 mg/dl (p<0.001).  The mean percentage of grafts with 
atherosclerosis was 27 percent in the aggressive-treatment group and 30 percent in the 
moderate-treatment group (p<0.001).  No significant differences were observed between 
the warfarin and placebo groups.  The authors concluded that aggressive lowering of 
LDL cholesterol to below 100mg/dl reduced the progression of atherosclerosis in patients 
who had undergone coronary bypass grafts.190 
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Lipoprotein and Coronary Atherosclerosis Study (LCAS) 
The aim of the study was to assess the effect of fluvastatin on the progression of 
coronary atherosclerotic lesions and on the development of new coronary lesions in 
patients with CHD and mild to moderate LDL levels.  It was a randomized, double-blind, 
placebo-controlled trial that concluded in 1996.  A total of 429 patients were randomized 
to receive 20 mg of fluvastatin twice daily or placebo.  The mean age of the patients was 
57.8 years.  Patients whose mean LDL levels pre-randomization was > 160 mg/dl were 
initiated on cholestyramine 12mg/day.  Progression of lesions as measured by the 
minimum lumen diameter was significantly less in the fluvastatin group compared to 
placebo (-0.028 + 0.021 mm vs. -0.100 + 0.022 mm, p=0.005).  The authors concluded 
that treatment with fluvastatin slowed the progression of coronary atherosclerosis in 
patients with mild to moderate LDL levels.191 
 
The Regression Growth Evaluation Statin Study (REGRESS) 
This study was a double-blind, placebo-controlled, multi-center trial conducted in 
the early 1990s to evaluate the effect of pravastatin on coronary atherosclerosis.  A total 
of 885 male patients having underwent a coronary arteriography and with a total serum 
cholesterol level of 155-310 mg/dl were included in the study.  Patients were randomized 
to receive pravastatin 40 mg/day or placebo.  The mean segment diameter in the placebo 
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group decreased by 0.10 mm whereas the decrease in the pravastatin group was 0.06 mm 
(95% CI: 0.01-0.07, p=0.019).  The median decrease in the minimum obstruction 
diameter in the placebo group was 0.09 mm whereas in the pravastatin the decrease was 
0.03 mm (95% CI: 0.02-0.08 mm, p=0.001).  The mean intimal-medial thickness values 
of the common femoral artery decreased by 0.06 mm in the pravastatin group and 
increased by 0.13 mm in the placebo group (p=0.004).  At the end of two years, 89 
percent of patients in the pravastatin group and 81 percent of patients in the placebo 
group were free of clinical events (p=0.002).  The authors concluded that treatment with 
pravastatin had beneficial effects on coronary atherosclerosis and changes in the coronary 
and peripheral arteries.192 
 
Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I) 
The study was randomized, double-blind, placebo-controlled, multi-center trial 
conducted in the early 1990s to evaluate the effect of pravastatin on the progression of 
coronary atherosclerosis and ischemic events in patients with coronary artery disease and 
mild to moderate hyperlipidemia.  A total of 408 patients with a mean age of 57 years 
were randomized to receive pravastatin or placebo for a period of three years.  Treatment 
with pravastatin was associated with a reduction in the progression of atherosclerosis by 
40 percent for minimal vessel diameter (p<0.04).  Pravastatin also reduced the formation 
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of newer lesions (p<0.03).  The risk reduction for the occurrence of MI was 60 percent in 
the pravastatin group (p<0.05).  The authors concluded that pravastatin reduced the 
progression of atherosclerosis and myocardial infarction in patients with mild to 
moderate cholesterol levels and presence of coronary artery disease.193 
 
Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II) 
This was a randomized, double-blind, placebo-controlled trial conducted in the 
early 1990s to evaluate the effect of pravastatin on the progression of early extracranial 
carotid atherosclerosis.  A total of 151 patients were randomized to receive pravastatin or 
placebo for a period of three years.  The pravastatin group had total cholesterol reduced 
by 21 percent, LDL cholesterol by 28 percent and triglycerides by 14 percent.  Treatment 
with pravastatin was associated with a 12 percent reduction in the mean carotid artery 
intimal-medial thickness though this association was not statistically significant.  
Pravastatin reduced the progression rate in the common carotid artery by 35 percent 
(p=0.03).  Pravastatin treatment was associated with a 61 percent reduction in combined 
endpoint of coronary event and death (p=0.04), 80 percent reduction in fatal and non-fatal 
myocardial infarctions (p=0.03).  The authors concluded that pravastatin treatment 
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reduced the progression of extracranial atherosclerosis in the common carotid artery and 
decrease coronary artery events.194 
 
Asymptomatic Carotid Artery Progression Study (ACAPS) 
This was a randomized, double-blind, placebo-controlled, multi-center clinical 
trial with a factorial design conducted in the early 1990s.  The purpose of the study was 
to evaluate the effect of lovastatin and/or warfarin on early stage carotid atherosclerosis.   
A total of 919 men (51.5%) and women between the ages of 40-79 years (mean age=62 
years) and no history of cardiovascular disease but having the development of early 
carotid atherosclerosis were included in the study.  Patients were randomized to receive 
20-40 mg/day of lovastatin, or lovastatin-placebo and warfarin 1 mg/day or warfarin-
placebo over a period of three years.  The average follow-up period was 34.1 months.  
The changes in lipoprotein levels in the lovastatin group were as follows: 17 percent 
reduction in total cholesterol levels, 28 percent reduction in LDL levels, a five percent 
reduction in triglyceride levels and a four percent and five percent rise in HDL levels in 
men and women respectively.  Treatment with lovastatin reduced the progression of 
mean maximum intimal-medial thickness in carotid artery segments (p<0.001).  
Lovastatin treatment as compared to placebo was associated with a reduction in 
cardiovascular events (5 vs.14 events, p<0.05). The authors concluded that treatment with 
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lovastatin reduced the progression of early stage carotid intimal-medial thickness and 
cardiovascular events in men and women with moderately elevated LDL levels.195 
 
The Kuopio Atherosclerosis Prevention Study (KAPS) 
   The study was a randomized, double-blind, placebo-controlled, primary 
prevention trial conducted in the early 1990s to evaluate the effect of pravastatin on 
atherosclerotic progression.  A total of 447 men with mean serum cholesterol levels of 
189 mg/dl were randomly assigned to pravastatin 40 mg/day or placebo for a period of 
three years.  The mean age of the patients was 57.3 years.  The LDL cholesterol level was 
29.2 percent lower in the pravastatin group compared to the placebo group. Pravastatin 
reduced the rate of progression of atherosclerosis in the carotid artery segments by 45 
percent (95% CI: 16-69%, p=0.005) and 66 percent in the common carotid arteries (95% 
CI: 30-90%, p=0.002).  The study further provided evidence on the benefits of lowering 
LDL cholesterol on the reduction on the rate of progression of carotid atherosclerosis in 
patients who are free of advanced atherosclerosis.196 
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Meta-analysis of Primary and Secondary Prevention Trials 
Primary and secondary prevention trials have established that cholesterol 
lowering therapy can reduce CHD events and CHD mortality.  However, the effect of 
treatment on total mortality and non-CHD mortality has been less clear.  A majority of 
the trials have included middle-aged men; thus, the data on women and elderly 
population is limited.  In an attempt to address these issues, several authors have used the 
meta-analysis technique.  Meta-analysis combines the results of individual trials in order 
to gain a better understanding of the effects of cholesterol lowering therapy on total 
mortality and in different patient subgroups.   
Results of six meta-analyses have been included in this section.  These studies 
pooled the results from both primary and secondary prevention trials of mainly treatment 
with statins.  Based on the results of these studies, treatment with cholesterol-lowering 
drugs was associated with a reduction in total mortality.  Two studies showed the 
beneficial effects of treatment in reducing the risk of CHD events in women and across 
different age groups including elderly patients over 65 years.197,198  The main findings of 
the studies are discussed below.    
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The Prospective Pravastatin Pooling (PPP) project was a pooled analysis of three 
large randomized trials: the LIPID, CARE and WOSCOPS to assess the effects of 
pravastatin on total mortality and cause-specific mortality.199  There was a reduction of 
fatal or non-fatal MI by 62 percent in the pravastatin group (p=0.001).  This was 
observed across different age groups, gender and in patients with or without histories of 
hypertension and infarction.  The risk for fatal or non-fatal stroke also reduced by 62 
percent (p=0.054).  The authors concluded that the pooled analysis provided strong 
support that the risk of cardiac events can be reduced with pravastatin.200 
LaRosa et al. carried out a meta-analysis of five randomized controlled trials 
(WOSCOPS, 4S, LIPID, CARE, and AFCAPS/TexCAPS) of statins to evaluate the effect 
on total mortality and risk of CHD in 30,817 subjects.201  Statin therapy decreased total 
cholesterol by 20 percent, LDL cholesterol by 28 percent, triglycerides by 13 percent and 
increased HDL cholesterol by five percent.  Major coronary events were reduced by 31 
percent (95% CI: 26%-36%) whereas all-cause mortality was reduced by 21 percent 
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(95% CI: 14%-28%).  The risk reduction was similar across gender and among those 
younger and older than 65 years of age.202 
Hebert et al. conducted a review of 16 trials including 29,000 subjects to evaluate 
the effect of statins on the risk of total mortality and stroke.203  On an average, total 
cholesterol levels were reduced by 22 percent and LDL levels by 30 percent.  The risk 
reduction for stroke was 29 percent (95% CI: 14%-41%) and for total mortality the risk 
reduction was 22 percent (95% CI: 16%-37%).  Death related to CVD was reduced by 28 
percent (95% CI: 16%-37%).  Overall, statins were beneficial in the reduction of 
mortality and stroke.204 
A meta-analysis conducted by Ross and associates showed a 20 to 30 percent 
reduction in death or major cardiovascular events with statin treatment compared to 
placebo.205  The meta-analysis included 21,303 patients from 17 studies.  Statins were 
effective in reducing adverse cardiovascular outcomes such as stroke, angina and MI.  
The odds ratio for total mortality was 0.76 (95% CI: 0.67-0.86), for fatal MI the odds 
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ratio was 0.61 (95% CI: 0.48-0.78), and for angina the odds ratio was 0.70 (95% CI: 
0.65-0.76) in patients receiving statin therapy.206 
Law et al. pooled data from 10 prospective studies, three studies conducted in 
different communities and 28 randomized controlled trials.207  Based on the results from 
the cohort studies, a decrease in serum cholesterol concentration by 10 percent (23 mg/dl) 
was associated with a decrease in incidence of ischemic heart disease by 54 percent at 
age 40 years, 39 percent at age 50, 27 percent at age 60, 20 percent at age 70, and 19 
percent at age 80.  The reduction in the risk was 38 percent in the three studies conducted 
in different communities.  There was an overall average reduction of the risk for ischemic 
heart disease by 18 percent (13%-22%, p<0.001) in the randomized controlled trials in 
men aged 55-64 years. The data for women in the above trials was limited but followed a 
similar trend.208  Pooling results from 42 trials of diet and pharmacological intervention 
showed that cholesterol reduction decreased the total mortality risk in patients with  
moderate and high CHD risk levels.209 This association was more predominant among the 
statin trials than trials with other lipid-lowering drugs.210 
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Cholesterol Reduction and the Risk For Stroke  
 The relationship between serum cholesterol levels and stroke is unclear and 
inconsistent.  In epidemiologic studies, the incidence of thromboembolic stroke increased 
with high cholesterol levels but a J-shaped curve was observed due to the inverse 
relationship between hemorrhagic stroke and cholesterol levels.211  Meta-analyses of 
randomized controlled trials of lipid-lowering therapy were conducted to examine the 
association between cholesterol reduction and the risk for stroke.  Of the seven meta-
analyses summarized below, three studies included only statin drug trials.212,213,214   
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Overall, use of statins was associated with a reduced risk for stroke.  However, the results 
of the meta-analyses were mixed with four studies showing a positive association 
between lipid-lowering and risk of stroke215,216,217,218 and three studies showing no such 
effect.219,220,221     
A meta-analysis conducted by Bucher et al. included 28 primary and secondary 
trials of statins.222  There were a total of 49,477 participants in the treatment group and 
56,636 participants in the control group.  Only those trials that reported the occurrence of 
fatal or non-fatal strokes were included in the meta-analysis whereas those trials in which 
patients previously had a stroke were excluded.  The reason for this exclusion was that  
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the trials would provide inadequate data on the cause of the stroke.  The risk ratio for 
non-fatal and fatal stroke for subjects on statin therapy was 0.76 (95% CI: 0.62-0.92).  
The authors concluded that statin therapy reduced the incidence of stroke.  However, this 
effect was not observed with other lipid-lowering agents or dietary interventions.223 
Warshafsky and colleagues investigated the effect of statins in preventing fatal 
and non-fatal strokes in patients with high cardiovascular risk.224  The authors concluded 
that statins reduced morbidity associated with stroke in patients with high cardiovascular 
risk.  The pooled odds ratio (OR) for total stroke was 0.70 (95% CI: 0.57-0.86, 
p=0.0005).  Only the secondary prevention trials showed a significant risk reduction for 
total and non-fatal stroke.  No association was found between cholesterol reduction and 
risk for stroke.  The authors stated that because of low stroke rates in the trials, the effect 
of statins on strokes was uncertain.225 
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Crouse et al. conducted a meta-analysis of 12 studies including primary and 
secondary prevention trials of statin mono-therapy in the treatment of CHD.226  A 27 
percent reduction in the incidence of stroke was observed in the trials (p=0.001).  Meta-
analysis of 13 primary or secondary prevention randomized, controlled trials revealed 
that cholesterol reduction through diet modification or with lipid-lowering agents did not 
reduce stroke mortality or morbidity in middle-aged men.  The odds ratio for fatal stroke 
associated with interventions to lower cholesterol was 1.32 (95% CI: 0.94-1.86).  The 
odds ratio for non-fatal stroke based on results from eight trials was 0.88 (95% CI: 0.70-
0.11).227 
Hebert and associates investigated whether lipid-lowering with the help of diet, 
drugs or surgical procedures reduces the risk of stroke.228  The 17 randomized controlled 
trials included were either primary prevention, secondary prevention or both primary and 
secondary prevention trials.  Among 36,000 participants, a total of 435 strokes were 
reported out of which 137 were fatal and 298 were non-fatal.  The relative risk for stroke 
(fatal and non-fatal) in the patients assigned to the treatment group was 1.0 (95% CI: 0.8-
1.2) whereas the relative risk for fatal stroke was 1.1 (95% CI: 0.8 to 1.6).  The authors  
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concluded that lowering cholesterol did not show any beneficial effect on the risk of 
stroke and there is a need for large trials to further research this issue. 119  In a separate 
analysis conducted by Hebert et al. on 16 randomized trials revealed that treatment with 
statins reduced the risk of stroke by 29 percent (95% CI: 14% -41%). The authors 
concluded that statins were beneficial in reducing the risk for strokes.229 
A more recent meta-analysis conducted by Corvol and colleagues that included 38 
trials and 83,161 patients revealed that lipid-lowering treatment lowered the relative risk 
of stroke by 17 percent.230  Statin trials as well as secondary prevention trials had the best 
relative risk reduction of the incidence of stroke.  The relative risk reduction of stroke 
incidence was significantly associated with cholesterol reduction (r=0.46, p<0.001).  This 
was true when cholesterol levels were reduced to less than 232 mg/dl.231 
 
Summary 
 Primary, secondary and angiographic trials have demonstrated the beneficial 
effects of lipid-lowering drugs especially statins in the reduction of CHD associated 
mortality and morbidity.  These benefits have been observed irrespective of the age 
group, cholesterol levels, various CHD risk factors and in the presence or absence of 
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prior CHD.  Given the beneficial effects of statin therapy in the prevention of CHD, 






COMPLIANCE WITH LIPID-LOWERING THERAPY 
 
Compliance 
Compliance is defined as “the extent to which a person's behavior (in terms of 
taking medications, following diets, or executing lifestyle changes) coincides with 
medical or health advice.”232 Other terms used to denote compliance include adherence, 
obedience, cooperation, concordance, collaboration and therapeutic alliance.233  The term 
‘adherence’ is most often interchangeably used with the term “compliance.”  This is 
mainly due to the concern that the term compliance is associated with negative 
connotation since the patient is considered to be submissive to the doctor’s orders to 
comply with the medication regimen.234  The measures of compliance for the purpose of 
this study include adherence and persistence.  Adherence refers to “how well a patient 
follows physician orders within a designated time frame” whereas persistence “addresses 
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how long a patient remains on therapy.”235  For the purpose of this research, compliance 
with statins will be assessed with the help of adherence and persistence to therapy.   
Variability in patient compliance to the prescribed medication regimen can have a 
crucial effect on the drug response as well as alter the number of patients required to 
detect a difference between the treatment and the placebo group.236,237  In addition, non- 
compliance can decrease the overall effectiveness of interventions and increase the health 
care costs.238  The economic costs of medication non-adherence exceed $100 billion 
annually including the costs of hospitalizations, nursing home admissions, lost 
productivity, premature deaths and treatments.239 
Patients can be non-compliant with their medication regimens for a number of 
reasons including lack of understanding of the need for medication, especially in 
asymptomatic conditions such as hyperlipidemia.240  Moreover, complexity of medication 
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regimens, side effects of the drugs and the cost of medications also contribute to lack of 
compliance with medication regimens.241   
 
Measures of Non-Compliance 
 Non-compliance with drug therapy can be evaluated through indirect methods 
such as pill counts, medication refill rates, self-reports, interviews, electronic monitoring 
devices or direct methods such as biologic markers, presence of drug or its metabolite in 
the body fluids, and direct observation of patient taking the medication.242,243   
Direct methods are more reliable in assessing compliance, however; they may not 
be practical in most situations and might be considered invasive.  Moreover, in 
retrospective database studies such as this research, it would be nearly impossible to 
obtain the direct measurements of non-compliance unless laboratory tests were part of the 
database. 
Indirect methods are most often used to measure compliance and have some 
advantages and disadvantages.  Indirect methods of collecting non-adherence information 
are relatively inexpensive and noninvasive.  However, they are less reliable than direct 
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methods.244  For example, pill counts can verify the quantity of medication removed from 
the bottle but cannot verify the correct timing of doses or the actual taking of 
medications.245 
Pill counts have been found to overestimate the patient’s actual compliance 
behavior since the patient might not return all the pills in order to conceal their non-
compliant behaviors.246  Completion of self-reports or patient diaries are burdensome on 
the patients.  It might not capture the patient’s medication taking behavior and could be 
subjected to recall bias.  Electronic monitoring devices offer an unobtrusive and 
convenient method to track the quantity and the timing of doses but the devices may be 
costly.  Moreover, there is no way to verify if the dose was actually consumed.247 
Measuring compliance based on prescription refill records has been commonly 
used in retrospective database analysis.  However, prescription refill limits such as those 
in the Texas Medicaid program can hamper the compliance measures since only those 
claims that are covered will appear in the database and those that are not covered will be 
missing from the database.  In addition to the pharmacy claims data, researchers must  
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have access to the eligibility file to verify continuous eligibility which would help in 
differentiating between non-compliance and drop-outs from the insurance plans.248  
Steiner et al. published a review of methodologies to assess compliance and found a 
significant correlation between refill compliance and other compliance behaviors such as 
appointment-keeping or consumption of medication.249  Moderate association was found 
between compliance measures and drug plasma levels and blood pressure control.  The 
authors concluded that assessing prescription refills based on pharmacy records is a 
useful source for measuring compliance when direct measurements of compliance are not 
feasible.250  In summary, there is no ‘perfect’ method to measure compliance to 
medication regimens.  There exists a trade-off between complete reliability of the 
measures versus the practicality in terms of time, money and ease in obtaining the 
measures. 
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Impact of the Variable Compliance on CHD Outcomes 
Adherence with cholesterol-lowering therapy plays an important role in the 
achievement of NCEP goals.251  Poor adherence is more frequent in treatments that are 
preventive than curative.  Hyperlipidemia is a chronic, painless condition that is 
perceived by patients to have harmful effects sometime in the future.  Moreover, primary 
prevention CHD patients who have not yet experienced a CHD event would be more 
likely to be non-adherent than secondary prevention patients.  For example, in primary 
prevention trials, such as WOSCOPS, the discontinuation rates were 30 percent in five 
years whereas in secondary prevention trials, such as 4S, the rate was 10 percent in five 
years.252  Patient adherence to the drug regimen is of paramount importance since statin 
therapy could be a life-long therapy.  However, discontinuation rates of anti-
hyperlipidemic agents are high, ranging from 10 to 60 percent.253  Appropriate dosing 
and titration of lipid-lowering agents is required in order to attain lipid goals. 
There have been very few studies in the literature that have examined the impact 
of medication compliance on CHD outcomes.  McDermott and his colleagues conducted 
a literature review to examine the impact of non-adherence to medication on CHD 
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mortality and morbidity. 254  The authors studied the impact of medication adherence on 
survival, hospitalization and readmission.  Twenty research articles met their inclusion 
criteria. These articles included patients with CHD or MI (6 trials), congestive heart 
failure (9 trials), hypertension (2 trials), hypercholesterolemia (1 trial), and CHD (2 
trials).  The studies used different definitions of adherence and different methods of 
adherence measurements.  The authors could not identify any randomized clinical trials  
that specifically evaluated the effect of compliance with medication regimen on CHD 
outcomes.  There were three clinical trials that included strategies to improve medication  
adherence as part of an intervention to reduce hospitalization and/or mortality in elderly 
congestive heart failure patients.  Of these, two trials showed a positive impact of the 
intervention on mortality and morbidity.  Six studies compared hospitalization rates 
between adherent and non-adherent patients; of these, three studies showed a significant 
impact of adherence on hospitalization.  Out of seven studies that assessed the impact of 
adherence on mortality, four studies showed a favorable impact of adherence on survival.   
The review also included findings from lipid-lowering trials such as the Coronary 
Drug Project Research (CDRP) and the Lipid Research Clinics Primary Prevention trial 
(LRCPPT) that described the impact of compliance with lipid-lowering drugs on 
mortality.  In the LRCPPT a 10 percent reduction in LDL levels was associated with 
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patient compliance with cholestyramine.255  In the CDRP study, the 5-year mortality rates 
were lower for patients who were adherent 80 percent or more to their clofibrate drug 
regimen than those who were not.  However, similar findings were observed in the 
placebo group as well.256  Patients in the WOSCOPS trial who were 75 percent adherent 
with  statin therapy had a 50 percent higher reduction in cardiovascular risk than those 
who were not adherent.257  In summary, few studies have determined the impact of 
medication compliance on CHD outcomes.  Medication compliance has been associated 
with improved CHD outcomes in the majority of the studies included in the meta-
analysis.  Despite very few studies of the impact of compliance on CHD outcomes, a 
number of studies have assessed the compliance of lipid-lowering agents in primary care 
settings.  The next section provides an overview of a summary of the findings of these 
studies.  
 
Compliance with Lipid-lowering Drugs in Primary Care Settings 
There were seven studies that assessed compliance with lipid-lowering drugs, 
mainly statins, in primary care settings.  Three studies used data from health maintenance 
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organizations (HMOs),258,259,260 two studies used the New Jersey Medicaid data,261,262 one 
study used data from a preventive cardiology service263 and one study examined 
population-based administrative data from Ontario.264  These studies highlight the lack of 
compliance to lipid-lowering therapy in clinical practice and increased discontinuation of 
drugs with time. 
The discontinuation rates of antihyperlipidemic agents in HMO settings are higher 
than those reported in clinical trials.  For example, the discontinuation rates after one year 
of treatment in the HMO settings was 41 percent for bile acid sequestrants, 46 percent for 
niacin, 15 percent for lovastatin and 37 percent for gemfibrozil.  In a randomized clinical 
trial, discontinuation rates (except for lovastatin) were lower with 31 percent for bile acid 
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sequestrants, four percent for niacin and 15 percent for gemfibrozil.265  LDL cholesterol 
reduction in clinical practice was also observed to be lower than projected in the package 
inserts of the drugs mainly due to non-compliance.266  In a retrospective HMO study 
conducted by Sung et al., only 37 percent of participants adhered to their lipid-lowering 
therapy throughout the study period.267  In another study of HMO patients, only 62 
percent of the therapies were continued at the end of six months and 21 percent at the end 
of two years.268 
Two studies showed a decline in adherence to statin therapy among the elderly.  
Jackevicius et al. reported that at the end of two years, the adherence to statins was 36.1 
percent for elderly patients with chronic CHD and 25.4 percent for primary prevention 
patients.269  A retrospective cohort study of enrollees in the New Jersey Medicaid 
program showed that adherence to statin therapy declined with time. The proportion of 
days covered by statin therapy decreased from 79 percent in the first three months of 
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treatment to 42 percent after 120 months.270  Another study of elderly patients on statins 
in the New Jersey Medicaid and the Quebec medical care program showed that at the end 
of one year, patients failed to fill the prescriptions 40 percent of the time and five years 
later only half the patients were still getting their prescription filled.  Persistence rates 
with statins were higher than those with other lipid-lowering agents, particularly with bile 
acid sequestrants, cholestyramine and colestipol.  Patients with hypertension, diabetes 
and CHD had better adherence to therapy than those without these risk factors.271   
 In summary, compliance with lipid-lowering drugs in primary care setting is an 
issue of concern since compliance with statin therapy decreases over time in 
hyperlipidemic patients including elderly patients, especially those with CHD and with 
established risk factors.  In order to improve patient compliance with lipid-lowering 
medications in clinical practice, it is vital to gain an understanding of the various factors 
that affect compliance. 
 
Factors Affecting Compliance with Lipid-Lowering Drugs 
A number of factors affect compliance with drug therapy.  Studies have evaluated 
the factors that affect compliance with lipid-lowering drugs.  A brief description of the 
study results is given below. 
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Factors inversely associated with compliance include occurrence of side-effects 
with the lipid-lowering therapy, high number of prescription medications, smoking status, 
break in physician visits, young age, female gender, and presence of               
comorbidities. 272,273,274  Other factors that negatively affected compliance with statin 
therapy include days’ supply of medications, number of concomitant medications and 
copayment.275  Factors positively associated with compliance include increased 
physician-patient interaction regarding cholesterol and cardiovascular disease and 
patient’s perception about the efficacy of lipid-lowering drugs in preventing 
cardiovascular diseases.276  Predictors of poor compliance with statins among elderly 
include nonwhite race, lower income, older age, less cardiovascular morbidity at 
initiation of therapy, depression, dementia, and occurrence of coronary heart disease 
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events after initiation of therapy.277  In an elderly Medicaid population, age, ethnicity and 
severity of CHD were significant predictors of persistence to statin therapy. 278 
Bruckert et al. conducted an open-label study in hyperlipidemic patients to 
evaluate three objectives: to assess compliance with fluvastatin; to understand the 
relationship between treatment compliance and sociodemographic, clinical and 
psychological factors; and to evaluate the effect of raising patient awareness through the 
distribution of information.279  The control group received regular information from their  
physician, whereas the treatment group received information on diet and role of 
cholesterol in coronary heart disease.  A majority of the patients (75 percent, 
2,888/3,845) were compliant with therapy (i.e., they filled more than 90 percent of 
fluvastatin prescriptions).  Both of the groups were similar with respect to demographic 
characteristics and different risk factors with the exception of diabetes.  The non-
compliant group had a higher occurrence of adverse events compared with the compliant 
group (10% vs. 3.4%, p=0.001).  In the non-compliant group, there were a large number  
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of symptomatic patients who thought that the drug did not improve the symptoms (17.1% 
vs. 20.3%, p=0.005).280  Muhlestein and colleagues reported that prescription of statin 
therapy at the time of hospital discharge following an angiographic diagnosis of CHD 
was a predictor of long-term statin compliance as well as reduced mortality.281   
 
Summary 
Lack of compliance with lipid-lowering medications is an issue of concern in the 
treatment of hyperlipidemia.  The literature reports a decrease in compliance with drug 
regimens with time.  Despite the literature lacking in studies assessing the impact of 
medication compliance on CHD outcomes, some studies have shown poor CHD 
outcomes in non-compliant patients.  Lack of compliance with statin drug regimens have 
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LIPID MANAGEMENT IN PRIMARY CARE SETTINGS AND IN SPECIAL 
POPULATIONS 
 
Lipid Management in Primary Care Settings 
Under-diagnosis and under-treatment of hyperlipidemia in “real-world settings” 
are contributors to the failure to achieve NCEP treatment goals.  Under-utilization of 
lipid-lowering therapy could be attributed to the relatively expensive cost of drugs as well 
as long-term duration of treatment.282  Despite the presence of the NCEP guidelines for 
cholesterol management, there exists a gap between the guidelines and its implementation 
in clinical practices.  A number of studies provide support for the lack of translation of 
lipid-lowering benefits observed in clinical trials to practice settings. 
Andrade et al. attributed the lack of positive association between the use of 
antihyperlipidemic agents and CHD hospitalization to discontinuation of therapy or 
failure to achieve the LDL goals while on therapy.283  In a retrospective analysis of data 
for 48,586 patients, 61 percent of CHD patients were not treated with lipid-lowering  
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agents.284 The Lipid Treatment Assessment Project (L-TAP) which evaluated the percent 
of hyperlipidemic patients on lipid-lowering therapy and achieving LDL goals showed 
that overall only 38 percent of the patients on drug therapy achieved LDL goals and the 
success rates were lowest for high-risk patients and those with CHD.285 
Pearson et al. stated that there is gap between NCEP guidelines and attainment of 
goals in clinical settings and cited a few studies supporting this.286  For example, in the 
Heart and Estrogen/Progestin Replacement Study, only 47 percent of eligible patients 
were on lipid-lowering drugs and 63 percent of the patients did not achieve the LDL 
target levels.287  In a study conducted at a Veterans Affairs Medical Center, only 33 
percent of the patients achieved the LDL goals.  Factors affecting the achievement of 
lipid goals included lower baseline LDL levels and triglyceride levels, use of 
combination drug therapy, and patient adherence to therapy.288  Based on a study in a 
German outpatient population, lack of implementation of treatment guidelines was 
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observed in which only 6.2 percent of a total of 2,856 CHD patients were found to meet 
the target LDL levels.289 
A retrospective analysis of data from a national managed care organization 
showed that only 43 percent (12,781/29,534) of eligible patients were on statin 
therapy.290  Of these, only 46 percent continued statin therapy at the end of two years. 
Over half (59 percent) had one or more cholesterol monitoring tests during the two year 
study period.  Statin users (OR=1.78, 95% CI: 1.23-2.56) with a higher rate of 
compliance (OR=2.09, 95% CI: 1.32-3.31) were more likely to attain the NCEP goals 
compared with non-statin users with lower compliance rate.291  The problem of under-
treatment is also evident in the NHANES where 82.5 percent of patients with CHD and 
over half of those without CHD and with greater than two risk factors were not meeting 
the treatment goals.292  The recently conducted Genetic Epidemiology Network of 
Arteriopathy study concluded that less than one-third of the hypertensive patients in the 
study were treated for hyperlipidemia and fewer than half of these were attaining the lipid 
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goals.  Moreover, nine out of 10 hypertensive patients with hyperlipidemia were not 
adequately treated for hyperlipidemia.293   
 
Lack of Physician Adherence to Guidelines 
Screening and treatment of hyperlipidemia is a crucial component in the primary 
and secondary prevention of CHD.  Physician compliance with cholesterol management 
guidelines is limited.294  Hyperlipidemic patients are counseled on cholesterol 
management at a mean rate of only 34 percent annually which translates to once every 
three years.  Cholesterol counseling is more likely in the presence of cardiovascular 
diseases and related risk factors such as diabetes, hypertension and obesity.295   
Yarzebski et al. conducted a survey of physicians in 1999 to evaluate their 
attitudes towards cholesterol management in patients with acute MI.296  Lipid-lowering 
therapy was more likely to be initiated in younger patients at lower cholesterol levels than 
older patients (p=0.03).  Older physicians were likely to adhere to recommended 
guidelines to cholesterol management than younger physicians.  A majority of the 
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physicians stated that they would consider both diet and drug therapy as the initial form 
of treatment to lower cholesterol levels, with less than one percent stating that they would 
consider lipid-lowering drug therapy as the initial therapy.  Some of the physician 
barriers affecting the use of lipid-lowering therapy, included the fact that physicians do 
not adequately inform their patients about the use of these drugs and the lack of 
conviction in the benefits of lipid-lowering drugs.   
The most important factor affecting the use of lipid-lowering drugs among 
patients as perceived by the physician was the cost of the medication followed by lack of 
understanding of the importance of lipid-lowering drugs.297  Lai et al. conducted a chart 
review to study the cholesterol treatment in an HMO setting.  A majority of the patients 
(65 percent, 224/348) needed either diet or drug therapy based on the NCEP-II 
guidelines.  The authors stated that there exists poor adherence to guidelines among 
primary care physicians. 298  Based on a retrospective chart review of patients 
hospitalized in coronary care unit, a full lipid panel was ordered only 50 percent of the 
time.  Assessment of CHD risk factors and treatment of hyperlipidemia by physicians 
was sub-optimal even for patients who were at a high risk for CHD.299   
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Gaw et al.300 stated that in the primary care setting, physicians often fail to 
achieve the recommended LDL goals for their patients due to a number of factors 
including lack of adequate effectiveness of lipid-lowering drugs in reducing the LDL 
levels in frequently used doses.301  Failure to achieve lipid goals are attributed to a large 
extent to inadequate doses of lipid-lowering agents.  Most patients who begin treatment 
with statins remain at the initial dose.302 
Danias and colleagues noted that less than 50 percent of hyperlipidemic patients 
in a Veterans Administration Medical Center were achieving the NCEP ATP II 
guidelines for cholesterol management mainly due to physicians’ lack of adherence to 
guidelines.  Of the total of 147 patients, only 94 (65%) had an additional cholesterol level 
measured during a 12 month follow-up.  Only half the subjects who were eligible for 
cholesterol lowering drugs were receiving therapy and only one-third of patients who 
were on drugs attained desired LDL goals.303   
Maviglia et al. showed that among secondary prevention patients only 31 percent 
were in compliance with the NCEP guidelines and 44 percent were on lipid-lowering 
therapy.  Over half of the patients were not diagnosed or monitored for hyperlipidemia.  
                                                 
300 Gaw A. A new reality: achieving cholesterol-lowering goals in clinical practice. 
Atherosclerosis Supplements. 2002;2(4):5-8. 
301 Gaw A. A new reality: achieving cholesterol-lowering goals in clinical practice. 
Atherosclerosis Supplements. 2002;2(4):5-8. 
302 Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National 
Cholesterol Education Program low-density lipoprotein cholesterol goals with five 
statins. American Journal of Medicine. 2001;111(3):185-191. 
303 Danias PG, O'Mahony S, Radford MJ, et al. Serum cholesterol levels are 





Patient characteristics such as being male, white, having visited a cardiologist and having 
had a recent hospitalization for myocardial infarction, unstable angina or angina were 
significantly related to compliance to guidelines.  The compliance rates did not differ 
with physician related characteristics such as age, gender, level of training, type and size 
of practice and volume of secondary prevention patients.304       
 
Barriers to Physician Adherence to Guidelines 
Barriers to physicians’ adherence to guidelines include lack of awareness and 
familiarity to the guidelines.  Even if physicians are aware of the guidelines they may 
lack the knowledge of the details of the guidelines.  Lack of agreement to guidelines may  
also translate into physician non-adherence.  Physicians’ lack of self-efficacy in 
implementing preventive care guidelines in cardiology could decrease the likelihood of 
adhering to guidelines.  Moreover, physicians’ lack of confidence in achieving positive 
outcomes as a result of counseling patients on prevention due to patients’ lack of 
compliance to physicians’ recommendations also present a barrier to guideline 
implementation.  Other barriers to adherence to guidelines include “clinical inertia” 
which is described as “the failure of health care providers to initiate or intensify therapy 
when indicated.”305  This is true especially for disorders such as hyperlipidemia which 
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does not manifest symptoms initially.  Practice-related barriers include lack of time, 
reimbursement or reminder systems.306,307      
In summary, lipid management in clinical practice is suboptimal mainly due to the 
lack of achievement of goals for LDL levels and lack of physician adherence to 
guidelines.  Moreover, few patients who are eligible for drug therapy for the treatment of 
hyperlipidemia actually receive it.  There has been no published study in the literature 
that has evaluated management of hyperlipidemia in the Medicaid population.  Thus, this 
study aims to address that gap in literature.  In addition, there have been few studies that  
have looked at lipid management in special populations including women and minority 
groups.  Since the Medicaid data covers a large number of women and ethnic groups such 
as Hispanics and African Americans, this study aims to contribute to the understanding of 
lipid management in women and minorities.   
 
Lipid Management in Special Populations 
The following section provides an overview of lipid management in women, 




                                                 
306 Cabana MD, Kim C. Physician adherence to preventive cardiology guidelines for 
women. Women's Health Issues. 2003;13(14):143-149. 
307 Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice 






Cardiovascular diseases are the leading cause of death among women accounting 
for over half a million deaths annually.  The “long-held belief” that heart disease is 
predominantly a male disease is a myth, as more women have died due to cardiovascular 
diseases than men since 1984.  Based on results from the Framingham Heart Study, 
women have a three-fold greater chance of having a CHD event than developing breast 
cancer.308   
The prevalence of CHD among white females, Mexican-American females and 
black females is 5.4 percent, 6.8 percent and 9.0 percent respectively.309  The ATP III 
guidelines recommend a similar treatment approach for women as for men in both the 
primary and secondary prevention of CHD.310  Recently published guidelines for the 
prevention of CVD in women calls for aggressive treatment based on the risk for CVD.  
The guidelines also strongly recommend lipid lowering therapy, preferably statins, for 
high-risk women.311  
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Risk factors that predispose women to CHD include menopause that leads to a 
three-fold increase in the risk of CHD.  A decrease in estrogen in postmenopausal women 
causes changes in lipid profiles, thus menopause accounts for an increased risk of 
CHD.312  Cohort studies have established the association of hyperlipidemia with 
anincrease in CHD risk in women.313  Increased levels of total cholesterol, LDL 
cholesterol and triglycerides have been observed in postmenopausal women.   
The mean LDL-cholesterol levels are 24 percent higher (145 vs. 177 mg/dl) in 
women aged 55 to 64 years than those aged 35-44 years.314  In addition, HDL cholesterol 
levels are a stronger predictor of CHD in women than in men.315,316  For example in the 
Framingham Heart Study, a 1mg/dl increase in HDL cholesterol was associated with a 
three percent decrease in the incidence of CHD in women compared with two percent in 
men.317  It is vital to recognize CHD risk factors in women at an early stage since two-
thirds of sudden deaths occur in women with no CHD and they have a poorer prognosis 
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and outcomes after CVD related procedures such as MI, PTCA and CABG compared to 
men.  Moreover, women are more likely to die than men after a first MI.318 
There exists a gender gap in treatment of hyperlipidemia.319  Most studies have 
included only men or a small number of women, thus, data on lipid-lowering therapy in 
women are limited.  In a review by Welty et al., the authors drew upon examples from the 
literature to show the existence of a gender gap in the treatment of hyperlipidemia. 320  
For example, in a study of hospitalized CHD patients in the U.S. and Canada, the use of 
lipid-lowering therapy was greater in men than women.321  In the HERS study, only 47 
percent of the postmenopausal women with CHD were taking lipid-lowering drugs and 
91 percent of the women had LDL levels above the NCEP goals.322  Based on NHANES 
III, only 35 percent of women eligible for treatment were receiving treatment and only 42 
percent of women with existing CHD were receiving lipid-lowering medications. 323 
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Some randomized clinical trials have established the beneficial effects of statins 
in the primary and secondary prevention of CHD in women.  AFCAPS/TexCAPS was the  
first primary prevention trial to include women.  Treatment with lovastatin was 
associated with a reduction of first acute major coronary event by 46 percent which was 
nine percent higher than that observed in men.324  In the secondary prevention 4S study, 
simvastatin treatment reduced the risk of by 34 percent in both men and women.325  
LIPID study analyzed a subgroup of 1,516 women and found that “women benefited no 
differently than men,” with regards to lipid-lowering treatment.326  The WATCH trial 
studied the efficacy of atorvastatin in achieving ATP II LDL cholesterol targets in 
hyperlipidemic women with either confirmed CVD or risk factors for CVD. The authors 
concluded that atorvastatin was highly effective in achieving the ATP II target levels for 
LDL cholesterol in women with dyslipidemia and having CVD or risk factors for 
CVD.327 In the more recent Heart Protection Study which included 5,082 women, a 24 
percent reduction in major vascular events was observed in both sexes with simvastatin 
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treatment.328 These studies provide support for the benefits of using cholesterol-lowering 
drugs in the prevention of CHD in women. 
 
Elderly 
There is limited evidence on the effect of statins in elderly patients aged 70 and 
older.329,330  Studies have demonstrated the effectiveness of statins in both the primary 
and secondary prevention of CHD among the elderly.331  Data suggest that 
hyperlipidemia plays a major role in the progression of CHD and is an independent risk  
factor of CHD in older adults.332,333,334,335  The NHANES III demonstrated that 50 percent 
of patients above the age of 65 years qualify for dietary therapy and 10-25 percent for 
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drug therapy for hyperlipidemia.336  In the 4S study, treatment with pravastatin was 
associated with 26 percent reduction in total cholesterol, 36 percent reduction in LDL 
cholesterol, 14 percent reduction in triglycerides and a seven percent increase in HDL 
cholesterol in elderly patients.337  A meta-analysis conducted by LaRosa et al. showed 
that statin therapy was associated with a reduction in LDL levels and risk of major 
coronary events in patients aged 65 years or older (32 percent, 95% CI: 23-39%, 
p<0.001).338  Aronow et al. studied the effect of statins on the incidence of new coronary  
events in older patients (ages ranged from 60 to 99 years) with peripheral arterial disease 
and LDL cholesterol levels > 125 mg/dl.  A total of 264 men and 396 women in a long-
term care facility who were treated with either a statin or with no lipid-lowering agent, 
were followed prospectively.339  The use of statin was significantly associated with the 
reduction in new coronary events in patients with (p<0.0001) (risk ratio 0.476, 95% CI: 
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0.367-0.617) and without (p<0.0001) (risk ratio 0.411, 95% CI: 0.288-0.586) prior 
myocardial infarction.340   
Eaton et al. conducted a retrospective cohort study to determine the effect of statin 
use on one-year hospitalization and mortality rates for older patients in nursing homes.341  
The prevalence of statin use among patients with cardiovascular disease was 2.6 percent 
(1,313/51,559).  The mortality rate at the end of one year was 31 percent lower for statin 
users compared to nonusers  (hazard ratio=0.69, CI=0.58-0.81).  Despite limited data on 
the effectiveness of cholesterol-lowering therapy in women and elderly, research supports  




Cardiovascular diseases are the leading cause of death among Hispanics and 
African Americans.  There has been a lack of sufficient studies of CHD in minorities.342  
Minority populations have a higher relative risk for death related to stroke as compared to 
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the non-Hispanic white population.343  Among Mexican Americans aged 20 years and 
older the prevalence of CHD is 7.2 percent in men and 6.8 percent in women.  The 
prevalence of CHD among non-Hispanic blacks 20 years and older is 7.1 percent and 9.0 
percent in men and women respectively.  The prevalence of CHD among whites is, 6.9 
percent among males and 5.4 percent among females.344   
A cross-sectional survey of 417 Mexican cities revealed a high prevalence of low 
HDL concentrations and mixed hyperlipidemia among the Mexican population.  Over 
twelve percent of the subjects had simultaneous elevation of cholesterol and triglyceride 
concentrations.345  Hispanics with diabetes have a higher risk of hyperlipidemia than 
those without.346  Thus, it is important to understand the risk factors and the management 
of hyperlipidemia among the minority populations.  In the Corpus Christi Heart Project, 
Mexican Americans had greater hospitalization rates due to myocardial infarction than 
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non-Hispanic whites (age-adjusted rate ratios=1.59 95% CI: 1.05-2.41 for women and 
1.31; 95% CI: 1.18-1.45 for men).347    
There exist disparities in cholesterol management among the minority population.  
Data from the NHANES III showed that African Americans and Mexican Americans 
were significantly less likely than whites to have ever had their blood cholesterol checked 
(OR=0.7 for both groups, p<0.001) and they were less likely than whites to take 
cholesterol lowering medications (p=0.05).348  Non-whites were more likely to receive 
counseling for cholesterol management than whites (1.7% vs. 1.0%, p<0.001); however, 
they were slightly less likely to be screened for cholesterol than whites (2.5% vs. 2.9%, 
p=0.034).349  Adherence to statin therapy among African-Americans was lower as 
compared to whites (59.9% vs. 74.1%, p<0.001).350  African Americans were less likely 
than whites to achieve the NCEP-II goals for LDL-C (40.9% vs. 56.9%, p<0.001).351 
In summary, cholesterol management among the minority population remains 
suboptimal.  Very few studies have addressed the management of hyperlipidemia and 
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CHD in the minority populations.  The current research utilizes the Texas Medicaid 
database that includes a large proportion of minority population thus presenting the 







 IMPACT OF PHYSICIAN SPECIALTY ON THE MANAGEMENT OF 
HYERLIPIDEMIA AND CHD 
 
Impact of Physician Specialty 
In the U.S. health care system, primary care physicians act as “gatekeepers” to 
reduce healthcare costs.  Access to specialists such as cardiologists in managed care 
organizations could be restricted due to the belief that specialists are costlier than 
generalists.  There is a need for more data to understand the differences in cost and 
quality of care provided by specialists versus generalists.352  A few studies have evaluated 
the differences in management and outcomes of hyperlipidemic patients with respect to 
physician specialty.   
Whyte et al. found that management of hyperlipidemia in secondary prevention 
patients varied by physician specialty (general practitioners or cardiologists).353  Patients 
visiting cardiologists were twice as likely to receive drug therapy for LDL levels >130 
mg/dl.  However, there was no difference in the type of cholesterol lowering medication 
prescribed by the two specialties.  
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Strafford et al. showed that physician specialty also affected cholesterol screening 
practices.354  The rate of screening among patients without known hyperlipidemia was 
higher among cardiologists (5.5%), and other internists (6.1%), compared to family 
physicians and general practitioners (3.3%) and other physicians (1.5%) (p < 0.001).  
Internists (38.7%), cardiologists (35.3%), family physicians and general practitioners 
(36.4%) were more likely to counsel patients with hyperlipidemia than other physicians 
(16.2%, p < 0.001). Patients visiting cardiologists were five times more likely to be 
counseled about cholesterol management compared to those visiting other physicians.  
Cardiologists (37.7%) and internists (28.5%) were more likely to prescribe lipid-lowering 
medications than general practitioners and family physicians (17.6%) and other 
physicians (15%) (p < 0.001).355  A cross-sectional mail survey of generalists and 
cardiologists which included primary prevention case simulations revealed that general 
physicians and family physicians overestimated the baseline cardiovascular risk and 
benefit of therapy as compared with cardiologists.356 
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Patients treated by cardiologists were more likely to receive aspirin, heparin or 
beta-adrenergic blocking agents than those treated by internists.  Similarly, cardiologists 
were more likely to treat patients with aspirin and thrombolytic agents than general 
physicians.357  Cardiovascular-related procedures such as coronary revascularization, 
coronary angioplasty and heart catheterization were more likely to be performed in 
patients treated by cardiologists versus internists.358  Cardiologists used coronary 
angiography more frequently compared to general physicians.359   Similar results were 
observed among Medicare patients with acute MI, with cardiologists using a high rate of 
cardiac procedures as well as medications such as aspirin, beta-blockers and thrombolytic 
agents.  Patients admitted to the hospital by a cardiologist were 12 percent less likely to 
die within a year than those admitted by a primary care physician.360   
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The above studies show that there is a disparity in management of cholesterol and 
CHD between physician specialties.  Cardiologists use more resources such as 
cardiovascular procedures and lipid-lowering therapy than general physicians.  Some 
studies have also indicated better outcomes associated with treatment with cardiologists.  
These findings could be attributed to additional training and experience in treating 






PHARMACOECONOMIC EVALUATIONS OF LIPID-LOWERING THERAPY 
 
CHD accounts for huge expenditures of healthcare resources.  Lipid-lowering 
therapy, primarily statins, have proved to be effective in lowering CHD mortality and 
morbidity in both primary and secondary prevention trials.  Despite the proven benefits of 
statin therapy, if all patients with hyperlipidemia were treated with statins, the cost of 
treatment would exceed billions of dollars.  Pharmacoeconomic evaluations such as cost-
effectiveness analyses help in providing a framework for the effective allocation of 
limited healthcare resources.361  The most commonly used pharmacoeconomic evaluation 
used in cardiovascular disease intervention is a form of cost-effectiveness analysis called 
cost per year of life saved.  For any lipid-lowering medication, a ratio of ≤$50,000 per 
year of life saved is considered to be cost-effective since it is comparable with other 
interventions such as chronic hemodialysis, breast cancer screening or coronary artery 
bypass graft surgery.362  The cost-effectiveness of lipid-lowering therapy varies with 
respect to its use in primary or secondary prevention of CHD.   
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Primary prevention statin trials such as the WOSCOPS and AFCAPS/TexCAPS 
have shown significant reduction in risk of CHD.  The WOSCOPS study has been used 
as a model for determining the benefit of statin therapy in primary prevention.  Cato et al. 
used data from the WOSCOPS study to assess the efficiency of pravastatin in preventing 
a cardiovascular event in men with hypercholesterolemia.  The results showed that if 
10,000 men were treated with pravastatin, 318 would not make a transition from health to 
cardiovascular disease (number needed to treat would be 31.4).  This would translate to a 
net discounted cost of £2 million over five years and an undiscounted gain of 2460 years 
of life amounting to £8,121 per year of life gained or £20,375 per year of life gained if 
benefits were discounted.  When the analysis included only the top 40 percent of high-
risk men, there was a reduction in the number needed to treat to prevent one 
cardiovascular event to 22.5 (£5601 per life year gained (undiscounted) and £13995 per 
life year gained (discounted).  The study implied that use of pravastatin in primary 
prevention is cost-beneficial in patients with hyperlipidemia.   
Badia and colleagues compared the economics of treatment with simvastatin and 
atorvastatin in reducing LDL levels in primary prevention patients in ten European 
countries.363  Data for the analysis were obtained from a one-year, double-blind, parallel- 
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group clinical trial.  Patients were randomized to receive atorvastatin 20 mg/day or 
simvastatin 20 mg/day.  There was no significant difference in the percentage of patients 
achieving the LDL goals between the two groups.  However, the total cost of treatment 
was lower in the simvastatin group than in the atorvastatin group (euros 429 vs. 538, 
p<0.0001).  In eight out of the ten countries, the cost of treatment was lower for 
simvastatin than atorvastatin, and in the remaining two countries there were no cost 
differences.  Only drug costs were used in the study due to lack of availability of data on 
the rates of hospitalization and procedures in the atorvastatin group.       
Hilleman et al. conducted a pharmacoeconomic evaluation of statins based on the 
CURVES study.  The CURVES study was a multicenter, open-label trial that compared 
the efficacy of five statins (atorvastatin, fluvastatin, lovastatin, pravastatin and 
simvastatin).  A total of 534 patients were randomized to 15 different treatment groups 
over a period of eight weeks.  The results of the CURVES study showed that atorvastatin 
10, 20 and 40 mg/day were significantly associated with reduction in LDL cholesterol 
levels as compared to other statins.  Hilleman et al., calculated cost-effectiveness 
expressed as annual acquisition cost per percentage LDL reductions.  The results showed 
that atorvastatin 10 mg/day ($17.96) was the most cost-effective, followed by fluvastatin 
40 mg/day ($19.83), atorvastatin 20 mg/day ($22.85), and atorvastatin 40 mg/day 
($24.96).364  
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Spearman et al. evaluated the cost-effectiveness of statins for initial therapy in a 
primary care setting of a managed care organization.365  Effectiveness was defined as the 
percent reduction in LDL levels based on six months of initial therapy.  Both direct and 
indirect costs were included in the analyses.  Indirect costs included time lost due to 
physician visits or laboratory testing, transit time and work days missed due to adverse 
events.  The number of patients who remained on the same drug with no dose changes 
were highest in  those receiving fluvastatin (72 percent), followed by simvastatin (71 
percent), pravastatin (48 percent), lovastatin (43 percent) (p=0.001).  The cost-
effectiveness ratio for fluvastatin was lower than the other statins (p<0.01).  Drug 
compliance that was measured in terms of possession ratio was highest for fluvastatin and 
simvastatin and lowest for lovastatin.     
Hamilton et al. evaluated the lifetime cost-effectiveness of lovastatin 20mg/day in 
preventing CHD in patients with hyperlipidemia.366  This study took into account the 
benefits of lowering total cholesterol and increasing HDL cholesterol.  The authors used a 
computer model to estimate the benefits of risk factors modification.  The results of the 
analysis showed that an increase in HDL cholesterol lowered the cost-effectiveness ratio 
by 40 percent.  The cost-effectiveness ratio ranged from $20,882 for men aged 50 years 
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to $36,627 for women aged 60 years with additional risk factors.  The ratio increased by 
23 percent for elderly patients aged 70 years due to non-CHD costs resulting from longer 
life expectancy.  Indirect costs and direct costs related to side effects were not considered 
in the analysis.367 
Martens and Guibert calculated the cost-effectiveness of different statins available 
in Canada for the primary prevention of CHD.368  Risk functions from the Framingham 
Heart Study were used in the model.  The cost-effectiveness ratio varied from 
$56,200/year of life saved for pravastatin 20 mg to $38,800/year of life saved for 
fluvastatin 40 mg.  The results showed that treatment with fluvastatin was most cost-
effective as compared to pravastatin, lovastatin and simvastatin in the primary prevention 
of CHD.  The cost-effectiveness ratio varied with the pretreatment risk factors such as 
cholesterol levels and presence of additional risk factors.369 
Huse et al. studied the cost-effectiveness of five statins: atorvastatin (10 mg), 
fluvastatin (20 mg), lovastatin (20 mg), pravastatin (20 mg), simvastatin (10 mg) in the 
primary and secondary prevention of CHD.370  The model evaluated the cost-
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effectiveness of statins across gender, the presence or absence of three risk factors, across 
three age groups (45, 55 and 65 years) and across two LDL levels (190 mg/dl and 220 
mg/dl).  Effects of statins on serum lipids were obtained from data on the product labels.  
Framingham Heart Study coronary risk equations were developed to estimate the annual 
risks of coronary event occurrences.  Outcome measures included net cost as calculated 
by the difference in the cost of statin therapy and the savings in CHD treatment, gain in 
life expectancy and cost per-life saved.  Atorvastatin was more cost-effective than the 
other statins in both primary and secondary prevention of CHD.  For example, in a 55 
year old male primary prevention patient with LDL levels of 220 mg/dl and no other risk 
factors, the cost-effectiveness ratio (incremental cost/year of life saved) for atorvastatin 
was $32,609, followed by simvastatin $39,247, fluvastatin $42,738, pravastatin $47,077 
and lovastatin 59,036.  The cost-effectiveness ratio for statin therapy was favorable for 
secondary prevention in both men and women with multiple risk factors.  For primary 
prevention, the cost-effectiveness ratio was favorable for men with risk factors and 
women with “highest risk” profiles.  Overall, secondary prevention was more cost-
effective than primary prevention.371 
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Cost-effectiveness ratios based on different patient characteristics for primary and 
secondary prevention of CHD were calculated.372 Men and women between the ages of 
35 to 84 years of age were divided into subgroups based on age, sex, and the presence or 
absence of four CHD risk factors.  The authors used the Coronary Heart Disease Policy 
Model to evaluate the effects and costs of cholesterol lowering therapy in each risk 
groups.  Results from five studies were pooled to estimate the effects of a low-cholesterol 
diet.  Data to estimate the effectiveness of primary prevention with a statin were obtained 
from three long-term studies of pravastatin.  Estimates for effectiveness of statins in 
secondary prevention were obtained from the results of the Scandinavian Simvastatin 
Survival Study.  The cost-effectiveness for primary prevention ranged from $54,000 to 
$420,000 per QALY controlling for individual risk factors.  Cost-effectiveness ratio for 
the secondary prevention with a statin was less than $50,000 per QALY across all patient 
subgroups and risk categories.  Overall, the secondary prevention was more cost-effective 
than primary prevention.  The ratios were more favorable for higher risk factors 
(especially for blood pressure and HDL levels), increasing age and for male gender.  373   
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Russell et al. evaluated the cost-effectiveness of statins versus no drug therapy in 
primary and secondary prevention of CHD disease in Canada using a Markov model.374  
Risk factors were estimated using the Canadian population survey data and coronary risk 
was estimated using the coronary risk equations from the Framingham Heart Study.  
Results of the analyses showed that the cost per year of life gained was lowest for 
atorvastatin and highest for pravastatin across all risk profiles.  For example, for patients 
55 years of age and LDL levels of 160 mg/dl, the incremental cost per year of life saved 
was Can$ 64,419 for atorvastatin, Can$ 83,226 for lovastatin, Can$ 87,906 for 
simvastatin, Can$ 88,077 for fluvastatin and Can$ 109,034 for pravastatin.375  
Russell et al.376 calculated the direct medical costs (pharmacy, professional, 
hospital, and home health) related to the treatment of CHD in the U.S. using a Markov 
model.  The medical cost (in 1995 dollars) for the first year of treatment of CHD was 
estimated to be $17,532 for fatal acute myocardial infarction, $15,540 for non-fatal AMI, 
$2,569 for stable angina, $12,058 for unstable angina and $713 for sudden CHD death.  
Based on the annual incidence of 616,900 cases of CHD in the U.S., the first-year 
treatment cost totaled $5.54 billion.  Five and ten year projected total direct medical costs 
in 1995 dollars for patients with CHD were estimated to be $71.5 billion and $126.6 
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billion, respectively.  For patients initially free of CHD the cumulative direct costs for 
five and ten years were estimated to be $9.2 billion and $16.5 billion respectively. 
Koren et al. conducted a 54-week, randomized controlled trial to assess the total 
cost associated with reaching NCEP goals with different statins (atorvastatin, simvastatin, 
lovastatin and fluvastatin).377  The mean total cost of care to reach NCEP goals was lower 
for atorvastatin ($1064) compared with simvastatin ($1471), lovastatin ($1972), and 
fluvastatin ($1542).  Patients treated with atorvastatin were more likely to reach NCEP 
goals (p<0.05), required fewer office visits (p<0.001) and less likely to be on 
combination therapy with colestipol (p=0.001) than other statins.   
 
Secondary Prevention 
A number of studies have evaluated the cost-effectiveness of lipid-lowering 
therapy in the secondary prevention of CHD.  Elliott et al. compared the cost 
effectiveness of six statins (atorvastatin, fluvastatin, lovastatin, pravastatin or simvastatin) 
in the secondary prevention of acute myocardial infarction in patients between 60 and 85 
years of age.378  A Markov model was used to project the number of survivors and the  
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annual direct and indirect cost per survivor associated with the reduction in non-fatal MI 
recurrences.  Doses and costs of statins necessary to reduce the LDL cholesterol by 36 
percent were considered for the analysis.  Transition probabilities for the Markov model 
were obtained from the 4S trial.  Lovastatin had the highest cost per life saved (YOLS) 
($15,073) whereas atorvastatin had the lowest cost/YOLS ($5,421).  The cost/YOLS for 
simvastatin was $9,232, for pravastatin $8,575, for cerivastatin $6,158 and for fluvastatin 
$5,790.  The cost-effectiveness of statin therapy was impacted by the patient’s age with 
higher cost-effectiveness per year of life saved for older than younger patients.  
Maclaine and Patel conducted a cost-effectiveness analysis of five statins to 
achieve target LDL levels in secondary prevention patients based on an economic model.  
Efficacy estimates of each statin were derived from meta-analysis.379  The model 
estimated the proportion of patients achieving target LDL levels under different 
scenarios.  The incremental cost per patient treated to target LDL levels compared to no 
treatment was lowest for atorvastatin (£383), followed by simvastatin (£431), cerivastatin 
(£501), fluvastatin (£820) and pravastatin (£1213).  Overall, the cost-effectiveness ratios 
were lowest for atorvastatin.  Under a fixed drug budget, more patients could be treated 
effectively with atorvastatin compared to other statins.380    
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Grover et al. studied the long-term benefits and cost-effectiveness of lipid 
modification in secondary prevention patients based on data from the Lipid Research 
Clinics cohort.381  Among low-risk individuals, long-term benefit of lipid modification 
ranged from $5424 to $9548 per year of life saved for men and $8389 to $13,747 per year 
of life saved for women.  Among high risk patients, the cost ranged from $4487 to $8532 
per year of life saved for men and $5138 to $8398 per year of life saved for women. 
 Ashraf and associates evaluated the cost-effectiveness of pravastatin in the 
secondary prevention of CHD using data from two plaque regression trials.382  Mortality 
data were estimated from the Framingham Heart Study.  Life-years saved for a 10 year 
time period were calculated with the help of a Markov model.  Cost per year of life saved 
in men with CHD decreased with the increase in the number of risk factors. The ratios 
were $9632 (for one risk factor) $7156 (for two risk factors) and $5473 (for more than or 
equal to three risk factors).  Due to lack of data indirect costs were not included in the 
model.383      
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Based on a review of the literature, treatment for secondary prevention is more 
cost-effective than primary prevention.  This could be due to the fact that individuals for 
secondary prevention are at a higher risk for recurrent coronary events than primary 
prevention patients; thus, there would be increased cost savings from events avoided at 
similar treatment costs.  Cost-effectiveness ratios are sensitive to baseline cholesterol 
levels and risk factors with higher ratios associated with greater number of risk factors 






ADVANTAGES AND DISADVANTAGES OF THE USE OF CLAIMS 
DATABASES IN HEALTH OUTCOMES RESEARCH 
 
The proposed study uses the Texas Medicaid prescriptions claims and healthcare 
services utilization claims database.  A brief discussion of the advantages and 
disadvantages for the use of claims databases follows.384 
 
Advantages  
The major advantage of using a medical claims database is its scope to link 
pharmacy claims and other health care resource utilization databases allowing for the 
examination of the relationships between different aspects of healthcare use.  Claims 
databases allow the evaluation of treatments in real life situations.  Patient information 
and patient care information are available for long periods of time, thus enabling the use 
of databases for longitudinal studies.  Because databases are large, they can be used for 
epidemiological research including studying patients with rare diseases and specific 
subpopulations.  Any changes in study designs can be easily implemented in research 
involving the use of database.  Research using databases is less costly and less time 
consuming compared to collecting primary data such as those in clinical trials.   
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Moreover, the large number of cases in a claims database offers statistical power at lower 
costs compared to clinical trials.   
 
Disadvantages 
Despite the number of advantages for use in outcomes research, claims databases 
do pose threats to internal, external and construct validity.385  Moreover, administrative 
databases are collected for the purpose of verifying and paying claims; thus, they contain 
a minimum set of information to carry out that purpose rather than include information 
for research purposes.386  Motheral and Fairman enumerates the following examples of 
threats to internal validity imposed by claims database research.387  
1) Diagnostic information such as the use of the International Classification of 
Diseases, 9th Revision, Clinical Modification (ICD-9-CM) in database research 
may not always be reliable or valid.  Under-coding and over-coding of diagnoses 
can occur that could result in a study bias.  Over-coding can occur either 
intentionally or unintentionally as a result of economic incentives related to 
diagnostic-related groups.  Under-coding might occur as the physician might not 
record secondary diagnoses due to limitations in the number of diagnoses that can 
be recorded in the insurance claims forms. 
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2) Differences in compliance between various therapeutic categories need to be 
taken into account before concluding about relationships between treatment and 
outcome variables. 
3)  Misclassification of exposure could lead to bias in the study results.  Moreover, 
the results could also be affected by the possibility of referral bias and protopathic 
bias. 
4)  Another potential threat to internal validity includes the presence of confounding 
variables.  Severity of illness is frequently cited as a confounder in outcomes 
research. Inadequate clinical information present in databases limits the 
adjustments for severity.388  Important confounding variables such as smoking 
status, family history of illness, alcohol use, drug use and use of over-the-counter-
drugs are missing from the Medicaid database hence they cannot be controlled for 
in the study.389 
 Construct validity refers to the degree to which a variable measures what it is 
meant to measure.  In the database, the use of a drug as a proxy for the presence of a 
medical condition can be misleading.  Some drugs have multiple uses and thus, it may be 
difficult to determine the disease state.  Also, the use of drugs for off-label purposes 
could lead to the risk of misidentifying patients to a medical condition that they might not 
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have.  Similarly, patients with the medical condition of interest might not be included 
since not all diagnosed individuals receive treatment.  
External validity refers to the degree of generalizability of the study.  For 
example, a study conducted using a Medicaid database would not be generalizable to a 
large population since the characteristics of the Medicaid population include low income 
and disabled individuals who might have different patterns of health care utilization as 
compared to the rest of the population.  Similarly, plan design, geographic variations and 
differences in cost across time and place limit the generalizability of the study.  With 
increasing use of healthcare databases in research, the right to safeguard patient privacy 
and confidentiality has become an important issue.  Unauthorized persons or agencies 
might get access to health care information which could be sold to marketing firms.390 
In addition to the above limitations, eligibility changes to the insurance program 
such as Medicaid may cause patients to be terminated from the study.  Thus, it could lead 
to misinterpretation that the outcome of interest did not occur in the patient when in 
reality, the patient was no longer part of the database.  This limitation can be addressed 
using the eligibility files to ensure that the patient is enrolled in the database.391  Medical 
claims for individuals above 65 years of age may be incomplete due to dual eligibility in 
Medicaid and Medicare programs.  Missing data such as those for prescription claims 
could be problematic especially when assessing prescription refill patterns since failure to 
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refill prescriptions could be a result of missing claims rather than lack of patient 
adherence.392  Despite the disadvantages of the use of databases, they are an important 
resource in outcomes research.  Nevertheless, the limitations of database research need to 
be acknowledged.  
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TEXAS MEDICAID DATABASE AND CARDIOVASCULAR DISEASE IN 
TEXAS 
 
Texas Medicaid Program 
The Medicaid program in Texas, established in 1967, is a jointly funded state-
federal program administered by the Texas Health and Human Services Commission. As 
of February 2004, 2.5 million Texans were enrolled in the Medicaid program.393  For the 
year fiscal year 2004, Medicaid expenditures were projected to be $15.5 billion.394  The 
categories of individuals eligible for Medicaid include low income families and children 
including pregnant women, recipients of Temporary Assistance to Needy Families 
(TANF) or Supplemental Security Income (SSI) and the aged and disabled.  Females 
(56%) and non disabled children (59%) make up the largest share of the Texas Medicaid 
program.  Hispanics constitute the largest portion of Medicaid recipients (51%) followed 
by Caucasians (26%) and African Americans (19%).395  Medicaid covers basic health 
care including physician services, outpatient and inpatient services, pharmacy, laboratory 
and x-ray services.  Long-term care facilities, nursing facilities, and intermediate care 
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facilities for persons with mental retardation as well as hospice care are also funded by 
Medicaid.  Medicaid also provides coverage for prescription drugs through the Texas 
Medicaid Vendor Drug Program.   
 
Texas Medicaid Vendor Drug Program 
 
The Texas Medicaid program offers coverage for prescription drug services to its 
enrollees.  This program is administered by the Texas Medicaid Vendor Drug Program 
(VDP).  The VDP covers up to three outpatient prescriptions per month per adult 
recipient.  Medicaid clients who are in an inpatient hospital, long-term care residents, 
managed care recipients and children under 21 years are not subject to the three 
prescription drug limit.396  In the year 2001, the Vendor Drug Program spent a total of 
$1.4 billion for 28.7 million claims.397  The prescription claims information is stored in a 
data warehouse maintained by the National Heritage Insurance Company (NHIC) which 
is the claims administrator for the Texas Department of Health and Human Services. 
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Prevalence of Hyperlipidemia in Texas 
 
According to the Behavior Risk Factor Surveillance System survey which is an 
ongoing monthly telephone survey conducted by the Texas Department of Health in 
conjunction with the Centers for Disease Control and Prevention (CDC) reported that the 
overall prevalence of high cholesterol in 2002 was 31.8 percent (Table 1.6).398  Overall, 
the trend in the prevalence of high cholesterol has been increasing gradually since 1990 
with the sharpest rise observed between 1997 to 1999 (Figure 1).  The prevalence of high 
cholesterol was 61.4 percent and 27.7 percent amongst CVD and non-CVD patients, 
respectively.399  
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http://www.tdh.state.tx.us/wellness/cvd/cvdsurv2003.pdf. Accessed November 17, 2003. 
399 Cardiovascular Health and Wellness Program. Cardiovascular disease in Texas: A risk 
factor report. 1999 Survey Data. Bureau of Chronic Disease and Tobacco Prevention, 
Texas Department of Health. Available at: 





Table 1.6: Prevalence of High Cholesterol in Texas By Gender and Ethnicity in 2002 




African Americans 29.2% 
Hispanics 24.5% 
Overall 31.8% 
Source: Bureau of Chronic Disease and Tobacco Prevention, Texas Department of 










Source: Bureau of Chronic Disease and Tobacco Prevention, Texas Department of 






Cardiovascular Disease in Texas 
 
Cardiovascular diseases including ischemic heart disease, stroke and congestive 
heart failure were the leading causes of death in Texas claiming 55,000 lives every 
year.400  In 2001, the prevalence of myocardial infarction was 3.6 percent (548,000), 
angina pectoris was 4.2 percent (590,000), and stroke was 2.3 percent (350,000).  The 
prevalence of CHD by ethnicity is as follows: 8.9 percent for non-white Hispanics, 5.7 
percent for African Americans and 5.4 percent for Hispanics.401 
It was estimated that CVD cost Texas over $9 billion a year.  In 1995, there were 
approximately 185,000 Medicare hospitalizations in which CVD was the primary 
diagnosis.  In 1996, CVD was responsible for 40 percent of all deaths in Texas.  
Medicare spent a total of $500 million for CVD-related procedures in the year 1994.  
CVD remains the number one cause of emergency room visits.402  CVD-related hospital 
discharges in the first two quarters of 1999 accounted for 18 percent of total discharges.  
Of these, ischemic heart disease accounted for 35 percent of all discharges, followed by 
                                                 
400 Texas Council on Cardiovascular Disease & Stroke 2001 Legislative Report. 
Available at: http://www.tdh.state.tx.us/wellness/cvd/cvd.htm. Accessed September 15, 
2003. 
401 Cardiovascular Health and Wellness Program. Cardiovascular Disease (CVD) in 
Texas: A surveillance report and program strategy 2003. Bureau of Chronic Disease and 
Tobacco Prevention, Texas Department of Health. Available at: 
http://www.tdh.state.tx.us/wellness/cvd/cvdsurv2003.pdf. Accessed November 17, 2003. 
402 Cardiovascular Health and Wellness Program. Cardiovascular disease in Texas: A 
state plan with disease indicators and strategies for action. Bureau of Chronic Disease 
and Tobacco Prevention, Texas Department of Health. Available at: 




stroke (17.5%) and congestive heart failure (16.8%).403  In the year 2001, there were 
approximately 136,863 CHD-related hospital discharges accounting for $4.4 billion.404          
In the year 2002, the prevalence of CVD risk factors such as high cholesterol, 
blood pressure and diabetes was 31.8 percent, 25.6 percent and 7 percent, respectively.  
Overall there has been an increasing trend in the prevalence of CVD risk factors    
(Figure 1.2).  There is a high prevalence of risk factors such as hypertension (63.6 
percent), high blood cholesterol (61.4 percent), diabetes (23.1 percent), obesity (71.9 
percent) and smoking (66.4 percent) among patients with CVD.  Thus, the management 
of these risk factors including hyperlipidemia is important to alleviate the burden of 
CVD.405    
 
                                                 
403 Texas Council on Cardiovascular Disease & Stroke 2001 Legislative Report. 
Available at: http://www.tdh.state.tx.us/wellness/cvd/cvd.htm. Accessed September 15, 
2003. 
404 Cardiovascular Health and Wellness Program. Cardiovascular Disease (CVD) in 
Texas: A surveillance report and program strategy 2003. Bureau of Chronic Disease and 
Tobacco Prevention, Texas Department of Health. Available at: 
http://www.tdh.state.tx.us/wellness/cvd/cvdsurv2003.pdf. Accessed November 17, 2003. 
405 Cardiovascular Health and Wellness Program. Cardiovascular Disease (CVD) in 
Texas: A surveillance report and program strategy 2003. Bureau of Chronic Disease and 
Tobacco Prevention, Texas Department of Health. Available at: 




Use of Statins in the Texas Medicaid 
Statins are the most widely prescribed lipid-lowering agents in the Texas 
Medicaid program.  The Texas Medicaid program spent over $170 million on 
cardiovascular drugs in the year 2002.406  Statins accounted for a number of the top 50 
drugs in the Medicaid program in the year 2001, with Lipitor® 10 mg, Lipitor® 20 mg and 
Zocor® 20 mg tablets ranking 9th, 18th and 23rd respectively.  Approximately $21 million 
was expended on these statin drugs in the year 2001.407   
 
Criteria for Outpatient Use of Statins in the Texas Medicaid  
The Texas Medicaid has review criteria for the use of HMG-CoA reductase 
inhibitors for outpatient use.408  It emphasizes the use of dietary intervention prior to 
initiating patients on statins.  If patients respond poorly to the initial doses, higher doses 
may be prescribed.  Doses of statins drugs can be increased every four weeks based on 
the patient’s response to the drug.  Hepatic function should be monitored periodically on  
                                                 
406 Pharmaceutical Benefits Under State Assistance Programs. Pharmacy program 
charateristics. Available at: 
http://www.npcnow.org/resources/PDFs/medicaid2003/03Sec4.pdf. Accessed December 
14, 2004. 
407 Texas Medicaid: Top 50 drugs cost analysis: Center for Pharmacoeconomics Studies.  
The University of Texas at Austin.  
408 Drug Information Service, The University of Texas Health Science Center at San 
Antonio, and the College of Pharmacy, et al. Medicaid drug use review criteria for 
outpatient use: HMG-CoA reductase inhibitors. Available at: 




initiating statin therapy.  Additionally, hepatic function should also be monitored 
following any dose increase or addition of medications to the statin therapy that could 
initiate a drug interaction.  Concomitant use of other lipid-lowering drugs such as 
gemfibrozil and niacin should be reviewed due to the increased incidence of myopathy 
and rhabdomylosis.  Use of other drugs such as immunosuppressive agents, nefazodone, 
azole antifungals, macrolide antibiotics and selected protease inhibitors in conjunction 
with HMG-CoA reductase inhibitors should be reviewed for potential adverse events.       
 
Rationale for the Study 
Cardiovascular diseases are the leading cause of mortality and morbidity in the 
U.S.  Epidemiologic studies support the association between hyperlipidemia and 
increased risk of CHD.  The management of hyperlipidemia is crucial in preventing the 
occurrence of CHD with the treatment of hyperlipidemia being a life-long process.  
Statins are recommended as the first line of drug therapy in the treatment of 
hyperlipidemia.  Texas Medicaid spent $21 million on statin drugs in the year 2001.  
Given the expense as well as the life-long treatment of the condition, it is important to 
understand the treatment of hyperlipidemia in the Texas Medicaid so that decision-
makers can implement effective strategies to improve the management of the condition.  
The literature review has revealed a lack of adequate management of 




have used data from managed care organizations.  There has been no published study on 
the management of hyperlipidemia and adherence to cholesterol guidelines in the Texas 
Medicaid program.  Moreover, the literature also revealed a gap in data on the 
management of hyperlipidemia among women and minority populations such as 
Hispanics and African Americans.  The current research project aims to fill the gap in the 
literature with respect to understanding the treatment patterns, general adherence to 
guidelines and adherence to statin drug regimens among hyperlipidemic patients enrolled 







GOALS, OBJECTIVES AND HYPOTHESES OF THE STUDY 
 
Goals 
The two major goals for this study are: 
1. Evaluation of statin treatment patterns and patient adherence to statin therapy; 
and 
2. Evaluation of how well physicians follow lipid and safety monitoring guidelines.  
These goals apply to the Texas Medicaid program. 
 
Specific Objectives of the Study  
The specific objectives for each of these goals follow:  
Evaluation of Statin Treatment Patterns and Patient Adherence to Statin Therapy 
1. To provide descriptive statistics on statin drug use and the starting dose; 
2. To determine the association between statin dose prescribed at index date and 
CHD status at or prior to the index date; 
3. To determine the use of lipid lowering drugs other than statins; 
4.  To determine the proportion of physicians by specialty who prescribed the initial 
statin therapy; 
5. To provide descriptive statistics on the demographic characteristics (age, gender, 




6. To determine the proportion of primary and secondary CHD prevention patients 
initiated on statins; 
7. To determine the frequency distribution of patients initiated on statin therapy 
based on the number and type of risk factors (males > 45 years, females > 55 
years, presence of hypertension and diabetes) for CHD; 
8. To determine patient adherence to statin therapy based on prescription refill 
records; 
9. To determine the persistence with statin therapy; 
10. To determine the total amount reimbursed by Medicaid for statin drugs; 
11. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic diseases, and total number of prescriptions are predictors of 
adherence to statin therapy; and 
12. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic diseases, and total number of prescriptions are predictors of 









Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines 
13. To determine lipoprotein measurements at baseline (three months prior to index 
date) and follow-up (three months after index date and six months thereafter) after 
initiating statin therapy and within three months of a change in therapy; 
14. To assess the frequency and proportion of liver function tests (LFTs) to monitor 
adverse events in patients on statin therapy; 
15. To assess the presence of LFTs following the initial dose increase; 
16. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic diseases, are predictors of the occurrence of lipid monitoring tests 
at baseline (within three months prior to start of therapy); 
17. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic disease, physician specialty at index date and lipid testing at 
baseline are predictors of the  occurrence of lipid monitoring after the start of 
therapy (within three months, but not earlier than six weeks since the start of 
therapy); 
18. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic disease, physician specialty at index date and lipid testing at 
baseline are predictors of the occurrence of lipid monitoring (within three months, 




19. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic disease, physician specialty at index date and lipid testing at 
baseline are predictors of the occurrence of lipid monitoring (within three months, 
but not earlier than six weeks) following the initial change in statin dose; 
20. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic diseases are predictors of the occurrence of LFTs at baseline 
(within three months prior to start of therapy); 
21. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic disease, physician specialty at index date and LFTs at baseline are 
predictors of the occurrence of LFTs (within three months, but not earlier than six 
weeks) after the start of therapy; and 
22. To determine if factors such as demographic characteristics (age, gender and 
ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic disease, physician specialty at index date and LFTs at baseline are 
predictors of the occurrence of LFTs  (within three months, but not earlier than 




Hypotheses for the Study Objectives 
The study will test the following hypotheses: 
Goal: Evaluation of Statin Treatment Patterns and Patient Adherence to Statin 
Therapy 
Objective 2: Starting Dose and Type of CHD Prevention 
 
Hypothesis 1:  The starting dose for statin therapy for secondary prevention patients will 
be higher than for primary prevention patients, controlling for the type of statin. 
 
Objective 11: Predictors of MPR 
Hypothesis 2: The MPR will be higher for males than for females, controlling for age, 
ethnicity, presence of CHD, diabetes, hypertension, atherosclerotic diseases, and total 
number of prescriptions. 
 
Hypothesis 3: The MPR will be higher for older patients than for younger patients, 
controlling for gender, ethnicity, presence of CHD, diabetes, hypertension, 
atherosclerotic disease, and total number of prescriptions. 
 
Hypothesis 4: The MPR will be higher for non-Hispanic whites than for other ethnic 
groups, controlling for age, gender, presence of CHD, diabetes, hypertension, 
atherosclerotic diseases, and total number of prescriptions. 
 
Hypothesis 5: The MPR will be higher for secondary prevention CHD patients than for 
primary prevention CHD patients, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, atherosclerotic diseases, and total number of prescriptions. 
 
Hypothesis 6: The MPR will be higher for diabetics than for non-diabetics, controlling 
for age, gender, ethnicity, presence of CHD, hypertension, atherosclerotic diseases, and 
total number of prescriptions. 
 
Hypothesis 7: The MPR will be higher for hypertensives than for non-hypertensives, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, atherosclerotic 
diseases, and total number of prescriptions. 
 
Hypothesis 8:  The MPR will be higher for those patients with atherosclerotic diseases 
than for those without atherosclerotic diseases, controlling for age, gender, ethnicity, 





Hypothesis 9: The MPR will be higher for those patients on a lower number of total 
prescriptions other than statins than for those on a higher number of prescriptions, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic disease.  
 
Objective 12: Predictors of Persistence 
Hypothesis 10: Females will have a higher hazard of becoming non-persistent to statin 
therapy than males controlling for age, ethnicity, presence of CHD, hypertension, 
diabetes, atherosclerotic diseases, and total number of prescriptions. 
 
Hypothesis 11: Younger patients will have a higher hazard of becoming non-persistent to 
statin therapy than older patients, controlling for gender, ethnicity, presence of CHD, 
hypertension, diabetes, atherosclerotic diseases, and total number of prescriptions. 
 
Hypothesis 12: Other ethnic minorities will have a higher hazard of becoming non-
persistent to statin therapy than non-Hispanic whites, controlling for age, gender, 
presence of CHD, hypertension, diabetes, atherosclerotic diseases, and total number of 
prescriptions. 
 
Hypothesis 13: Patients without CHD will have a higher hazard of becoming non-
persistent to statin therapy than those with CHD, controlling for age, gender, ethnicity, 
presence of hypertension, diabetes, atherosclerotic diseases, and total number of 
prescriptions. 
 
Hypothesis 14: Patients without diabetes will have a higher hazard of becoming non-
persistent to statin therapy than those with diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, atherosclerotic diseases, and total number of 
prescriptions. 
 
Hypothesis 15: Patients without hypertension will have a higher hazard of becoming non-
persistent to statin therapy than those with hypertension, controlling for age, gender, 






Hypothesis 16: Patients without atherosclerotic diseases will have a higher hazard of 
becoming non-persistent to statin therapy than those with atherosclerotic diseases 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension, and total 
number of prescriptions. 
 
Hypothesis 17:  Patients on greater number of total prescriptions other than statins will 
have a higher hazard of becoming non-persistent than those on fewer prescriptions, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
 
Goal: Evaluation of How Well Physicians Follow Lipid and Safety Monitoring 
Guidelines 
Objective 16: Predictors of Lipid Testing Prior to Start of Therapy 
Hypothesis 18: The likelihood of a lipid test at baseline will be higher for males than for 
females, controlling for age, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
 
Hypothesis 19: The likelihood of a lipid test at baseline will be higher for older patients 
than for younger patients, controlling for gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
 
Hypothesis 20: The likelihood of a lipid test at baseline will be higher for non-Hispanic 
whites than for other ethnic groups, controlling for age, gender, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases. 
 
Hypothesis 21: The likelihood of a lipid test at baseline will be higher for patients with 
CHD than for those without CHD, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, and atherosclerotic diseases. 
 
Hypothesis 22: The likelihood of a lipid test at baseline will be higher for patients with 
diabetes than for those without diabetes, controlling for age, gender, ethnicity, presence 
of CHD, hypertension, and atherosclerotic diseases. 
 
Hypothesis 23: The likelihood of a lipid test at baseline will be higher for patients with 
hypertension than for those without hypertension, controlling for age, gender, ethnicity, 





Hypothesis 24: The likelihood of a lipid test at baseline will be higher for patients with 
atherosclerotic diseases than for those without atherosclerotic diseases, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and hypertension. 
 
Objective 17: Predictors of Lipid Testing After the  Start of Therapy 
Hypothesis 25: The likelihood of a lipid test after start of therapy will be higher for males 
than for females controlling for age, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, and lipid testing prior to index date. 
 
Hypothesis 26: The likelihood of a lipid test after start of therapy will be higher for older 
patients than for younger patients, controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty and lipid testing 
prior to index date. 
 
Hypothesis 27: The likelihood of a lipid test after start of therapy will be higher for non-
Hispanic whites than for other ethnic groups, controlling for age, gender, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, physician specialty and lipid 
testing prior to index date. 
 
Hypothesis 28: The likelihood of a lipid test after start of therapy will be higher for 
patients with CHD than for those without CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and atherosclerotic diseases, physician specialty and 
lipid testing prior to index date. 
 
Hypothesis 29: The likelihood of a lipid test after start of therapy will be higher for 
patients with diabetes than for those without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 30: The likelihood of a lipid test after start of therapy will be higher for 
patients with hypertension than for those without hypertension, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 31: The likelihood of a lipid test after start of therapy will be higher for 
patients with atherosclerotic diseases than for those without atherosclerotic diseases, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, 







Hypothesis 32: The likelihood of a lipid test after start of therapy will be higher for 
patients treated by a cardiologist at index date than for those treated by other physician 
specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension 
and atherosclerotic diseases, and lipid testing prior to index date. 
 
Hypothesis 33: The likelihood of a lipid test after start of therapy will be higher for 
patients with lipid tests at baseline than those without lipid tests at baseline, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, atherosclerotic 
diseases, and physician specialty. 
 
Objective 18: Predictors of Lipid Testing After an Initial Change in Statin Type 
Hypothesis 34: The likelihood of a lipid test after an initial change in statin type will be 
higher for males than for females controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
 
Hypothesis 35: The likelihood of a lipid test after an initial change in statin type will be 
higher for older patients than for younger patients, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 36: The likelihood of a lipid test after an initial change in statin type will be 
higher for non-Hispanic whites than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 37: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with CHD than for those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 38: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with diabetes than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
 
Hypothesis 39: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with hypertension than for those without hypertension, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, 





Hypothesis 40: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and lipid testing prior to index date. 
 
Hypothesis 41: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients treated by a cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and lipid testing prior to index date. 
 
Hypothesis 42: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with lipid tests at baseline than those without lipid tests at baseline, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, 
atherosclerotic diseases, and physician specialty. 
 
Objective 19: Predictors of Lipid Testing After an Initial Change in Statin Dose 
Hypothesis 43: The likelihood of a lipid test after an initial change in statin dose will be 
higher for males than for females controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
 
Hypothesis 44: The likelihood of a lipid test after an initial change in statin dose will be 
higher for older patients than for younger patients, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 45: The likelihood of a lipid test after an initial change in statin dose will be 
higher for non-Hispanic whites than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 46: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with CHD than for those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Hypothesis 47: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with diabetes than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, 





Hypothesis 48: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with hypertension than for those without hypertension, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
 
Hypothesis 49: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and lipid testing prior to index date. 
 
Hypothesis 50: The likelihood of a lipid test after an initial change in statin dose  will be 
higher for patients treated by a cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and lipid testing prior to index date. 
 
Hypothesis 51: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with lipid tests at baseline than those without lipid tests at baseline, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, 
atherosclerotic diseases, and physician specialty. 
 
 
Objective 20: Predictors of LFTs Prior to Start of Therapy 
Hypothesis 52: The likelihood of a LFT at baseline will be higher for males than for 
females, controlling for age, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
 
Hypothesis 53: The likelihood of a LFT at baseline will be higher for older patients than 
for younger patients, controlling for gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
 
Hypothesis 54: The likelihood of a LFT at baseline will be higher for non-Hispanic 
whites than for other ethnic groups, controlling for age, gender, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases. 
 
Hypothesis 55: The likelihood of a LFT at baseline will be higher for patients with CHD 
than for those without CHD, controlling for age, gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases. 
 
Hypothesis 56: The likelihood of a LFT at baseline will be higher for patients with 
diabetes than for those without diabetes, controlling for age, gender, ethnicity, presence 





Hypothesis 57: The likelihood of a LFT at baseline will be higher for patients with 
hypertension than for those without hypertension, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and atherosclerotic diseases. 
 
Hypothesis 58: The likelihood of a LFT at baseline will be higher for patients with 
atherosclerotic diseases than for those without atherosclerotic diseases, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and hypertension. 
 
Objective 21: Predictors of LFTs After Start of Therapy 
Hypothesis 59: The likelihood of an LFT after start of therapy will be higher for males 
than for females controlling for age, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, and presence of LFT prior to index 
date. 
 
Hypothesis 60: The likelihood of an LFT after start of therapy will be higher for older 
patients than for younger ones, controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
 
Hypothesis 61: The likelihood of an LFT after start of therapy will be higher for non-
Hispanic whites than for other ethnic groups, controlling for age, gender, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, physician specialty and 
presence of LFT prior to index date. 
 
Hypothesis 62: The likelihood of an LFT after start of therapy will be higher for patients 
with CHD than for those without CHD, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
 
Hypothesis 63: The likelihood of an LFT after start of therapy will be higher for patients 
with diabetes than for those without diabetes, controlling for age, gender, ethnicity, 
presence of CHD, hypertension, and atherosclerotic diseases, physician specialty, and 
presence of LFT prior to index date. 
 
Hypothesis 64: The likelihood of an LFT after start of therapy will be higher for patients 
with hypertension than for those without hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, physician specialty 





Hypothesis 65: The likelihood of an LFT after start of therapy will be higher for patients 
with atherosclerotic diseases than for those without atherosclerotic diseases, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, physician 
specialty, and presence of LFT prior to index date. 
 
Hypothesis 66: The likelihood of an LFT after start of therapy will be higher for patients 
treated with a cardiologist at index date than for those treated by other physician 
specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension 
and atherosclerotic diseases, and presence of LFT prior to index date. 
 
Hypothesis 67: The likelihood of an LFT after start of therapy will be higher for patients 
with LFTs at baseline than those without LFTs at baseline, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and hypertension, atherosclerotic diseases, and 
physician specialty. 
 
Objective 22: Predictors of LFTs After an Initial Increase in Statin Dose 
Hypothesis 68: The likelihood of an LFT after an initial increase in statin dose will be 
higher for males than for females controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
 
Hypothesis 69: The likelihood of an LFT after an initial increase in statin dose will be 
higher for older patients than for younger patients, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
 
Hypothesis 70: The likelihood of an LFT after initial increase in statin dose will be 
higher for non-Hispanic whites than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
 
Hypothesis 71: The likelihood of an LFT after an initial increase in statin dose will be 
higher for patients with CHD than for those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
 
Hypothesis 72: The likelihood of an LFT after an initial increase in statin dose will be 
higher for patients with diabetes than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, 





Hypothesis 73: The likelihood of an LFT after an initial increase  in statin dose will be 
higher for patients with hypertension than for those without hypertension, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, 
physician specialty, and presence of LFT prior to index date. 
 
Hypothesis 74: The likelihood of an LFT after an initial increase in statin dose will be 
higher for patients with atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and presence of LFT prior to index date. 
 
Hypothesis 75: The likelihood of an LFT after an initial increase in statin dose will be 
higher for patients treated by a cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and presence of LFT prior to index date 
 
Hypothesis 76: The likelihood of an LFT after start of therapy will be higher for patients 
with LFTs at baseline than those without LFTs at baseline, controlling for age, gender, 













This chapter presents a description of the study design, study population, data sources, 
study variables and the data analysis plan.   
 
STUDY DESIGN AND POPULATION 
This study was a retrospective cohort analysis using the Texas Medicaid database. 
The study population included patients who had started taking a statin drug and were 
between ages of 21 and 64 years and who were eligible for Texas Medicaid benefits 
between September 1, 1998 to August 31, 2003.  Recipients over 65 years old were not 
included in the analysis since the researcher was not able to obtain complete medical 
claims for patients who had dual eligibility (i.e., some patients were covered under both 
the Medicaid and Medicare programs).   
 
Identification of Study Subjects 
The design was a retrospective cohort study of statin users in the Texas Medicaid 
system.  The study period was from September 1, 1998 to August 31, 2003.  Patients who 
filled at least one prescription for a statin (atorvastatin, fluvastatin, lovastatin, pravastatin 
or simvastatin) between September 1, 1999 and August 31, 2001 were included.  Patients 
on cerivastatin were excluded from the study since this drug was recalled in 2001.  The 




between September 1, 1999 and August 31, 2001.  An explanation of the timeline for the 
study is presented in Figure 2.1.  To ensure the inclusion of only new statin users, 
enrollees who had at least one prescription for any drug, but no statin prescriptions in the 
twelve-month period prior to the index date were included in the study.  Individuals were 
followed for two years from the index date.  Individuals should have had one and two 
years of continuous enrollment prior to and after the index date, respectively, to be 
included in the study.  Enrollment in the Medicaid system was determined from the 
eligibility start and end dates present in the Texas Medicaid Eligibility File.  In addition, 
patients should have had at least two fills of statin drugs on separate dates within the first 







Figure 2.1:  Time-frame for the Study 
DATA SOURCES 
Data were collected from Texas Medicaid claims data files: (1) Medicaid 
Eligibility File; (2) Texas Medicaid Medical Claims File; (3) Texas Medicaid 
Prescription Claims File; and (4) Texas State Board of Medical Examiners database.  The 
databases were used to extract information on Medicaid eligibility of statin users, their 
demographic characteristics, statin use, clinical conditions, lipid and hepatic function 
monitoring, and physician demographics characteristics. The information contained in 
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The Texas Medicaid Eligibility File 
 A unique client identification number was assigned to each Medicaid patient in 
the eligibility file and it was used to link the prescription and the medical claims 
databases.  Table 2.1 presents information found in the Texas Medicaid Eligibility File.  
Table 2.1:  Texas Medicaid Eligibility File Information 
1. Unique client identification number 
2. Date of birth 
3. Gender of patient  
4. Ethnicity of patient  
5. Eligibility start date 
6. Eligibility end date 
 
 
The Texas Medicaid Medical Claims File 
 
Only the medical claims from fee-for-service (FFS) and primary care case 
management (PCCM) Medicaid recipients were extracted and included in the Texas 
Medicaid Medical Claims file.  This was done out of concern that the managed care 
Medicaid claims were incomplete due to the capitation payment method of the managed 













Table 2.2:  Texas Medicaid Medical Claims File Information 
 
1. Unique client identification number 
2. Performing provider number 
3. Diagnosis 1 
4. Diagnosis 2 
5. Diagnosis 3 
6. Diagnosis 4 
7. Diagnosis 5 
8. Procedure code 
9. Beginning date of service for the claim 
10. Last date of service covered by the claim 
11. Place of service (e.g. emergency room, inpatient hospital, physician’s 
office, etc.) 
12. Type of service (e.g. surgery, consultation, anesthesia etc.) 
13. Admit date 
14. Admit diagnosis  
15. Type of admission (e.g. emergency, elective, newborn etc.) 
16. Days of service 
17. Medicaid payment for the service 
18. County code 
19. DRG code 







The Texas Medicaid Prescription Claims File 
Medicaid reimbursed prescription claims records of individuals identified to be 
eligible for the study were extracted from the Texas Medicaid Vendor Drug paid claims 
database.  Table 2.3 presents information included in the prescription claims file. 
 
Table 2.3:  Texas Medicaid Prescription Claims File Information 
1. Unique client identification number 
2. Pharmacy provider number 
3. Date prescription filled 
4. Number of refills authorized 
5. Prescribing physician number 
6. Prescribing physician specialty 
7. Amount reimbursed by Medicaid 
8. National Drug Code (NDC) (unique code for drugs that 
identifies the labeler/vendor, product, and package size) 
9. Generic product sequence code (unique product code provided 
by First DataBank and assigned to all products having the same 
active ingredient and dosage form regardless of manufacturer) 
10. Generic product identifier (GPI) (classified drugs with respect to 
the compound regardless of the strength) 
11. Quantity dispensed 
12. Day’s supply 
13. Strength 
14. Age of patient at prescription dispensing 






APPROVAL TO USE HUMAN SUBJECTS 
 The study did not involve direct contact with patients and the information was de-
identified.  However, since health information of subjects from the Medicaid database 
was used for the study, it was necessary to file a petition to The University of Texas 
Institutional Review Board to obtain a waiver of informed consent. The study received 
approval for a waiver of informed consent from the Institutional Review Board at the 
University of Texas at Austin (UT-IRB #2003-09-0132).  As noted in the request for a 
waiver, the use of health information for this study involved no more than a minimal risk 
to the privacy of individuals since the study was a retrospective analysis of claims 
database and the researcher did not have access to personal names, social security 
numbers or addresses of the Medicaid patients.   
The Medicaid unique identification number was used only to link the pharmacy 
claims with the healthcare utilization claims and was replaced by alpha numeric 
characters which were linked to the identification number.   The de-identified records 
were stored on the Center for Pharmacoeconomic Studies server computer and only the 
principal investigator, the supervisor of the dissertation (Marvin D. Shepherd, Ph.D.) and 
the associate director of the Center for Pharmacoeconomic Studies (Michael T. Johnsrud, 








All dependent and independent variables included in the study are defined in 
Table 2.4.  The operationalization of the study variables is explained later in this chapter.   
Table 2.4: Explanation of the Variables Used in the Study 
 
Variable Explanation 
Age Age was reported as the age of the person at the index date.  Only those 
patients who were between the ages of 21-62 years at the index date were 
included.  Age was analyzed as a continuous variable. 
Gender Gender was indicated as “male or “female.”   
Ethnicity Ethnicity was coded as non-Hispanic whites, non-Hispanic blacks, 




Information on the specialty of the prescribing physician at index date 
was obtained from the Texas State Board of Medical Examiners 
(TSBME) database.  The physician’s unique license number was used to 
link the Medicaid file with the database obtained from TSBME. Specialty 
of the physician prescribing the statin at the index date was classified into 
three groups: general practice/family practice and internal medicine; 
cardiologists; and others. 
Physician 
Demographics 
Demographic characteristics such as age, gender and years of licensure of 
the physician prescribing the statin at index date was determined from the 
TSBME database. 
Type of CHD 
prevention 
Patients were classified as primary or secondary prevention patients based 
on the diagnosis for established CHD in the year prior to or at the index 
date.  The development of a new diagnosis for CHD during the follow-up 
period was also assessed.  
Diabetes Presence or absence of diabetes as a risk factor for CHD in the year prior 
to or at the index date was coded as “yes” or “no,” respectively.  The 
development of a new diagnosis for diabetes during the follow-up period 
was also assessed. 
Total number of 
prescriptions 
The total number of unique prescriptions (other than statins) that the 
patient was on during the two-year follow-up period was assessed using 
the Generic Product Identifier (GPI) that classifies products based on the 








Table 2.4:  Explanation of the Variables in the Study (continued) 
 
Variable Explanation 
Hypertension Presence or absence of hypertension as a risk factor for CHD in the year 
prior to or at the index date was coded as “yes” or “no,” respectively.  The 
development of a new diagnosis for hypertension during the follow-up 




Presence or absence of other atherosclerotic disease including 
atherosclerosis, stroke and peripheral vascular disease was assessed prior 
to or at the index date and during the follow-up period and was coded as 




Two measures were used to assess compliance to statins: 
• Medication Possession Ratio (MPR)  
 The MPR was calculated as a ratio of the sum of the days’ supply 
dispensed (except supply at the last refill date) and the sum of the 
days between the first and the last prescription 
• Persistence  
 Persistence was expressed as number of days of statin therapy 
before discontinuation.  Discontinuation was defined as failure to 
refill the prescription within 60 days of exhausting the last supply. 
A sensitivity analysis was conducted using a gap of 45 days. 
Lipid 
measurements 
The presence of a lipid test was assessed at: 
• Baseline (within three months prior to initiation of statin therapy). 
• Follow-up (within three months, but not earlier than six weeks, 
after initiation of statin therapy and six months, thereafter). 
• Within three months, but not earlier than six weeks, following 
initial change in dose of statin drug. 
• Within three months, but not earlier than six weeks, following the 
initial change in statin type. 




The presence of LFT was assessed at: 
• Baseline (within three months prior to initiation of statin therapy). 
• Follow-up (within three months but not earlier than six weeks after 
initiation of statin therapy and six months thereafter). 
• Within three months but not earlier than six weeks, following an 
initial increase in statin dose. 








MEASURES OF VARIABLES 
 
 A description of how each of the variables described in Table 2.4 was 
operationalized is presented in this section. 
 
Type of Coronary Heart Disease (primary or secondary) Prevention Patients 
Patients were classified as either primary or secondary prevention patients at the 
index date based on the diagnosis of coronary heart disease (CHD) in the year prior to or 
at the index date.  The development of a new diagnosis for CHD during the follow-up 
period was also assessed.  Primary prevention patients were defined as patients without a 
history of established CHD whereas secondary prevention patients were those who had a 
history of established CHD including indications for acute myocardial infarction, angina, 
chronic ischemic heart disease, history of percutaneous coronary intervention or coronary 
artery bypass graft.  Primary and secondary prevention patients were differentiated based 
on the diagnostic codes (International Classification of Diseases, 9th Revision, Clinical 
Modifications [ICD-9-CM]) (Table 2.5) and procedural codes (Current Procedural 









Table 2.5: Description of Diagnostic Codes to Identify the Presence of Established 
CHD 
ICD-9-CM Codes Description 
410.xx Acute myocardial infarction 
411.xx Other acute or subacute forms of ischemic heart disease 
412 Old myocardial infarction 
413  Angina pectoris 
414.xx Other forms of chronic ischemic heart disease 
36.0x Percutaneous coronary intervention 
36.1x Coronary artery bypass graft (CABG) 
 
Table 2.6: Description of Procedural Codes to Identify the Presence of CHD 
CPT codes Description 
33510-33516 Coronary artery bypass-venous grafting only procedures 
33517-33530 Coronary artery bypass-combined arterial-venous grafting 
33533-33536 Coronary artery bypass-arterial grafting 
33572 Open coronary endarterectomy 
92975 Thrombolysis, coronary; by intracoronary infusion, including 
selective coronary angiography 
92977 Thrombolysis, coronary; by intravenous infusion 
92980-92981  Transcatheter placement of an intracoronary stent(s) 
 Other forms of chronic ischemic heart disease 
92982 Percutaneous transluminal coronary balloon angioplasty; single 
vessel 
92984 Percutaneous transluminal coronary balloon angioplasty; each 
additional vessel 
92995 Percutaneous transluminal coronary atherectomy; by mechanical 
or other method, with or without balloon angioplasty; single 
vessel 
92996 Percutaneous transluminal coronary atherectomy; by mechanical 







Presence of Risk Factors and Atherosclerotic Diseases 
The presence of atherosclerotic diseases such as stroke, atherosclerosis, and 
peripheral vascular disease was also assessed.  In addition, the presence of hypertension 
and diabetes as risk factors for CHD in the database was determined.  The data were 
obtained from the medical claims file.  The presence of conditions such atherosclerotic 
diseases, diabetes and hypertension was assessed in the year prior to or at the index date 
and during the follow-up period. The ICD-9-CM codes are listed in Tables 2.7 and 2.8.  

















Table 2.7: Description of Diagnostic Codes to Identify the Presence of 
Atherosclerotic Disease 
 
ICD-9-CM Codes Description 
Atherosclerosis  
429.2 Cardiovascular disease, unspecified 
   Arteriosclerotic CVD 
   Cardiovascular arteriosclerosis 
   Cardiovascular disease: degeneration, disease, sclerosis (with 
    mention of arteriosclerosis) 
440.xx 
  440.0 
  440.1 
  440.2 
  440.3 
  440.8 
  440.9 
 
Atherosclerosis 
  Of aorta 
  Of renal artery 
  Of native arteries of the extremities 
  Of bypass graft of extremities 
  Of other specified arteries 
  Generalized and unspecified atherosclerosis 
 
Stroke  
433.xx Occlusion and stenosis of precerebral arteries 
434.xx Occlusion of cerebral arteries 
435.xx Transient cerebral ischemia 




















Table 2.8: ICD-9-CM Codes to Identify Hypertension and Diabetes as Risk Factors 
for CHD 
 








362.01 Background diabetic retinopathy 
362.02 Proliferative diabetic retinopathy 
366.41 Diabetic cataract 
362.11 Hypertension retinopathy 
 
Lipid Measurements and Monitoring for Adverse Effects 
The ATP II guidelines recommend lipid monitoring prior to initiating drug 
therapy as well as follow-up measurements.  Based on the guidelines, it is important to 
have a minimum of two lipoprotein measurements during one to two months of diet 
therapy prior to initiating the drug therapy.  After starting drug therapy, the first 
lipoprotein measurement is recommended at six to eight weeks.  Once the target LDL 
levels are reached, patients should be monitored every eight to twelve week intervals 
through 52 weeks.  After a year of therapy, once the LDL levels are attained, monitoring 
of lipids and adverse effects should be conducted at four- to six-month intervals.  




measurements.409  In addition, the ATP III guidelines recommend lipid monitoring within 
six to eight weeks following a change in drug regimen.410   
For the purpose of this study, lipid measurement included measurement of LDL 
levels since the guidelines recommend the assessment of LDL levels for the attainment of 
lipid goals.  The presence of a LDL monitoring test will be identified with the help of 
CPT codes (Table 2.9) in the medical claims file.  The presence of a CPT code for a lipid 
panel would indicate LDL measurement since this includes a separate measurement for 
LDL.  The presence of CPT codes for total cholesterol (TC), high density lipoprotein 
(HDL) and very low-density lipoprotein (VLDL) on the same date would indicate 
assessing the LDL levels since the LDL levels can be calculated using the formula below.  
Similarly, the presence of CPT codes for TC, HDL and triglycerides (TG) on the same 
date would also indicate LDL monitoring.  The LDL levels can be calculated using the 
Friedwall equation as follows: 
LDL = TC –HDL-VLDL    or        LDL = TC –HDL – (TG/5) 
Similarly, adverse event monitoring will be identified based on the presence of 
liver function tests (Table 2.10).  LDL measurements and tests for monitoring for adverse 
events were assessed as two separate variables. 
                                                 
409 Second report of the Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda (MD): U.S. 
Department of Health and Human Services, Public Health Service, National Institutes of 
Health, National Heart, Lung and Blood Institute; 1993. NIH Publication No: 93-3095.  
410 Grundy SM, Becker DM, Clark L, et al. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal 




Table 2.9: Description of Procedural Codes for Lipid Monitoring Tests 
CPT codes Description 
80061 Lipid Panel  
82465 Cholesterol, Serum, Total 
83718 Lipoprotein, Direct Measurement, High Density Cholesterol 
83719 Lipoprotein, Direct Measurement; VLDL Cholesterol 
83721 Lipoprotein, Direct Measurement; LDL Cholesterol 
84478 Triglycerides 
 
Table 2.10: Description of Procedural Codes for Liver Function Tests 
CPT codes Description 
80076 Hepatic Function Panel 
84450 Transferase; aspartate amino (AST) (SGOT) 
84460 Alanine amino; (ALT) (SGPT) 
 
Lipid Measurements 
Lipid measurements were assessed using the medical claims data.  The NCEP 
guidelines recommend lipid measurements prior to the start of therapy, following the start 
of therapy and lipid monitoring thereafter.411,412  For the purpose of the present study, 
baseline LDL monitoring was assessed within three months prior to the initiation of statin 
                                                 
411 Grundy SM, Becker DM, Clark L, et al. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal 
of the American Medical Association. 2001;285(19):2486-2497. 
412 Second report of the Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda (MD): U.S. 
Department of Health and Human Services, Public Health Service, National Institutes of 




therapy (index date).  Follow-up LDL monitoring was assessed within three months but 
not earlier than six weeks, after the initiation of statin therapy and within six months 
thereafter.  In addition, LDL monitoring within three months following an initial change 
in dose or type of statin drug was also evaluated.  A patient should have had a minimum 
of two lipid tests in a nine month follow-up period from the start of statin therapy.  LDL 
measurements were assessed as follows: 
1. LDL monitoring before the start of therapy: LDL monitoring was assessed three 
months prior to the start of therapy.   
2. LDL monitoring at start of therapy:  LDL monitoring at the start of therapy was 
assessed within three months at the initiation of statin therapy but not earlier than 
six weeks, and six months from the first LDL test.  For example, if the first LDL 
test was conducted at time T1, then a second LDL test should be conducted 
between the time period from T1 to T1+180 days. 
 
Fig 2.2: LDL Monitoring at the Start of Statin Therapy for Patients without a 
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3. LDL monitoring following initial change in dose of statin:  The presence of a 
LDL test within three months but not earlier than six weeks following an initial 
change in dose of statin therapy was assessed.  The proportion of patients with 
LDL tests following an initial change in dose of statin therapy was determined.   
4. LDL monitoring following an initial change in the type of statin:  The presence of 
a lipid test within three months but not earlier than six weeks following an initial 
change in the type of statin therapy was assessed.  The proportion of patients with 
lipid tests following an initial change in type of statin therapy was determined.   
In addition to the above measurements, the proportions of patients with LDL tests six 
months and a year prior to the start of therapy and six months and a year after the start 
of therapy were assessed. 
 
Monitoring for Adverse Effects 
The occurrence of liver function tests (LFTs) was monitored in the medical claims 
data.  Baseline LFTs were assessed within three months prior to the initiation of statin 
therapy (index date).  Follow-up LFTs were assessed within three months but not earlier 
than six weeks after the initiation of statin therapy and within six months thereafter.  In 
addition, LFTs within three months following an initial increase in the dose of the statin 
drug were also evaluated.  A patient should have had a minimum of two LFTs in a nine 
month follow-up period from the start of statin therapy.  Hepatic function monitoring was 




1. Monitoring of LFTs at baseline:  Monitoring for LFT was assessed three months 
prior to the start of therapy.   
2. Monitoring of LFTs at start of therapy:  LFTs at the start of therapy were assessed 
within three months at the initiation of statin therapy but not earlier than six 
weeks and six months from the first LFT test.  For example, if the first LFT was 
conducted at time T1, then the second LFT should be conducted between the time 
period from T1 to T1+180 days. 
3. Monitoring of LFTs following an initial increase in dose of statin:  The presence 
of LFTs within three months but not earlier than six weeks following an initial 
increase in dose of statin therapy were assessed.  The proportion of patients with 
LFTs following an increase in statin dose was determined. 
In addition to the above measurements, LFT monitoring six months and a year prior 
to the start of therapy and six months and a year after the start of therapy was also 
evaluated. 
 
Physician Characteristics  
Information on the specialty of the prescribing physician at index date was 
obtained from the Texas State Board of Medical Examiners (TSBME).  The physician’s 
unique license number was used to link the Medicaid file with the database obtained from 
TSBME.  The physician specialty was classified into three groups: general 




characteristics such as the physicians’ age, gender and years of licensure were obtained 
from the TSBME database.   
 
Compliance Measures 
Compliance with statin therapy was calculated using prescription refill dates and 
days’ supply data present in the prescription claims file.  Compliance was calculated for 
those patients with at least two fills of the prescription for statin drugs on two different 
dates.  The medication possession ratio was calculated by summing the number of days’ 
supply of medication dispensed (except the supply on the last refill date), and dividing 
this by the number of days between the initial and the last statin prescription fill date.   
MPR = Sum of days’ supply dispensed (except supply at last refill date) 
Sum of days between the first and the last prescription 
 
This method assumes that patients cannot be compliant unless they have an 
adequate supply of medications.  This MPR method has been previously validated by 
Steiner et al.413 and has been used previously to measure compliance with 
antihyperlipidemic drugs therapy regimens.414,415  An MPR ratio of 80 percent adherence 
                                                 
413 Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment 
using centralized pharmacy records: Description and validation. Medical Care. 
1988;26(8):814-823. 
414 Sung JCY, Nichol MB, Venturini F, et al. Factors affecting patient compliance with 
antihyperlipidemic medication in an HMO population. American Journal of Managed 
Care. 1998;4(10):1421-1430. 
415 Omar MA. An evaluation of the clinical and economic outcomes associated with 
switching hyperlipidemic patients to preferred statin therapy in the United States 
Department of Defense. Dissertation: Department of Pharmacy Practice and 




to the medication regimen is considered as a standard since this threshold is used 
conventionally in clinical trials.416     
Although MPR has been used extensively in the literature to assess compliance, it 
is important to acknowledge its limitations.417  Firstly, the calculation of an MPR is 
limited based on the time length involved.  Patients with shorter follow-up periods would 
inflate the compliance measures since they have been observed for fewer days and have a 
lesser chance to discontinue their medications compared to patients who have longer 
periods of follow-up.  Secondly, the compliance patterns during the entire follow-up 
period cannot be evaluated using the MPR since the MPR summarizes the compliance to 
medications as a single number.418          
Owing to the limitations of the MPR, persistence of statin therapy using survival 
analysis was assessed in addition to the MPR.  Persistence measures how long the patient 
remains on therapy and is defined as total days from index prescription fill date until 
termination of statin therapy.419  Patients were classified as being persistent if they did 
not discontinue therapy.  Patients failing to refill their prescriptions within 60 days of 
exhausting their last supply were characterized as having discontinued their statin 
                                                 
416 Insull W. The problem of compliance to cholesterol altering therapy. Journal of 
Internal Medicine. 1997;241(4):317-325. 
417 Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using 
methods for the design and analysis of natural history studies. American Journal of 
Managed Care. 2002;8(10):S249-S254. 
418 Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using 
methods for the design and analysis of natural history studies. American Journal of 
Managed Care. 2002;8(10):S249-S254. 
419 Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using 
methods for the design and analysis of natural history studies. American Journal of 




therapy.  Days of persistency was the time between the index prescription fill date and the 
date of last prescription preceding a 60-day gap.  A sensitivity analysis was conducted 
using a gap of 45 days. 
An example of the measurement of persistence is shown Figure 2.3.  Consider a 
patient whose index date for the first statin prescription is January 1, 2000.  The patient is 
dispensed a 30 days supply of a statin on January 1, 2000.  Based on the days supply, the 
patient should run out of medication by January 30, 2000 if the patient is taking the statin 
once a day as prescribed.  The next refill date of the prescription for the same patient is 
February 15, 2000 for a 30-day supply of the statin.  At this point, the patient is still 
persistent with the statin therapy since the patient refilled the prescription within 60 days 
of the exhaustion of the last prescription.  The patient gets the third prescription fill of a 
30 days supply of the statin on May 31, 2000.  The patient at this point is considered to 
have discontinued the therapy since the gap between the date of exhaustion of the last 
prescription (March 16, 2000) and the date of the third refill (May 31, 2000) exceeded the 
60-day permissible gap to be persistent.  The patient was considered to be persistent from 





Fig 2.3: Example of Measurement of Persistence with Statin Therapy in Days 
 
*All supply is assumed to be for 30 days 
 
Cost of Statin Drugs 
The total amount reimbursed by Texas Medicaid for statin drugs was calculated 
by summing the total amount spent on each patient for the two year follow-up period.  
The number of statin prescriptions filled per year was assessed and the total amount 
reimbursed by Medicaid for statin drugs per patient per year was calculated.  In addition, 
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 Data manipulation and statistical analyses were conducted using Microsoft 
Access and Statistical Packages for Social Sciences (SPSS) v11.0.  The “a priori” level of 
significance of 0.05 was used for all statistical tests conducted.  All tests were two-tailed 
unless otherwise specified.  A description of statistical tests conducted for each objective 
and related hypothesis follows. 
 
Evaluation of Statin Treatment Patterns and Patient Adherence to Statin Therapy 
Appropriate descriptive statistics (frequency, mean, standard deviation) were used 
to examine the demographic characteristics (age, gender, and ethnicity) of the subjects.  
Frequency distributions of the type and starting dose of the statin drugs and the specialty 
of the index statin prescriber were presented.  Similarly, frequency distributions were 
obtained for the type of CHD prevention patients, and type of CHD risk factors and 
presence of atherosclerotic diseases.  The proportion of patients who experienced an 
initial change in therapy with respect to dose and type of statin was calculated.  
The predictors of compliance with statin therapy were determined with the help of 
multiple regression and Cox regression models.  The predictor variables in the model  
included age, gender, ethnicity, presence of CHD, diabetes or hypertension as risk 
factors, presence of atherosclerotic disease (stroke, atherosclerosis and peripheral 
vascular disease) and total number of prescription other than statins during the two-year 
follow-up period.  Survival analysis was used to assess the time to statin discontinuation.  




The coding scheme for the predictor variables is shown in Table 2.11.   
Table 2.11: Coding of Variables Included in Regression Models 
 
Variables Variable Code 
Age Age at the index date 
Gender 1=Male; 2=Female 
Ethnicity 1=Non-Hispanic whites; 2=Non-Hispanic 
blacks; 3=Hispanics; 4=Asians or Pacific 
Islanders; and 5=American Indians or 
Alaskan Natives. 
CHD 1 = No disease; 2 = Disease prior to index 
date; 3 = Disease developed during follow-
up period. 
Presence of diabetes 1 = No disease; 2 = Disease prior to index 
date; 3 = Disease developed during follow-
up period. 
Presence of hypertension 1 = No disease; 2 = Disease prior to index 
date; 3 = Disease developed during follow-
up period. 
Presence of atherosclerotic disease 1 = No disease; 2 = Disease prior to index 
date; 3 = Disease developed during follow-
up period. 
Total number of prescriptions  Total number of unique prescriptions, other 
than statins, that the patients were on for 





Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines 
 Descriptive statistics were used to determine the frequency of lipid monitoring 
tests and liver function tests at baseline (within three months prior to the index date) and 
follow-up (within three months after initiation of statin therapy) and six months thereafter 
and also following initial changes in the medication regimen.  The proportion of patients 
with lipid tests and liver function tests was evaluated.  Logistic regression analysis was 




Statistical Tests for the Study Hypotheses 
 
The statistical tests for the study hypotheses are tabulated in Table 2.12.   
Table 2.12: Proposed Statistical Tests for the Study Hypotheses 
 
Study Hypotheses Statistical Test 
Goal : Evaluation of Statin Treatment Patterns and Adherence to Statin Therapy 
 
Hypothesis 1:  The starting dose for statin therapy for 
secondary prevention patients will be higher than for primary 
prevention patients, controlling for the type of statin. 
Chi-square analysis 
Hypothesis 2: The MPR will be higher for males than for 
females, controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, atherosclerotic diseases, and total 
number of prescriptions. 
 
Multiple regression analysis  
Hypothesis 3: The MPR will be higher for older patients than 
for younger patients, controlling for gender, ethnicity, presence 
of CHD, diabetes, hypertension, atherosclerotic disease, and 
total number of prescriptions. 
Multiple regression analysis 
Hypothesis 4: The MPR will be higher for non-Hispanic whites 
than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, atherosclerotic 
diseases, and total number of prescriptions. 
Multiple regression analysis 
Hypothesis 5: The MPR will be higher for secondary prevention 
CHD patients than for primary prevention CHD patients, 
controlling for age, gender, ethnicity, presence of diabetes, 
hypertension, atherosclerotic diseases, and total number of 
prescriptions. 
Multiple regression analysis 
Hypothesis 6: The MPR will be higher for diabetics than for 
non-diabetics, controlling for age, gender, ethnicity, presence 
of CHD, hypertension, atherosclerotic diseases, and total 
number of prescriptions. 
Multiple regression analysis 
Hypothesis 7: The MPR will be higher for hypertensives than 
for non-hypertensives, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, atherosclerotic diseases, and total 
number of prescriptions. 





Table 2.12: Proposed Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal : Evaluation of Statin Treatment Patterns and Adherence to Statin Therapy 
Hypothesis 8: The MPR will be higher for those patients with 
atherosclerotic diseases than for those without,  atherosclerotic 
diseases controlling for age, gender, ethnicity, presence of 
CHD, diabetes, hypertension, and total number of 
prescriptions. 
Multiple regression analysis 
Hypothesis 9: The MPR will be higher for those patients on a 
lower number of total prescriptions other than statins than for 
those on a higher number of prescriptions, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic disease.  
Multiple regression analysis 
Hypothesis 10: Females will have a higher hazard of becoming 
non-persistent to statin therapy than males controlling for age, 
ethnicity, presence of CHD, hypertension, diabetes, 
atherosclerotic diseases, and total number of prescriptions. 
Cox regression analysis 
Hypothesis 11: Younger patients will have a higher hazard of 
becoming non-persistent to statin therapy than older patients, 
controlling for gender, ethnicity, presence of CHD, 
hypertension, diabetes, atherosclerotic diseases, and total 
number of prescriptions. 
Cox regression analysis 
Hypothesis 12: Other ethnic minorities will have a higher 
hazard of becoming non-persistent to statin therapy than non-
Hispanic whites, controlling for age, gender, presence of CHD, 
hypertension, diabetes, atherosclerotic diseases, and total 
number of prescriptions. 
Cox regression analysis 
Hypothesis 13: Patients without CHD will have a higher 
hazard of becoming non-persistent to statin therapy than those 
with CHD, controlling for age, gender, ethnicity, presence of 
hypertension, diabetes, atherosclerotic diseases, and total 
number of prescriptions. 
Cox regression analysis 
Hypothesis 14: Patients without diabetes will have a higher 
hazard of becoming non-persistent to statin therapy than those 
with diabetes, controlling for age, gender, ethnicity, presence of 
CHD, hypertension, atherosclerotic diseases, and total number 
of prescriptions. 





Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal : Evaluation of Statin Treatment Patterns and Adherence to Statin Therapy 
Hypothesis 15: Patients without hypertension will have a 
higher hazard of becoming non-persistent to statin therapy than 
those with hypertension, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, atherosclerotic diseases, and total 
number of prescriptions. 
Cox regression analysis 
Hypothesis 16: Patients without atherosclerotic diseases will 
have a higher hazard of becoming non-persistent to statin 
therapy than those with atherosclerotic diseases controlling for 
age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and total number of prescriptions. 
Cox regression analysis 
Hypothesis 17: Patients on greater number of total 
prescriptions other than statins will have a higher hazard of 
becoming non-persistent than those on fewer prescription, 
controlling for age, gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases. 
Cox regression analysis 
Goal: Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines: Lipid 
Monitoring at Baseline 
Hypothesis 18: The likelihood of a lipid test at baseline will be 
higher for males than for females, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic 
diseases. 
Logistic regression analysis 
Hypothesis 19: The likelihood of a lipid test at baseline will be 
higher for older patients than for younger patients, controlling 
for gender, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 20: The likelihood of a lipid test at baseline will be 
higher for non-Hispanic whites than for other ethnic groups, 
controlling for age, gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 21: The likelihood of a lipid test at baseline will be 
higher for patients with CHD compared to those without CHD, 
controlling for age, gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases. 





Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines: Lipid 
Monitoring at Baseline 
Hypothesis 22: The likelihood of a lipid test at baseline will be 
higher for patients with diabetes than for those without 
diabetes, controlling for age, gender, ethnicity, presence of 
CHD, hypertension, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 23: The likelihood of a lipid test at baseline will be 
higher for patients with hypertension than for those without 
hypertension, controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 24: The likelihood of a lipid test at baseline will be 
higher for patients with atherosclerotic diseases than for those 
without atherosclerotic disease, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and hypertension. 
Logistic regression analysis 
Goal:  Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines: Lipid 
Monitoring After Start of Therapy 
Hypothesis 25: The likelihood of a lipid test after start of 
therapy will be higher for males than for females controlling 
for age, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
Logistic regression analysis 
Hypothesis 26: The likelihood of a lipid test after start of 
therapy will be higher for older patients than for younger 
patients, controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 27: The likelihood of a lipid test after start of 
therapy will be higher for non-Hispanic whites than for other 
ethnic groups, controlling for age, gender, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 














Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Lipid Monitoring After Start of Therapy 
Hypothesis 28: The likelihood of a lipid test after start of 
therapy will be higher for patients with CHD than for those 
without CHD, controlling for age, gender, ethnicity, presence 
of diabetes, hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 29: The likelihood of a lipid test after start of 
therapy will be higher for patients with diabetes than for those 
without diabetes, controlling for age, gender, ethnicity, 
presence of CHD, hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 30: The likelihood of a lipid test after start of 
therapy will be higher for patients with hypertension than for 
those without hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and atherosclerotic 
diseases, physician specialty, and lipid testing prior to index 
date. 
Logistic regression analysis 
Hypothesis 31: The likelihood of a lipid test after start of 
therapy will be higher for patients with atherosclerotic diseases 
than for those without atherosclerotic diseases, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and lipid testing prior to 
index date. 
Logistic regression analysis 
Hypothesis 32: The likelihood of a lipid test after start of 
therapy will be higher for patients treated by a cardiologist at 
index date than those treated by other physician specialty, 
controlling for age, gender, ethnicity, presence of CHD, 
diabetes, hypertension and atherosclerotic diseases,  and lipid 
testing prior to index date. 
Logistic regression analysis 
Hypothesis 33: The likelihood of a lipid test after start of 
therapy will be higher for patients with lipid tests at baseline 
than those without lipid tests at baseline, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and hypertension, 
atherosclerotic diseases, and physician specialty. 
 







Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Lipid Monitoring After an Initial Change in Statin Type 
Hypothesis 34: The likelihood of a lipid test after an initial 
change in statin type will be higher for males than for females 
controlling for age, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, physician specialty, 
and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 35: The likelihood of a lipid test after an initial 
change in statin type will be higher for older patients than for 
younger patients, controlling for age, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 36: The likelihood of a lipid test after an initial 
change in statin type will be higher for non-Hispanic whites 
than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior to index 
date. 
Logistic regression analysis 
Hypothesis 37: The likelihood of a lipid test after an initial 
change in statin type will be higher for patients with CHD than 
for those without CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and atherosclerotic 
diseases, physician specialty and lipid testing prior to index 
date. 
Logistic regression analysis 
Hypothesis 38: The likelihood of a lipid test after an initial 
change in statin type will be higher for patients with diabetes 
than for those without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and atherosclerotic 
diseases, physician specialty and lipid testing prior to index 
date. 
Logistic regression analysis 
Hypothesis 39: The likelihood of a lipid test after an initial 
change in statin type will be higher for patients with 
hypertension than for those without hypertension, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and 
atherosclerotic diseases, physician specialty, and lipid testing 
prior to index date. 





Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Lipid Monitoring After an Initial Change in Statin Type 
Hypothesis 40: The likelihood of a lipid test after an initial 
change in statin type will be higher for patients with 
atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and hypertension, physician specialty, and lipid 
testing prior to index date. 
Logistic regression analysis 
Hypothesis 41: The likelihood of a lipid test after an initial 
change in statin type will be higher for patients treated by a 
cardiologist at index date than those treated by other physician 
specialty, controlling for age, gender, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, and 
lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 42: The likelihood of a lipid test after an initial 
change in statin type will be higher for patients with lipid tests 
at baseline than those without lipid tests at baseline, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, atherosclerotic diseases, and physician specialty. 
 
Logistic regression analysis 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Lipid Monitoring After an Initial Change in Statin Dose 
Hypothesis 43: The likelihood of a lipid test after an initial 
change in statin dose will be higher for males than for females 
controlling for age, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 44: The likelihood of a lipid test after an initial 
change in statin dose will be higher for older patients than for 
younger patients, controlling for ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 45: The likelihood of a lipid test after an initial 
change in statin dose will be higher for non-Hispanic whites 
than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior to index 
date. 





Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Lipid Monitoring After an Initial Change in Statin Dose 
Hypothesis 46: The likelihood of a lipid test after an initial 
change in statin dose will be higher for patients with CHD than 
for those without CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior to index 
date. 
Logistic regression analysis 
Hypothesis 47: The likelihood of a lipid test after an initial 
change in statin dose will be higher for patients with diabetes 
than for those without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior to index 
date. 
Logistic regression analysis 
Hypothesis 48: The likelihood of a lipid test after an initial 
change in statin dose will be higher for patients with 
hypertension than for those without hypertension, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and 
atherosclerotic diseases, physician specialty, and lipid testing 
prior to index date. 
Logistic regression analysis 
Hypothesis 49: The likelihood of a lipid test after an initial 
change in statin dose will be higher for patients with 
atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and hypertension, physician specialty and lipid 
testing prior to index date. 
Logistic regression analysis 
Hypothesis 50: The likelihood of a lipid test after an initial 
change in statin dose will be higher for patients treated by a 
cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic 
diseases, and lipid testing prior to index date. 
Logistic regression analysis 
Hypothesis 51: The likelihood of a lipid test after an initial 
change in statin dose will be higher for patients with lipid tests 
at baseline than those without lipid tests at baseline, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, atherosclerotic diseases, and physician specialty. 
 




Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Safety Monitoring at Baseline 
Hypothesis 52: The likelihood of an LFT at baseline will be 
higher for males than for females, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic 
diseases.  
Logistic regression analysis 
Hypothesis 53: The likelihood of an LFT at baseline will be 
higher for older patients than for younger patients, controlling 
for gender, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 54: The likelihood of an LFT at baseline will be 
higher for non-Hispanic whites than for other ethnic groups, 
controlling for age, gender, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 55: The likelihood of an LFT at baseline will be 
higher for patients with CHD than for those without CHD, 
controlling for age, gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 56: The likelihood of an LFT at baseline will be 
higher for patients with diabetes than for those without 
diabetes, controlling for age, gender, ethnicity, presence of 
CHD, hypertension, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 57: The likelihood of an LFT at baseline will be 
higher for patients with hypertension than for those without 
hypertension, controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and atherosclerotic diseases. 
Logistic regression analysis 
Hypothesis 58: The likelihood of an LFT at baseline will be 
higher for patients with atherosclerotic diseases than those 
without atherosclerotic diseases, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and hypertension. 




Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Safety Monitoring after Start of Therapy 
Hypothesis 59: The likelihood of an LFT after start of therapy 
will be higher for males than for females controlling for age, 
ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
Logistic regression analysis 
Hypothesis 60: The likelihood of an LFT after start of therapy 
will be higher for older patients than for younger ones, 
controlling for gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, physician specialty, 
and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 61: The likelihood of an LFT after start of therapy 
will be higher for non-Hispanic whites than for other ethnic 
groups, controlling for age, gender, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, physician specialty 
and presence of LFT  prior to index date. 
Logistic regression analysis 
Hypothesis 62: The likelihood of an LFT after start of therapy 
will be higher for patients with CHD than for those without 
CHD, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 63: The likelihood of an LFT after start of therapy 
will be higher for patients with diabetes than for those without 
diabetes, controlling for age, gender, ethnicity, presence of 
CHD, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 64: The likelihood of an LFT after start of therapy 
will be higher for patients with hypertension as compared to 
those without hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and atherosclerotic 
diseases, physician specialty and presence of LFT prior to 
index date. 




Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Safety Monitoring after Start of Therapy 
Hypothesis 65: The likelihood of an LFT after start of therapy 
will be higher for patients with atherosclerotic diseases than 
for those without atherosclerotic diseases, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and hypertension, 
physician specialty, and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 66: The likelihood of an  LFT after start of therapy 
will be higher for patients treated by a cardiologist at index 
date than for those treated by other physician specialty, 
controlling for age, gender, ethnicity, presence of CHD, 
diabetes, hypertension and atherosclerotic diseases, and 
presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 67: The likelihood of an LFT after start of therapy 
will be higher for patients with LFTs at baseline than those 
without LFTs  at baseline, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and hypertension, 
atherosclerotic diseases, and physician specialty. 
 
Logistic regression analysis 
Goal: Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Safety Monitoring after an Initial Increase in Statin Dose 
Hypothesis 68: The likelihood of an LFT after an initial 
increase in statin dose will be higher for males than for females 
controlling for age, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, physician specialty, 
and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 695: The likelihood of an LFT after an initial 
increase in statin dose will be higher for older patients than for 
younger patients, controlling for gender, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, 
physician specialty, and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 70: The likelihood of an LFT after an initial 
increase in statin dose will be higher for non-Hispanic whites 
than for ethnic groups, controlling for age, gender, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, 
physician specialty, and presence of LFT prior to index date. 




Table 2.12: Statistical Tests for the Study Hypotheses (continued) 
 
Study Hypotheses Statistical Test 
Goal:  Evaluation of How Well Physicians Follow Efficacy and Safety Monitoring Guidelines: 
Safety Monitoring after an Initial Increase in Statin Dose 
Hypothesis 71: The likelihood of an LFT after an initial 
increase in statin dose will be higher for patients with CHD as 
compared to those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and 
atherosclerotic diseases, physician specialty and presence of 
LFT prior to index date. 
Logistic regression analysis 
Hypothesis 72: The likelihood of an LFT after an initial 
increase in statin dose will be higher for patients with diabetes 
as compared to those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and 
atherosclerotic diseases, physician specialty and presence of 
LFT prior to index date. 
Logistic regression analysis 
Hypothesis 73: The likelihood of an LFT after an initial 
increase in statin dose will be higher for patients with 
hypertension as compared to those without hypertension, 
controlling for age, gender, ethnicity, presence of CHD, 
diabetes, and atherosclerotic diseases, physician specialty, and 
presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 74: The likelihood of an LFT after an initial 
increase in statin dose will be higher for patients with 
atherosclerotic diseases as compared to those without 
atherosclerotic diseases, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and hypertension, physician 
specialty, and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 75: The likelihood of an LFT after an initial 
increase in statin dose will be higher for patients treated by a 
cardiologist at index date as compared to those treated by other 
physician specialty, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic 
diseases, and presence of LFT prior to index date. 
Logistic regression analysis 
Hypothesis 76: The likelihood of an LFT after start of therapy 
will be higher for patients with LFTs at baseline than those 
without LFTs at baseline, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and hypertension, atherosclerotic 
diseases, and physician specialty. 
 









This chapter reports the results of the data analyses.  The results are presented in 
the order of the objectives listed in Section IX of Chapter 1.  These objectives are divided 
in the following two sections: 
 
1. Evaluation of statin treatment patterns and patient adherence to statin therapy; and 
2. Evaluation of how well physicians follow lipid and safety monitoring guidelines. 
 
A total of 7,440 patients met the study inclusion criteria as new statin users 
between the index date of September 1, 1999 and August 31, 2001 and who were 
continuously enrolled in the Texas Medicaid System for a year prior to the index date and 
two years following the index date.  In addition, these patients had at least two statin 
prescriptions filled in a year of follow-up on two different dates.  A total of 68,770 statin 




ANALYSES OF THE STUDY OBJECTIVES 
There were 22 objectives addressing the two main goals of the study: 
1. Evaluation of statin treatment patterns and patient adherence to statin therapy; and 
2. Evaluation of how well physicians follow lipid and safety monitoring guidelines. 
There were 12 objectives addressing the first goal, and 10 objectives addressing 
the second goal of the study.  Objectives 1 through 10 (except objective 2) addressing the 
first goal of the study were exploratory in nature with no corresponding hypotheses.  
There was one hypothesis corresponding to study objective 2.  There were 16 hypotheses 
corresponding to the study objectives 11 and 12, which aimed at assessing the predictors 
of adherence to statin therapy.  There were 10 objectives assessing the second study goal.  
Under the second goal, objectives 16 through 22 that assessed the predictors of the 
occurrence of lipid and liver function tests had 59 hypotheses.  In total, 76 hypotheses 
were tested.  The study objectives that are exploratory in nature are presented first 
followed by analyses of the study hypotheses.    
   
Evaluation of Statin Treatment Patterns and Patient Adherence to Statin Therapy 
Objective 1: Descriptive Statistics on Statin Drug Use and Strength Prescribed at Index 
Date  
 
In the present study, a majority (78.7%) of the statin users were initiated on a 
statin drug at the recommended starting dose.  Based on the package inserts, the 




daily;420 Zocor® 20 or  40 mg once daily;421 Pravachol® 40 mg once daily;422 Lescol® 40 
mg once daily;423 and Mevacor® 20 mg once daily.424  Only 94 (1.3%) were initiated on 
the maximum recommended dose of the statins.  Overall, 40 percent of the patients were 
started on Lipitor® 10mg tablet, and 13.7 percent on Zocor® 20mg tablet.  Table 3.1 
presents information on the statin type and strength prescribed at the index date. 
The most commonly prescribed statins during the two-year follow-up period were 
Lipitor® (57.1%), Zocor® (23.2%) and Pravachol® (14.2%).  Table 3.2 provides 
information on the type of statin and strength based on the total number of claims for the 
two-year period.   
Of the total 68,770 statin claims for a two-year follow-up period, 60.7 percent     
(N = 41,766) of the claims were for 30-days supply, 10.2 percent (N = 7,009) were for 
60-days supply, and 18.4 percent (N = 12,680) for 90-days supply.  Table 3.3 presents the 
means for quantity, number of days supply and amount paid.  
 
                                                 
420 Lipitor package insert. Morris Plains, NJ: Parke-Davis; April 2003. 
421 Zocor package insert. West Point, PA: Merck & Co.; April 2003. 
422 Pravachol package insert. Princeton, NJ: Bristol-Myer Squibb Company.  April 2003. 
423 Lescol package insert. East Hanover, NJ: Novartis Pharmaceuticals; April 2003. 




Table 3.1:  Frequency and Percent of Patients Based on Statin Type and Strength 
Prescribed at the Index Date  
 


















































































Total number of patients 7,440 100.0%




Table 3.2: Frequency and Percent of Total Prescription Drug Claims Based on 
Statin Type and Dose Prescribed to Texas Medicaid Statin Users in a Two-Year 
Follow-up Period 
Statin Type and Strength Number of 
Prescriptions 













































































































Total number of prescriptions 68,770 100.6%*





Table 3.3:  Means, Medians and Standard Deviations for Number of Dosage Units 
per Claim, Number of Days Supply, and Amount Paid for Texas Medicaid Statin 
Prescriptions for a Two-Year Follow-up Period 
 
 Mean (S.D.) Median
Number of dosage units per claim 48.3 (28.0) 30.0
Number of days supply per claim 47.4 (26.3) 30.0
Dollar amount paid per claim $122.8 (103.6) $96.5
 
 
Objective 3: Descriptive Statistics on Lipid Lowering Drugs Prescribed Other Than 
Statins 
 
Table 3.4 presents information on lipid lowering drugs other than statins that were 
prescribed to patients during the follow-up period.  A total of 761 (10.2%) patients were 
prescribed other lipid-lowering drugs.  A majority of the patients (N = 616; 80.9%) who 
received other lipid lowering agents were prescribed fibrates.  Only 114 patients received 
a nicotinic acid derivative product.    
 
Table 3.4: Frequency and Percent of Patients on Other Lipid-Lowering Drugs 






Percent of Patients on 
Other Lipid-Lowering 
Drugsa,b
Percent of Total 
Patientsc
Fibrates 616 80.9% 8.3%




aCalculated as a percent of  761, which is the total number of patients on other lipid-lowering drugs. 
bPercentages do not total to 100 as some patients may be prescribed more than one class of drugs. 





Objective 4:  Specialty of the Physician Prescribing Statin at Index Date 
 
Information on the specialty of the prescribing physician at index date was 
obtained from the Texas State Board of Medical Examiners (TSBME) database.  The 
physician’s unique license number was used to link the Medicaid file with the database 
obtained from TSBME.  Overall, the specialty of index prescriber was available for 6,531 
(87.8%) out of the total 7,440 patients.  Family practice/general practice physicians wrote 
44.6 percent of the index prescriptions (Table 3.5). 
 
Table 3.5:  Frequency and Percent at Index Date of Physician Specialty for 
Statin Users Aged 21-62 Years 
 




Internal medicine 2,108 32.3%
Cardiovascular diseases 515 7.9%
Othera 992 15.2%
Totalb 6,531 100.0%
aOther category includes all physician specialty except family practice/general practice, internal medicine 
and cardiovascular diseases. 




Objective 5:  Demographic Characteristics (age, gender and ethnicity) of Statin Users  
 
Tables 3.6 and 3.7 present demographic information of statin users. The mean age 
of the statin user at index date was 49.7 years (S.D. = 9.4 years) and the majority (N = 
4,854; 65.2%) of the statin users were females.  The age at index date ranged from 21 
years to 62 years and the median age was 52 years.  The frequency distribution of 
patients based on three age categories is as follows: 38.8 percent of the patients were 
between 45-55 years, 34.2 percent of the patients were between 56-62 years and 27.0 
percent were between 21-44 years.   
Data on ethnicity were missing for 386 patients due to omission or inappropriate 
coding in the Medicaid files.  Of those patients for whom the data were available, the 
42.7 percent of the statin users were non-Hispanic whites (N = 3,015), followed by 
Hispanics (N = 2,304; 32.7%) and non-Hispanic blacks (N = 1,585; 22.5%).  
 
Table 3.6: Frequency and Percent for Gender and Mean Age at Index Date for 
Statin Users 
   






Females 4,854 (65.2%) 50.3 (8.9) 52 (21-62)
Males 2,586 (34.8%) 48.4 (9.2) 50 (21-62)















Table 3.7: Frequency and Percent of Patients Based on Ethnicity  
 
Ethnicity Number of Patients Percent 
White, non-Hispanic 3,015 42.7%
Hispanic 2,304 32.7%
Black, non-Hispanic 1,585 22.5%
Asian or Pacific Islander 122 1.7%
American Indian or Alaskan Native 28 0.4%
Total* 7,054 100.0%
*Data on ethnicity were missing for 386 (5.2%) of the patients due to omission or inappropriate coding in 




Objective 6:  Proportion of Primary and Secondary Prevention Coronary Heart 
Disease (CHD) Patients Started on Statin Therapy 
  
Primary prevention patients were defined as patients without a history of 
established CHD, whereas secondary prevention patients were those who had a history of 
established CHD including indications for acute myocardial infarction, angina, chronic 
ischemic heart disease, history of percutaneous coronary intervention or coronary artery 
bypass graft.  The presence for a diagnosis of CHD was determined at or a year prior to 
the index date. 
A majority of the patients initiated on statin therapy were primary prevention 
patients (N = 5,597; 75.2%), i.e., they did not have a history of CHD prior to start of 
therapy.  Of those with a diagnosis for CHD, the majority had a diagnosis for other 
chronic ischemic heart disease (N = 1,467; 79.6%) followed by angina (N = 848; 46.0%) 
(Table 3.8).  Table 3.9 provides information on patients with a diagnosis for CHD, 




those who presented a diagnosis for these conditions during the follow-up period.  A total 
of 4,616 new diagnoses for hypertension, diabetes, CHD or atherosclerotic disease 
occurred after the index date. 
 
Table 3.8:  Frequency and Percent of Secondary Prevention CHD Patients 
 
Types of CHD Number of Patients  Percente,f 
Other chronic ischemic heart diseasea 1,467 79.6%
Anginab 848 46.0%
Acute and old myocardial infarctionc 508 27.6%
Other acute ischemic heart diseased 456 24.7%
aICD-9 codes:  414.xx;    bICD-9-codes: 413,   cICD-9 codes:  410.33, 412;   dICD-9 codes: 411.xx.  
ePercentages will not total to 100 since some patients may have more than one type of CHD. 
fCalculated as a percent of 1,843, which is the total number of patients with a diagnosis for CHD at or a 
year prior to index date. 
 
 
Table 3.9: Frequency and Percent of Patients with a Diagnosis for Diabetes, 
Hypertension, Coronary Heart Disease (CHD) and Atherosclerotic Disease at or a 
Year Prior to the Index Date and During Follow-up 
 
Disease At or Year Prior to 
Index Date 
N (%)a,b 
Newly Diagnosed During 
Follow-up 
N (%)a 
Hypertension 4,157 (55.9%) 1,556 (47.4%c)
Diabetes 3,332 (44.8%) 833 (20.3%d)
CHD 1,843 (24.8%) 1,145(20.4%e)
Atherosclerotic Diseases 1,012 (13.6%) 1,082 (16.8%f)
Total 7,440 4,616
aPercentages will not total to 100 since patients may be classified into more than one disease states. 
bCalculated as a percent of 7,440, which is the total number of patients in the study. 
cCalculated as a percent of 3,283, which is the number of patients with an absence of a diagnosis for 
hypertension at or a year prior to the index date. 
dCalculated as a percent of 4,108, which is the number of patients with an absence of a diagnosis for 
diabetes at or a year prior to the index date. 
eCalculated as a percent of 5,597, which is the number of patients with an absence of a diagnosis for CHD 
at or a year prior to the index date. 
fCalculated as a percent of 6,428, which is the number of patients with an absence of a diagnosis for 






Objective 7: Number and Type of CHD Risk Factors 
The frequency and percent of patients based on the number and types of risk 
factors were assessed a year prior to or at index date.  The results are presented in Tables 
3.10 and 3.11.  The risk factors for CHD that were assessed included age and gender 
(males > 45 years or females > 55 years), presence of a diagnosis for diabetes or 
hypertension or both.  The mean number of CHD risk factor per patient was 1.5 (S.D. = 
0.9).  A total of 48.7 percent (N = 3,625) of the patients had two or more CHD risk 
factors.  
 
Table 3.10: Frequency and Percent of Patients by the Number of Risk Factors for 
CHD a Year Prior or At Index Date 
 





Total  7,440 100.0%
*Calculated based on the presence of one or more of the following risk factors: diabetes, hypertension,  
age and gender (males > 45 years or females > 55 years). 
 
Table 3.11: Frequency and Percent of Patients by the Type of Risk Factors 
Type of Risk Factors Number of Patients 




Age and Gender (males > 45 years or 
females > 55 years) 
     Females > 55 years 






aCalculated as a percent of 7,440, which is the total number of patients in the study. 




Objective 8: Patient Adherence to Statin Therapy Based on Prescription Refill Records 
Adherence to statin therapy was assessed by calculating the medication 
possession ratio (MPR).  The MPR was calculated using the following formula: 
 
MPR = Sum of days supply dispensed (except supply at last refill date) 
                         Sum of days between the first and the last prescription refill dates 
  
 The mean MPR was 0.7 (S.D. = 0.2).  The median MPR was 0.74 and the MPR 
ranged from 0.08 to 2.00.  Table 3.12 presents the distribution of MPR into four 
categories (0.08 – 0.40; 0.41 – 0.79; 0.80 – 1.0; 1.01 – 2.0) and the number of patients in 
each category.  Over half of the patients (N = 4,222; 56.7%) had an MPR of less than 
0.80.  Table 3.13 presents the MPR controlling for gender and ethnicity.   
An independent samples t-test was conducted to assess the difference in MPR 
with respect to gender.  The mean MPR for males was found to be statistically different 
from females (0.73 vs. 0.68) (t –statistic = -6.596; df = 7438; p < 0.001).   However, the 
difference was just 0.05 which may not be practically different. 
A one-way analysis of variance was used to assess the differences in MPR with 
respect to ethnicity.  Overall, the MPR differed significantly with respect to ethnicity (F 
(4, 7049) = 40.7; p < 0.001).  Post-hoc comparisons using Bonferroni correction revealed 
significant differences in the mean MPR between non-Hispanic whites and non-Hispanic 
blacks (0.75 vs. 0.66; p < 0.001), and between non-Hispanic whites and Hispanics (0.75 




with respect to gender and ethnicity, and the statistical significance could be attributed to 
the large sample size. 
 
Table 3.12: Frequency and Percent of Patients Based on Categories of Medication 
Possession Ratio (MPR) 
 
MPR Category Number of Patients Percent 
0.08 through 0.40 1,320 17.7%
0.41 through 0.79 2,902 39.0%
0.80 through 1.00 2,355 31.7%





Table 3.13: Mean Medication Possession Ratio for Statin Therapy Controlling for 
Gender and Ethnicity 
 
Demographic Characteristic Mean MPR (S.D.) 
Gender 
   Male 





  White, non-Hispanic 
  Hispanic 
  Black, non-Hispanic 
  American Indian or Alaskan 







      Matched letters indicate  statistical difference   
 aMean difference = 0.04511; t-statistic = -6.596; df = 7,438; p < 0.001. 
 bF(4,7049) = 40.670; p < 0.001. 
 cMean difference  = 0.0817; p < 0.001. 
 dMean difference = 0.0913; p < 0.001. 
 
       







Objective 9:  Persistence to Statin Therapy 
 Persistence to statin drug therapy was expressed as the number of days on statin 
therapy before the patient discontinued the therapy.  Discontinuation was defined as 
failure to refill the prescription within 60 days of exhausting the last supply.  Thus, if the 
patient had greater than 60 days between the calculated last day of therapy and the date of 
the next refill, then the patient was categorized as discontinuing therapy.  Obviously, if 
there was no refill, then the patient was classified as discontinuing therapy.  A sensitivity 
analysis was conducted using a gap of 45 days.  Kaplan Meier survival estimate was 
conducted to show a graphical representation of the proportion of patients persistent with 
statins.  The results of the Kaplan Meier survival analysis are presented based on the 60 -




Based on a 60-day gap of failing to refill the prescription, the mean days of 
persistency to statin therapy was 381 days (95% CI: 374.0-389.0) or just over a year.  The 
days of persistence for 17.8 percent of the patients (N = 1,327) was zero, implying that 
these patients exceeded the 60-days gap for their first statin prescription refill.  Only 50 
percent (N = 3,720) of the patients were persistent with their statin therapy at the end of 
310 days.  The probability of being persistent at the end of the two year follow-up period 





Forty-five Day Gap 
Based on a 45-day gap of failing to refill the prescription, the mean days of 
persistency to statin therapy was 329 days (95% CI: 321.8-336.5).  The days of 
persistence for 21.8 percent of the patients (N = 1,620) was zero, implying that these 
patients exceeded the 45-day gap for their first statin prescription refill.  Only 50 percent 
(N = 3,720) of the patients were persistent with their statin therapy at the end of 206 days.  
The probability of being persistent at the end of the two year follow-up period was 0.33 
(Figure 3.2).  























Figure 3.1: Kaplan-Meier Survival Estimate of Persistence to Statin Therapy for a 














































Figure 3.2: Kaplan-Meier Survival Estimate of Persistence to Statin Therapy for a 
Two-Year Follow-Up Period with a Gap of Forty-Five Days of Failure to Refill 
































Days Since First Statin Prescription Fill 























Objective 10: Amount Reimbursed by Medicaid for Statin Drugs 
  
 In the analysis determining the total amount Texas Medicaid paid for statin drugs 
it was decided to sum the total amount spent on each patient for the two-year follow-up 
period.  This calculation would give us the total amount spent per patient by Medicaid for 
the two-year follow-up period.  The mean of the amount spent was $1,116.80 (S.D. = 
$729.38) and the median was $1,021.34.  The amount ranged from a minimum of $38.70 
to a maximum of $8,114.24.  Outliers on the cost data were detected with the help of Z-
scores.  Those scores in the excess of 3.3 are considered as potential outliers.425   
There were 20 cases with Z-scores above 3.3; these cases were examined. The 
extreme values on the cost data (above $3,540.18) was due to large quantities of statin 
drugs dispensed, thus a decision was made to retain them in the analysis.  However, only 
one case was deleted from the analysis because the total amount reimbursed for the two-
year period was unusually high ($8,114.24).  Thus, the amount reimbursed by Medicaid 
for statin drugs was calculated for 7,439 patients.  The total dollar amount reimbursed by 
Medicaid for statin drugs, for the two-year follow-up period, for 7,439 patients in the 
study, was $8.3 million.  The amount reimbursed ranged from a minimum of $38.70 to a 
maximum amount of $5,108.50.  The median cost reimbursed by Medicaid was 
$1,021.34 and the mean cost was $1,116.80 (S.D = $729.38).   Per member per month 
cost to Medicaid for statin drugs was $46.50.   
 
                                                 
425 Tabachnick BG, Fidell LS. Cleaning up your act: screening data prior to analysis. 




Objective 11 and 12: Factors Affecting Adherence and Persistence to Statin Therapy 
Study objectives 11 and 12, which aimed at determining the factors that are 
related to adherence and persistence to statin therapy, respectively, will be addressed in 
the section that tests the study hypotheses, later in this chapter.   
 
 
Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines 
 
Objective 13: Monitoring of Lipid Levels 
 
The ATP II guidelines recommend LDL monitoring prior to initiating drug 
therapy as well as follow-up measurements.  Based on the guidelines, it is important to 
have a minimum of two lipoprotein measurements during one to two months of diet 
therapy prior to initiating the drug therapy.  After starting drug therapy, the first 
lipoprotein measurement is recommended at six to eight weeks.  Once the target LDL 
levels are reached, patients should be monitored every eight to twelve week intervals 
through 52 weeks.  After a year of therapy, once the LDL levels are attained, monitoring 
of lipids and adverse effects should be conducted at four- to six-month intervals.  In 
addition, the ATP III guidelines recommend lipid monitoring within six to eight weeks 
following a change in drug regimen.426   
 To determine the extent physicians monitor patients’ lipid levels as per the 
guidelines, the monitoring of low-density lipoproteins (LDL) was assessed at baseline 
                                                 
426 Grundy SM, Becker DM, Clark L, et al. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal 




(within three months prior to index date), within three-months (but not earlier than six 
weeks) after the index date and six-months thereafter.  The presence of procedural codes 
for lipid tests in the medical claims file of Texas Medicaid were used to assess 
monitoring of lipid levels.  Table 3.14 presents the results.  
Within three months prior to the start of therapy, 42.5 percent (N = 3,163) of the 
total patients had their LDL levels monitored.  A majority of the patients   (N = 6,282; 
84.4%) did not have a follow-up lipid test within three months since the start of therapy.  
Of those patients who had their lipid levels monitored within three months since the start 
of therapy (N = 1,158), only 67 patients (5.8%) had lipid monitoring within six months 
thereafter. Thus, out of the total patients in the study (N = 7,440), only 0.9 percent of the 
patients (N = 67) had their LDL levels monitored as per the guidelines.  
In addition, LDL monitoring was assessed in patients who were persistent to 
statin therapy for three months or more.  A total of 4,888 (65.7%) were persistent to 
therapy for three months or more.  Of these only 43.8 percent (N = 2,118) had baseline 
lipid tests. Only 16.5 percent (N = 808) had LDL tests within three months after the start 
of therapy.  Only 0.8 percent (N = 40) had LDL levels tested at three months after the 
start of therapy and six months thereafter.  
Monitoring of LDL levels was also assessed among patients who were persistent 
to therapy for six months or more.  A total of 3,786 (50.8%) were persistent to therapy for 
six months or more.  Of these only 42.4 percent (N = 1,605) had baseline lipid tests. Only 




0.7 percent (N = 27) had LDL levels tested at three months after the start of therapy and 
six months thereafter.  
 LDL monitoring within six months and a year prior to the start of therapy were 
also assessed.  Table 3.15 presents these results.  Six months before the start of therapy, 
49.6 percent (N = 3,694) of the patients had their LDL levels monitored, whereas within a 
year following the start of therapy, 49.9 percent (N = 3,717) of the total patients had their 
LDL levels measured.  
 
Table 3.14: Frequency and Percent of Statin Users with LDL Monitoring at 






Number of Patients Percent 
Baseline (three months 
prior to start of therapy)a 
3,163 42.5%
Test within three months 
(but not earlier than six 
weeks) after start of 
therapya 
1,158 15.6%
Test within three months 
after start of therapy (but 
not earlier than six weeks) 




aCalculated as a percent of 7,440 which is the total number of patients started on statin therapy.  
bCalculated as a percent of 1,158 which is the total number of patients who had a test within three months 








Table 3.15: Frequency and Percent of Patients with LDL Monitoring Six Months 





Number of Patients Percent*
Prior to start of therapy  
     Six months 





After start of therapy 
     Six months 





*Calculated as a percent of 7,440 which is the total number of patients initiated on statin therapy.  
 
The guidelines also recommend LDL monitoring within three months (but not earlier 
than six weeks) of a change in dose or change in statin drug.  Table 3.16 presents the 
results for only LDL monitoring following the first time there was a change in statin type 
or dose.  A total of 2,160 patients had a change in statin dose and a total of 1,263 patients 
had a change in a statin drug type for the first time since the start of therapy.  Following a 
change in therapy, LDL monitoring was low, with only 15.5 (N = 335) and 14.1 percent 
(N = 178) of the patients having their LDL levels monitored within three months 










Table 3.16: Frequency and Percent of Statin Users with LDL Monitoring Following 





Number of Patients Percent
Within three months 
following a change in dosea   335 15.5%
Within three months 
following change in statin 
typeb 
178  14.1%
aPercent calculated from a total of 2,160 statin users who had an initial change in statin dose.  
bPercent calculated from a total of 1,263 statin users who had an initial change in statin type.  
 
There may be many reasons for a change in drug therapy.  It may be due to poor 
performance of the drug or may be due to side effects of the drug.  For those patients who 
had a change, the proportion of the patients with LDL monitoring three months prior to 




Table 3.17: Frequency and Percent of Patients with LDL Monitoring Three Months 





Number of Patients Percent
Three months prior to an 
initial change in dosea   889 41.2%
Three months prior to an 
initial change in statin typeb 491  38.9%
aPercent calculated from a total of 2,160 statin users who had an initial change in statin dose.  
bPercent calculated from a total of 1,263 statin users who had an initial change in statin type.  
  
The differences in lipid monitoring with respect to physician characteristics such 
as age, gender and years of licensure for the physician were also evaluated.  The number 
of tests based on the proportion of patients seen by a physician was calculated.  For 
example, if a physician saw three patients and of these three patients, the tests were 
conducted in only one patient then the proportion of tests conducted will be 0.33 for that 
physician.  Based on the frequency distribution, it was observed that most of the cases 
were concentrated where the proportions were either zero or one. Hence, for the purpose 
of statistical analysis, only those cases where the proportions were zero or one were 
included.  
A chi-square analysis was conducted to assess if there was an association between 
the proportion of tests per physician at baseline (three months prior to index date) and 
follow-up (within three months from the start of therapy) and physician’s gender.  No 
significant association was observed between the proportion of lipid tests at baseline 
(Chi-square = 1.070; df = 1; p = 0.301) and follow-up (Chi-square = 0.004; df = 1; p = 




A Pearson’s correlation was used to assess the relationship between the 
proportion of lipid tests at baseline and follow-up and physician’s age and the years of 
licensure. No significant correlation was observed between the age of the physician and 
the proportion of lipid tests at baseline (r = -0.007; p = 0.74) and follow-up (r = -0.003; p 
= 0.9).  Similarly, no significant correlation was observed between the year of licensure 
and the proportion of lipid tests at baseline (r = -0.25; p = 0.216) and follow-up (r = 
0.005; p = 0.789).   
 
Objective 14: Monitoring of Liver Function  
Adverse events associated with the use of statins include abnormalities in liver 
function and the occurrence of rhabdomylosis or muscle pain.  Thus, the guidelines call 
for conducting liver function tests (LFTs) to assess the side effects of statins before and 
after the start of therapy and following an increase in statin dose.  Presence of liver 
function tests (LFTs) was assessed to evaluate monitoring for adverse drug events 
associated with the use of statin drugs.  Presence of LFTs was assessed from the 
procedural codes in the Texas Medicaid Medical Claims file.  LFTs were assessed at 
baseline (three months prior to index date), within three months (but not earlier than six 
weeks) after the index date and six months thereafter.  Table 3.18 presents the results.  
  Within three months prior to the start of therapy, only 14.7 percent (N = 1,099) 
of the total patients had LFTs.  Only, 9.7 percent (N = 724) of the patients had an LFT  




function monitored within three months since the start of therapy (N = 724), only 35 
patients (4.8%) had LFTs within six months thereafter.  
Table 3.19 presents the results of the presence of LFTs within six months and a 
year prior to the start of therapy.  A greater number of patients had LFTs within a year as 
compared to three months since the start of therapy (31.6% vs. 9.7%). 
 
Table 3.18: Frequency and Percent of Statin Users with Liver Function Tests 
(LFTs) at Baseline, Within Three Months from Start of Statin Therapy and Six 
Months Thereafter 
 
Liver Function Tests 
 
Interval 
Number of Patients Percent
Baseline (three months 




Test within three months 
(but not earlier than six 
weeks) after start of  
therapy a 
724 9.7%
Test within three months 
after start of therapy (but 
not earlier than six weeks) 




aCalculated as a percent of 7,440 which is the total number of patients started on statin therapy. 
bCalculated as a percent of 724 which is the total number of patients who had a LFT within three months 
















Table 3.19: Frequency and Percent of Patients with Liver Function Tests (LFTs) Six 





Number of Patients Percent*
Prior to start of therapy  
     Six months 
     One year 
1,518 
  2,016 
20.4%
27.1%
After start of therapy 
     Six months 





*Calculated as a percent of 7,440 which is the total number of patients initiated on statin therapy. 
 
The differences in LFTs with respect to physician characteristics such as age, 
gender and years of licensure for the physician were also evaluated.  The number of tests 
based on the proportion of patients seen by a physician was calculated.  For example, if a 
physician saw three patients and of these three patients, the tests were conducted in only 
one patient, then the proportion of tests conducted will be 0.33 for that physician.  Based 
on the frequency distribution, it was observed that most of the cases were concentrated 
where the proportions were either zero or one. Hence, for the purpose of statistical 
analysis, only cases where the proportions were zero or one were included.  
A chi-square analysis was conducted to assess if there was an association between 
the proportion of tests per physician at baseline (three months prior to index date) and 
follow-up (within three months from the start of therapy) and physician’s gender.  No 




square = 0.690; df = 1; p = 0.406) and follow-up (Chi-square = 0.027;  df = 1; p = 0.869) 
and physician’s gender. 
A Pearson’s correlation was used to assess the relationship between the 
proportion of LFTs tests at baseline and follow-up and physician’s age and the years of 
licensure. No significant correlation was observed between the age of the physician and 
the proportion of LFTs at baseline (r = -0.040; p = 0.073) and follow-up  
(r = -0.031; p = 0.168).  Similarly, no significant correlation was observed between the 
year of licensure and the proportion of LFTs at baseline (r = -0.038; p = 0.62) and follow-
up (r = -0.013; p = 0.534). 
 
 
Objective 15: Monitoring of Liver Function Following an Increase in Statin Dose 
 
 A total of 2,352 statin users had an increase in statin dose for the first time 
following the start of therapy.  Of these, 1,896 had an increase in dose of their initial  
statin and 456 had a change in statin type along with an increase in dose.  Presence of 
LFTs within three months (but not earlier than six weeks) was assessed following the 
increase in dose.  Only 7.9 percent (N = 185) of the total patients who had an initial 





Objectives 16 through 22: Predictors of Lipid and Liver Function Monitoring 
 Objectives 16 through 22 that aimed at assessing the predictors of the occurrence 
of lipid monitoring and liver function monitoring are addressed in the analyses of study 
hypotheses section which follows. 
 
Testing of Study Hypotheses Related to the Objectives 
 
The study hypotheses that are tested relate to the following objectives: 
Objective 2 
To determine the association between statin dose prescribed at index date and CHD status 
at or prior to the index date. 
Objective 11 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic diseases, 
and total number of prescriptions are predictors of adherence to statin therapy. 
Objective 12 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic diseases, 
and total number of prescriptions are predictors of persistence to statin therapy. 
Objective 16 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 




are predictors of the occurrence of lipid monitoring tests at baseline (within three months 
prior to start of therapy). 
Objective 17 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic disease, 
physician specialty at index date and lipid testing at baseline are  predictors of the 
occurrence of lipid monitoring after the start of therapy (within three months, but not 
earlier than six weeks since the start of therapy). 
Objective 18 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic disease, 
physician specialty at index date and lipid testing at baseline are predictors of the 
occurrence of lipid monitoring (within three months, but not earlier than six weeks) 
following the initial change in statin type.  
Objective 19 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic disease, 
physician specialty at index date and lipid testing at baseline are predictors of the 
occurrence of lipid monitoring (within three months, but not earlier than six weeks) 







To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic disease, 
are predictors of the occurrence of LFTs at baseline (within three months prior to start of 
therapy). 
Objective 21 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic disease, 
physician specialty at index date and LFTs at baseline are predictors of the occurrence of 
LFTs (within three months, but not earlier than six weeks) after the start of therapy. 
Objective 22 
To determine if factors such as demographic characteristics (age, gender and ethnicity), 
type of CHD prevention, presence of diabetes, hypertension, and atherosclerotic disease, 
physician specialty at index date and LFTs at baseline are predictors of the occurrence of 
LFTs (within three months, but not earlier than six weeks) following the initial increase 
in statin dose. 
 
The following statistical tools were used to address the study hypotheses: 
1. Chi-square analysis; 
2. Multiple regression; 
3. Cox proportional hazards model; 




An a priori alpha level of 0.05 was used to test the study hypotheses. The evaluation of 
assumptions related to the statistical tests is presented. 
 
Assessment of Missing Data and Outliers for the Independent Variables 
 For the above analyses, the data were screened for any missing values and 
outliers. There were no missing values on any of the independent variables except for 
ethnicity and physician specialty, where 5.1 percent (386/7440) and 12.2 percent 
(909/7440) of the data were missing, respectively.  The missing cases on these variables 
were deleted from further analyses.   
Outliers for continuous predictor variables were evaluated using methods 
proposed by Tabachnick and Fidell.427  Z-scores were used to assess univariate outliers 
for the continuous variables such as age and the total number of prescriptions, used in the 
regression models.  Those cases with z-scores in excess of 3.3 were considered as outliers 
and were deleted from the dataset.  No outliers were detected for the variable age.  
Univariate outliers were detected for the total of number of prescriptions (Mean = 15.70; 
S.D. = 10.2; Minimum = 1; Maximum = 86) over the two-year follow-up period; and 
those cases with greater than 50 prescriptions (94 cases) were deleted from further 
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Testing of Assumptions 
 
 The statistical tests that were used to test the study hypotheses included multiple 
regression, logistic regression and Cox proportional hazards model. The assumptions 
with regards to each of these analyses were evaluated and presented in the following 
sections.    
 
 
Evaluation of Assumptions of Logistic Regression 
 
Although logistic regression makes no assumption of the distribution of the 
predictor variables, assumptions of sampling adequacy, multicollinearity, linearity of the 
logits and omission of outliers are critical to logistic regression.428  These assumptions 
were tested as a part of the analysis.  The assumption testing applies for all seven logistic 
regression models.  
Since the goodness-of-fit test in logistic regression compares the observed with 
expected frequencies in cells formed by the variables, the analysis may lack power if the 
cell counts are too small.  Thus, it is important to evaluate the expected cell frequencies 
for all pairs of variables including the outcome variables.  The requirement of sampling 
adequacy is that no cell should have expected frequencies less than one and no more than 
20 percent of the cells should have expected frequencies of less than five.  This 
assumption was violated in three models that assessed predictors of lipid monitoring 
following a dose and drug change, and liver function monitoring following a dose 
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increase.  This was caused by small cell size for the ethnicity categories of Asian or 
Pacific Islanders and American Indians or Alaskans.  In order to increase the size of the 
expected frequencies, Hosmer and Lemeshow recommend collapsing the categories.429  
Based on this recommendation, these two categories for ethnicity were collapsed into one 
to satisfy the assumption.  The collapsed category was titled “American Indian or 
Alaskan/Asian or Pacific Islander and consisted of 40 subjects in the analysis assessing 
the presence of lipid tests and LFTs following a dose increase and 32 subjects in the 
analysis assessing the presence of lipid test following a change in statin type.  
Logistic regression is sensitive to very high correlation among the predictor 
variables.  Very high correlations can be detected by high standard errors for the 
parameter estimates as well as failure of the model to converge.  However, there was no 
problem with model convergence and the standard errors of the parameters were not very 
large, therefore, multicollinearity was not an issue in any of the models.  The logistic 
regression results are tabulated later in the chapter.    
Although there are no linearity assumptions among the predictor variables in 
logistic regression, there exists an assumption of linearity between the continuous 
predictor variables and the logit transformation of the outcome variables.  Linearity of the 
logits among the predictors variables was assessed using the Box-Tidwell transformation 
of the continuous predictor variables (i.e., age) as proposed by Hosmer and Lemeshow.430  
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In the Box-Tidwell transformation, the interactions between each predictor and its natural 
logarithm are added to the logistic regression model.  There is a violation of the 
assumption if the interactions are significant.   Since the added interaction term was not 
statistically significant, this assumption was not violated.  No multivariate outliers were 
detected the in any of the regression solutions, hence presence of multivariate outliers 
was not an issue.  
 
Evaluation of Assumption for Cox Regression Analysis 
The proportionality of hazards assumption was evaluated.  The proportionality of 
hazards assumption is that the “shapes of the survival functions are the same for all 
groups over time.”  This implies that the failure rates across all groups are the same even 
if the “time to event” is different.  If the survival functions for different groups appear to 
be parallel this assumption is met.431,432  The survival curves were observed for each level 
of the predictor variables and the lines appeared parallel thus satisfying the assumption of 
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Evaluation of Assumptions for Multiple Regression 
 
The following assumptions for multiple regression were tested: absence of 
multicollinearity, normality, linearity and homoscedasticity of the residuals, 
independence of the error terms, and absence of outliers in the regression solution. 
Multicollinearity in regression models are high levels of intercorrelation among 
the predictor variables such that the effects of the variables cannot be separated.  
Tabachnick and Fidell indicate that a correlation of 0.90 or higher between the predictor 
variables would be a cause for concern.433  Multicollinearity will be detected with the 
variance proportions and the tolerance values of the variables. Variables with large 
variance proportions (i.e., greater than 0.5 on at least two variables for a given 
dimension) would present a collinearity problem.  Multicollinearity may be present if the 
tolerance for each of the independent variables is small (less than 0.1) since this would 
indicate that the variable is “almost a linear combination of other independent 
variables.”434  There was a lack of multicollinearity among the independent variables as 
the variance proportions were lower than 0.5 and none of the variables had a tolerance 
value of less than 0.1.     
The assumptions of normality, linearity and homoscedascticity of the residuals 
were assessed by examining the residual scatterplots.  The plots of standardized residuals 
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against the standardized estimates of the dependent variable (mean MPR) showed that the 
assumptions of normality, linearity, and homoscedascticity were satisfied.   
Another assumption of regression, that errors of prediction are independent of one 
another, was evaluated with the help of Durbin-Watson coefficient.  Durbin-Watson 
statistic is a “measure of autocorrelation of errors over the sequence of cases.”435   As a 
rule of thumb, the value of the coefficient between 1.5 and 2.5 indicates uncorrelated 
error terms. A Durbin-Watson statistic of 1.804 was obtained for the model, thus the error 
terms were independent.   
Multivariate outliers were assessed and cases with extreme values were detected 
by measuring the Cook’s distance, where values greater than one indicate presence of 
multicollinearity.  Cook’s distance measures the change in the regression coefficients as a 
result of elimination of a case from the analysis.436  In the analysis, very small values 
ranging from zero to 0.014 were obtained for the Cook’s distance indicating absence of 
multivariate outliers.  
 
Evaluation of Statin Treatment Patterns and Patient Adherence to Statin Therapy 
This objective tests the hypotheses related to assessing the differences in starting 
dose between primary and secondary prevention patients and assessing predictors of 
adherence to therapy.  Independent samples t-test, multiple regression, and Cox 
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regression were used to address the hypotheses.  The study objectives as well as the 
corresponding hypotheses will be restated along with the statistical analysis utilized.     
 
Objective 2: To determine the association between statin dose prescribed at index date 
and CHD status at or prior to the index date. 
 
 
Hypothesis 1:  The starting dose for statin therapy for secondary prevention patients will 
be higher than for primary prevention patients, controlling for the type of statin. 
 
A chi-square analysis was conducted to assess the association between the starting 
dose and CHD status, by statin type for the top three statins (Lipitor®, Zocor® and 
Pravachol®).  The patients on the top three statins represented 93.8 percent (N = 6,982) of 
the total patients.   A significant association was observed between the starting dose and 
CHD status for patients on Lipitor® (Chi-square = 36.016; df = 3; p < 0.001).  Table 3.20 
presents the frequency and proportion of patients with and without CHD, by the starting 
dose of Lipitor®.  For patients started on Lipitor®, 24.2 percent (N = 994) had CHD and 
75.8 percent did not have CHD (N = 3,116).  A chi-square analysis did not yield a 
significant association between the starting dose and CHD status for those patients on 
Zocor® (Chi-square = 7.398; df = 4; p = 0.116) or Pravachol® (Chi-square = 2.981; df = 









   
 
Table 3.20: Frequency and Proportion of Patients with CHD and without CHD by 
Starting Dose of Lipitor®  
 











Non-CHD 2299 705 105 7 3116 
(75.8%) 














Chi-square = 36.016; df = 3; p < 0.001 
 
 
Objective 11: To determine if factors such as demographic characteristics (age, gender 
and ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic diseases, and total number of other prescriptions are predictors of 
adherence to statin therapy. 
 
Study objective 11, which is represented by hypotheses 2 through 9, was assessed 
using multiple regression analysis. The dependent variable, MPR was calculated for each 
patient and regression analysis was employed.  The calculated MPR (mean = 0.70, S.D. = 
0.28) had a normal distribution. The predictor variables included in the model were 
patient’s age at index date, gender, ethnicity, presence of CHD, diabetes, hypertension, 
atherosclerotic disease, and total number of prescriptions other than lipid-lowering drugs 




Y = α + β1 age + β2 gender + β3 ethnicity + β4 CHD + β5 diabetes + β6 hypertension +      
β7 atherosclerotic disease + β8 total number of prescriptions + ε 
where Y = predicted value of the MPR 
βi (i=1,2,3,4,5,6,7,8)= coefficient for the change in the predicted value of MPR associated 
with a one unit change in gender, ethnicity, type of CHD prevention,  presence of 
diabetes as a risk factor, presence of hypertension as a risk factor, presence of 
atherosclerotic disease and total number of prescriptions. 
ε = error term  
In multiple regression analysis, the independent variables have to be either 
continuous or dummy coded dichotomous variables.  Some of the independent variables 
such as ethnicity and disease conditions (CHD, diabetes, hypertension or atherosclerotic 
diseases) in the model were discrete variables, having more than two categories.  These 
variables had to be dummy coded to convert them into a set of dichotomous variables 
with the categories being one less than the total number of discrete categories.  The 
variables were entered as a block in the regression analysis.  
Table 3.21 presents the results of the regression analysis. The overall regression 
F-test was used to evaluate the model fit, and the null hypothesis that there is no linear 
relationship between the dependent and the independent variables was rejected 
(F(15,6941) = 14.97; p < 0.001).  However, only 3.1 percent of the observed variability in 
the mean MPR was explained by the independent variables (R-square = 0.031).  Based on 




hypertension and diabetes was associated with an increase in MPR.  The study 





Table 3.21 Multiple Regression Analysis for “Medication Possession Ratio” and 









  B 
 
Beta     
Age at index date .000 .014 1.129 .259 
Gender (Male)a .040 .068 5.510 .000* 
Ethnicity (Black, non-Hispanic)b -.086 -.127 -9.668 .000* 
Ethnicity (Hispanic)b -.078 -.130 -9.907 .000* 
Ethnicity (American Indian or 
Alaskan Native)b -.009
-.002 -.171 .864 
Ethnicity (Asian or Pacific 
Islander)b -.029
-.014 -1.139 .255 
Diabetes prior to index datec -.009 -.016 -1.203 .229 
Diabetes developed during 
follow-upc -.023
-.025 -1.992 .046* 
Hypertension prior to index dated -.019 -.034 -2.082 .037* 
Hypertension developed during 
follow-upd -.029
-.042 -2.802 .005* 
CHD prior to index datee -.024 -.037 -2.810 .005* 
CHD developed during follow-upe -.022 -.028 -2.202 .028* 
Atherosclerosis prior to index 
datef .009
.011 .915 .360 
Atherosclerosis developed during 
follow-upf .000
.000 -.035 .972 
Total number of other 
prescriptions .000
.003 .271 .786 
F(15,6941) = 14.97; p<0.001, R-square = 0.031 
N = 6,957 
*p<0.05 
aReference category is female. 
bReference category is white, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 





Hypothesis 2: The MPR will be higher for males than for females, controlling for age, 
ethnicity, presence of CHD, diabetes, hypertension, atherosclerotic diseases, and total 
number of prescriptions. 
 
 Based on the results of the multiple regression analysis presented in Table 3.21, a 
positive significant relationship was observed between the MPR and gender (Beta = 0.07, 
p < 0.001), controlling for age, ethnicity, and disease conditions.  This implies that males 
had a higher MPR than females.  Hence, hypothesis 2 was not rejected.  
 
Hypothesis 3: The MPR will be higher for older patients than for younger patients, 
controlling for gender, ethnicity, presence of CHD, diabetes, hypertension, 
atherosclerotic disease, and total number of prescriptions. 
 
 Based on the results of the multiple regression analysis as presented in Table 3.21, 
there was no association between age and MPR (Beta = 0.014, p = 0.259), controlling for 
gender, ethnicity, disease conditions, and total number of prescriptions.  Thus, hypothesis 
3 was rejected as age was not related to MPR while controlling for other variables in the 
model. 
 
Hypothesis 4: The MPR will be higher for non-Hispanic whites than for other ethnic 
groups, controlling for age, gender, presence of CHD, diabetes, hypertension, 
atherosclerotic diseases, and total number of prescriptions. 
 
 Based on the results of the multiple regression analysis as presented in Table 3.21, 
a negative relationship was observed between the mean MPR and ethnicity, with non-
Hispanic blacks (Beta = -0.127, p < 0.001) and Hispanics (Beta = -0.130, p < 0.001) 




disease conditions, and total number of prescriptions.  Thus, hypothesis 4 was not 
rejected. 
 
Hypothesis 5: The MPR will be higher for secondary prevention CHD patients than for 
primary prevention CHD patients, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, atherosclerotic diseases, and total number of prescriptions. 
  
Based on the results of the multiple regression analysis as presented in Table 3.21, 
the MPR was lower for those having CHD a year prior to index date (Beta = -0.037, p = 
0.005) and those who developed CHD during the follow-up period (Beta = -0.028, p < 
0.028) as compared to those who did not have CHD, controlling for demographics and 
other disease conditions, and total number of prescriptions.  With every one unit increase 
in the diagnosis for CHD at or prior to index date and during the follow-up period, MPR 
decreased by 0.024 and 0.022, respectively.  Thus, hypothesis 5 was rejected as having a 
diagnosis for CHD before or after the index date was not positively related to MPR.     
 
Hypothesis 6: The MPR will be higher for diabetics than for non-diabetics, controlling 
for age, gender, ethnicity, presence of CHD, hypertension, atherosclerotic diseases, and 
total number of prescriptions. 
 
Based on the results of the multiple regression analysis as presented in Table 3.21,  
the MPR was lower for those patients who developed diabetes during the follow-up 
period (Beta = -0.025, p = 0.046) as compared to those who did not have diabetes, 
controlling for demographics, other disease conditions and total number of prescriptions.  
With every one unit increase in the number of diabetics prior to or at index date and 




hypothesis 6 was rejected as having a diagnosis for diabetes before or after the index date 
was not positively related to MPR.     
 
Hypothesis 7: The MPR will be higher for hypertensives than for non-hypertensives, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, atherosclerotic 
diseases, and total number of prescriptions. 
 
 Based on the results of the multiple regression analysis as presented in Table 3.21, 
patients who had hypertension a year prior to the index date (Beta = -0.034, p = 0.037) 
and those who developed hypertension during the follow-up period (Beta = -0.042, p = 
0.005) had a lower MPR as compared to those who did not have hypertension, controlling 
for demographics, disease conditions, and total number of prescriptions.  With every one 
unit increase in the diagnosis for hypertension prior to or at index date and during the 
follow-up period, MPR decreased by 0.019 and 0.029, respectively.   Thus, hypothesis 7 
was rejected. 
 
Hypothesis 8:  The MPR will be higher for those patients with atherosclerotic diseases 
than for those without atherosclerotic diseases, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and total number of prescriptions. 
 
 Based on the results of the multiple regression analysis as presented in Table 3.21, 
no significant association was observed between MPR and the presence of atherosclerotic 
diseases at or prior to index date (Beta = 0.011, p = 0.360) or during the follow-up period 
(Beta = 0.000, p = 0.972), controlling for demographics, disease conditions, and total 




atherosclerotic diseases before or after the index date was neither significantly nor 
positively related to MPR.       
 
Hypothesis 9: The MPR will be higher for those patients on a lower number of total 
prescriptions other than statins than for those on a higher number of prescriptions, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic disease.  
 
 Based on the results of the multiple regression analysis as presented in Table 3.21, 
no significant association was observed between MPR and the total number of 
prescriptions other than statins (Beta = 0.003, p = 0.786), controlling for demographics 
and disease conditions.  Thus, hypothesis 9 was rejected.  
 
Objective 12: To determine if factors such as demographic characteristics (age, gender 
and ethnicity), type of CHD prevention, presence of diabetes, hypertension, and 
atherosclerotic diseases, and total number of other prescriptions are predictors of 
persistence to statin therapy. 
 
Study objective 12, which is represented by hypotheses 10 through 17, was 
assessed using Cox regression analysis.  Days until patients discontinue their statin 
therapy was the dependent variable in the model.  Sixty days was used as a marker for 
discontinuation.  The predictor variables in the model included patient’s age at index 
date, gender, ethnicity, presence of CHD, diabetes, hypertension, atherosclerotic disease 
and the total number of prescriptions that the patient took during the two-year follow-up 








The Cox regression equation to test the study objectives is as follows: 
log hi(t) = α(t) + β1xi1 + β2xi2 + ……..+ β8xi8 
where 
hi = time to statin therapy discontinuation 
α(t) = log h0(t), baseline hazard function  
x1 = age 
x2 = gender 
x3 = ethnicity 
x4 = presence of diabetes 
x5 = presence of CHD 
x6 = presence of hypertension 
x7 = presence of atherosclerotic disease 
x8 = total number of prescriptions other than statins 
β = Regression coefficients for the change in the hazard ratio associated with a 
one unit change in the predictor variables 
Table 3.22 shows the regression coefficients, Wald statistics, degrees of freedom, 
p values and the hazard ratio for each predictor variable, following which the study 
hypotheses pertaining to this study objective are tested.  The test of model coefficients 
revealed that the variables reliably predicted the time to statin discontinuation since the 




df =15 ; p < 0.001).  In general, being male and white was associated with a lower hazard 
of becoming non-persistent whereas presence of disease conditions such as CHD, 
diabetes and hypertension was associated with a higher hazard of becoming non-
persistent, controlling for other variables in the model.   
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Interval for Hazard 














  Lower Upper 
Age at index date -.002 .002 1.589 1  .207 .998 .994 1.001
Gender (Male)a -.146 .036 16.190 1 .000* .864 .805 .928
Ethnicity (Black, non-Hispanic)b .369 .043 72.337 1 .000* 1.446 1.328 1.575
Ethnicity (Hispanic)b .315 .040 63.690 1 .000* 1.371 1.269 1.481
Ethnicity (American Indian or Alaskan)b .610 .237 6.592 1 .010* 1.840 1.155 2.930
Ethnicity (Asian or Pacific Islander)b .339 .124 7.502 1 .006* 1.403 1.101 1.788
Diabetes prior to index datec .109 .038 8.109 1 .004* 1.115 1.035 1.203
Diabetes developed during follow-upc .109 .056 3.762 1 .052 1.115 .999 1.244
Hypertension prior to index dated .094 .047 4.045 1 .044* 1.099 1.002 1.205
Hypertension developed during follow-upd .105 .053 3.978 1 .046* 1.111 1.002 1.233
CHD prior to index datee .123 .042 8.504 1 .004* 1.131 1.041 1.229
CHD developed during follow-upe .127 .048 7.012 1 .008* 1.136 1.034 1.248
Atherosclerosis prior to index datef -.105 .051 4.219 1 .040* .900 .814 .995
Atherosclerosis developed during follow-upf .010 .048 .044 1 .833 1.010 .919 1.111
Total number of prescriptions .001 .002 .285 1 .594 1.001 .997 1.005
-2 Log Likelihood = 62364.7      Overall Chi-square = 190.36, df = 15, (p<0.001);    N = 6,957  
*p <0.05  
#60 days without receiving a statin refill was used as a marker for discontinuation. 
aReference category is female. 
bReference category is white, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 




Hypothesis 10: Females will have a higher hazard of becoming non-persistent to statin 
therapy than males controlling for age, ethnicity, presence of CHD, hypertension, 
diabetes, atherosclerotic diseases, and total number of prescriptions. 
 
 Based on the results of the Cox regression analysis presented in Table 3.22, males 
had a 13 percent lower hazard of becoming non-persistent as compared to females 
(Hazard Ratio = 0.864; 95% CI: 0.805-0.928; p < 0.001), controlling for age, ethnicity, 
disease conditions, and total number of prescriptions.  Thus, hypothesis 10 was not 
rejected. 
 
 Hypothesis 11: Younger patients will have a higher hazard of becoming non-persistent 
to statin therapy than older patients, controlling for gender, ethnicity, presence of CHD, 
hypertension, diabetes, atherosclerotic diseases, and total number of prescriptions. 
 
 Based on the results of the Cox regression analysis presented in Table 3.22, the 
hazard of becoming non-persistent did not differ with age, controlling for gender, 
ethnicity, disease conditions, and total number of prescriptions (Hazard Ratio = 0.998 
95% CI: 0.994-1.001; p = 0.207).  Thus, hypothesis 11 was rejected. 
 
Hypothesis 12: Other ethnic minorities will have a higher hazard of becoming non-
persistent to statin therapy than non-Hispanic whites, controlling for age, gender, 
presence of CHD, hypertension, diabetes, atherosclerotic diseases, and total number of 
prescriptions. 
 
Based on the results of the Cox regression analysis presented in Table 3.22, the 
hazard of becoming non-persistent with statin therapy was higher in non-Hispanic blacks 
compared to non-Hispanic whites, (Hazard Ratio = 1.446; 95% CI: 1.328-1.575;   p < 




Indians or Alaskans (Hazard Ratio = 1.840; 95% CI: 1.155-2.930; p = 0.010), and Asians 
or Pacific Islanders (Hazard Ratio = 1.403; 95% CI: 1.101-1.788; p = 0.006), controlling 
for age, gender, disease conditions, and total number of prescriptions.  Thus, hypothesis 
12 was not rejected. 
 
Hypothesis 13: Patients without CHD will have a higher hazard of becoming non-
persistent to statin therapy than those with CHD, controlling for age, gender, ethnicity, 
presence of hypertension, diabetes, atherosclerotic diseases, and total number of 
prescriptions. 
 
 Based on the results of the Cox regression analysis presented in Table 3.22, 
contrary to the hypothesis, patients with CHD in the year prior to the index date (Hazard 
Ratio = 1.131; 95% CI: 1.041-1.229; p = 0.004) and those who developed CHD in the 
follow-up period (Hazard Ratio = 1.136; 95% CI: 1.034-1.248; p = 0.008) had a greater 
hazard of becoming non-persistent than those who did not have a diagnosis for CHD, 
controlling for demographic characteristics, other disease conditions, and total number of 
prescriptions.  Thus, hypothesis 13 was rejected. 
 
Hypothesis 14: Patients without diabetes will have a higher hazard of becoming non-
persistent to statin therapy than those with diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, atherosclerotic diseases, and total number of 
prescriptions. 
 
 Based on the results of the Cox regression analysis presented in Table 3.22, 
contrary to the hypothesis, patients with a diagnosis for diabetes in the year prior to the 
index date were at a greater hazard (Hazard Ratio = 1.115; 95% CI: 1.035-1.203;             




for demographic characteristics, other disease conditions, and total number of 
prescriptions.  The hazard of becoming non-persistent to statin therapy did not differ 
significantly between those patients who did not have diabetes versus those who 
developed diabetes during the follow-up period (Hazard Ratio = 1.115; 95% CI: 0.999-
1.244; p = 0.052).   Thus, hypothesis 14 was rejected based on having diabetes prior to 
index date. 
 
Hypothesis 15: Patients without hypertension will have a higher hazard of becoming non-
persistent to statin therapy than those with hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, atherosclerotic diseases, and total number of 
prescriptions. 
 
Based on the results of the Cox regression results presented in Table 3.22, patients 
with a diagnosis for hypertension in the year prior to index date (Hazard Ratio = 1.099; 
95% CI: 1.002-1.205; p = 0.044) or in the follow-up period (Hazard Ratio = 1.111; 95% 
CI: 1.002-1.233; p = 0.046) had a greater hazard of becoming non-persistent than those 
who did not have a diagnosis for hypertension, controlling for demographic 
characteristics, other disease conditions, and total number of prescriptions.  Thus, 













Hypothesis 16: Patients without atherosclerotic diseases will have a higher hazard of 
becoming non-persistent to statin therapy than those with atherosclerotic diseases 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension, and total 
number of prescriptions. 
 
Based on the results of the Cox regression results presented in Table 3.22, patients 
with a diagnosis for atherosclerosis in the year prior had a slightly lower hazard (Hazard 
Ratio = 0.900; 95% CI: 0.814-0.995; p = 0.04) of becoming non-persistent than those 
who did not have atherosclerosis.  However, the hazard of becoming non-persistent did 
not differ significantly between those who did not have atherosclerosis and those who 
developed atherosclerosis during the follow-up period (Hazard Ratio = 1.010; 95% CI: 
0.919-1.111; p = 0.833).  Thus, hypothesis 16 was not rejected based on presence of 
atherosclerotic disease prior to index date.  
  
Hypothesis 17:  Patients on a greater number of total prescriptions other than statins will 
have a higher hazard of becoming non-persistent than those on fewer prescriptions, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
  
 Based on the results of the Cox regression analysis presented in Table 3.22, the 
number of prescriptions that the patient was on during the study period did not have any 
effect on the hazard rate of becoming non-persistent (Hazard Ratio = 1.001; 95% CI: 
0.997 – 1.005; p = 0.594), controlling for demographic characteristics and disease 





Evaluation of How Well Physicians Follow Lipid and Safety Monitoring Guidelines 
 The study goal aimed at evaluating how well physicians follow lipid and safety 
monitoring guidelines (objectives 13 through 22) were assessed using hypotheses 18 
through 76.  The outcome variables (lipid and liver function tests) were dichotomized 
with 1 = presence of a test and 0 = absence of a test.  Seven logistic regression models 
were used.  The coding schemes for the predictor variables in the model are listed in 
Table 3.23.  The model fit was assessed using the model chi-square test and the Hosmer 
and Lemeshow statistic.437 
The model chi-square test presents the improvement in the model fit due to the 
predictor variables compared to a constant only model.  A model chi-square significant at 
a 0.05 level or less, leads to the rejection of the null hypothesis that there is no difference 
between the constant only model and the model with the predictor variables.  In other 
words, an acceptable model fit will produce a significant model chi-square. 
The Hosmer and Lemeshow goodness-of-fit test groups cases based on the 
predicted probabilities and computes a chi-square from the observed and expected 
frequencies.  If the statistic is significant at 0.05 level or less,  the null hypothesis that 
there is no difference between the observed and the predicted values of the predictor 
variables is rejected.  In other words, an acceptable model will produce a non-significant 
chi-square for the Hosmer and Lemeshow goodness-of-fit test.  
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Table 3.23: Coding of Variables to be Included in Logistic Regression Models 
 
Variables Variable Codes 
Age Age at the index date – continuous variable 
Gender 1=Male; 2=Female* 
Ethnicity 1=Non-Hispanic whites*; 2=Non-Hispanic 
blacks; 3=Hispanics; 4=American Indian or 
Alaskan; 5=Asian or Pacific Islander 
Presence of CHD 1=Yes; 2=No*  
Presence of diabetes 1=Yes; 2=No* 
Presence of hypertension 1=Yes; 2=No* 
Presence of atherosclerotic disease 1=Yes; 2=No* 
Physician specialty at index date 1=Cardiologists*; 2=Family 
practice/general practice; 3=Internal 
medicine; 4=Other 
Prior lipid test 1=Yes; 2=No* 
Prior LFT  1=Yes; 2=No* 
*Reference category in the model. 
 
Objective 16: To assess the predictors of the occurrence of lipid monitoring tests at 
baseline (within three months prior to start of therapy). 
 
Lipid monitoring was assessed three months prior to start of therapy.  Hypotheses 
18 to 24 addressing this study objective were tested using logistic regression analysis, 
with age, gender, ethnicity, presence of a diagnosis for CHD, diabetes, hypertension, and 




The following logistic regression model was used to test the hypotheses: 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + ε 
where: 
ln(OR) = overall logit of the likelihood of  a lipid test at baseline. 
βi (i=1,2,3,4,5,6,7)= coefficient for the change in ln(OR) associated with a one unit 
change in age, gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, and presence of atherosclerotic disease. 
α = intercept 
ε = error term 
Female gender, older age, being non-Hispanic Black, as well as presence of 
disease conditions such as CHD was associated with a decreased likelihood of lipid 
testing.  However, being Hispanic and presence of disease conditions such as diabetes 
and hypertension was associated with an increased likelihood of lipid testing.  The results 
of the logistic regression analysis are presented below in Table 3.24, following which 
hypotheses 18 to 24 are discussed.  Based on the Hosmer-Lemeshow statistic (p > 0.05), 
as well as the overall model chi-square (p < 0.001), the model presented an acceptable fit.  
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Table 3.24: Logistic Regression Analysis to Assess Predictors of Lipid Monitoring within Three Months Prior to Start 
of Statin Therapy 
 
95.0% Confidence 
Interval for Odds 














  Lower Upper 
Age at index date -.009 .003 10.130 1 .001* .991 .986 .997
Gender (Male) -.298 .053 32.266 1 .000* .742 .669 .823
Ethnicity (Black, non-Hispanic) -.405 .066 37.340 1 .000* .667 .586 .759
Ethnicity (Hispanic) .187 .058 10.562 1 .001* 1.206 1.077 1.350
Ethnicity (American Indian or Alaskan) .005 .389 .000 1 .991 1.005 .468 2.154
Ethnicity (Asian or Pacific Islander) .324 .188 2.968 1 .085 1.383 .956 1.999
Diabetes prior to index date .155 .052 8.984 1 .003* 1.168 1.055 1.292
Hypertension prior to index date .645 .054 142.524 1 .000* 1.907 1.715 2.120
CHD prior to index date -.233 .060 14.950 1 .000* .793 .704 .892
Atherosclerosis prior to index date -.099 .074 1.800 1 .180 .906 .784 1.047
Hosmer and Lemeshow Goodness of fit test: Chi-square = 3.837; df = 8; p = 0.872; Model Chi-square = 300.708; df = 13; p < 0.001 
*p < 0.05 
N = 7,054  
aReference category is female. 
bReference category is whites. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis. 




Hypothesis 18: The likelihood of a lipid test at baseline will be higher for males than for 
females, controlling for age, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
 
Based on the results of the logistic regression analysis presented in Table 3.24, 
males (Odds Ratio (OR) = 0.742; 95% CI: 0.669-0.823; p < 0.001) were associated with a 
decreased odds of getting a lipid test as compared to females, controlling for age, 
ethnicity, and disease conditions . Thus, hypothesis 18 was rejected. 
 
Hypothesis 19: The likelihood of a lipid test at baseline will be higher for older patients 
for than younger patients, controlling for gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.24, 
older age (OR = 0.991; 95% CI: 0.986-0.997; p = 0.001) was associated with a slight 
decrease in the odds of getting a lipid test compared to younger patients, controlling for 
gender, ethnicity, and presence of disease conditions.  Thus, hypothesis 19 was rejected. 
 
 
Hypothesis 20: The likelihood of a lipid test at baseline will be higher for non-Hispanic 
whites than for other age, ethnic groups, controlling for gender, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases. 
 
Based on the results of the logistic regression analysis presented in Table 3.24, 
being non-Hispanic black (OR = 0.667; 95% CI: 0.586-0.759; p < 0.001) was associated 
with decreased odds of getting a lipid test than non-Hispanic whites.  However, Hispanics 
were 1.2 times more likely to get a lipid test compared to non-Hispanic whites (p = 
0.001).  Asian/Pacific Islanders (OR = 1.383; 95% CI: 0.956 – 1.999; p = 0.085) were 




Hispanic whites, controlling for age, gender and disease conditions; however, the results 
were statistically non-significant.  The odds of receiving a lipid test did not differ 
significantly between American Indian/Alaskan (OR = 1.005; 95% CI: 0.468 – 2.154; p = 
0.991) and non-Hispanic whites, controlling for age, gender and disease conditions.  
Based on these results, hypothesis 20 was rejected. 
 
Hypothesis 21: The likelihood of a lipid test at baseline will be higher for patients with 
CHD than for those without CHD, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.24, 
patients with CHD (OR = 0.793; 95% CI: 0.704-0.892; p < 0.001) had a decreased 
likelihood of getting a lipid test compared to those without CHD, controlling for 
demographic characteristics and other disease conditions.  Thus, hypothesis 21 was 
rejected. 
 
Hypothesis 22: The likelihood of a lipid test at baseline will be higher for patients with 
diabetes than for those without diabetes, controlling for age, gender, ethnicity, presence 
of CHD, hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.24, 
patients with diabetes (OR = 1.168; 95% CI: 1.055-1.292; p = 0.003) had a greater 
likelihood of having their lipid levels tested compared to those without diabetes, 
controlling for demographic characteristics and other disease conditions.  Thus, 






Hypothesis 23: The likelihood of a lipid test at baseline will be higher for patients with 
hypertension than for those without hypertension, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.24, 
patients with hypertension (OR = 1.907; 95% CI: 1.715-2.210; p < 0.001) in the year 
prior to the index date had a higher likelihood of having their lipid levels tested compared 
to those without hypertension.  Thus, hypothesis 23 was not rejected. 
 
Hypothesis 24: The likelihood of a lipid test at baseline will be higher for patients with 
atherosclerotic diseases than for those without atherosclerotic diseases, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and hypertension. 
 
 Based on the results of the logistic regression analysis presented in Table 3.24, 
there was no significant differences in the likelihood of a lipid test between those patients 
with atherosclerotic diseases versus those without (OR = 0.906; 95% CI: 0.784-1.047; p 
= 0.180), controlling for demographic characteristics, and other disease conditions. Thus, 
hypothesis 24 was rejected.  
 
Objective 17: To assess the predictors of the occurrence of lipid monitoring after the 
start of therapy (within three months, but not earlier than six weeks since the start of 
therapy). 
 
Lipid monitoring was assessed within three months (but not earlier than six 
weeks) from the start of statin therapy.  Hypotheses 25 to 32, addressing this study 
objective, were tested using logistic regression analysis with age, gender, ethnicity, 
presence of a diagnosis for CHD, diabetes, hypertension and atherosclerotic disease, 





The following logistic regression model was used to test hypotheses 25 to 32. 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + β8 physician specialty at index date + β9 prior lipid test + ε 
where: 
ln(OR) = overall logit of the likelihood of  a lipid test at baseline. 
βi (i=1,2,3,4,5,6,7,8,9) = coefficient for the change in ln(OR) associated with a one unit 
change in gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, presence of atherosclerotic disease, 
physician specialty, and presence of lipid test at baseline. 
α = intercept 
ε = error term 
Being white, having CHD and a lipid test prior to index date were significant 
predictors of lipid testing after the start of therapy, controlling for age, gender, other 
disease conditions, and physician specialty at index date.  The results of the logistic 
regression analysis are presented below in Table 3.25, following which hypotheses 25 to 
33 are discussed.  Based on the Hosmer-Lemeshow statistic (p > 0.05), as well as the 
overall model chi-square (p < 0.001), the model presented an acceptable fit.  
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Table 3.25: Logistic Regression Analysis to Assess Predictors of Lipid Monitoring Within Three Months Following 
Start of Statin Therapy 
 
95.0% Confidence 
Interval for Odds 














  Lower Upper 
Age at index date -.006 .004 2.455 1 .117 .994 .986 1.002
Gender (Male)a .142 .077 3.460 1 .063 1.153 .992 1.339
Ethnicity (Black, non-Hispanic)b -.218 .106 4.226 1 .040* .804 .653 .990
Ethnicity (Hispanic)b .156 .082 3.625 1 .057 1.169 .995 1.373
Ethnicity (American Indian or Alaskan)b .639 .501 1.630 1 .202 1.895 .710 5.056
Ethnicity (Asian or Pacific Islander)b -.102 .286 .128 1 .721 .903 .516 1.580
Diabetes prior to index datec .015 .076 .039 1 .844 1.015 .874 1.179
Hypertension prior to index dated .131 .080 2.676 1 .102 1.140 .974 1.333
CHD prior to index datee .266 .090 8.714 1 .003* 1.305 1.093 1.556
Atherosclerosis prior to index datef .145 .104 1.963 1 .161 1.156 .944 1.416
Physician specialty (Family practice/general 
practice)g -.047 .151 .097 1 .755 .954 .710 1.282
Physician specialty (Internal medicine)g .011 .150 .005 1 .944 1.011 .753 1.357
Physician specialty (Others)g -.093 .168 .307 1 .579 .911 .655 1.267
Lipid test three months prior to index dateh 1.437 .079 334.613 1 .000* 4.207 3.607 4.908
Hosmer and Lemeshow Goodness of fit test: Chi-square = 8.244; df = 8; p = 0.410; Model Chi-square = 443.846; df = 14; p < 0.001  *p < 0.05 
N = 6,203; aReference category is female. 
bReference category is whites. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis. 
gReference category is cardiologists. 
hReference category is absence of lipid test
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Hypothesis 25: The likelihood of a lipid test after start of therapy will be higher for males 
than for females controlling for age, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, the 
likelihood of a lipid test after start of therapy did not differ with respect to gender  (OR = 
1.153; 95% CI: 0.992-1.339; p = 0.063) controlling for age, ethnicity, disease conditions, 
physician specialty, and prior lipid testing.  Thus, hypothesis 25 was rejected.   
 
Hypothesis 26: The likelihood of a lipid test after start of therapy will be higher for older 
patients than for younger patients, controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, the 
likelihood of a lipid test at start of therapy did not differ with age (OR = 0.994, 95% CI: 
0.986-1.002, p = 0.117), controlling for gender, ethnicity, disease conditions, physician 
specialty, and prior lipid testing.  Thus, hypothesis 26 was rejected. 
 
Hypothesis 27: The likelihood of a lipid test after start of therapy will be higher for non-
Hispanic whites than for other ethnic groups, controlling for age, gender, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, 
non-Hispanic blacks had a decreased likelihood of getting lipid tests compared to non-
Hispanic whites (OR = 0.804, 95% CI: 0.653-0.990; p = 0.04).  The likelihood of a lipid 
test did not differ significantly between non-Hispanic whites and Hispanics (OR = 1.169; 
95% CI: 0.995-1.373; p = 0.057).  American Indian or Alaskan were 1.8 times more 
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likely to get a lipid test compared to non-Hispanic whites (OR = 1.895; 95% CI: 0.710-
5.056); however, the result was not statistically significant (p = 0.202).  Based on the 
results, hypothesis 27 was rejected. 
 
Hypothesis 28: The likelihood of a lipid test after start of therapy will be higher for 
patients with CHD than for those without CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and atherosclerotic diseases, physician specialty, and 
lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, 
patients with a diagnosis of CHD at or a year prior to the index date were more likely to 
get a lipid test than those without a diagnosis for CHD (OR = 1.305; 95% CI: 1.093-
1.556; p = 0.003), controlling for demographic characteristics, other disease conditions, 
physician specialty, and lipid testing prior to index date.  Thus, hypothesis 28 was not 
rejected. 
 
Hypothesis 29: The likelihood of a lipid test after start of therapy will be higher for 
patients with diabetes than for those without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, physician 
specialty,  and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, 
patients with a diagnosis of diabetes did not differ significantly with respect to lipid 
monitoring as compared to those without a diagnosis for diabetes (OR = 1.015; 95% CI: 
0.874-1.179; p = 0.844), controlling for demographic characteristics, other disease 




Hypothesis 30: The likelihood of a lipid test after start of therapy will be higher for 
patients with hypertension than for those without hypertension, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, 
patients with a diagnosis of hypertension did not differ significantly with respect to lipid 
monitoring as compared to those without a diagnosis for hypertension, (OR = 1.140; 95% 
CI: 0.974-1.333; p = 0.102) controlling for demographic characteristics, other disease 
conditions, physician specialty, and lipid testing prior to index date.  Thus, hypothesis 30 
was rejected. 
 
Hypothesis 31: The likelihood of a lipid test after start of therapy will be higher for 
patients with atherosclerotic diseases than for those without atherosclerotic diseases, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, 
physician specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, 
patients with a diagnosis patients of atherosclerotic diseases did not differ significantly 
with respect to lipid monitoring as compared to those without a diagnosis for 
atherosclerotic diseases (OR = 1.156; 95% CI: 0.944-1.416; p = 0.161), controlling for 
demographic characteristics, other disease conditions, physician specialty, and lipid 









Hypothesis 32: The likelihood of a lipid test after start of therapy will be higher for 
patients treated by a cardiologist at index date than for those treated by other physician 
specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension 
and atherosclerotic diseases,  and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.25, the 
likelihood of a lipid test at the start of therapy did not differ significantly for those 
patients treated by a cardiologist at index date compared to family practice/general 
practice (OR = 0.954; 95% CI: 0.710-1.282; p = 0.755), internal medicine (OR = 1.011; 
95% CI: 0.753-1.357; p = 0.944) or other physician specialty (OR = 0.911; 95% CI: 
0.655-1.267; p = 0.579).  Thus, hypothesis 32 was rejected.  
 
Hypothesis 33: The likelihood of a lipid test after start of therapy will be higher for 
patients with lipid tests at baseline than those without lipid tests at baseline, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, atherosclerotic 
diseases, and physician specialty. 
 
Based on the results of the logistic regression analysis presented in Table 3.25, the 
the presence of a lipid test prior to the index date was a significant predictor for lipid test 
after the start of therapy.  Patients who had a lipid test prior to the start of therapy were 
4.2 times more likely to get a lipid test after the start of therapy (OR = 4.207; 95% CI: 










Objective 18: To assess the predictors of the occurrence of lipid monitoring (within 
three months, but not earlier than six weeks) from the initial change in statin type.  
 
Lipid monitoring was assessed within three months (but not earlier than six 
weeks) from the initial change in statin type.  Hypotheses 34 to 42, addressing this study 
objective, were tested using logistic regression with age, gender, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic disease, physician specialty at index 
date and lipid testing prior to start of therapy as the predictor variables.  
The following logistic regression model was used to address the hypotheses: 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + β8 physician specialty at index date + β9 prior lipid test + ε 
where:   
ln(OR) = overall logit of the likelihood of  a lipid test at baseline. 
βi (i=1,2,3,4,5,6,7,8,9)= coefficient for the change in ln(OR) associated with a one unit 
change in gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, presence of atherosclerotic disease, 
physician specialty, and presence of lipid test at baseline. 
α = intercept 
ε = error term 
 The only significant predictor of lipid monitoring after the initial change in statin 
type was baseline lipid monitoring, controlling for other variables.  The results of the 
logistic regression analysis are presented in Table 3.26 below, following which 
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hypotheses 34 to 42 are discussed.  Based on the Hosmer-Lemeshow statistic (p > 0.05), 
as well as the overall model chi-square (p < 0.001), the model presented an acceptable fit. 
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  Lower Upper 
Age at index date -.006 .011 .339 1 .560 .994 .973 1.015
Gender (Male)a .118 .193 .377 1 .539 1.125 .772 1.641
Ethnicity (Black, non-Hispanic)b -.294 .273 1.167 1 .280 .745 .437 1.271
Ethnicity (Hispanic)b .187 .205 .837 1 .360 1.206 .807 1.802
Ethnicity (American Indian or Alaskan/Asian or 
Pacific Islander)b .761 .448 2.886 1 .089 2.141 .890 5.151
Diabetes prior to index datec .082 .188 .189 1 .664 1.085 .751 1.569
Hypertension prior to index dated -.004 .199 .000 1 .985 .996 .674 1.473
CHD prior to index datee .172 .230 .556 1 .456 1.187 .756 1.864
Atherosclerosis prior to index datef .050 .277 .033 1 .857 1.051 .611 1.811
Physician specialty (Family practice/general 
practice)g .696 .516 1.820 1 .177 2.005 .730 5.511
Physician specialty (Internal medicine)g .690 .515 1.795 1 .180 1.993 .727 5.467
Physician specialty (Others)g .620 .552 1.264 1 .261 1.860 .631 5.483
Lipid test three months prior to index dateh .889 .189 22.065 1 .000* 2.432 1.679 3.525
Hosmer and Lemeshow Goodness of fit test: Chi-square = 11.270; df = 8; p = 0.187;  Model Chi-square = 37.238; df = 13; p < 0.001;  *p < 0.05 
N = 1,062; aReference category is female. 
bReference category is whites, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis. 
gReference category is cardiologists. 
hReference category is absence of lipid test.
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Hypothesis 34: The likelihood of a lipid test after an initial change in statin type will be 
higher for males than for females controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
  
 Based on the results of the logistic regression analysis presented in Table 3.26, 
lipid testing after the initial change in statin type did not differ by gender (OR = 1.125; 
95% CI: 0.772-1.641; p = 0.539) controlling for age, ethnicity, disease conditions, 
physician specialty, and lipid monitoring at baseline.  Thus, hypothesis 34 was rejected. 
 
Hypothesis 35: The likelihood of a lipid test after an initial change in statin type will be 
higher for older patients than for younger patients, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
Based on the results of the logistic regression analysis presented in Table 3.26, the 
likelihood of receiving a lipid test after an initial change in statin type did not differ 
significantly with age (OR = 0.994; 95% CI: 0.973-1.015; p = 0.560), controlling for 
gender, ethnicity, disease conditions, physician specialty, and lipid monitoring at 
baseline.  Thus, hypothesis 35 was rejected. 
 
Hypothesis 36: The likelihood of a lipid test after an initial change in statin type will be 
higher for non-Hispanic whites than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
  
Based on the results of the logistic regression analysis presented in Table 3.26, 
there was no significant difference in the likelihood of receiving a lipid test after the 
initial change in statin type between non-Hispanic whites and non-Hispanic blacks (OR = 
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0.745; 95% CI: 0.437-1.271; p = 0.280).  Hispanics were 1.2 times more likely to receive 
the test compared to non-Hispanic whites (OR = 1.206; 95% CI: 0.807-1.802; p = 0.360), 
however, this result was not statistically significant (p = 0.360).  Similarly, American 
Indian/Alaskan or Asian or Pacific Islanders were twice as likely than non-Hispanic 
whites to receive the lipid tests, however the confidence interval for the odds ratio was 
large (OR = 2.141; 95% CI: 0.809-5.151; p = 0.089) and the result was not statistically 
significant.  Thus, hypothesis 36 was rejected. 
 
Hypothesis 37: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with CHD than for those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and atherosclerotic diseases, physician 
specialty and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.26, the 
likelihood of lipid test following an initial change in statin type did not differ 
significantly between those with and without CHD (OR = 1.187; 95% CI: 0.756-1.864; p 
= 0.456), controlling for demographic characteristics, other disease conditions, physician 
specialty, and lipid testing prior to index date.  Thus, hypothesis 37 was rejected.  
 
Hypothesis 38: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with diabetes than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, 
physician specialty and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.26, the 
likelihood of a lipid test after an initial change in statin type did not differ significantly 
between diabetics versus non-diabetics (OR = 1.085; 95% CI: 0.751-1.569; p = 0.664), 
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controlling for demographic characteristics, other disease conditions, physician specialty 
and lipid testing prior to index date.  Thus, hypothesis 38 was rejected.  
 
Hypothesis 39: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with hypertension than for those without hypertension, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.26, the 
likelihood of a lipid test after an initial change in statin type did not differ significantly 
between hypertensives versus non-hypertensives (OR = 0.996; 95% CI: 0.674-1.473;      
p = 0.985), controlling for demographic characteristics, other disease conditions, 
physician specialty, and lipid testing prior to index date.  Thus, hypothesis 39 was 
rejected.  
 
Hypothesis 40: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and lipid testing prior to index date. 
  
Based on the results of the logistic regression analysis presented in Table 3.26, the 
likelihood of a lipid test after an initial change in statin type did not differ significantly 
between those with atherosclerotic disease versus those without (OR = 1.051; 95% CI: 
0.611-1.811; p = 0.857), controlling for demographic characteristics, other disease 
conditions, physician specialty and lipid testing prior to index date.  Thus, hypothesis 40 
was rejected.  
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Hypothesis 41: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients treated by a cardiologist at index than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.26, 
patients treated by a family practice/general practice physician at index date were twice 
as likely to receive lipid tests after an initial change in statin dose as compared to 
cardiologists.  However, the result was statistically non-significant (p = 0.177), and the 
confidence interval for the odds ratio was large (95% CI: 0.730-5.511). Similar results 
were obtained for physician with specializations in internal medicine (OR = 1.993; 95% 
CI: 0.727-5.467; p = 0.180) and other specialties (OR = 1.860; 95% CI: 0.631-5.483; p = 
0.261).  Thus, hypothesis 41 was rejected. 
 
Hypothesis 42: The likelihood of a lipid test after start of therapy will be higher for 
patients with lipid tests at baseline than those without lipid tests at baseline, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, atherosclerotic 
diseases, and physician specialty. 
 
Based on the results of the logistic regression analysis presented in Table 3.26, the 
presence of a lipid test prior to the index date was a significant predictor for lipid 
monitoring after the initial change in statin type.  Patients who had a lipid test prior to the 
start of therapy were 2.4 times more likely to get a lipid test after the change in statin type 







Objective 19: To assess the predictors of the occurrence of lipid monitoring (within 
three months, but not earlier than six weeks) following the initial change in statin dose. 
 
Lipid monitoring was assessed within three months (but not earlier than six 
weeks) following an initial change in statin dose.  Hypotheses 43 to 51 that addressed this 
study objective were tested using logistic regression with age, gender, ethnicity, presence 
of CHD, diabetes, hypertension, and atherosclerotic disease, physician specialty at index 
date, and lipid monitoring at baseline as the predictor variables.   
The following logistic regression model was used to assess predictors of lipid 
monitoring after initial change in statin dose: 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + β8 physician specialty at index date + β9 prior lipid test + ε 
where:   
ln(OR) = overall logit of the likelihood of  a lipid test after initial change in statin dose. 
βi (i=1,2,3,4,5,6,7,8,9) = coefficient for the change in ln(OR) associated with a one unit 
change in gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, presence of atherosclerotic disease, 
physician specialty, and presence of lipid test at baseline. 
α = intercept 
ε = error term 
 The only significant predictor of lipid monitoring after the initial change in statin 
dose was baseline lipid monitoring, controlling for other variables.  The results of the 
logistic regression analysis are presented in Table 3.27, following which hypotheses 43 to 
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51 are discussed.  Based on the Hosmer-Lemeshow statistic (p > 0.05), as well as the 
overall model chi-square (p < 0.001), the model presented an acceptable fit 
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  Lower Upper 
Age at index date -.007 .008 .796 1 .372 .993 .978 1.008
Gender (Male)a .031 .146 .044 1 .834 1.031 .775 1.372
Ethnicity (Black, non-Hispanic)b -.096 .196 .241 1 .623 .908 .619 1.334
Ethnicity (Hispanic)b  .105 .155 .460 1 .498 1.111 .820 1.505
Ethnicity (American Indian or Alaskan/Asian or 
Pacific Islander)b -.472 .548 .742 1 .389 .624 .213 1.826
Diabetes prior to index datec .253 .143 3.112 1 .078 1.288 .972 1.706
Hypertension prior to index dated -.117 .151 .606 1 .436 .889 .662 1.195
CHD prior to index datee -.181 .176 1.057 1 .304 .835 .591 1.178
Atherosclerosis prior to index datef .359 .189 3.621 1 .057 1.432 .989 2.073
Physician specialty (Family practice/general 
practice)g -.323 .309 1.092 1 .296 .724 .395 1.327
Physician specialty (Internal medicine)g -.206 .308 .445 1 .505 .814 .445 1.490
Physician specialty (Others)g -.211 .338 .391 1 .532 .809 .417 1.570
Lipid test three months prior to index dateh 1.352 .150 81.425 1 .000* 3.865 2.881 5.183
Hosmer and Lemeshow Goodness of fit test: Chi-square = 6.377; df = 8; p = 0.605;          Model Chi-square = 108.127; df = 13; p < 0.001;  *p < 0.05 
N = 1,740;  aReference category is female. 
bReference category is whites, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis. 
gReference category is cardiologists. 
hReference category is absence of lipid test. 
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Hypothesis 43: The likelihood of a lipid test after an initial change in statin dose will be 
higher for males than for females controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.27, the 
likelihood of lipid test did not differ by gender (OR = 1.031; 95% CI: 0.775-1.372;          
p = 0.834), controlling for age, ethnicity, disease conditions, physician specialty, and 
lipid monitoring at baseline.  Thus, hypothesis 43 was rejected. 
 
Hypothesis 44: The likelihood of a lipid test after an initial change in statin dose will be 
higher for older patients than for younger patients, controlling for ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, physician specialty, and lipid 
testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.27, the 
likelihood of lipid test did not differ by age (OR = 0.993; 95% CI: 0.978-1.008;               
p = 0.372), controlling for age, ethnicity, disease conditions, physician specialty, and 
lipid monitoring at baseline.  Thus, hypothesis 44 was rejected. 
 
Hypothesis 45: The likelihood of a lipid test after an initial change in statin dose will be 
higher for non-Hispanic whites than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
  
Based on the results of the logistic regression analysis presented in Table 3.27, the 
likelihood of lipid test for non-Hispanic whites did not differ from non-Hispanic blacks 
(OR = 0.908; 95% CI: 0.619-1.334; p = 0.623), and Hispanics (OR = 1.111; 95% CI: 
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0.820-1.505; p = 0.498).   Although statistically non-significant (p = 0.389), the odds of 
American Indian/Alaskan or Asian/Pacific Islander receiving a test was lower as 
compared to non-Hispanic whites (OR = 0.624; 95% CI: 0.213-1.826), controlling for 
age, gender, disease conditions, physician specialty, and lipid monitoring at baseline.  
Thus, hypothesis 45 was rejected. 
 
Hypothesis 46: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with CHD than for those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.27, 
there was no difference in the likelihood of lipid tests between CHD and non-CHD 
patients (OR = 0.835; 95% CI: 0.591-1.178; p = 0.304), controlling for demographic 
characteristics, other disease conditions, physician specialty and lipid monitoring at 
baseline.  Thus, hypothesis 46 was rejected. 
 
Hypothesis 47: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with diabetes than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.27, the 
likelihood of a lipid test after an initial change in statin type was 1.3 times higher for 
diabetics compared to non-diabetics (OR = 1.288; 95% CI: 0.972-1.706), controlling for 
demographic characteristics, other disease conditions, physician specialty and lipid 
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testing prior to index date.  However, the result was not statistically significant               
(p = 0.078).  Thus, hypothesis 47 was rejected.  
 
Hypothesis 48: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with hypertension than for those without hypertension, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.27, the 
likelihood of a lipid test after an initial change in statin type did not differ significantly 
between hypertensives versus non-hypertensives (OR = 0.889; 95% CI: 0.662-1.195; p = 
0.436), controlling for demographic characteristics, other disease conditions, physician 
specialty, and lipid testing prior to index date.  Thus, hypothesis 48 was rejected.  
 
Hypothesis 49: The likelihood of a lipid test after an initial change in statin dose will be 
higher for patients with atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty and lipid testing prior to index date. 
 
Based on the results of the logistic regression analysis presented in Table 3.27,  
patients with atherosclerotic diseases had a 1.4 times greater likelihood of receiving a 
lipid test following an initial change in statin dose compared to those patients without 
atherosclerotic diseases (OR = 1.432; 95% CI: 0.989-2.073), controlling for demographic 
characteristics, other disease conditions, physician specialty and lipid testing prior to 
index date.  However, the result was statistically non-significant (p = 0.057).  Thus, 




Hypothesis 50: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients treated by a cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and lipid testing prior to index date. 
  
Based on the results of the logistic regression analysis presented in Table 3.27, the 
likelihood of lipid testing was slightly lower among those patients treated by family 
practice/general practice physicians (OR = 0.724; 95% CI: 0.395-1.327; p = 0.296), 
physicians with specialization in internal medicine (OR = 0.814; 95% CI: 0.445-1.490; p 
= 0.505) and those with other specialties (OR = 0.809; 95% CI: 0.417-1.570; p = 0.532) 
compared to cardiologists.  However, the results were statistically non-significant.  Thus, 
hypothesis 50 was rejected. 
 
Hypothesis 51: The likelihood of a lipid test after an initial change in statin type will be 
higher for patients with lipid tests at baseline than those without lipid tests at baseline, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, 
atherosclerotic diseases, and physician specialty. 
 
Based on the results of the logistic regression analysis presented in Table 3.27, the 
presence of a lipid test prior to the index date was a significant predictor for lipid 
monitoring after the initial change in statin dose.  Patients who had a lipid test prior to the 
start of therapy were 3.8 times more likely to get a lipid test after the change in statin type 
(OR = 3.865; 95% CI: 2.881-5.183;  p < 0.001), controlling for other variables. Thus, 




Objective 20: To assess the predictors of the occurrence of LFTs at baseline (within 
three months prior to start of therapy). 
 
Presence of liver function tests (LFTs) was assessed within three months (but not 
earlier than six weeks) prior to the start of statin therapy.  The dependent variable LFT 
was coded as 1 = presence of an LFT; and 0 = no LFT.  Hypotheses 52 to 58 that 
addressed this study objective were tested using logistic regression analysis. The 
predictor variables included age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic disease as well as physician specialty at index date as 
the predictor variables.  
 The following logistic regression model was used to assess predictors of LFT at 
baseline: 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + ε 
ln(OR) = overall logit of the likelihood of  a LFT at baseline. 
βi (i=1,2,3,4,5,6,7)= coefficient for the change in ln(OR) associated with a one unit 
change in gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, and presence of atherosclerotic disease,  
α = intercept 
ε = error term 
Younger age, being female and being diabetic or hypertensive was associated 
with the increased likelihood of an LFT prior to start of therapy, controlling for other 
variables.  The results of the logistic regression analysis are presented in Table 3.28, 
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following which hypotheses 49 to 55 are discussed.  Based on the Hosmer-Lemeshow 
statistic (p > 0.05) as well as overall model chi-square (p < 0.001), the model presented 
an acceptable fit.   
  
286
Table 3.28: Logistic Regression Analysis to Assess Predictors of Liver Function Tests (LFT) Within Three Months 


















  Lower Upper 
Age at index date -.010 .004 7.063 1 .008* .990 .982 .997
Gender (Male)a -.212 .074 8.268 1 .004* .809 .700 .935
Ethnicity (Black, non-Hispanic)b -.156 .091 2.892 1 .089 .856 .715 1.024
Ethnicity (Hispanic)b .115 .079 2.150 1 .143 1.122 .962 1.309
Ethnicity (American Indian or 
Alaskan)b -.792 .738 1.151 1 .283 .453 .107 1.925
Ethnicity (Asian or Pacific Islander)b -.297 .311 .912 1 .340 .743 .404 1.366
Diabetes prior to index datec .275 .071 14.971 1 .000* 1.316 1.145 1.513
Hypertension prior to index dated .570 .076 55.543 1 .000* 1.768 1.522 2.054
CHD prior to index datee -.059 .081 .530 1 .467 .943 .804 1.105
Atherosclerosis prior to index datef .044 .098 .206 1 .650 1.045 .863 1.266
Hosmer and Lemeshow Goodness of fit test: Chi-square = 4.437; df = 8; p = 0.816;          Model Chi-square = 113.460; df = 10; p < 0.001 
*p < 0.05 
N = 7,054 
aReference category is female. 
bReference category is white, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis.
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Hypothesis 52: The likelihood of an LFT at baseline will be higher for males than for 
females, controlling for age, ethnicity, presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
 
Based on the results of the logistic regression analysis presented in Table 3.28, 
males (OR = 0.809; 95% CI: 0.700-0.935; p = 0.004) were associated with decreased 
odds of getting an LFT as compared to females, controlling for age, ethnicity, and disease 
conditions . Thus, hypothesis 52 was rejected. 
 
Hypothesis 53: The likelihood of an LFT at baseline will be higher for older patients than 
for younger patients, controlling for gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.28,  
older age (OR = 0.990; 95% CI: 0.982-0.997; p = 0.008) was associated with a slight but 
significant decrease in the odds of getting an LFT compared to younger patients, 
controlling for gender, ethnicity, and presence of disease conditions.  Thus, hypothesis 53 
was rejected. 
 
Hypothesis 54: The likelihood of an LFT at baseline will be higher for non-Hispanic 
whites than for other ethnic groups, controlling for age, gender, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.28, the 
odds of an LFT at baseline did not differ significantly between non-Hispanic whites and 
non-Hispanic blacks (OR = 0.856; 95% CI: 0.715-1.024; p = 0.089) or Hispanics (OR = 
1.122; 95% CI: 0.962-1.309; p = 0.143).  Though statistically non-significant (p = 0.283), 
American Indian or Alaskans had a decreased likelihood of LFT at baseline (OR = 0.453; 
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95% CI: 0.107-1.925) compared to non-Hispanic whites, controlling for age, gender, and 
disease conditions.  Thus, hypothesis 54 was rejected.   
 
Hypothesis 55: The likelihood of an LFT at baseline will be higher for patients with CHD 
than for those without CHD, controlling for age, gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.28, the 
odds of an LFT at baseline did not differ significantly between those patients with and 
without a prior diagnosis for CHD (OR = 0.943; 95% CI: 0.804-1.105; p = 0.467), 
controlling for demographic characteristics, and other disease conditions.  Thus, 
hypothesis 55 was rejected. 
 
Hypothesis 56: The likelihood of an LFT at baseline will be higher for patients with 
diabetes than for those without diabetes, controlling for age, gender, ethnicity, presence 
of CHD, hypertension, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.28, 
patients with diabetes (OR = 1.316; 95% CI: 1.145-1.513; p < 0.001) had a greater 
likelihood of having an LFT compared to those without diabetes, controlling for 








Hypothesis 57: The likelihood of an LFT at baseline will be higher for patients with 
hypertension than those without hypertension, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and atherosclerotic diseases. 
 
 Based on the results of the logistic regression analysis presented in Table 3.28, 
patients with hypertension (OR = 1.768; 95% CI: 1.522-2.054; p < 0.001) in the year 
prior to the index date had a higher likelihood of having an LFT compared to those 
without hypertension, controlling for demographic characteristics and other disease 
conditions.  Thus, hypothesis 57 was not rejected. 
 
Hypothesis 58: The likelihood of an LFT at baseline will be higher for patients with 
atherosclerotic diseases than those without atherosclerotic diseases, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and hypertension. 
  
Based on the results of the logistic regression analysis presented in Table 3.28, 
there was no significant difference in the likelihood of an LFT between those patients 
with atherosclerotic diseases versus those without (OR = 1.045; 95% CI: 0.863-1.266; p 
= 0.650), controlling for demographic characteristics, and other disease conditions. Thus, 
hypothesis 58 was rejected.  
 
Objective 21: To assess the predictors of the occurrence of LFTs (within three months, 
but not earlier than six weeks) after the start of therapy. 
 
Presence of liver function tests (LFTs) was assessed within three months (but not 
earlier than six weeks) from the start of statin therapy.  The dependent variable LFT was 
coded as 1 = presence of a LFT; and 0 = no LFT.  Hypotheses 59 to 67 addressing this 
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study objective were tested using logistic regression analysis with age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic disease, physician specialty  
at index date, and LFT prior to start of therapy as the predictor variables in the model.    
The following logistic regression model was used to assess predictors of LFTs 
after start of therapy: 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + β8 physician specialty at index date + β9 prior LFT + ε 
where: 
ln(OR) = overall logit of the likelihood of  LFT after start of therapy. 
βi (i=1,2,3,4,5,6,7,8,9)= coefficient for the change in ln(OR) associated with a one unit 
change in gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, presence of atherosclerotic disease, 
physician specialty, and presence of LFT at baseline. 
α = intercept ;  ε = error term 
Older age and being non-Hispanic black was associated with a decreased 
likelihood of the presence of LFTs than being younger and non-Hispanic whites, 
controlling for other variables.  However, patients with hypertension and those with prior 
LFTs were more likely to have their LFTs after start of therapy.  The results of the 
logistic regression analysis are presented in Table 3.29, following which hypotheses 59 to 
67 are discussed.  Based on the Hosmer-Lemeshow statistic (p > 0.05), as well as overall 
model chi-square (p < 0.001), the model presented an acceptable fit. 
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Table 3.29: Logistic Regression Analysis to Assess Predictors of Liver Function Tests (LFTs) within Three Months 
From the Start of Statin Therapy 
 
95.0% Confidence 














Ratio Lower Upper 
Age at index date -.013 .005 6.885 1 .009* .987 .977 .997
Gender (Male)a -.071 .095 .560 1 .454 .931 .772 1.122
Ethnicity (Black, non-Hispanic)b -.611 .139 19.263 1 .000* .543 .413 .713
Ethnicity (Hispanic) b .016 .099 .026 1 .872 1.016 .836 1.235
Ethnicity (American Indian or Alaskan)b -.830 1.030 .649 1 .421 .436 .058 3.286
Ethnicity (Asian or Pacific Islander)b -.186 .379 .240 1 .624 .831 .396 1.744
Diabetes prior to index datec .012 .095 .015 1 .901 1.012 .840 1.218
Hypertension prior to index dated .271 .099 7.527 1 .006* 1.312 1.081 1.592
CHD prior to index datee .157 .112 1.963 1 .161 1.170 .939 1.456
Atherosclerosis prior to index datef .074 .128 .332 1 .565 1.076 .838 1.383
Specialty (Family practice/general practice)g -.118 .183 .414 1 .520 .889 .621 1.272
Specialty (Internal medicine)g .120 .181 .440 1 .507 1.127 .791 1.607
Specialty (Other)g -.052 .203 .065 1 .799 .950 .638 1.414
LFT three months prior to index datef 1.270 .098 168.280 1 .000* 3.561 2.939 4.315
Hosmer and Lemeshow Goodness of fit test: Chi-square = 2.996; df = 8; p = 0.935;          Model Chi-square = 213.648.; df = 14; p < 0.001 
N = 6,203; *p < 0.05 
aReference category is female. 
bReference category is white, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis. 
gReference category is cardiologists. 
fReference category is absence of liver function test.
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Hypothesis 59: The likelihood of an LFT after start of therapy will be higher for males 
than for females controlling for age, ethnicity, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, and presence of LFT prior to index 
date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, the 
likelihood of a LFT after start of therapy did not differ significantly with respect to 
gender (OR = 0.931; 95% CI: 0.772-1.122; p = 0.454), controlling for age, ethnicity, 
disease conditions, physician specialty, and presence of LFT prior to index date.  Thus, 
hypothesis 59 was rejected.   
 
Hypothesis 60: The likelihood of an LFT after start of therapy will be higher for older 
patients than for younger ones, controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, the 
there was a slight decrease in the likelihood of an LFT after start of therapy with an 
increase in age (OR = 0.987, 95% CI: 0.977-0.997, p = 0.009), controlling for gender, 
ethnicity, disease conditions, and physician specialty.  Thus, hypothesis 60 was rejected. 
 
Hypothesis 61: The likelihood of an LFT after start of therapy will be higher for non-
Hispanic whites than for other ethnic groups, controlling for age, gender, presence of 
CHD, diabetes, hypertension, and atherosclerotic diseases, physician specialty and 
presence of LFT  prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, 
non-Hispanic blacks had  a decreased likelihood of getting LFTs compared to non-
Hispanic whites (OR = 0.543, 95% CI: 0.413-0.713; p < 0.001).  Non-Hispanic whites 
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did not have a greater likelihood of getting an LFT compared to Hispanics (OR = 1.016; 
95% CI: 0.836-1.235; p = 0.872).  American Indians or Alaskan had a decreased odd of 
receiving an LFT compared to non-Hispanic whites (OR = 0.436), though the result was 
non-significant (p = 0.421) and the confidence interval for the odds ratio was large (95% 
CI: 0.058-3.286).  The likelihood of receiving an LFT did not differ significantly between 
non-Hispanic whites and Asians or Pacific Islanders (OR = 0.831; 95% CI: 0.396-1.744; 
p = 0.624).  Based on the results, hypothesis 61 was rejected. 
 
Hypothesis 62: The likelihood of an LFT after start of therapy will be higher for patients 
with CHD than for those without CHD, controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, 
patients with a diagnosis of CHD at or a year prior to the index date did not have a 
greater likelihood of an LFT at the start of therapy than those without CHD (OR = 1.170; 
95% CI: 0.939-1.456; p = 0.161), controlling for demographic characteristics, other 
disease conditions, physician specialty, and LFT prior to index date.  Thus, hypothesis 62 
was rejected. 
 
Hypothesis 63: The likelihood of an LFT after start of therapy will be higher for patients 
with diabetes than for those without diabetes, controlling for age, gender, ethnicity, 
presence of CHD, hypertension, and atherosclerotic diseases, physician specialty, and 
presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, the 
odds of receiving an LFT between those patients with a diagnosis of diabetes and those 
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without did not differ significantly from one (OR = 1.012; 95% CI: 0.840-1.218;              
p = 0.901), controlling for demographic characteristics, other disease conditions, 
physician specialty, and presence of LFT prior to index date.  Thus, hypothesis 63 was 
rejected. 
 
Hypothesis 64: The likelihood of an LFT after start of therapy will be higher for patients 
with hypertension than for those without hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, physician specialty 
and presence of LFT to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, 
patients with a diagnosis for hypertension were 1.3 times more likely to receive an LFT 
compared to those without a diagnosis for hypertension (OR = 1.312; 95% CI: 1.081-
1.592; p = 0.006), controlling for demographic characteristics, other disease conditions, 
physician specialty, and presence of LFT prior to index date.  Thus, hypothesis 64 was 
not rejected. 
 
Hypothesis 65: The likelihood of an LFT after start of therapy will be higher for patients 
with atherosclerotic diseases than for those without atherosclerotic diseases, controlling 
for age, gender, ethnicity, presence of CHD, diabetes, and hypertension, physician 
specialty, and presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, the 
odds of receiving an LFT did not differ significantly between those patients with 
atherosclerotic diseases and those without, controlling for demographic characteristics, 
other disease conditions, physician specialty, and presence of LFT prior to index date 
(OR = 1.076; 95% CI: 0.838-1.383; p = 0.565).  Thus, hypothesis 65 was rejected. 
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Hypothesis 66: The likelihood of an LFT at start of therapy will be higher for patients 
treated by a cardiologist at index date than for those treated by other physician specialty, 
controlling for age, gender, ethnicity, presence of CHD, diabetes, hypertension and 
atherosclerotic diseases, and presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.29, the 
likelihood of an LFT at the start of therapy did not differ significantly for those patients 
treated by a cardiologist at index date compared to family practice/general practice (OR = 
0.889; 95% CI: 0.621-1.272; p = 0.520), internal medicine (OR = 1.127; 95% CI: 0.791-
1.607; p = 0.507) or other physician specialty (OR = 0.950; 95% CI: 0.638-1.414;            
p = 0.799).  Thus, hypothesis 66 was rejected.  
 
Hypothesis 67: The likelihood of an LFT  after start of therapy will be higher for patients 
with LFTs at baseline than those without LFTs at baseline, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and hypertension, atherosclerotic diseases, and 
physician specialty. 
 
Based on the results of the logistic regression analysis presented in Table 3.29, the 
presence of an LFT prior to the index date was a significant predictor of LFTs after the 
start of therapy.  Patients who had an LFT prior to the start of therapy were 3.6 times 
more likely to get an LFT after the start of therapy   (OR = 3.561; 95% CI: 2.939-4.315; p 










Objective 22: To assess the predictors of the occurrence of LFTs (within three months, 
but not earlier than six weeks) following the initial increase in statin dose. 
 
Presence of liver function tests (LFTs) was assessed within three months (but not 
earlier than six weeks) of an increase in statin dose.  The dependent variable LFT was 
coded as 1= presence of an LFT; and 0 = no LFT.  Hypotheses 68 to 76, addressing this 
study objective were tested using a logistic regression analysis with age, gender, 
ethnicity, presence of CHD, diabetes, hypertension, and atherosclerotic disease, physician 
specialty at index date, and presence of LFT prior to start of therapy as the predictor 
variables in the model.  
The following logistic regression model was used to assess predictors of LFTs after an 
increase in statin dose: 
ln(OR) = α + β1 age + β2 gender + β3 ethnicity +  β4 CHD + β5 diabetes + β6 hypertension 
+ β7 atherosclerotic disease + β8 physician specialty at index date + β9 prior lipid test + ε 
ln(OR) = overall logit of the likelihood of  LFT after increase in statin dose. 
βi (i=1,2,3,4,5,6,7,8,9)= coefficient for the change in ln(OR) associated with a one unit 
change in gender, ethnicity, type of CHD prevention,  presence of diabetes as a risk 
factor, presence of hypertension as a risk factor, presence of atherosclerotic disease, 
physician specialty, and presence of LFT at baseline. 
α = intercept 
ε = error term 
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Being treated by a cardiologist at index date, presence of CHD prior to index date, 
and having a prior LFT were significant predictors of the likelihood of LFT after an 
increase in statin dose, controlling for other variables.  The results of the logistic 
regression analysis are presented in Table 3.30, following which the study hypotheses 68 
to 76 are discussed.  Based on the Hosmer-Lemeshow statistic (p > 0.05), as well as 




Table 3.30: Logistic Regression to Assess Predictors of Liver Function Tests Within Three Months Following an 
Increase in Dose 
 
95.0% Confidence 














Ratio  Lower Upper 
Age at index date .006 .010 .332 1 .564 1.006 .986 1.026
Gender (Male)a .066 .185 .127 1 .722 1.068 .744 1.534
Ethnicity (Black, non-Hispanic)b -.309 .747 .171 1 .679 .734 .170 3.175
Ethnicity (Hispanic) b .310 .195 2.526 1 .112 1.364 .930 2.000
Ethnicity (American Indian or Alaskan/Asian or 
Pacific Islander)b -.145 .259 .316 1 .574 .865 .520 1.436
Diabetes prior to index datec .097 .184 .281 1 .596 1.102 .769 1.579
Hypertension prior to index dated .053 .189 .080 1 .777 1.055 .729 1.527
CHD prior to index datee -.471 .239 3.862 1 .049 .625 .391 .999
Atherosclerosis prior to index datef -.202 .271 .556 1 .456 .817 .481 1.389
Specialty (Family practice/general practice)g -1.065 .347 9.425 1 .002* .345 .175 .680
Specialty (Internal medicine)g -.791 .342 5.346 1 .021* .453 .232 .886
Specialty (Other)g -.535 .375 2.044 1 .153 .585 .281 1.220
LFT three months prior to index datef 1.084 .191 32.174 1 .000* 2.956 2.033 4.299
Hosmer and Lemeshow Goodness of fit test: Chi-square = 9.256; df = 8; p = 0.321;          Model Chi-square = 47.888; df = 13; p < 0.001 
N = 1,910; *p < 0.05 
aReference category is female. 
bReference category is white, non-Hispanic. 
cReference category is absence of diabetes. 
dReference category is absence of hypertension. 
eReference category is absence of CHD. 
fReference category is absence of atherosclerosis. 
gReference category is cardiologists. 
hReference category is absence of liver function test.
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Hypothesis 68: The likelihood of an LFT after an initial change in statin dose will be 
higher for males than for females controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic diseases, physician specialty, and presence of 
LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of an LFT did not differ by gender (OR = 1.068; 95% CI: 0.744-1.534;              
p = 0.722), controlling for age, ethnicity, disease conditions, physician specialty, and 
presence of LFT at baseline.  Thus, hypothesis 68 was rejected. 
 
Hypothesis 69: The likelihood of an LFT after an initial increase in statin dose will be 
higher for older patients than for younger patients, controlling for gender, ethnicity, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of LFT did not differ by age (OR = 1.006; 95% CI: 0.986-1.026; p = 0.564), 
controlling for ethnicity, gender, disease conditions, physician specialty, and presence of 
LFT at baseline.  Thus, hypothesis 69 was rejected. 
 
Hypothesis 70: The likelihood of an LFT after initial increase in statin dose will be 
higher for non-Hispanic whites than for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, and atherosclerotic diseases, physician 
specialty, and presence of LFT prior to index date. 
 
Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of LFT for non-Hispanic whites did not differ from non-Hispanic blacks (OR 
= 0.734; 95% CI: 0.170-3.175; p = 0.679), Hispanics (OR = 1.364; 95% CI: 0.930-2.000; 
p = 0.112) and American Indians/Alaskans or Asians/Pacific Islanders                         
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(OR = 0.865; 95% CI: 0.520-1.436; p = 0.574), controlling for age, gender, disease 
conditions, physician specialty, and presence of LFT at baseline.  Thus, hypothesis 70 
was rejected. 
 
Hypothesis 71: The likelihood of a LFT after an initial increase in statin dose will be 
higher for patients with CHD than for those without CHD, controlling for age, gender, 
ethnicity, presence of diabetes, hypertension, and atherosclerotic diseases, physician 
specialty and presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of a LFT was significantly lower among patients with CHD and than in non-
CHD patients (OR = 0.625; 95% CI: 0.391-0.999; p = 0.049), controlling for 
demographic characteristics, other disease conditions, physician specialty, and presence 
of LFT at baseline.    Thus, hypothesis 71 was rejected. 
 
Hypothesis 72: The likelihood of a LFT after an initial increase in statin dose will be 
higher for patients with diabetes than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, and atherosclerotic diseases, 
physician specialty and presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of a LFT after an initial increase in statin dose did not differ significantly 
between diabetics and non-diabetics (OR = 1.102; 95% CI: 0.769-1.579; p = 0.596), 
controlling for demographic characteristics, other disease conditions, physician specialty, 





Hypothesis 73: The likelihood of a LFT after an initial increase in statin dose will be 
higher for patients with hypertension than for those without hypertension, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and atherosclerotic diseases, 
physician specialty, and presence of LFT prior to index date. 
 
 Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of a LFT after an initial change in statin type did not differ significantly 
between hypertensives versus non-hypertensives (OR = 1.055; 95% CI: 0.729-1.527;       
p = 0.777), controlling for demographic characteristics, other disease conditions, 
physician specialty and presence of LFT prior to index date.  Thus, hypothesis 73 was 
rejected.  
 
Hypothesis 74: The likelihood of a LFT after an initial increase in statin dose will be 
higher for patients with atherosclerotic diseases than for those without atherosclerotic 
diseases, controlling for age, gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and lipid testing prior to index date. 
 
Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of a LFT after an initial change in statin type did not differ significantly 
between those with atherosclerotic diseases versus those without (OR = 0.817;           
95% CI: 0.481-1.389; p = 0.456), controlling for demographic characteristics, other 
disease conditions, physician specialty, and presence of LFT prior to index date.  Thus, 








Hypothesis 75: The likelihood of a LFT after an initial increase in statin dose will be 
higher for patients treated by a cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and presence of LFT prior to index date 
 
 Based on the results of the logistic regression analysis presented in Table 3.30, the 
likelihood of LFT was lower among those patients treated by family practice/general 
practice physicians (OR = 0.345; 95% CI: 0.175-0.680; p = 0.002), physicians with 
specialization in internal medicine (OR = 0.453; 95% CI: 0.232-0.886; p = 0.021) and 
those with other specialties (OR = 0.585; 95% CI: 0.281-1.220) compared to 
cardiologists. However, the results for the “other specialty” group were not significant (p 
= 0.153).  Thus, hypothesis 75 was rejected. 
 
Hypothesis 76: The likelihood of an LFT after an initial increase in dose will be higher 
for patients with LFTs at baseline than those without LFTs at baseline, controlling for 
age, gender, ethnicity, presence of CHD, diabetes, and hypertension, atherosclerotic 
diseases, and physician specialty. 
 
Based on the results of the logistic regression analysis presented in Table 3.30, the 
presence of an LFT prior to the index date was a significant predictor for LFT after the 
initial increase in statin dose.  Patients who had a LFT prior to the start of therapy were 
2.9 times more likely to get an LFT after an initial increase in statin dose (OR = 2.956; 






SUMMARY OF THE STUDY HYPOTHESES 
Table 3.31 presents a summary of the study hypotheses and the results. 
Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 1 The starting dose for statin therapy for secondary 
prevention patients will be higher than for primary 
prevention patients, controlling for the type of statin. 
 
Rejected 
Hypothesis 2 The MPR will be higher for males than for females, 
controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, atherosclerotic diseases, and 
total number of prescriptions. 
 
Not rejected 
Hypothesis 3 The MPR will be higher for older patients than for 
younger patients, controlling for gender, ethnicity, 
presence of CHD, diabetes, hypertension, 




Hypothesis 4 The MPR will be higher for non-Hispanic whites than 
for other ethnic groups, controlling for age, gender, 
presence of CHD, diabetes, hypertension, 




Hypothesis 5 The MPR will be higher for secondary prevention 
CHD patients than for primary prevention CHD 
patients, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, atherosclerotic 
diseases, and total number of prescriptions. 
 
Rejected 
Hypothesis 6 The MPR will be higher for diabetics than for non-
diabetics, controlling for age, gender, ethnicity, 
presence of CHD, hypertension, atherosclerotic 





Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 7 The MPR will be higher for hypertensives than for 
non-hypertensives, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, 
atherosclerotic diseases, and total number of 
prescriptions. 
Rejected 
Hypothesis 8 The MPR will be higher for those patients with 
atherosclerotic diseases than for those without, 
atherosclerotic diseases, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, 
hypertension, and total number of prescriptions. 
Rejected 
Hypothesis 9 The MPR will be higher for those patients on a 
lower number of total prescriptions other than 
statins than for those on a higher number of 
prescriptions, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic disease.  
 
Rejected 
Hypothesis 10 Females will have a higher hazard of becoming 
non-persistent to statin therapy than males 
controlling for age, ethnicity, presence of CHD, 
hypertension, diabetes, atherosclerotic diseases, 
and total number of prescriptions. 
 
Not rejected 
Hypothesis 11 Younger patients will have a higher hazard of 
becoming non-persistent to statin therapy than older 
patients, controlling for gender, ethnicity, presence 
of CHD, hypertension, diabetes, atherosclerotic 
diseases, and total number of prescriptions. 
Rejected 
Hypothesis 12 Other ethnic minorities will have a higher hazard of 
becoming non-persistent to statin therapy than non-
Hispanic whites, controlling for age, gender, 
presence of CHD, hypertension, diabetes, 









Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 13 Patients without CHD will have a higher hazard of 
becoming non-persistent to statin therapy than those 
with CHD, controlling for age, gender, ethnicity, 
presence of hypertension, diabetes, atherosclerotic 
diseases, and total number of prescriptions. 
 
Rejected 
Hypothesis 14 Patients without diabetes will have a higher hazard 
of becoming non-persistent to statin therapy than 
those with diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, 
atherosclerotic diseases, and total number of 
prescriptions. 
Rejected 
Hypothesis 15 Patients without hypertension will have a higher 
hazard of becoming non-persistent to statin therapy 
than those with hypertension, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, 
atherosclerotic diseases, and total number of 
prescriptions. 
Rejected 
Hypothesis 16 Patients without atherosclerotic diseases will have a 
higher hazard of becoming non-persistent to statin 
therapy than those with atherosclerotic diseases 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, hypertension, and total number of 
prescriptions. 
Not rejected 
Hypothesis 17 Patients on greater number of total prescriptions 
other than statins will have a higher hazard of 
becoming non-persistent than those on fewer 
prescription, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
Rejected 
Hypothesis 18 The likelihood of a lipid test at baseline will be 
higher for males than for females, controlling for 
age, ethnicity, presence of CHD, diabetes, 








Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 19 The likelihood of a lipid test at baseline will be 
higher for older patients than for younger patients, 
controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic 
diseases. 
Rejected 
Hypothesis 20 The likelihood of a lipid test at baseline will be 
higher for non-Hispanic whites than for other ethnic 
groups, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
Rejected 
Hypothesis 21 The likelihood of a lipid test at baseline will be 
higher for patients with CHD than for those without 
CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and 
atherosclerotic diseases. 
Rejected 
Hypothesis 22 The likelihood of a lipid test at baseline will be 
higher for patients with diabetes than for those 
without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and 
atherosclerotic diseases. 
Not rejected 
Hypothesis 23 The likelihood of a lipid test at baseline will be 
higher for patients with hypertension than for those 
without hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and 
atherosclerotic diseases. 
Not rejected 
Hypothesis 24 The likelihood of a lipid test at baseline will be 
higher for patients with atherosclerotic diseases 
than those without atherosclerotic diseases, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and hypertension. 
Rejected 
Hypothesis 25 The likelihood of a lipid test at start of therapy will 
be higher for males than for females controlling for 
age, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, 









Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 26 The likelihood of a lipid test at start of therapy will 
be higher for older patients than for younger 
patients, controlling for gender, ethnicity, presence 
of CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior 
to index date. 
Rejected 
Hypothesis 27 The likelihood of a lipid test at start of therapy will 
be higher for non-Hispanic whites than for other 
ethnic groups, controlling for age, gender, presence 
of CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior 
to index date. 
Rejected 
Hypothesis 28 The likelihood of a lipid test at start of therapy will 
be higher for patients with CHD than for those 
without CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and 
atherosclerotic diseases, physician specialty, and 
lipid testing prior to index date. 
Not rejected 
Hypothesis 29 The likelihood of a lipid test at start of therapy will 
be higher for patients with diabetes than for those 
without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and 
atherosclerotic diseases, physician specialty, and 
lipid testing prior to index date. 
Rejected 
Hypothesis 30 The likelihood of a lipid test at start of therapy will 
be higher for patients with hypertension than for  
those without hypertension, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and 
atherosclerotic diseases, physician specialty, and 







Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 31 The likelihood of a lipid test at start of therapy will 
be higher for patients with atherosclerotic diseases 
than for those without atherosclerotic diseases, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and hypertension, physician 
specialty, and lipid testing prior to index date. 
Rejected 
Hypothesis 32 The likelihood of a lipid test at start of therapy will 
be higher for patients treated by a cardiologist at 
index date than for those treated by other physician 
specialty, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension and 
atherosclerotic diseases, and lipid testing prior to 
index date. 
Rejected 
Hypothesis 33 The likelihood of a lipid test after start of therapy 
will be higher for patients with lipid tests at baseline 
than those without lipid tests at baseline, controlling 
for age, gender, ethnicity, presence of CHD, 
diabetes, and hypertension, atherosclerotic 
diseases, and physician specialty. 
 
Not rejected 
Hypothesis 34 The likelihood of a lipid test after an initial change 
in statin type will be higher for males than for 
females controlling for age, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and lipid testing prior 
to index date. 
Rejected 
Hypothesis 35 The likelihood of a lipid test after an initial change 
in statin type will be higher for older patients than 
for younger patients, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases, physician specialty, and 
lipid testing prior to index date. 
Rejected 
Hypothesis 36 The likelihood of a lipid test after an initial change 
in statin type will be higher for non-Hispanic whites 
than for other ethnic groups, controlling for age, 
gender, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, 








Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 37 The likelihood of a lipid test after an initial change 
in statin type will be higher for patients with CHD 
than for those without CHD, controlling for age, 
gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases, 
physician specialty and lipid testing prior to index 
date. 
Rejected 
Hypothesis 38 The likelihood of a lipid test after an initial change 
in statin type will be higher for patients with 
diabetes than for those without diabetes, controlling 
for age, gender, ethnicity, presence of CHD, 
hypertension, and atherosclerotic diseases, 
physician specialty and lipid testing prior to index 
date. 
Rejected 
Hypothesis 39 The likelihood of a lipid test after an initial change 
in statin type will be higher for patients with 
hypertension than  for those without hypertension, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index 
date. 
Rejected 
Hypothesis 40 The likelihood of a lipid test after an initial change 
in statin type will be higher for patients with 
atherosclerotic diseases than for those without 
atherosclerotic diseases, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and lipid testing 
prior to index date. 
Rejected 
Hypothesis 41 The likelihood of a lipid test after an initial change 
in statin type will be higher for patients treated by a 
cardiologist at index date than for those treated by 
other physician specialty, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and 
lipid testing prior to index date. 
Rejected 
Hypothesis 42  The likelihood of a lipid test after an initial change 
in statin type will be higher for patients with lipid 
tests at baseline than those without lipid tests at 
baseline, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and hypertension, 





Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 43 The likelihood of a lipid test after an initial change 
in statin dose will be higher for males than for 
females controlling for age, ethnicity, presence of 
CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, lipid testing prior to 
index date 
Rejected 
Hypothesis 44 The likelihood of a lipid test after an initial change 
in statin dose will be higher for older patients than 
for younger patients, controlling for ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases, physician specialty, and 
lipid testing prior to index date. 
Rejected 
Hypothesis 45 The likelihood of a lipid test after an initial change 
in statin dose will be higher for non-Hispanic whites 
than for other ethnic groups, controlling for age, 
gender, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, 
and lipid testing prior to index date.  
Rejected 
Hypothesis 46 The likelihood of a lipid test after an initial change 
in statin dose will be higher for patients with CHD 
as compared to those without CHD, controlling for 
age, gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index 
date. 
Rejected 
Hypothesis 47 The likelihood of a lipid test after an initial change 
in statin dose will be higher for patients with 
diabetes than for those without diabetes, controlling 
for age, gender, ethnicity, presence of CHD, 
hypertension, and atherosclerotic diseases, 
physician specialty, and lipid testing prior to index 
date. 
Rejected 
Hypothesis 48 The likelihood of a lipid test after an initial change 
in statin dose will be higher for patients with 
hypertension than for those without hypertension, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and atherosclerotic diseases, 







Table 3.31: Results of Hypotheses Testing 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 49 The likelihood of a lipid test after an initial change in 
statin dose will be higher for patients with 
atherosclerotic diseases than for those without 
atherosclerotic diseases, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and hypertension, 
physician specialty and lipid testing prior to index date. 
Rejected 
Hypothesis 50 The likelihood of a lipid test after an initial change in 
statin dose will be higher for patients treated by a 
cardiologist at index date than for those treated by other 
physician specialty, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases, and lipid testing prior to index 
date. 
Rejected 
Hypothesis 51  The likelihood of a lipid test after an initial change in 
statin dose will be higher for patients with lipid tests at 
baseline than those without lipid tests at baseline, 
controlling for age, gender, ethnicity, presence of CHD, 




Hypothesis 52 The likelihood of an LFT at baseline will be higher for 
males than for females, controlling for age, ethnicity, 
presence of CHD, diabetes, hypertension, and 
atherosclerotic diseases. 
Rejected 
Hypothesis 53 The likelihood of an LFT at baseline will be higher for 
older patients than for younger patients, controlling for 
gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
Rejected 
Hypothesis 54 The likelihood of an LFT at baseline will be higher for 
non-Hispanic whites than for other ethnic groups, 
controlling for age, gender, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases. 
Rejected 
Hypothesis 55 The likelihood of an LFT at baseline will be higher for 
patients with CHD than for those without CHD, 
controlling for age, gender, ethnicity, presence of 
diabetes, hypertension, and atherosclerotic diseases. 
Rejected 
Hypothesis 56 The likelihood of an LFT at baseline will be higher for 
patients with diabetes than for those without, diabetes 
controlling for age, gender, ethnicity, presence of CHD, 






Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 57 The likelihood of an LFT at baseline will be higher 
for patients with hypertension than for those without 
hypertension, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, and atherosclerotic 
diseases. 
Not rejected 
Hypothesis 58 The likelihood of an LFT at baseline will be higher 
for patients with atherosclerotic diseases than for 
those without atherosclerotic diseases, controlling 
for age, gender, ethnicity, presence of CHD, 
diabetes, and atherosclerotic diseases. 
Rejected 
Hypothesis 59 The likelihood of an LFT at start of therapy will be 
higher for males than for females controlling for 
age, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, 
physician specialty, and presence of LFT prior to 
index date. 
Rejected 
Hypothesis 60 The likelihood of an LFT at start of therapy will be 
higher for older patients than for younger patients, 
controlling for gender, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and presence of LFT 
prior to index date. 
Rejected 
Hypothesis 61 The likelihood of an LFT at start of therapy will be 
higher for non-Hispanic whites than for other ethnic 
groups, controlling for age, gender, presence of 
CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty and presence of LFT  
prior to index date. 
Rejected 
Hypothesis 62 The likelihood of an LFT at start of therapy will be 
higher for patients with CHD than for those without 
CHD, controlling for age, gender, ethnicity, 
presence of diabetes, hypertension, and 
atherosclerotic diseases, physician specialty, and 










Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 63 The likelihood of an LFT at start of therapy will be 
higher for patients with diabetes than for those 
without diabetes, controlling for age, gender, 
ethnicity, presence of CHD, hypertension, and 
atherosclerotic diseases, physician specialty, and 
presence of LFT prior to index date. 
Rejected 
Hypothesis 64 The likelihood of an LFT at start of therapy will be 
higher for patients with hypertension than for those 
without hypertension, controlling for age, gender, 
ethnicity, presence of CHD, diabetes, and 
atherosclerotic diseases, physician specialty and 
presence of LFT prior to index date. 
Not rejected 
Hypothesis 65 The likelihood of an LFT at start of therapy will be 
higher for patients with atherosclerotic diseases  
than for those without atherosclerotic diseases, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and hypertension, physician 
specialty, and presence of LFT prior to index date. 
 
Rejected 
Hypothesis 66 The likelihood of an LFT at start of therapy will be 
higher for patients treated with a cardiologist at 
index date than for those treated by other physician 
specialty, controlling for age, gender, ethnicity, 
presence of CHD, diabetes, hypertension and 
atherosclerotic diseases, and presence of LFT prior 
to index date. 
Rejected 
Hypothesis 67 The likelihood of an LFT after start of therapy will 
be higher for patients with LFTs at baseline than 
those without LFTs at baseline, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and 




Hypothesis 68 The likelihood of an LFT after an initial increase in 
statin dose will be higher for males than for females 
controlling for age, ethnicity, presence of CHD, 
diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and presence of LFT 








Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 69 The likelihood of an LFT after an initial increase in 
statin dose will be higher for older patients than for 
younger patients, controlling for ethnicity, presence 
of CHD, diabetes, hypertension, and atherosclerotic 
diseases, physician specialty, and presence of LFT 
prior to index date. 
Rejected 
Hypothesis 70 The likelihood of an LFT after initial increase in 
statin dose will be higher for non-Hispanic whites 
than for other ethnic groups, controlling for age, 
gender, presence of CHD, diabetes, hypertension, 
and atherosclerotic diseases, physician specialty, 
and presence of LFT prior to index date. 
Rejected 
Hypothesis 71 The likelihood of an LFT after an initial increase in 
statin dose will be higher for patients with CHD  
than for those without CHD, controlling for age, 
gender, ethnicity, presence of diabetes, 
hypertension, and atherosclerotic diseases, 
physician specialty and presence of LFT prior to 
index date. 
Rejected 
Hypothesis 72 The likelihood of an LFT after an initial increase in 
statin dose will be higher for patients with diabetes 
than for those without diabetes, controlling for age, 
gender, ethnicity, presence of CHD, hypertension, 
and atherosclerotic diseases, physician specialty 
and presence of LFT prior to index date. 
Rejected 
Hypothesis 73 The likelihood of an LFT after an initial increase in 
statin dose will be higher for patients with 
hypertension than for those without hypertension, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and atherosclerotic diseases, 






Table 3.31: Results of Hypotheses Testing 
 
Hypothesis Description  Rejected/Not rejected 
Hypothesis 74 The likelihood of an LFT after an initial increase in 
statin dose will be higher for patients with 
atherosclerotic diseases than for those without 
atherosclerotic diseases, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, and 
hypertension, physician specialty, and LFT prior to 
index date. 
Rejected 
Hypothesis 75 The likelihood of an LFT after an initial increase in 
statin dose will be higher for patients treated by a 
cardiologist at index date than for those treated by 
other physician specialty, controlling for age, 
gender, ethnicity, presence of CHD, diabetes, 
hypertension, and atherosclerotic diseases, and 
presence of LFT prior to index date 
Rejected 
Hypothesis 76 The likelihood of an LFT after an initial increase in 
statin dose will be higher for patients with LFTs at 
baseline than those without LFTs at baseline, 
controlling for age, gender, ethnicity, presence of 
CHD, diabetes, and hypertension, atherosclerotic 
















Hyperlipidemia plays a central role in the development of atherosclerotic plaque 
that impairs arterial blood flow leading to arterial obstruction and myocardial infarction 
in coronary vessels.438  The management of hyperlipidemia is crucial in the prevention of 
CHD.  Primary, secondary, and angiographic trials have demonstrated the beneficial 
effects of lipid-lowering drugs, especially statins, in the reduction of CHD associated 
mortality and morbidity.  These benefits have been observed irrespective of the age 
group, cholesterol levels, CHD risk factors, and in the presence or absence of prior CHD.   
Given the beneficial effects of statin therapy in the prevention of CHD, 
compliance with these drugs and the effective monitoring of drug response are important 
in the management of hyperlipidemia.  The Adult Treatment Panel (ATP) calls for 
monitoring of lipid levels and monitoring of adverse events for patients initiated on statin 
therapy.  Frequent monitoring of drug response, as well as, monitoring of side effects by 
conducting liver function tests (LFTs) is crucial for the success of statin drug therapy.  
The purpose of the study was to evaluate drug utilization patterns, medication adherence, 
and lipid and safety monitoring of patients on statin drug therapy in the Texas Medicaid  
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system.  This chapter presents a summary and discussion of the study results.  Limitations 
of the study are also discussed.  Finally, the chapter concludes with the suggestions for 
future research, overall study conclusion and implications of the study to Texas 
Medicaid.  
The results are discussed in six sections: (1) demographic characteristics; (2) 
clinical conditions; (3) use of statins and other lipid lowering drugs; (4) specialty of 
physician prescribing statin at index date; (5) compliance with statin therapy; (6) lipid 
and liver function monitoring. 
 
DEMOGRAPHIC CHARACTERISTICS 
The majority of patients in this study were females (65.2%).  Texas Medicaid is 
comprised mainly of women (56%) and non-disabled children (59%).439  The present 
study included only patients between 21-64 years; the mean age of patients in the study at 
index date was 49.7 years.  The reason patients 65 or older were not a part of the study 
was because the medical claims for individuals above 65 years of age may be incomplete 
due to dual eligibility in Medicaid and Medicare programs.  The age of the subjects is 
slightly lower than the average age of statin users in other studies conducted in primary 
care settings.  In those studies, the mean age of new statin users was 58.5 years,440,441,442 
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except in studies that were conducted in the Medicaid population443,444 and those 
conducted in nursing home settings,445 which included patients 65 years and older.   
A total of 42.7 percent of the patients were non-Hispanic whites, followed by 
Hispanics (N = 2,304; 32.7%) and non-Hispanic blacks (N = 1,585; 22.5%).  A greater 
percentage of non-Hispanic whites in this study suffered from hyperlipidemia and were 
on statin drugs.  This finding is not surprising; based on the statistics from the state of 
Texas, there is a higher prevalence of hyperlipidemia among whites (35.2%) than other 
ethnic minorities such as African Americans (29.2%) and Hispanics (24.5%).446  The 
findings are also consistent with those obtained from a national sample where, based on 
the ATP II guidelines, a greater percentage of whites (29.5%) qualified for dietary and 
drug therapy, compared to non-Hispanic blacks (24.7%), and Mexican-Americans 
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(18.2%) 447  This study can only be generalized to the Texas Medicaid population and 
lacks generalizability to other populations.  
 
CLINICAL CONDITIONS 
The majority of the statin users (75.0%) were classified as primary prevention 
patients, i.e., they did not have a diagnosis of CHD within a year prior to the start of 
therapy.  This shows that statins were primarily used for the prevention of CHD.  Over 
half of the patients had a hypertension diagnosis at or prior to index date, and a little less 
than half had a diagnosis for diabetes at or a year prior to index date.  The majority of the 
diabetics (96.5%) were type 2 diabetics.  Over half (51.7%) of the primary prevention 
patients in the present study were type 2 diabetics.  Other risk factors such as age and 
gender were also assessed.  According to the ATP guidelines, males below 45 years of 
age, and females over 55 years have an increased risk of CHD.448  In this study, 45.9 
percent of the patients were males greater than 45 years and females over 55 years.  
Overall, the mean number of CHD risk factors in the study population was 1.5 (S.D. = 
0.9).   
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The high prevalence of statin use among patients with risk factors such as 
diabetes and hypertension follows the recommendations by the ATP guidelines to 
aggressively treat hyperlipidemia among patients with these risk factors.  As per the ATP 
III guidelines, diabetes confers an absolute, 10-year risk for developing major coronary 
events equal to that of a person with CHD; thus, there is a need to aggressively treat 
hyperlipidemia among diabetics. The majority of the diabetics in the present study were 
type 2 diabetics; this finding is consistent with the national statistics, where according to 
the National Diabetes Database Clearinghouse, around 90-95 percent of diabetics have 
type 2 diabetes.449  The American College of Physicians guidelines recommend the 
treatment of hyperlipidemia among diabetics, particularly type 2 diabetics.450  The higher 
prevalence of diabetes among statin users in this study population could be attributed to 
increased awareness for treating this important risk factor for CHD and the publishing of 
primary451,452 and secondary prevention453,454 trials showing the beneficial effects of 
statins.  
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USE OF STATINS AND OTHER-LIPID LOWERING DRUGS 
The most commonly prescribed statins, based on the total number of prescription 
claims for the two-year follow-up period were Lipitor® (57.1%), Zocor® (23.2%) and 
Pravachol® (14.2%).  Overall, only 11.6 percent of the total patients were taking other 
lipid lowering drugs (non-statin drugs) such as fibrates (8.3%), bile acid sequestrants 
(1.6%), and nicotinic acid derivatives (1.5%).  This finding is not surprising, since statins 
are the most widely prescribed lipid lowering therapy and are recommended as the first 
line of drug therapy under the ATP guidelines.  The use of other lipid lowering drugs has 
decreased since the introduction of statins.  Studies have shown similar results, where 
majority of the patients were initiated on statin therapy for the treatment of 
hyperlipidemia, followed by fibrates and other lipid lowering therapy.455,456  In the 
present study, a majority (78.7%) of the statin users were initiated on a statin drug at the 
recommended starting dose.  Based on the package inserts, the recommended starting 
doses for the statins were as follows: Lipitor® 10 or 20 mg once daily;457 Zocor® 20 or  
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 40 mg once daily;458 Pravachol® 40 mg once daily;459 Lescol® 40 mg once daily;460 and 
Mevacor® 20 mg once daily.461  There were no practical differences in the dose 
prescribed at the index date of statin drugs between CHD and non-CHD patients.  Similar 
findings were reported by Sueta et al., where most patients were on the recommended 
starting dose and 65 percent of patients with CHD were on the recommended starting 
dose.462  Although calculating a mean dose across drug products has its limitations, in the 
present study, the mean daily dose on which the patients were started on was 19.2 mg, 
which is consistent with that reported in the study by Catalan et al.,463 where the mean 
initial statin dose was 18 mg.  
In the present study, only 31.6 percent (N = 2,352) of the patients received a 
prescription for an increase in statin dose following the start of therapy.  Gaw et al. stated 
that in primary care settings, physicians often fail to achieve the recommended LDL 
goals for their patients due to a number of factors including lack of adequate 
effectiveness of lipid-lowering drugs in reducing the LDL levels in frequently used  
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doses.464  Failure to achieve lipid goals are attributed to a large extent to inadequate doses 
of lipid-lowering agents.  As found in this study, most patients who began statin 
treatment remained at the initial dose.  As per the NCEP guidelines, the decision to 
initiate lipid lowering therapy is based on the LDL cholesterol levels, the number of risk 
factors, and presence or absence of CHD.  In the Texas Medicaid database, the 
information on LDL levels as well as risk factors such as smoking status, family history 
of CHD were absent; thus, it was not possible to evaluate if statin therapy was initiated 
appropriately based on the guidelines.  
 
SPECIALTY OF PHYSICIAN PRESCRIBING THE STATIN AT INDEX DATE 
Family practice/general practice physicians (44.6%) and internal medicine 
physicians (32.3%) wrote a majority of the prescriptions at the index date, whereas, only 
7.9 percent of the statin prescriptions were written by a cardiologist.  It is important to 
note that the number of patients treated by cardiologists was lower than that seen in 
managed care organizations or primary care settings, where 28 percent and nine percent 
of the index prescriptions were written by cardiologists, respectively.465,466  One possible 
reason for this difference is the lack of access to specialists due to the indigent nature of 
the Medicaid population.   
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COMPLIANCE WITH STATIN THERAPY 
Compliance with statin therapy was estimated using the medication possession 
ratio (MPR) and number of days of persistence with the therapy.  Persistence was 
assessed as the length of time until statin therapy discontinuation.  A gap of 60 days after 
exhausting the last medication supply was used as defining discontinuation.  A sensitivity 
analysis was also conducted using a gap of 45 days.  The mean MPR was 0.7 and over 
half of the patients had an MPR of less than 0.80.  The mean MPR in this study was 
slightly lower than that seen in other studies; however, it should be noted that these 
studies were not conducted in the Medicaid population.  The literature lacks information 
about adherence to statin therapy for the Medicaid population under 65 years of age.  The 
mean MPR in the study that used pharmacy claims from a managed care organization 
was slightly higher (0.8) than the one observed in the present study.  However, the study 
included only secondary prevention patients who had experienced an acute MI or 
atherosclerotic disease.467  Another study that used information from an HMO showed a 
mean MPR of 0.8 for those filling prescription in a community pharmacy; however, the 
mean age of the patients in the study was 61.4 years.468     
Using the 60 -day gap for failing to refill the prescription, the mean number of 
days of persistency to statin therapy was 381 days (95% CI: 374.0-389.0).  Only 50 
percent of the patients were persistent with their statin therapy at the end of 310 days, and 
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the probability of being persistent at the end of the two-year follow-up was 0.41.  The 
number of days of persistence for 17.8 percent of the patients was zero, implying that 
17.8 percent of the patients exceeded the 60-day gap after getting their first statin 
prescription filled.  In other words, close to one in five patients did not get their first 
statin prescription refilled within 60-days after the last day of therapy.  There was a sharp 
fall in persistence in the first year of therapy, but the fall decreased gradually over time 
after 12 months.  These results were consistent with other studies which showed a 
slowdown in the rate of discontinuation after the first year.469,470   
Sensitivity analysis using a gap of 45 days showed a similar pattern of statin 
therapy discontinuation over time.  Based on a 45-day gap of failing to refill the 
prescription, the mean days of persistency to statin therapy was 329 days (95% CI: 321.8-
336.5).  The days of persistence for 21.8 percent of the patients (N = 1,620) was zero, 
implying that these patients exceeded the 45-day gap for their first statin prescription 
refill.  Only 50 percent (N = 3,720) of the patients were persistent with their statin 
therapy at the end of 206 days.  The probability of being persistent at the end of the two 
year follow-up period was 0.33.  The number of days of persistence for 21.8 percent of 
the patients was zero, implying that 21.8 percent of the patients exceeded the 45-day gap 
after getting their first statin prescription filled.  As observed with the 60-day gap, there 
was a sharp fall in persistence in the first year of therapy, but the fall decreased gradually 
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over time after 12 months.  These results were consistent with other studies which 
showed a slowdown in the rate of discontinuation after the first year.471,472,473 The results 
point to a need to find a means of improving patient adherence within the first few 
months of therapy since patients are more likely to stop therapy early on than later.  
Statins are expensive drugs and most often statin therapy is a life long therapy.  If half the 
people are discontinuing their therapy, then the full benefit of the drug is not being 
achieved.  Texas Medicaid is wasting its resources if the patients are discontinuing 
therapy and there is an increased risk of long-term costs associated with CHD.  
The discontinuation rates in the present study were 52.6 percent at the end of one 
year, and 59.3 percent at the end of two years.  Based on the study results, the 
discontinuation rates in the present study are higher than those observed in clinical trials 
(4-15%) and those observed by Andrade et al. (15%).474  The rate was lower than those 
observed in studies conducted by Simons and Catalan where the discontinuation rates 
were 60% and 67% at the end of one year, respectively.475,476  However, it should be 
noted that these studies were not conducted among the Medicaid population and included 
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older patients.  There were two studies that were conducted in the Medicaid population, 
but both studies included patients above the age of 65 years.477,478 In these studies, 43 
percent of the patients were persistent at the end of six months and the two-year 
adherence rate was 36.1 percent among secondary prevention patients, and 25.4 percent 
among primary prevention patients.   
Texas Medicaid patients are entitled to receive at least three prescriptions per 
month without a charge.  Thus, in the vast majority of the cases economics cannot be 
blamed for the poor persistence because quantities of drug therapies are usually adjusted 
so that a patient may be taking more than three drug products, but have them filled at 
different months.  However, despite prescription coverage, Medicaid recipients have 
reported a higher rate of non-compliance due to high costs of prescription drugs.479  
Despite the fact that drug quantities are used to get around the three prescriptions per 
month limit, Medicaid recipients could incur out of pocket expenses for drugs which 
could lead to discontinuation of therapy.   
The majority of the patients in the study were females and primary prevention 
patients.  Heart disease is often viewed as a “male disease” and women may not view 
themselves at as high a risk as compared to men; thus, they may not perceive the 
importance of controlling hyperlipidemia. Since hyperlipidemia is a silent disease, 
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primary prevention patients who have not yet experienced CHD may not understand the 
importance of treating high cholesterol.   
Despite the claim that statins are well-tolerated, physicians view side-effects of 
statins to be one of the barriers to treatment.480  The risk of statin-associated myopathy 
increases with the concomitant use of other drugs and in special populations such as 
elderly, and those with impaired metabolic processes.481  There could be a possibility that 
potential drug-drug interactions could have increased the occurrence of side-effects and 
led to statin discontinuation in this study population.  However, due to the lack of data, 
this cannot be confirmed.  It is noteworthy to mention that in clinical trials, such as the 
WOSCOPS and 4S, the rates of adverse events and withdrawal from the study did not 
differ between the statin and the placebo group.482,483  However, the withdrawal of statin 
drug cerivastatin due to increased risk of rhabdomylosis,484 as well as the more recent 
safety concern on the latest statin drug rosuvastatin485 has put forth concerns about the 
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safety of this class of drugs.  The database did not have laboratory values of the liver 
function tests (LFTs) to evaluate if the rate of occurrence of adverse events was 
associated with poor compliance.   
In further analysis of adherence, a multiple regression and Cox regression 
analyses were employed to assess predictors of MPR and persistence, respectively.    
MPR was used as the dependent variable in one model while days until statin therapy 
discontinuation were used as the dependent variable in the other.  In a previous study, the 
MPR was dichotomized into compliant (MPR greater than 80 percent) and non-compliant 
(MPR less than 80 percent) groups and logistic regression was employed.  An MPR of 80 
has been the threshold used in clinical trials; however, it may not be appropriate in “real-
world” settings.  The predictors in the model used in this study were patient’s age at 
index date, gender, ethnicity, presence of CHD, diabetes, hypertension, atherosclerotic 
diseases, and total number of prescriptions other than lipid-lowering drugs during the 
two-year follow-up period.  The multiple regression results showed that being male, non-
Hispanic white and the absence of CHD, hypertension and diabetes were associated with 
an increase in MPR.   
Cox regression analysis was employed to assess the predictors of persistence.  
The time until statin therapy discontinuation was used as the dependent variable in the 
model.  The predictors of persistence were assessed using a Cox regression model with 
time until statin therapy discontinuation as the dependent variable.  The Cox regression 
yielded similar results, where being male and white were associated with a lower hazard 




atherosclerotic disease) was associated with a greater hazard of becoming non-persistent 
to statin therapy. 
Results showed that female gender was associated with decreased adherence and 
this result was consistent with the results obtained by Sung et al.,486 and Andrade et al.487  
Andrade et al. attributed the higher rates of discontinuation of lipid lowering therapy 
among females to the occurrence of adverse events.  Due to the data limitations, the rate 
of occurrence of adverse events associated with the use of statins could not be evaluated.  
Another potential reason for higher discontinuation rate among females could be the 
perception that CHD is a male disease and females are less susceptible to it.  Thus, the 
management of hyperlipidemia, which is a major risk factor for the occurrence of CHD, 
may not be viewed that important by females as compared to males. 
Age was not a significant predictor of MPR or persistence to statin therapy.  This 
is consistent with the literature where most studies do not show an association of 
age488,489,490,491 with adherence, except for one, where older age was associated with poor 
long-term persistence, but this study included elderly patients.492  Consistent with other  
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studies in the literature493,494,495,496,there exists an ethnic disparity in adherence to statin 
therapy, with whites being more adherent than other ethnic groups.  Using multiple 
regression analysis, a negative relationship was found between MPR and non-Hispanic 
blacks (Beta = -0.127, p < 0.001), and MPR and Hispanics (Beta = -0.130, p < 0.001).  
These ethnic groups had a lower MPR as compared to non-Hispanic whites, controlling 
for age, gender, disease conditions, and total number of prescriptions.     
Disease conditions such as CHD, diabetes, hypertension, and the presence of 
atherosclerotic diseases were assessed prior to or at the index date and during the follow-
up period.  These variables were included in the model to assess their relationship with 
MPR and persistence.  Presence of diabetes during follow-up, hypertension both prior 
and during follow-up, and presence of CHD both prior to and after the start of therapy 
had a negative relationship with MPR.  The presence of diabetes prior to index date, 
presence of CHD, hypertension both prior to and during the follow-up period were 
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significant predictors of poor persistence to statin therapy.  These results are contrary to 
what is observed in the literature, where in a majority of the studies, except in one, 497 the 
presence of CHD was associated with increased compliance with lipid lowering  
therapy.498,499,500,501,502 Similarly, the presence of other disease conditions, such as 
diabetes, hypertension and atherosclerotic diseases that impose a risk for CHD were 
associated with improved compliance.  However, some of these studies have included 
elderly patients.503,504,505  The presence of CHD had no effect on patient adherence in one 
study; however, it should be noted that this study classified diabetics as secondary 
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prevention patients as well, thus the results might not be comparable to the current 
study.506   
Results of this study show that compliance with statin therapy was low and the 
presence of CHD risk factors did not improve compliance.  In other words, one would 
think that having a risk factor would be positively related to drug compliance, but this 
was not found in this study.  One possible reason is that having a risk factor is related to 
poor maintenance of one’s health and thus, it is not a surprise to observe an inverse 
relationship between risk factors and MPR and persistence.  This calls for greater 
intervention by healthcare practitioners to counsel patients about the importance of lipid 
management, especially for patients with risk factors, since they have an increased risk of 
experiencing coronary events.   
One study has noted that patients’ perceptions of increased time spent by 
physicians in discussing cholesterol management and related cardiovascular issues had a 
positive correlation with increased compliance.507  However, patients’ perceptions about 
the role of cholesterol in the development of cardiovascular diseases (CVD) and their 
own personal views about their risk of developing a CVD event did not influence 
adherence to lipid lowering therapy.508  This may be the one of the reasons for the lack of 
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adherence to statin therapy among patients in the present study.  This reemphasizes the 
importance of counseling by healthcare practitioners on management of hyperlipidemia 
and reenforcing the importance of adherence to lipid lowering therapy in preventing 
CHD, as well as promoting the understanding of the association between hyperlipidemia 
and the increased risk of CHD.  Based on the literature, there appears to be scope for 
improvement in lipid management as only few physicians think that they are doing a 
good job in educating patients about the risks of high cholesterol and also there is a 
general lack of knowledge about the link between high cholesterol and CHD.509 
Based on a study that assessed patients’ perceptions of statin therapy for the 
treatment of hyperlipidemia,510 patients who were compliant with their statin therapy 
mentioned that their health care providers explained the importance and benefits of statin 
therapy and in some instances, the providers mentioned the consequences of 
hyperlipidemia.  Among patients who had discontinued their medications, the main issue 
was the absence of symptoms associated with raised cholesterol and their perception of 
being “healthy.”  The above provides the opportunity for health care providers to 
intervene and promote adherence to statin therapy by explaining the consequences of the 
lack of adherence.   
 The total number of prescriptions that the patients were taking other than statins 
was evaluated as one of the predictors to MPR and persistence.  The mean number of 
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total other prescriptions in the current study during the two-year follow-up period was 
15.70 (S.D. = 10.2).  This variable was not a significant predictor of adherence while 
controlling for demographics and disease conditions.  Studies have assessed the influence 
of number of medications dispensed either prior to the start of lipid lowering therapy or 
during the study period.  Some studies have shown a negative relationship between 
increased number of prescriptions dispensed and adherence,511,512,513,514 whereas other 
studies have shown no relationship.515,516   
 
LIPID AND LIVER FUNCTION MONITORING 
The ATP II guidelines recommend lipid monitoring prior to initiating drug 
therapy as well as follow-up measurements.  Based on the guidelines, it is important to 
have a minimum of two lipoprotein measurements during one to two months of diet 
therapy prior to initiating the drug therapy.  After starting drug therapy, the first 
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lipoprotein measurement is recommended at six to eight weeks.  Once the target LDL 
levels are reached, patients should be monitored every eight to twelve week intervals 
through 52 weeks.  After a year of therapy, once the LDL levels are attained, monitoring  
of lipids and adverse effects should be conducted at four- to six-month intervals.  
Monitoring for toxicity should be carried out at the same time as lipid and lipoprotein 
measurements.517  In addition, the ATP III guidelines recommend lipid monitoring within 
six to eight weeks following a change in drug regimen.518  Based on the criteria set in this 
study, monitoring for LDL levels were assessed within three months prior to the start of 
therapy, three months after the start of therapy and within six months thereafter.  
Similarly, presence of liver function tests (LFTs) was assessed during the same time 
intervals. 
Within three months PRIOR to the start of therapy, less than half (42.5%) of the 
patients had their LDL levels monitored.  A majority of the patients (N = 6,282; 84.4%) 
DID NOT have a follow-up lipid test within three months since the start of therapy; in 
other words, only 15.6 percent had a lipid test within three months since the start of 
therapy.  Of those patients who had their lipid levels monitored within three months since 
the start of therapy (N = 1,158), only 67 patients (5.8%) had lipid monitoring within six 
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months thereafter. Thus, out of the total number of patients (N = 7,440), only 0.9 percent 
of the patients (N = 67) had their LDL levels monitored as per the criteria.   
It is disturbing to find that over half of the patients were started on statin therapy 
without having their LDL levels tested.  It could be due to the fact that majority of the 
patients had risk factors such as diabetes and hypertension and these risk factors call for 
aggressive management of cholesterol.  Physicians might start the patient on statins based 
on the presence of the CHD risk factors. Nevertheless, lack of testing the LDL levels 
prior to start of therapy cannot be justified by the presence of risk factors; rather it 
denotes either poor patient care on the part of the physician or lack of patient compliance 
with lipid tests.  Prior to the index date only 53.1 percent (N = 3,954) had a diagnosis for 
hyperlipidemia. Of those without a diagnosis for hyperlipidemia prior to index date 67.7 
percent (N = 2,361) presented with a diagnosis in the follow-up period.  This could be 
due to the fact that hyperlipidemia may not always be coded in the medical claims file.  
Under-reporting of hyperlipidemia was also observed in a study by Lewis et al., where of 
only 43 percent of the patients had a diagnosis for hyperlipidemia.519 Also, missing data 
could be a contributing factor to the low occurrence of LDL monitoring tests and LFTs.  
Within a year following the start of therapy, only 49.9 percent of the patients had 
their LDL levels measured.  This is low compared to a managed care organization, where 
60 percent of statin users had a claim for cholesterol monitoring in the first year of 
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follow-up.520  Based on national Medicaid rates, in the year 2000, only 43.8 percent of 
patients with CHD were screened for cholesterol.521  In the present study LDL levels 
were monitored in 62.9% and 56.7% of the diabetics (based on diagnosis at or year prior 
to index date) a year prior to and after the start of therapy.  This is higher than that 
observed in the Texas Medicaid managed care program, where less than half (34.4%) of 
the diabetics had a lipid panel measured in a year of follow-up.522  Considering the high 
cost of the statin drugs, it is disturbing to observe that less than half of the patients had 
their lipid levels tested prior to initiating statin therapy.  It must be mentioned that the 
literature lacks information on lipid and liver function tests monitoring among Medicaid 
patients.  These results show that adherence to the ATP guidelines is low when treating 
Texas Medicaid patients.  It should be noted that these tests may have been ordered by 
physicians, but patients did not go ahead and get their lipid levels monitored.  This can be 
compared by the findings by O’Donnell et al., where despite being advised by 
pharmacists to get their lipid levels tested within six months after discharge from a lipid 
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clinic, only about half of them got themselves tested.523 However, due to the data 
limitations, this could not be evaluated.  In addition, this study found that the monitoring 
of LDL levels after changes in therapy was suboptimal.  Following a change in therapy, 
only 15.5 (N = 335) and 14.1 percent (N = 178) of the patients who had a change in statin 
type or dose, respectively, had their LDL monitored.   
Only 14.7 percent (N = 3,163) of the total patients had a liver function test (LFT) 
within three months PRIOR to the start of therapy, and only 9.7 percent (N = 724) of the 
patients had a LFT within three months since the start of therapy.  Of those patients who 
had their liver function monitored within three months since the start of therapy             
(N = 724), only 35 patients (4.8%) had LFTs within six months thereafter.  A greater 
number of patients had LFTs within a year as compared to three months since the start of 
therapy (31.6% vs. 9.7%).  One possible explanation could be that physicians are 
ignoring the guidelines and might be ordering tests only if the patient complains of 
muscle pain or weakness.  The lack of LFTs could also be explained by the fact that the 
risk of occurrence of statin-associated myopathy is greater at higher doses, and the 
majority of the patients in the study were on low (5mg, 10mg or 20mg) doses.  Due to 
this, physicians might not be viewing monitoring for side-effects to be cost-effective.  
There have been no known studies that have evaluated the rate of occurrence of LFTs in 
patients on statins.  However, one study looked at safety monitoring among patients on 
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lipid lowering drugs in a pharmacist run lipid management clinic, 95 percent of the 
patients received safety monitoring at least once a year.524 
There are no known studies in the literature that have assessed the predictors of 
lipid tests in the Medicaid population or in the general population.  The factors 
significantly associated with an increased likelihood of having a lipid test at baseline, 
included female gender, younger age, being white, absence of CHD, presence of diabetes 
and hypertension.  Being non-Hispanic white was associated with an increased likelihood 
of a lipid test compared to other ethnic groups, except for Hispanics who had an 
increased likelihood of lipid tests compared to whites.  In addition, having a diagnosis for 
CHD was associated with a decreased likelihood of having a lipid test.  This is an 
unexpected finding since it would be desired that monitoring of lipid levels would be 
higher for those patients who had a prior history of CHD.  Similarly, Hispanics having a 
greater likelihood of being tested compared to whites was an unexpected finding since it 
has been reported that ethnic minorities have a lower rate of cholesterol screening.525   
When the predictors of lipid testing after the start of therapy were assessed, non-
Hispanic whites had a greater likelihood of having a lipid test compared to non-Hispanic 
Blacks.  Contrary to the results obtained for baseline lipid testing, prior CHD as well as 
prior lipid monitoring were significantly associated with increased likelihood of LDL 
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monitoring following the start of statin therapy.  Prior lipid testing also was a significant 
predictor of LDL monitoring following a change in therapy or an increase in statin dose.  
Since CHD patients are considered as high risk patients, monitoring of lipid levels was 
greater compared to non-CHD patients.  Lipid testing prior to the start of therapy should 
be promoted since this is a positive predictor of future lipid monitoring.  Suboptimal LDL 
monitoring may indicate a lack of patient compliance since the physicians could have 
ordered these tests but the patients might not be completing the tests.  
The factors associated with an increased likelihood of LFTs prior to the start of 
therapy were younger age, presence of diabetes and hypertension.  However, older age, 
being non-Hispanic black and presence of hypertension were associated with an 
increased likelihood of LFTs after the start of therapy.  Patients treated by a cardiologist 
at the index date and those having prior LFTs had an increased likelihood of having a test 
following an increase in statin dose.  The lower occurrence of LFTs prior to the start of 
therapy could be due to the fact that even though the current guidelines recommend LFTs 
prior to the start of therapy, there is a lack of agreement among experts regarding the 
need to do so.  Increased likelihood of LFTs among older patients after the start of 
therapy could be due to the increase in the chance of occurrence of side effects with 
increasing age.526   
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There are a number of study limitations which need to be addressed.  The first set 
of limitations concerns the use of the Texas Medicaid database.  Claims data may be 
subject to coding errors, errors in data entry and missing data. Furthermore, the data 
lacked information on the results of the lipid and liver function tests.  Since only Texas 
Medicaid patients between the ages of 21 to 62 years were included in the study, the 
results cannot be generalized to non-Medicaid and younger or older Medicaid patients. 
Medicaid patients older than 21 years and not residing in a long-term care facility have a 
three prescription drug limit per month. Thus, patients’ lack of adherence to their statin 
medication may be due to choices faced by patients who have more than three 
prescriptions per month.  This could have a potential threat on the MPR and persistence.  
However, it must be noted that for many Medicaid patients who need more than three 
prescriptions per month, adjustments maybe made in quantities of drugs dispensed so a 
patient can be taking more than three prescription drugs.  Also, if the patient bought statin 
drugs out-of-pocket, then no medical claim is available.  Free drug samples given to the 
patient could also affect the adherence measures, however, this information could not be 
captured in the data.  Furthermore, since the data lacked information on the results of 
LFTs, the discontinuation of statins due to abnormal LFTs could not be evaluated.  
Appropriate or inappropriate use of statins as per the guidelines could not be evaluated 
due to lack of lipid levels and information on all the risk factors.  
Overall, the data were complete except for information on physician 




missing values.  Thus, results related to these variables need to be interpreted with 
caution.  One major limitation of the study is the lack of information on other risk factors 
such as obesity, smoking status and family history of premature CHD.  All of this 
information would have permitted the categorizing of patients into different risk 
categories as per the ATP guidelines.  The presence of LDL levels would have helped in 
understanding the impact of adherence on the lowering of lipid levels.  The lack of 
monitoring of lipid and LFTs could not be wholly attributed to physicians’ lack of 
adherence to the guidelines, since the physician could have ordered the test but the 
patient may not have completed the test and the data did not capture this information.  
Due to multiple statistical tests there could be a possibility of inflated type I errors.  
 
FUTURE RESEARCH 
The current research has generated a number of questions which need to be 
addressed in future studies.  Since this study has shown that physicians’ adherence to 
lipid and safety monitoring guidelines is low, further research is needed to understand if 
indeed the physicians are not ordering the tests or the patients are not getting the tests 
completed and the reasons for such behavior.  Perhaps a survey of physicians or an 
interview could be conducted to obtain information regarding their awareness of 
cholesterol guidelines, their perception of the importance of the guidelines, and barriers 
to adherence to the guidelines.  It would be useful to compare physicians’ orders with 
laboratory data.  This will indicate who is at fault, the physician not ordering the tests or 




and most likely would be an expensive study.  Moreover, if physicians are ordering the 
tests, then it will be useful to understand the barriers that the patient faces that prohibit 
them from getting their lipid levels tested.   
In regard to the issue of patient non-adherence to statin therapy, it would be useful 
to understand if the discontinuation of statins was associated with the occurrence of 
adverse events or increased awareness of the possible side effects of statin therapy.  
Medical consequences of non-adherence can also be assessed to observe if lack of 
adherence to statin therapy was associated with increased cardiovascular-related 
hospitalizations and procedures.  Moreover, the rate of occurrence of statin-associated 
myopathy increases with the concomitant use of certain drugs.  It would be interesting to 
evaluate if LFTs are being conducted among those patients on concomitant drugs.  The 
rate of hospitalization due to the occurrence of statin-associated adverse events could be 
determined using the medical claims data.  Assessing the side-effects would present a 
better understanding if indeed the discontinuation of therapy was due to the occurrence of 
statin-associated myopathy.  In the present study, only the first change in dose or type of 
statin drug was assessed; a  future study could look at subsequent changes to therapy and 
monitoring for LDL and side effects.   
As an attempt to control the costs, Texas Medicaid implemented the prior 
authorization program and a preferred drug list was implemented starting March 2004.  
Preferred drugs do not require prior authorization while non-preferred drugs require 
authorization prior to dispensing.  Statins such as Lipitor® was listed as a non-preferred 




useful to understand if the patients on Lipitor® were switched to other drugs that were on 
the preferred list and also study the economic and medical consequences of such a 
switch.  
 
STUDY IMPLICATIONS AND CONCLUSION 
 Despite the limitations, the present study presents a view of the management of 
hyperlipidemia among Texas Medicaid patients.  The study shows the lack of adherence 
to statin drugs and lack of monitoring of the response to the drugs, as well as associated 
adverse events, both of which are probably costing Texas Medicaid program valuable 
dollars in the long run.  Texas Medicaid should take steps to educate the physicians to be 
proactive in promoting patient compliance with statins, perhaps by handing out flyers and 
reminders to patients, to inform them about the importance for treating the condition.  
Moreover, efforts should also be made to educate physicians about the cholesterol 
guidelines as well as the importance of regular monitoring of lipid levels and adverse 
effects of statins.   
Steps should be taken to promote the participation of health care practitioners 
such as pharmacists and nurses to educate patients about cholesterol management.  Lipid 
management programs run by pharmacists could be cost-effective and efficient in 
promoting cholesterol management and patient adherence to lipid-lowering drugs.  
Similarly, nurses’ intervention in educating patients on the importance of cholesterol 
management and its association with CHD could be very valuable.  Steps also need to be 




of high cholesterol and the occurrence of CHD.  Medicaid needs to address the gender 
gap and ethnic disparity with respect to adherence to statins.  Promoting the management 
of high cholesterol in primary prevention patients could save the Medicaid system long-
term costs of CHD-related hospitalizations and procedures.   
The primary purpose of this study was to evaluate adherence to statin therapy and 
monitoring of lipid and adverse events among Medicaid patients on statin therapy.  The 
results show that adherence to statin is suboptimal.  There is lack of monitoring of lipid 
levels and adverse events among patients on statins.  The combination of the lack of 
adherence and inadequate monitoring of lipid levels could result in failure of the NCEP 
goals. Long-term costs associated with CHD could be reduced by promoting patient 








COX PROPORTIONALITY HAZARD ASSUMPTION  




































































































































































































































American Heart Association. Heart Disease and Stroke Statistics - 2004 Update. 
American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed January 15, 
2004. 
American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. 
American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=1928. Accessed January 15, 
2005. 
Cholesterol statistics. American Heart Association. Available at: 
http://www.americanheart.org/presenter.jhtml?identifier=4506. Accessed February 1, 
2005. 
Lescol package insert. East Hanover, NJ: Novartis Pharmaceuticals; April 2003. 
Lipitor package insert. Morris Plains, NJ: Parke-Davis; April 2003. 




Pharmaceutical Benefits Under State Assistance Programs. Pharmacy program 
charateristics. Available at: 
http://www.npcnow.org/resources/PDFs/medicaid2003/03Sec4.pdf. Accessed December 
14, 2004. 
Pravachol package insert. Princeton, NJ: Bristol-Myer Squibb Company.  April 2003. 
Second report of the Expert Panel on Detection, Evaluation, and Treatment of High 
Blood Cholesterol in Adults (Adult Treatment Panel II). Bethesda (MD): U.S. 
Department of Health and Human Services, Public Health Service, National Institutes of 
Health, National Heart, Lung and Blood Institute; 1993. NIH Publication No: 93-3095.  
Texas Council on Cardiovascular Disease & Stroke 2001 Legislative Report. Available 
at: http://www.tdh.state.tx.us/wellness/cvd/cvd.htm. Accessed September 15, 2003. 
Texas Medicaid Managed Care 2001: Star+Plus Diabetes Focused Study. Available at: 
http://www.hhsc.state.tx.us/medicaid/mc/about/reports/2001annrpts/StarPlus_Diabetes_S
FY2001_Tech.pdf. Accessed December 15, 2004. 
Texas Medicaid: Top 50 drugs cost analysis: Center for Pharmacoeconomics Studies.  
The University of Texas at Austin.  




Abbasi F, Brown B, Lamendola C, et al. Relationship between obesity, insulin resistance, 
and coronary heart disease risk. Journal of the American College of Cardiology. 
2002;40(5):937-943. 
Abhughosh SM, Kogut SJ, Andrade SE, et al. Persistence with lipid lowering therapy: 
Influence of the type of lipid-lowering agent and drug benefit plan option in elderly 
patients. Journal of Managed Care Pharmacy. 2004;10(5):404-411. 
Aguilar-Salinas CA, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol 
concentrations and mixed hyperlipidemia in a Mexican nationwide survey. Journal of 
Lipid Research. 2001;42(8):1298-1307. 
Allison PD. Estimating Cox regression models with PROC PHREG. Survival Analysis 
Using the SAS Sytem: A Practical Guide. Cary, NC: SAS Institute Inc.; 1995:111-184. 
Andrade S, Walker AM, Gottolieb L, et al. Discontinuation of antihyperlipidemic drugs-
do rates reported in clinical trials reflect rates in primary care settings? New England 
Journal of Medicine. 1995;332(17):1125-1131. 
Andrade SE, Saperia GM, Berger ML, et al. Effectiveness of antihyperlipidemic drug 




Andrade SE, Walker AM, Gottolieb LK, et al. Discontinuation of antihyperlipidemic 
drugs-do rates reported in clinical trials reflect rates in primary care settings? New 
England Journal of Medicine. 1995;332(17):1125-1131. 
Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National 
Cholesterol Education Program low-density lipoprotein cholesterol goals with five 
statins. American Journal of Medicine. 2001;111(3):185-191. 
Aronow WS, Ahn C. Frequency of new coronary events in older persons with peripheral 
arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated 
with statins versus no lipid-lowering drug. American Journal of Cardiology. 
2002;90(7):789-791. 
Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in the secondary 
prevention of coronary artery disease. American Journal of Cardiology. 1996;78(4):409-
414. 
Atkins D, Psaty B, Koepsell T, et al. Cholesterol reduction and the risk for stroke in men: 
a meta-analysis of randomized controlled trials. Annals of Internal Medicine. 
1993;119(2):136-145. 
Austin M, Breslow J, Hennekens CH, et al. Low-density lipoprotein subclass patterns and 





Avorn J, Monette J, Lacour A, et al. Persistence of the use of lipid lowering medications: 
A cross national study. Journal of the American Medical Association. 
1998;279(18):1458-1452. 
Ayanian JZ, Guadagnoli E, McNeil BJ, et al. Treatment and outcomes of acute 
myocardial infarction among patients of cardiologists and generalist physicians. Archives 
of Internal Medicine. 1997;157(22):2570-2576. 
Badia X, Russo P, Attanasio E. A comparative economic analysis of simvastatin versus 
atorvastatin: Results of the Surrogate Marker Cost-Efficacy (SMaC) study. Clinical 
Therapeutics. 1999;21(10):1788-1796. 
Ballantyne C M. Current and future aims of lipid-lowering therapy: changing paradigms 
and lessons from the Heart Protection Study on standards of efficacy and safety. 
American Journal of Cardiology. 2003;92(4B):3K-9K. 
Barrett A. A bare-knuckle battle over cholesterol drugs. Business Week Online; 2003. 
Barrett-Connor E. Postmenopausal estrogen and heart disease. Atherosclerosis. 
1995;118(suppl):S7-10. 
Benfante R, Reed D. Is elevated serum cholesterol levels a risk factor for coronary heart 





Benner J, Glynn R, Mogun H, et al. Long-term persistence in use of statin therapy in 
elderly patients. Journal of the American Medical Association. 2002;288(4):455-461. 
Berchtold P, Berger M, Jorgens V, et al. Cardiovascular risk factors and HDL-cholesterol 
levels in obesity. International Journal of Obesity. 1981;5(1):1-10. 
Berge KG, Canner P. Coronary Drug Project: experience with niacin. European Journal 
of Clinical Pharmacology. 1991;40(suppl 1):S49-51. 
Bermudez OI, Velez-Carrasco W, Schaefer EJ, et al. Dietary and plasma lipid, 
lipoprotein, and apolipoprotein profiles among elderly Hispanics and non-Hispanics and 
their association with diabetes. Am J Clin Nutr. 2002;76(6):1214-1221. 
BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing 
triglycerides in patients with coronary artery disease: The Bezafibrate Infarction 
Prevention (BIP) Study. Circulation. 2000;102(1):21-27. 
Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with 
lovastatin therapy: The Monitored Atherosclerosis Regression Study (MARS). Annals of 
Internal Medicine. 1993;119(10):969-976. 
Blasetto J, Stein EA, Brown WV, et al. Efficacy of Rosuvastatin compared with other 
statins at selected starting doses in hypercholesterolemic patients and in special 




Boden WE. High-density lipoprotein cholesterol as an independent risk factor in 
cardiovascular disease: Assessing the data from Framingham to the Veterans Affairs 
High-Density Lipoprotein Intervention Trials. American Journal of Cardiology. 
2000;86(suppl 12A):19L-22L. 
Bond WS, Hussar DA. Detection methods and strategies for improving medication 
compliance. American Journal of Health System Pharmacy. 1991;48(9):1978-1988. 
Brown AS. Use of combination therapy for dyslipidemia: a lipid clinic approach. 
American Journal of Cardiology. 2002;90(2):44-49. 
Brown G, Albers J, Fisher L, et al. Regression of coronary artery disease as a result of 
lipid lowering therapy in men with high levels of apolipoprotein B. New England Journal 
of Medicine. 1990;323(19):1289-1298. 
Bruckert E, Simonetta C, Giral P. Compliance with fluvastatin treatment characterization 
of the noncompliant population within a population of 3845 patients with hyperlipidemia. 
Journal of Clinical Epidemiology. 1999;52(6):589-594. 
Bucher H, Griffith L, Guyatt G. Effect of HMGCoA reductase inhibitors on stroke: A 





Byington RP, Furberg CD, Crouse III JR, et al. Pravastatin, lipids, and atherosclerosis in 
the Carotid Arteries (PLAC-II). American Journal of Cardiology. 1995;76(9):54C-59C. 
Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during 
pravastatin therapy : Pooled analysis of clinical events of the pravastatin atherosclerosis 
intervention program. Circulation. 1995;92(9):2419-2425. 
Cabana MD, Kim C. Physician adherence to preventive cardiology guidelines for women. 
Women's Health Issues. 2003;13(14):143-149. 
Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice 
guidelines: A framework for improvement. Journal of the American Medical Association. 
1999;282(15):1458-1465. 
Canner P, Berge K, Wenger N, et al. Fifteen year mortality in Coronary Drug Project 
patients: long-term benefit with niacin. Journal of the American College of Cardiology. 
1986;8(6):1245-1255. 
Cardiovascular Health and Wellness Program. Cardiovascular Disease (CVD) in Texas: 
A surveillance report and program strategy 2003. Bureau of Chronic Disease and 
Tobacco Prevention, Texas Department of Health. Available at: 




Cardiovascular Health and Wellness Program. Cardiovascular disease in Texas: A risk 
factor report. 1999 Survey Data. Bureau of Chronic Disease and Tobacco Prevention, 
Texas Department of Health. Available at: 
http://www.tdh.state.tx.us/chronicd/cvdrep.pdf. Accessed September 15, 2003. 
Cardiovascular Health and Wellness Program. Cardiovascular disease in Texas: A state 
plan with disease indicators and strategies for action. Bureau of Chronic Disease and 
Tobacco Prevention, Texas Department of Health. Available at: 
http://www.tdh.state.tx.us/wellness/stats/cvdrpt.pdf. Accessed November 17, 2003. 
Carlsson CM, Carnes M, McBride  PE, et al. Managing dyslipidemia in older adults. 
Journal of American Geriatric Society. 1999;47(12):1458-1465. 
Carmena R, Ascaso JF, Real JT. Impact of obesity in primary hyperlipidemias. Nutrition 
Metabolism & Cardiovascular Diseases. 2001;11(5):354-359. 
Carson J, Wayne R, Strom B. Medicaid Databases. In: Strom B, ed. 
Pharmacoepidemiology. New York: John Wiley & Sons, Ltd.; 2000:307-324. 
Castelli WP. Cholesterol and lipids in the risk of coronary heart disease: the Framingham 
Heart Study. Canadian Journal of Cardiology. 1988;4(suppl 1):5A-10A. 
Castelli WP, Anderson K, Wilson PW, et al. Lipids and risk of coronary heart disease. 




Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and 
lipoprotein cholesterol levels. The Framingham Study. Journal of the American Medical 
Association. 1986;256(20):2835-2838. 
Catalan V, LeLorier J. Predictors of long-term persistence on statins in a subsidized 
clinical population. Value in Health. 2000;3(6):417-426. 
Charles H, Good CB, Hanusa B, et al. Racial differences in adherence to cardiac 
medications. Journal of National Medical Association. 2003;95(1):17-27. 
Chin-Dusting JP, Shaw JA. Lipids and atherosclerosis: clinical management of 
hypercholesterolaemia. Expert Opinion on Pharmacotherapy. 2001;2(3):419-430. 
Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy 
records, and pill counts with electronic monitoring of adherence to antihypertensive 
therapy. Medical Care. 1999;37(9):846-857. 
Cleemput I, Kesteloot K. Economic implications of non-compliance in health care. 
Lancet. 2002;359(9324):2129-2130. 
Colditz GA, Rimm EB, Giovannucci E, et al. A prospective study of parental history of 





Coombs JH, Cornish L, Hiller P, et al. Compliance and refill pattern behavior with HMG-
CoA reductase inhibitors after acute myocardial infarction. Managed Care Interface. 
2002;15(1):54-58. 
Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. 
Journal of the American Medical Association. 1975;231(4):360-381. 
Coronary Drug Project Research Group. Influence of adherence to treatment and 
response of cholesterol on mortality in the Coronary Drug Project. New England Journal 
of Medicine. 1980;303(18):1038-1041. 
Corti MC, Guralnik K, Salive ME, et al. Clarifying the direct relation between total 
cholesterol levels and death from coronary heart disease in older persons. Annals of 
Internal Medicine. 1997;126(10):753-760. 
Corvol J, Bouzamondo A, Sirol M, et al. Differential effects of lipid-lowering therapies 
on stroke prevention. Archives of Internal Medicine. 2003;163(6):669-676. 
Crouse III JR, Byington RP, Furberg CD. HMG-CoA reductase inhibitor therapy and 
stroke risk reduction: an analysis of clinical trials data. Atherosclerosis. 1998;138(1):11-
24. 
Cziraky M. Clinical positioning of HMG-CoA reductase inhibitors in lipid management 




Danias PG, O'Mahony S, Radford MJ, et al. Serum cholesterol levels are underevaluated 
and undertreated. American Journal of Cardiology. 1998;81(11):1353-1356. 
Davidson MH. Combination therapy for dyslipidemia: safety and regulatory 
considerations. American Journal of Cardiology. 2002;90(2):50-60. 
Davidson MH. Does differing metabolism by cytochrome P450 have clinical importance. 
Current Atherosclerosis Reports. 2000;2(1):14-19. 
Denke MA, Sempos CT, Grundy S. Excess body weight: an underrecognized contributor 
to high blood cholesterol levels in white American men. Archives of Internal Medicine. 
1993;153(9):1093-1103. 
Dezii C. Persistence with drug therapy: A practical approach using administrative claims 
data. Managed Care. 2001;10(2):42-45. 
DiMatteo MR, DiNicola DD. The compliance problem: An introduction. In: DiNicola 
DD, ed. Achieving Patient Compliance: The Psychology of the Medical Practitioner's 
Role. New York: Pergamon Press Inc.; 1982:1-27. 
Downs JR, Beere PA, Whitney E, et al. Design & Rationale of the Air Force/Texas 





Downs JR, Clearfield M, S W, et al. Primary prevention of acute coronary events with 
lovastatin in men and women with average cholesterol levels. Results of 
AFCAPS/TexCAPS. Journal of the American Medical Association. 1998;279(20):1615-
1622. 
Drug Information Service, The University of Texas Health Science Center at San 
Antonio, and the College of Pharmacy, et al. Medicaid drug use review criteria for 
outpatient use: HMG-CoA reductase inhibitors. Available at: 
http://www.hhsc.state.tx.us/HCF/vdp/Criteria/hmg-coa.html. Accessed October 1, 2003. 
Eaker ED, Chesebro JH, Sacks FM, et al. Cardiovascular disease in women. Circulation. 
1993;88(4 pt 1):1999-1909. 
Eaton C, Lapane K, Murphy J, et al. Effect of statin (HMG-CoA reductase inhibitor) use 
on 1-year mortality and hospitalization rates in older patients with cardiovascular disease 
living in nursing homes. Journal of American Geriatric Society. 2002;50(8):1389-1395. 
Elliott WJ, Weir DR. Comparative cost-effectiveness of HMG-CoA reductase inhibitors 
in secondary prevention of acute myocardial infarction. American Journal of Health 
System Pharmacy. 1999;56(17):1726-1732. 
Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and 
discontinuation in primary and secondary prevention populations. Journal of General 




Expert Panel on Detection Evaluation and  Treatment of High Blood Cholesterol in 
Adults. Summary of the Second Report of the National Cholesterol Education Program 
(NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults (Adult Treatment Panel II). Journal of the American Medical 
Association. 1993;269(23):3015-3023. 
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in 
Adults. Executive Summary of The Third Report of The National Cholesterol Education 
Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood 
Cholesterol In Adults (Adult Treatment Panel III). Journal of the American Medical 
Association. 2001;285(19):2486-2497. 
Farmer KC. Methods for measuring and monitoring medication regimen adherence in 
clinical trials and clinical practice. Clinical Therapeutics. 1999;21(6):1074-1090. 
Farnier M, Davignon J. Current and future treatment of hyperlipidemia: the role of 
statins. American Journal of Cardiology. 1998;82(4B):3J-10J. 
Fedder DO, Koro CE, L'Italien GJ. New National Cholesterol Education Program III 
guidelines for primary prevention lipid-lowering drug therapy: projected impact on the 





Ferguson JJ. Meeting Highlights : Highlights of the 70th Scientific Sessions of the 
American Heart Association. Circulation. 1998;97(13):1217-1220. 
Ford E, Mokdad A, Giles W, et al. Serum total cholesterol concentrations and awareness, 
treatment, and control of hypercholesterolemia among US adults: Findings from the 
National Health and Nutrition Examination Survey 1999 to 2000. Circulation. 
2003;107(17):2185-2189. 
Franklin S, Khan S, Wong ND, et al. Is pulse pressure useful in predicting risk for 
coronary heart disease? The Framingham Heart Study. Circulation. 1999;100(4):354-
360. 
Frick M, Elo O, Haapa K, et al. Helsinki Heart Study: Primary-prevention trial with 
Gemfibrozil in middle-aged men with dyslipidemia. Journal of the American Medical 
Association. 1987;317(20):1237-1245. 
Friedmann PD, Brett AS, Mayo-Smith MF. Differences in generalists' and cardiologists' 
perceptions of cardiovascular risk and the outcomes of preventive therapy in 
cardiovascular disease. Annals of Internal Medicine. 1996;124(4):414-421. 
Frolkis J, Zyzanski S, Schwartz J, et al. Physician noncompliance with the 1993 National 





Frolkis JP, Pearce GL, Nambi V, et al. Statins do not meet expectations for lowering low-
density lipoprotein cholesterol levels when used in clinical practice. American Journal of 
Medicine. 2002;113(8):625-629. 
Gaw A. A new reality: achieving cholesterol-lowering goals in clinical practice. 
Atherosclerosis Supplements. 2002;2(4):5-8. 
Goff DC, Nichaman MZ, Chan W, et al. Greater incidence of hospitalized myocardial 
infarction among Mexican Americans than Non-Hispanic Whites : The Corpus Christi 
Heart Project, 1988-1992. Circulation. 1997;85(6):1433-1440. 
Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and 
cardiovascular disease: Four prospective American studies. Circulation. 1989;79(1):8-15. 
Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective 
factor against coronary heart disease: the Framingham Study. American Journal of 
Medicine. 1977;62(5):707-714. 
Gostin L. Health care information and the protection of personal privacy: Ethical and 
legal considerations. Annals of Internal Medicine. 1997;127(8 pt 2):683-690. 
Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 
years of hormone therapy: Heart and estrogen/progestin replacement study follow-up 




Grady D, Rubin S, Petitti D, et al. Hormone therapy to prevent disease and prolong life in 
post-menopausal women. Annals of Internal Medicine. 1992;117(12):1016-1037. 
Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use 
and the risk of cardiovascular disease. New England Journal of Medicine. 
1996;335(7):453-461. 
Groot E, Jukema JW, van Boven J, et al. Effect of pravastatin on progression and 
regression of coronary atherosclerosis and vessel wall changes in carotid and femoral 
arteries: A report from the Regression Growth Evaluation Statin Study. American Journal 
of Cardiology. 1995;76(9):40C-46C. 
Grover SA, Coupal L, Paquet S, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-
coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease. 
Archives of Internal Medicine. 1999;159(6):593-600. 
Grundy S. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. New 
England Journal of Medicine. 1988;319(1):24-33. 
Grundy SM. Cholesterol and coronary heart disease:  A new era. Journal of the American 
Medical Association. 1986;256(20):2849-2858. 
Grundy SM, Cleeman JI, Rifkind BM, et al. Cholesterol lowering in the elderly 




Grundy SM, Becker DM, Clark L, et al. Executive summary of the Third Report of the 
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, 
and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Journal 
of the American Medical Association. 2001;285(19):2486-2497. 
Grundy SM, Vega GL, Garg A. Use of 3-hydroxy-3-methylglutaryl coenzyme A 
reductase inhibitors in various forms of dyslipidemia. American Journal of Cardiology. 
1990;66(8):31B-38B. 
Guyton JR, Goldberg AC, Kreisberg RA, et al. Effectiveness of once-nightly dosing of 
extended-release niacin alone and in combination for hypercholesterolemia. American 
Journal of Cardiology. 1998;82(6):737-743. 
Harley CR, Setareh WA, McDonough KL, et al. Cholesterol management in a population 
of managed care enrollees. Journal of Clinical Outcomes Management. 2003;10(3):147-
154. 
Harris T, Cooks EF, Kannel  WB, et al. Proportional hazards analysis of risk factors for 
coronary heart disease in individuals aged 65 or older: The Framingham Heart Study. 
Journal of the American Geriatric Society. 1988;36(11):1023-1028. 
Harris-Hooker S, Sanford GL. Lipids, lipoproteins and coronary heart disease in minority 




Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary 
and secondary prevention of coronary artery disease. Pharmacoeconomics. 
1999;15(1):47-74. 
Haynes RB. Introduction. In: Sackett DL, ed. Compliance in Health Care: The Johns 
Hopkins University Press, Baltimore and London; 1979:1-10. 
Hebert BJ, Gaziano M, Hennekens CH. An overview of trials of cholesterol lowering and 
risk of stroke. Archives of Internal Medicine. 1995;155(1):50-55. 
Hebert P, Gaziano M, Chan K, et al. Cholesterol lowering with statins drugs, risk of 
stroke, and total mortality: an overview of randomized trials. Journal of the American 
Medical Association. 1997;278(4):313-311. 
Hennessy S, Bilker W, Weber A, et al. Descriptive analyses of the integrity of a US 
Medicaid claims database. Pharmacoepidemiology and Drug Safety. 2003;12(2):103-111. 
Herd JA, Ballantyne CM, Farmer JA, et al. Effects of fluvastatin on coronary 
atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and 
Coronary Atherosclerosis Study [LCAS]). American Journal of Cardiology. 
1997;80(3):278-286. 
Herrington D, Reboussin D, Brosnihan K, et al. Effects of estrogen replacement on the 





Hillemann DE, Heineman SM, Foral PA. Pharmacoeconomic assessment of HMG-CoA 
reductase inhibitor therapy: An analysis based on the CURVES study. Pharmacotherapy. 
2000;20(7):819-822. 
Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-
artery atherosclerosis in postmenopausal women. New England Journal of Medicine. 
2003;349(6):535-545. 
Hoerger TJ, Bala MV, Bray JW, et al. Treatment patterns and distribution of low-density 
lipoprotein cholesterol levels in treatment-eligible United States adults. American Journal 
of Cardiology. 1998;82(1):61-65. 
Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular 
disease independent of high-density lipoprotein cholesterol level: a meta-analysis of 
population-based prospective studies. Journal of Cardiovascular Research. 
1996;3(2):213-219. 
Holme I. Cholesterol reduction and its impact on coronary artery disease and total 
mortality. The American Journal of Cardiology. 1995;76(1):10C-17C. 
Hopkins PN, Williams RR, Kuida H, et al. Family history as an independent risk factor 
for incident coronary artery disease in a high-risk cohort in Utah. American Journal of 




Hosmer DW, Lemeshow S. Assessing the fit of the model. Applied Logistic Regression. 
New York: John Wiley & Sons; 1989:135-173. 
Hsu I, Spinler SA, Johnson NE. Comparative evaluation of the safety and efficacy of 
HMG-CoA reductase inhibitor monotherapy in the treatment of primary 
hypercholesterolemia. Annals of Pharmacotherapy. 1995;29:743-759. 
Hughes D, Bagust A, Haycox A, et al. Accounting for noncompliance in 
pharmacoeconomics. Pharmacoeconomics. 2001;19(12):1185-1197. 
Hulley S. Randomized trial of estrogen plus progestin for secondary prevention of 
coronary heart disease in postmenopausal women. Journal of the American Medical 
Association. 1998;280(7):605-613. 
Hunt D, Young P, Simes J, et al. Benefits of pravastatin on cardiovascular events and 
mortality in older patients with coronary heart disease are equal to or exceed those seen 
in younger patients: Results from the LIPID trial. Annals of Internal Medicine. 
2001;134(10):931-940. 
Huse DM, Russell MW, Miller GE, et al. Cost-effectiveness of statins. American Journal 
of Cardiology. 1998;82(11):1357-1363. 
Iezzoni LI. Assessing quality using administrative data. Annals of Internal Medicine. 




Insull W. The problem of compliance to cholesterol altering therapy. Journal of Internal 
Medicine. 1997;241(4):317-325. 
Jackevicius C, Mamdani M, Tu J. Adherence with statin therapy in elderly patients with 
and without acute coronary syndromes. Journal of the American Medical Association. 
2002;288(4):462-467. 
Jacobson TA. Maximizing the cost-effectiveness of lipid-lowering therapy. Archives of 
Internal Medicine. 1998;158(18):1977. 
Jamal SM, Eisenberg MJ, Christopoulos S. Rhabdomyolysis associated with 
hydroxymethylglutaryl-coenzyme A reductase inhibitors. American Heart Journal. 
2004;147(6):956-965. 
Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods 
for the design and analysis of natural history studies. American Journal of Managed 
Care. 2002;8(10):S249-S254. 
Jollis JG, Delong ER, Peterson ED, et al. Outcome of acute myocardial infarction 





Jones P, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of 
rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR 
Trial). American Journal of Cardiology. 2003;92(2):152-160. 
Jones P, Kafonek S, Laurora I, et al. Comparative dose efficacy study of atorvastatin 
versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with 
hypercholesterolemia (the CURVES study). American Journal of Cardiology. 
1998;81(5):582-587. 
Kannel  WB, Wilson PW. Risk factors that attentuate the female coronary disease 
advantage. Archives of Internal Medicine. 1995;155(1):57-61. 
Kannel WB. The Framingham Study: historical insight on the impact of cardiovascular 
risk factors in men versus women. Journal of Gender Specific Medicine. 2002;5(2):27-
37. 
Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins, and the risk of 
coronary heart disease. The Framingham study. Annals of Internal Medicine. 
1971;74(1):1-12. 
Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular 




Kaplan RC, Bhalodkar NC, Brown EJ, et al. Race, ethnicity and sociocultural 
characteristics predict noncompliance with lipid-lowering medications. Preventive 
Medicine. 2004;39:1249-1255. 
Kennedy J, Coyne J, Sclar  D. Drug affordability and prescription noncompliance in the 
United States: 1997-2002. Clinical Therapeutics. 2004;26(4):607-614. 
Khan S, Malhotra S. Effect of hormone replacement therapy on cardiovascular disease: 
current opinion. Expert Opinion on Pharmacotherapy. 2003;4(5):667-674. 
Kiortsis D, Giral P, Bruckert E, et al. Factors associated with low compliance with lipid-
lowering drugs in hyperlipidemic patients. Journal of Clinical Pharmacy & Therapeutics. 
2000;25(6):445-451. 
Kjekshus J, Berg K, Pedersen TR, et al. Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 
The Lancet. 1994;344(8934):1383-1389. 
Kjekshus J, Berg K, Pedersen T, et al. Randomised trial of cholesterol lowering in 4444 
patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). 
The Lancet. 1994;344(8934):1383-1389. 
Kjekshus J, Pedersen TR. Reducing the Risk of Coronary Events: Evidence from the 





Knopp RH. Drug treatment of lipid disorders. New England Journal of Medicine. 
1999;341(7):498-411. 
Knopp RH, Brown WV, Dujovne CA, et al. Effects of finofibrate on plasma lipoproteins 
in hypercholesterolemia and combined hyperlipidemia. American Journal of Medicine. 
1987;83(5):50-59. 
Koren M, Smith DG, Hunninghake D, et al. The cost of reaching National Cholesterol 
Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of 
atorvastatin, simvastatin, lovastatin and fluvastatin. Pharmacoeconomics. 1998;14(1):59-
70. 
Kreisberg RA, Oberman A. Medical management of hyperlipidemia/dyslipidemia. 
Journal of Clinical Endocrinology & Metabolism. 2003;88(6):2445-2461. 
Lai L, Poblet M, Bello C. Are patients with hyperlipidemia being treated? Investigation 
of cholesterol treatment practices in an HMO primary care setting. Southern Medical 
Journal. 2000;93(3):283-286. 
LaRosa J, Jiang H, Vupputuri S. Effect of statins on risk of coronary disease: A meta- 





Law MR, Wald NJ, Thompson SG. By how much and how quickly does reductionin 
serum cholesterol concentration lower risk of ischaemic heart disease? British Medical 
Journal. 1994;308(6925):367-373. 
Leaf DA, Connor WE, Illingworth DR, et al. The hypolipidemic effects of gemfibrozil in 
type V hyperlipidemia: a doube-blind, crossover study. Journal of the American Medical 
Association. 1989;262(22):3154-3160. 
Lewis BE, KL M. Dyslipidemia treatment among patients with coronary artery disease in 
a managed care organization. American Journal of Health System Pharmacy. 
2004;61:1032-1038. 
Li R, Bensen JT, Hutchinson RG, et al. Family risk score of coronary heart disease 
(CHD) as a predictor of CHD: the Atherosclerosis Risk in Communities (ARIC) Study 
and the NHLBI Family Heart Study. Genetic Epidemiology. 2000;18(3):236-250. 
Libby P, Schoenbeck U, Mach F, et al. Current concepts in cardiovascular pathology: 
The role of LDL cholesterol in plague rupture and stabilization. American Journal of 
Medicine. 1998;104(2A):14S-18S. 
Lipid Research Clinic Program Group. The Lipid Research Clinics Coronary Primary 
Prevention results. I: Reduction in the incidence of coronary heart disease. Journal of the 




Lipid Research Clinics Program Group. The Lipid Research Clinics Coronary Primary 
Prevention Trial results. II. The relationship of reduction in incidence of coronary heart 
disease to cholesterol lowering. Journal of the American Medical Association. 
1984;251(3):365-374. 
Maclaine GD, Patel H. A cost-effectiveness model of alternative statins to achieve target 
LDL-cholesterol levels. International Journal of Clinical Practice. 2001;55(4):243-249. 
Manolio TA, Pearson TA, Wenger NK, et al. Cholesterol and heart disease in older 
persons and women: review of an NHLBI workshop. Annals of Epidemiology. 1992;2(1-
2):161-176. 
Manson J, Hsia J, Johnson K, et al. Estrogen plus progestin and the risk of coronary heart 
disease. New England Journal of Medicine. 2003;349(6):523-534. 
Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of obesity and risk of 
coronary heart disease in women. New England Journal of Medicine. 1990;322(13):882-
889. 





Martens LL, Guibert R. Cost-effectiveness analysis of lipid-modifying therapy in 
Canada: Comparison of HMG-CoA reductase inhibitors in the primary prevention of 
coronary heart disease. Clinical Therapeutics. 1994;16(6):1052-1062. 
Matthews KA, Meilahn E, Kuller LH, et al. Menopause and risk factors for coronary 
heart disease. New England Journal of Medicine. 1989;321(10):641-646. 
Maviglia SM, Teich JM, Fiskio J, et al. Using an electronic medical record to identify 
opportunities to improve compliance with cholesterol guidelines. Journal of General 
Internal Medicine. 2001;16(8):531-537. 
McDermott M, Schmitt B, Wallner E. Impact of medication nonadherence on coronary 
heart disease outcomes: A critical review. Archives of Internal Medicine. 
1997;157(17):1921-1928. 
Mckenney J. Combination therapy for elevated low-density lipoprotein cholesterol: the 
key to coronary artery disease risk reduction. American Journal of Cardiology. 
2002;90(suppl):8K-20K. 
McKenney JM. Pharmacotherapy of dyslipidemia. Cardiovascular Drugs & Therapy. 
2001;15(5):413-422. 
McPherson R, Angus C, Murray P, et al. Efficacy of atorvastatin in achieving National 
Cholesterol Education Program low-density lipoprotein targets in women with severe 




Women's Atorvastatin Trial on Cholesterol (WATCH). American Heart Journal. 
2001;141(6):949-956. 
Miettinen TA, Pyorala K, Olsson AG, et al. Cholesterol-Lowering Therapy in Women 
and Elderly Patients With Myocardial Infarction or Angina Pectoris : Findings From the 
Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96(12):4211-4218. 
Miller M, Byington RP, Hunninghake D, et al. Lipid lowering therapy in CAD patients in 
academic medical centers: undertreatment and evidence of a gender gap. Journal of the 
American College of Cardiology. 1998;31(suppl):A186. 
Miller N. Compliance with treatment regimens in chronic asymptomatic diseases. 
American Journal of Medicine. 1997;102(2A):43-49. 
Mosca L, Appel LJ, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular 
disease prevention in women. Circulation. 2004;109(4):672-693. 
Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, 
challenges, and strategies. Clinical Therapeutics. 1997;19(2):346-366. 
Muhlestein JB, Horne BD, Bair TL, et al. Usefulness of in-hospital prescription of statin 
agents after angiographic diagnosis of coronary artery disease in improving continued 





Nash IS, Nash DB, Fuster V. Do cardiologists do it better? Journal of the American 
College of Cardiology. 1997;29(3):475-478. 
National Diabetes Information Clearinghouse. Diabetes Overview. Available at: 
http://diabetes.niddk.nih.gov/dm/pubs/overview/index.htm. Accessed December 1, 2004. 
National Pharmaceutical Council. Emerging issues in pharmaceutical cost containment. 
Reston, VA. 1992;2(2):1-16. 
Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and 
death from coronary heart disease. Archives of Internal Medicine. 1992;152(1):56-64. 
Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings 
for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor 
Intervention Trial Research Group. Archives of Internal Medicine. 1992;152(7):1490-
1500. 
Nelson K, Norris K, Mangione CM. Disparities in the diagnosis and pharmacologic 
treatment of high serum cholesterol by race and ethnicity: data from the Third National 
Health and Nutrition Examination Survey. Archives of Internal Medicine. 
2002;162(8):929-935. 
Norusis MJ. Building multiple regression models. SPSS 10.0 Guide to Data Analysis. 




Norusis MJ. Multiple regression diagnostics. SPSS 10.0 Guide to Data Analysis. New 
Jersey: Prentice-Hall; 2000:489-503. 
O'Donnell DC, Chen NT, Piziak V. Goals attainment and maintenance of serum 
cholesterol level in a pharmacist-coordinated lipid clinic. American Journal of Health 
System Pharmacy. 2001;58:325-330. 
O'Keefe J, Kim SC, Hall R, et al. Estrogen replacement therapy after coronary 
angioplasty in women. Journal of the American College of Cardiology. 1997;29(1):1-5. 
Omar MA. An evaluation of the clinical and economic outcomes associated with 
switching hyperlipidemic patients to preferred statin therapy in the United States 
Department of Defense. Dissertation: Department of Pharmacy Practice and 
Administration, University of Texas at Austin; 2001. 
Omar MA, Wilson J, Cox TS. Rhabdomylosis and HMG-CoA reductase inhibitors. 
Annals of Pharmacotherapy. 2001;35(9):1096-1107. 
O'Meara JG, Kardia SL, Armond JJ, et al. Ethnic and sex differences in the prevalence, 
treatment, and control of dyslipidemia among hypertensive adults in the GENOA study. 
Archives of Internal Medicine. 2004;164(12):1313-1318. 
Palmer RH. Effects of fibric acid derivatives on biliary lipid composition. American 




Pasternak R. The ALLHAT lipid lowering trial - Less is less. Journal of the American 
Medical Association. 2002;288(23):3042-3044. 
Pasternak RC, Mckenney J, Brown V, et al. Understanding physician and consumer 
attitudes concerning cholesterol management: Results from the National Lipid 
Association Surveys. American Journal of Cardiology. 2004;94(9A):9F-157. 
Pasternak RC, Smith S, Bairey-Merz CN, et al. ACC/AHA/NHLBI clinical advisory on 
the use and safety of statins. Journal of the American College of Cardiology. 
2002;40(3):567-572. 
Patsch JR. An introduction to the biochemistry and biology of blood lipids and 
lipoproteins. Berlin Heidelberg: Springer-Verlag; 1994. 
Pearson T. The undertreatment of LDL-cholesterol: Addressing the challenge. 
International Journal of Cardiology. 2000;74(suppl 1):S23-S28. 
Pearson T, Laurora I, Chu H, et al. The Lipid Treatment Assessment Project (L-TAP): A 
multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-
lowering therapy and achieving low-density lipoprotein cholesterol goals. Archives of 




Pedersen TR, Olsson AG, Færgeman O, et al. Lipoprotein Changes and Reduction in the 
Incidence of Major Coronary Heart Disease Events in the Scandinavian Simvastatin 
Survival Study (4S). Circulation. 1998;97(15):1453-1460. 
Pitt B, Mancini GBJ, Ellis S, et al. Pravastatin limitation of atherosclerosis in the 
coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events. 
Journal of the American College of Cardiology. 1995;26(5):1133-1139. 
Pogson GW, Kindred LH, Carper BG. Rhabdomyolysis and renal failure associated with 
cerivastatin-gemfibrozil combination therapy. American Journal of Cardiology. 
1999;83(7):1146. 
Probstfield J, Margitic S, Byington RP, et al. Results of the primary outcome measure 
and clinical events from the asymptomatic carotid artery progression study. American 
Journal of Cardiology. 1995;76(9):47C-53C. 
Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering 
therapies according to selected patient characteristics. Annals of Internal Medicine. 
2000;132(10):769-779. 





Rodriguez J. Rhabdomylosis in heart transplant patients on HMG-CoA reductase 
inhibitors and cyclosporine. Transplantation Proceedings. 1999;31(6):2522-2523. 
Rosenson RS. The rationale for combination therapy. American Journal of Cardiology. 
2002;90(2):2-7. 
Ross S, Allen E, Connelly J, et al. Clinical outcomes in statin treatment trials: a meta 
analysis. Archives of Internal Medicine. 1999;159(15):1793-1802. 
Rossouw J, Anderson G, Prentice R, et al. Risks and benefits of estrogen plus progestin 
in healthy postmenopausal women: principal results from the Women's Health Initiative 
randomized controlled trial. Journal of the American Medical Association. 2002 
2002;288(3):321-334. 
Rossouw JE. Lipid-Lowering Interventions in Angiographic Trials. The American 
Journal of Cardiology. 1995;76(1):86C-92C. 
Rubin SM, Sidney S, Black D, et al. High blood cholesterol in elderly men and the excess 
risk for coronary heart disease. Annals of Internal Medicine. 1990;113(12):916-920. 
Rubins H, Robins S, Iwane M, et al. Rationale and design of the department of Veterans 
Affairs high-density lipoprotein cholesterol intervention trial (HIT) for secondary 
prevention of coronary artery disease in men with low high-density lipoprotein 





Rubins HB, Robins SJ. Conclusions from the VA-HIT study. American Journal of 
Cardiology. 2000;86(5):543-544. 
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of 
coronary heart disease in men with low levels of high-density lipoprotein cholesterol. 
New England Journal of Medicine. 1999;341(6):410-418. 
Ruof J, Klein G, Marz W, et al. Lipid-lowering medication for secondary prevention of 
coronary heart disease in a German outpatient population: The gap between treatment 
guidelines and real life treatment patterns. Preventive Medicine. 2002;35(1):48-53. 
Russell MW, Huse DM, Drowns S, et al. Direct Medical Costs of Coronary Artery 
Disease in the United States. American Journal of Cardiology. 1998;81(9):1110-1115. 
Russell MW, Huse DM, Miller JD, et al. Cost-effectiveness of HMG-CoA reductase 
inhibition in Canada. Canadian Journal of Clinical Pharmacology. 2001;8(1):9-16. 
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events 
after myocardial infarction in patients with average cholesterol levels. New England 
Journal of Medicine. 1996;335(14):1001-1009. 
Sacks FM, Moye LA, Davis BR, et al. Relationship between plasma LDL concentrations 
during treatment with pravastatin and recurrent coronary events in the Cholesterol and 




Salonen R, Nyyssonen K, Sarataho E, et al. The Kuopio Atherosclerosis Prevention 
Study (KAPS): Effect of pravastatin treatment on lipids, oxidation resistance of 
lipoproteins, and atherosclerotic progression. American Journal of Cardiology. 
1995;76(9):34C-39C. 
Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with 
cardiovascular disease: Factors limiting achievement of lipid goals. American Journal of 
Medicine. 1996;100(2):197-204. 
Schreiber TL, Elkhatib A, Grines CL, et al. Cardiologist versus internist management of 
patients with unstable angina: Treatment patterns and outcomes. Journal of the American 
College of Cardiology. 1995;26(3):577-582. 
Schrott H, Bittner V, Vittinghoff E, et al. Adherence to National Cholesterol Education 
Program treatment goals in postmenopausal women with heart disease: the Heart and 
Estrogen/Progestin Replacement study. Journal of the American Medical Association. 
1997;277(16):1281-1286. 
Schwandt P. Fibrates and triglyceride metabolism. European Journal of Clinical 
Pharmacology. 1991;40 (suppl 1):S41-S43. 
Schwartz G, Olsson AG, Ezekowitz M, et al. Effects of Atorvastatin of early recurrent 
ischemic events in acute coronary syndromes: A randomized controlled trial. Journal of 




Selwyn AP, Kinlay S, Ganz P. Atherogenesis and ischemic heart disease. American 
Journal of Cardiology. 1997;80(2):3H-7H. 
Sempos C, Cleeman JI, Carroll M, et al. Prevalence of high blood cholesterol among US 
adults: an update based on guidelines from the second report of the National Cholesterol 
Education Program Adult Treatment Panel. Journal of the American Medical 
Association. 1993;269(23):3009-3014. 
Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with 
atorvastatin in hypertensive patients who have average or lower-than-average cholesterol 
concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial- Lipid Lowering Arm 
(ASCOT-LLA): A multicentre randomised controlled trial. The Lancet. 
2003;361(9364):1149-1158. 
Shea S, Ottman R, Gabrieli C, et al. Family history as an independent risk factor for 
coronary artery disease. Journal of the American College of Cardiology. 1984;4(4):793-
801. 
Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. 
Cardiology. 1989;76(suppl 1):65-74. 





Shepherd J. The West of Scotland Coronary Prevention Study: A Trial of Cholesterol 
Reduction in Scottish Men. American Journal of Cardiology. 1995;76(1):113C-117C. 
Shepherd J, Blauw G, Murphy J, et al. Pravastatin in elderly individuals at risk of 
vascular disease (PROSPER): A randomised controlled trial. The Lancet. 
2002;360(9346):1623-1630. 
Shepherd J, Blauw G, Murphy M, et al. The design of a prospective study of Pravastatin 
in the elderly at risk (PROSPER). American Journal of Cardiology. 1999;84(10):1192-
1197. 
Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin 
in men with hypercholesterolemia. New England Journal of Medicine. 
1995;333(20):1301-1307. 
Shepherd J, Hunninghake D, Barter P, et al. Guidelines for lowering lipids to reduce 
coronary artery disease risk: A comparison of Rosuvastatin with Atorvastatin, 
Pravastatin, and Simvastatin for achieving lipid-lowering goals. American Journal of 
Cardiology. 2003;91(suppl):11C-19C. 
Simes RJ. Prospective Meta-Analysis of Cholesterol-Lowering Studies: The Prospective 
Pravastatin Pooling (PPP) Project and the Cholesterol Treatment Trialists (CTT) 




Simes RJ, Marschner IC, Hunt D, et al. Relationship Between Lipid Levels and Clinical 
Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) 
Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained 
by On-Study Lipid Levels? Circulation. 2002;105(10):1162-1169. 
Simons L, Simons J, McManus P, et al. Discontinuation rates for use of statins are high. 
British Medical Journal. 2000;321(7268):1084-. 
Slater E, MacDonald J. Mechanism of action and biological profile of HMG-CoA 
reductase inhibitors: a new therapeutic alternative. Drugs. 1988;36(suppl 3):72-82. 
Smoller-Wassertheil S, Hendrix S, Limacher M, et al. Effect of estrogen plus progestin 
on stroke in postmenopausal women: The Women's Health Initiative: A randomized trial. 
Journal of the American Medical Association. 2003;289(20):2673-2684. 
Snow V, Aronson MD, Hornbake ER, et al. Lipid control in the management of type 2 
diabetes mellitus: A clinical practice guideline from the American College of Physicians. 
Annals of Internal Medicine. 2004;140(8):644-649. 
Spearman M, Summers K, Moore V, et al. Cost-effectiveness of initial therapy with 3-
hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia 





Sprecher DL. Triglyceride as a risk factor for coronary artery disease. American Journal 
of Cardiology. 1998;82(2):49U-56U. 
Staels B, Dallongeville J, Auwerz J, et al. Mechanism of action of fibrates on lipid and 
lipoprotein metabolism. Circulation. 1998;98(19):2088-2093. 
Staffa J, Chang J, Green L. Cerivastatin and reports of fatal rhabdomylosis. New England 
Journal of Medicine. 2002;346(7):539-540. 
Stafford RS, Blumenthal D, Pasternak R. Variations in cholesterol management practices 
of U.S physicians. Journal of the American College of Cardiology. 1997;29(1):139-146. 
Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and 
cardiovascular risk.  US population data. Archives of Internal Medicine. 
1993;153(5):598-615. 
Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk 
of premature death from coronary heart disease continuous and graded? Findings in 
356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). 
Journal of the American Medical Association. 1986;256(20):2823-2828. 
Steiner J, Prochazka A. The assessment of refill compliance using pharmacy records: 





Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment 
using centralized pharmacy records: Description and validation. Medical Care. 
1988;26(8):814-823. 
SteinerA, Weisser B, Vetter WA. Comparative review of the adverse effects of 
treatments for hyerlipidemia. Drug Safety. 1991;6(2):118-130. 
Steinmetz K. Colesevelam hydrochloride. American Journal of Health System Pharmacy. 
2002;59(10):932-939. 
Stevenson JC, Crook D, Godsland IF. Influence of age and menopause on serum lipids 
and lipoproteins in healthy women. Atherosclerosis. 1993;98(1):83-90. 
Sueta C, Chowdhury M, Boccuzzi S, et al. Analysis of the degree of undertreatment of 
hyperlipidemia and congestive heart failure secondary to coronary artery disease. 
American Journal of Cardiology. 1999;83(9):1303-1307. 
Sueta C, Massing M, Chowdhury M, et al. Undertreatment of hyperlipidemia in patients 
with coronary artery disease and heart failure. Journal of Cardiac Failure. 2003;9(1):36-
41. 
Sung JCY, Nichol MB, Venturini F, et al. Factors affecting patient compliance with 





Tabachnick BG, Fidell LS. Cleaning up your act: screening data prior to analysis. Using 
Multivariate Statistics. Fourth ed. Boston: Allyn and Bacon; 2001:56-107. 
Tabachnick BG, Fidell LS. Logistic regression. Using Multivariate Statistics. Fourth ed. 
Boston: Allyn and Bacon; 2001:517-581. 
Tabachnick BG, Fidell LS. Model building strategies and methods for logistic regression. 
Applied Logistic Regression. New York: John Wiley & Sons; 1989:82-133. 
Tabachnick BG, Fidell LS. Multiple regression. Using Multivariate Statistics. Fourth ed. 
Boston: Allyn and Bacon; 2001:111-176. 
Tabachnick BG, Fidell LS. Survival/failure analysis. Using Multivariate Statistics. Fourth 
ed. Boston: Allyn and Bacon; 2001:772-836. 
Taher TH, Dzavik V, Reteff EM, et al. Tolerability of statin-fibrate and statin-niacin 
combination therapy in dyslipidemic patients at high risk for cardiovascular events. 
American Journal of Cardiology. 2002;89(4):390-394. 
Teo KK, Burton JR, Buller CE, et al. Long-Term Effects of Cholesterol Lowering and 
Angiotensin-Converting Enzyme Inhibition on Coronary Atherosclerosis : The 





Texas Health and Human Services Commission. Clients and Benefits. Texas Medicaid in 
Perspective. Austin; 2004:4-1-4-24. 
Texas Health and Human Services Commission. Overview of the Texas Medicaid 
Vendor Drug Program. Available at: 
http://www.window.state.tx.us/specialrpt/hcc2003/section2/1overview.html. Accessed 
November 17, 2003. 
Texas Health and Human Services Commission. Texas Medicaid In Perspective. Texas 
Medicaid in Perspective. Austin; 2004:1-1-1-4. 
The ALLHAT Group. Major outcomes in moderately hypercholesterolemic, hypertensive 
pateints randomized to pravastatin vs. usual care. Journal of the American Medical 
Association. 2002;288(23):2998-2907. 
The Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of 
cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomized 
placebo-controlled trial. Lancet. 2002;360(9326):7-22. 
The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin 
in patients with coronary heart disease and a broad range of initial cholesterol levels. New 




The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive 
lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on 
obstructive changes in saphenous-vein coronary-artery bypass grafts. New England 
Journal of Medicine. 1997;336(3):153-162. 
Thompson CA. Cerivastatin withdrawn from market. American Journal of Health System 
Pharmacy. 1685;58(18):15. 
Thompson P, Clarkson P, Karas R. Statin-associated myopathy. Journal of the American 
Medical Association. 2003;289(13):1681-1690. 
Tolmie EP, Lindsay GM, Kerr SM, et al. Patients' perspectives on statin therapy for 
treatment of hypercholesterolaemia: a qualitative study. European Journal of 
Cardiovascular Nursing. 2003;2(2):141-149. 
Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3260 patients with 
unstable angina: results from the LIPID study. The Lancet. 2000;356(9245):1871-1875. 
Tribble DL, Rizzo M, Chait A, et al. Enhanced oxidative susceptibility and reduced 
antioxidant content of metabolic precursors of small, dense low-density lipoproteins. 
American Journal of Medicine. 2001;110(2):103-110. 
Urquhart J. Pharmacoeconomic consequences of variable patient  compliance with 




Vivian HH, Francois-Eric R, Hanna Z, et al. The cost-effectiveness of HMG-CoA 
reductase inhibitors to prevent coronary heart disease: estimating the benefits of 
increasing HDL-C. Journal of the American Medical Association. 1995;273(13):1032-
1038. 
Warshafsky S, Packard D, Marks S, et al. Efficacy of 3-hydroxy-3-methylglutaryl 
coenzyme A reductase inhibitors for prevention of stroke. Journal of General Internal 
Medicine. 1999;14(12):763-774. 
Welty F. Cardiovascular disease and dyslipidemia in women. Archives of Internal 
Medicine. 2001;161(4):514-522. 
West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma 
lipids on clinical events in the West of Scotland Coronary Prevention Study 
(WOSCOPS). Circulation. 1998;97(15):1440-1445. 
White J, Chang E, Leslie S, et al. Patient adherence with HMG reductase inhibitor 
therapy among users of two types of prescription services. Journal of Managed Care 
Pharmacy. 2002;8(3):186-191. 
Whyte JJ, Filly AL, Jollis JG. Treatment of hyperlipidemia by specialists versus 





Willett WC, Green A, Stampfer MJ, et al. Relative and absolute excess risks of coronary 
heart disease among women who smoke cigarettes. New England Journal of Medicine. 
1987;317(21):1303-1309. 
Williams ML, Morris M, Ahmad U, et al. Racial differences in compliance with NCEP-II 
recommendations for secondary prevention at a Veterans Affairs medical center. 
Ethnicity & Disease. 2002;12(1):58-62. 
Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using 
risk factor categories. Circulation. 1998;97(18):1837-1847. 
Wolf PA, D'Agostino RB, Kannel WB, et al. Cigarette smoking as a risk factor for 
stroke: the Framingham Study. Journal of the American Medical Association. 
1988;259(7):1025-1029. 
Wolfe SM. Dangers of rosuvastatin identified before and after FDA approval. Lancet. 
2004;363(9427):2189-2190. 
Yang Y, Kao S, Chan A. A retrospective drug utilization evaluation of 
antihyperlipidaemic agents in a medical centre in Taiwan. Journal of Clinical Pharmacy 
& Therapeutics. 1997;22(4):291-299. 
Yarnell J, Yu S, Patterson C, et al. Family history, longevity, and risk of coronary heart 




Yarzebski J, Bujor CF, Goldberg RJ, et al. A community-wide survey of physician 
practices and attitudes toward cholesterol management in patients with recent acute 










Homa Boman Dastani was born in Tehran, Iran on January 23, 1977, the daughter of 
Farkhondeh and Boman Dastani.  After completing her Bachelors in Pharmacy from the 
S.N.D.T. University in Bombay, India, she came to the USA to pursue a Masters in 
Pharmacy Administration from the University of Toledo, Ohio and received the degree in 
May 2000.  In the fall of 2000, she joined the University of Texas at Austin to pursue a 
doctoral degree.  During her time at University, she published in several journals such as 
the Indian Journal of Pharmaceutical Sciences, American Journal of Health-System 
Pharmacy, Journal of Pharmacy Technology and Annals of Pharmacotherapy, and has 
presented in various national and international meetings. 
 
Permanent Address: 1644 West Sixth Street, Apt C, Austin TX 78703 
 
This dissertation was typed by the author. 
 
